aibio.space

Latest

Every aibio.space story, newest first: financings, distress, legal, listings and mergers at public biotech companies. Each one links its filing or press release.

Want only the companies you care about? Build your own feed on Following.

October 2026

1. Oct 30, 2026Debt Financing

   Repligen announces $1.0 billion private convertible notes transaction

   The 0.25% notes due 2031 will be issued partly in exchange for 2028 notes and partly for cash, with a conversion price of approximately $226.37.

   RGEN
2. Oct 30, 2026Debt Financing

   Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J

   Horizon Technology Finance is collateral agent and a lender on the amended loan. The new Loan I and Loan J commitments run to December 31, 2027.

   PTHS
3. Oct 29, 2026Legal

   Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit

   The ITC affirmed sanctions against Ascletis Bioscience, Gannex, Ascletis Pharmaceuticals, Ascletis Pharma and Jinzi Jason Wu in May 2025. Both sides appealed, and argument is expected in Q4 2027.

   VKTX
4. Oct 29, 2026Legal

   Viking and Ligand dispute VK2809 license termination in San Diego court

   Ligand sued Viking on May 19, 2026 after purporting to end the TR-Beta license. Viking cross-sued Ligand and Metabasis. A hearing on Ligand's demurrer is set for February 26, 2027.

   VKTXLGND
5. Oct 29, 2026Listings

   Reviva asks stockholders to approve reverse split of up to 1-for-100

   The proposal goes to a virtual annual meeting on December 18, 2026. The board would pick the ratio and could decide not to split at all.

   RVPH
6. Oct 29, 2026Listings

   Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal

   Nasdaq gave Propanc no 180-day compliance period because it reverse split within the past year. The company says it will appeal by October 30, 2026. Its fiscal 2026 net loss was $18.9 million.

   PPCB
7. Oct 29, 2026Company Updates

   Processa clears VT-7208 CSU IND and names a new executive chair

   Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029.

   PCSA
8. Oct 29, 2026Financings

   ProKidney files $650 million shelf with $200 million Jefferies sales program

   ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026.

   PROK
9. Oct 29, 2026Company Updates

   PTC reports third-quarter 2026 revenue of $358 million and raises product guidance

   Sephience revenue reached $182 million in the quarter, the company acquired ST-920 for $111.0 million upfront, and it now expects total revenue of $1.29 to $1.32 billion for 2026.

   PTCT
10. Oct 29, 2026Distress

    Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts

    A termination agreement ends the license and assigns the patents and know-how to Mineralys. Up to $255.0 million in commercial milestones still applies.

    MLYS
11. Oct 29, 2026Financings

    Lexeo Therapeutics files $300 million shelf registration

    Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced.

    LXEO
12. Oct 29, 2026Company Updates

    Kiora in-licenses late-stage KIO-401 for retinal artery occlusion

    Kiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027.

    KPRX
13. Oct 29, 2026Legal

    Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028

    Indivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc.

    INDV
14. Oct 29, 2026Financings

    INmune Bio raises $4.50 million in registered direct offering with warrants

    The offering priced at $1.50 a share, and the warrants carry a $1.65 exercise price. The auditor's report on the 2025 accounts includes a going-concern paragraph, and cash was $18.4 million at June 30, 2026.

    INMB
15. Oct 29, 2026Debt Financing

    FOXO to buy Ludwig Enterprises preferred stock with majority voting power

    FOXO Technologies signed agreements to acquire preferred stock carrying majority voting power in Ludwig Enterprises, Inc. and to buy certain Ludwig notes. The transactions have not closed.

    FOXO
16. Oct 29, 2026Legal

    European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer

    The Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded.

    ENTA
17. Oct 29, 2026Company Updates

    Dermata enrolls first participant in Tome Clearing Treatment trial

    Dermata Therapeutics enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch its second commercial product in the first half of 2027.

    DRMA
18. Oct 29, 2026Legal

    Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits

    A Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits.

    VNDA
19. Oct 29, 2026Distress

    Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones

    Bristol Myers Squibb will end its PRX019 license on January 28, 2027, dropping up to $617.5 million in milestones it could have owed. The 8-K cites an internal strategic review and gives no further reason.

    PRTA
20. Oct 29, 2026Company Updates

    Azitra expands ATR-04 trial to rash from KRAS and MEK inhibitors

    Protocol amendments add patients with rash from KRAS and MEK inhibitors, including people with neurofibromatosis type 1, and shorten some washout periods.

    AZTR
21. Oct 29, 2026Debt Financing

    Altimmune draws $10.0 million third tranche from Hercules loan facility

    Altimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.

    ALT
22. Oct 29, 2026Legal

    Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena

    Alnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open.

    ALNY
23. Oct 28, 2026Legal

    Skye Bioscience faces nimacimab securities class action and two derivative suits

    Stout v. Skye Bioscience alleges misleading statements about nimacimab from November 4, 2024 to October 3, 2025. Two derivative suits captioned against Dhillon are stayed, and consolidation was sought on August 11.

    SKYE
24. Oct 28, 2026Legal

    Skye Bioscience faces October 2026 retrial of Cunning whistleblower suit

    A jury found for former employee Wendy Cunning in 2023. The Ninth Circuit vacated the judgment in 2024. Skye now estimates the legal contingency at $5,417,250 and cites settlement talks.

    SKYE
25. Oct 28, 2026Financings

    Silexion files to register resale of up to 8,813,531 shares

    Silexion's S-3 registers resale of up to 8,813,531 ordinary shares by selling shareholders from an August warrant inducement, a converted sponsor note and stock paid to LifeSci Advisors. The filing also discloses a June 2026 complaint from the sponsor, which seeks repayment of $3.433 million.

    SLXN
26. Oct 28, 2026Debt Financing

    SANUWAVE gets JPMorgan waiver on fixed charge ratio, tightens limits

    The amendment lowers a prepayment figure and three investment baskets from $500,000 to $250,000 and requires Required Lenders consent for certain acquisitions and equity redemptions. JPMorgan Chase Bank, N.A. is administrative agent.

    SNWV
27. Oct 28, 2026Legal

    Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits

    The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action.

    REPL
28. Oct 28, 2026Listings

    Nasdaq to delist Glucotrack shares after bid price exception ends

    Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026.

    GCTK
29. Oct 28, 2026Listings

    Nasdaq panel delists OSR Health over $1.00 bid price rule

    OSR Health, whose shares have traded over the counter since Nasdaq suspended them on August 26, 2026, says it will update shareholders by November 6, 2026 on how it plans to regain a listing.

    OSRH
30. Oct 28, 2026Listings

    Milestone Pharmaceuticals falls below Nasdaq's $1.00 minimum bid rule

    Milestone has until April 21, 2027 to close at $1.00 or more for 10 consecutive business days, after 30 consecutive business days below that level.

    MIST
31. Oct 28, 2026Company Updates

    MetaVia to present Phase 1 DA-1726 data at Precision Liver Symposium

    An abstract on the Phase 1 trial of DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver on November 4, 2026.

    MTVA
32. Oct 28, 2026Distress

    LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%

    The VIZZ maker targets approximately $70 million to $75 million in 2027 operating expenses, and CEO Eef Schimmelpennink will step down December 1, 2026.

    LENZ
33. Oct 28, 2026Company Updates

    Jaguar Health adds six-fold stock plan increase ahead of November vote

    A proxy supplement filed after a stock dividend explains a six-fold increase in shares available under the 2014 Stock Incentive Plan, which stockholders vote on November 6, 2026.

    JAGX
34. Oct 28, 2026Company Updates

    Genprex to present TUSC2 aging research at GSA 2026 meeting

    A poster from the company's Meharry Medical College collaboration is scheduled for the Gerontological Society of America meeting in National Harbor, Maryland, in November 2026.

    GNPX
35. Oct 28, 2026Legal

    Amarin settles Hikma patent and antitrust cases over generic Vascepa

    The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey.

    AMRN
36. Oct 28, 2026Financings

    Adial Pharmaceuticals renames itself Azora Therapeutics after preferred stock vote

    Adial Pharmaceuticals becomes Azora Therapeutics and is expected to trade as AZR from October 29, 2026, after stockholders approved converting the preferred stock issued in its June 2026 acquisition of Azora. The October release does not mention AD04, the drug the company's March 2026 annual report called its lead asset.

    ADIL
37. Oct 28, 2026Financings

    Actuate Therapeutics prices $11.0 million offering of shares and warrants

    Actuate Therapeutics priced 30,985,900 shares and warrants for 15,492,950 more shares at $0.71 per set, for about $11.0 million before costs. The stock last sold at $0.40, and the company reported $4.4 million of cash at June 30, 2026.

    ACTU
38. Oct 27, 2026Listings

    aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29

    The split cuts aTyr's outstanding common stock from approximately 100.5 million shares to approximately 2.5 million. The 8-K does not give a reason for the ratio.

    ATYR
39. Oct 27, 2026Debt Financing

    VolitionRx prepays $500,000 on Lind note and defers two monthly payments

    The remaining balance is $706,667 after the payment. Lind agreed not to convert before January 1, 2027 unless the stock closes at $0.275 or more.

    VNRX
40. Oct 27, 2026Financings

    Valion Bio sells preferred stock, mostly to settle overdue Series C payments

    Valion Bio sold 4,717.73 Series C preferred shares for $4,717,717.61, but $3,217,717.61 of that stays with the buyers to cover overdue cash true-up payments. The company receives $1,500,000 in cash.

    VBIO
41. Oct 27, 2026Distress

    Sangamo ends July in Chapter 11 with $16,906,955 in cash

    An amended monthly operating report for the period ended July 31, 2026 shows $16,906,955 in cash and a July loss of $11,165,298. It also lists an $18 million replacement debtor-in-possession loan.

    SGMOQ
42. Oct 27, 2026Financings

    Rapport Therapeutics launches stock offering and convertible notes due 2032

    Rapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary.

    RAPP
43. Oct 27, 2026Listings

    Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split

    Pulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted.

    PULM
44. Oct 27, 2026Company Updates

    Lifeward names Ronen Tsimerman chief financial officer

    The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy.

    LFWDICCM
45. Oct 27, 2026Mergers

    InMed sets November 5 record date for CVRs tied to Mentari merger

    Holders of record on November 5, 2026 would get one CVR per share, but only if shareholders approve a return of capital proposal on November 4. The company had $2.2 million in cash at June 30, 2026.

    INM
46. Oct 27, 2026Financings

    Imunon files for share offering with 350% warrant coverage in four tranches

    Imunon's preliminary prospectus covers up to 20,000,000 shares, sold with warrants that could cover up to 70,000,000 more. The auditor's opinion on 2025 results includes substantial doubt about the company's ability to continue as a going concern.

    IMNN
47. Oct 27, 2026Listings

    GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance

    The board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026, against 9,093,871 shares outstanding at the record date.

    GOVX
48. Oct 27, 2026Listings

    GeoVax signs $1,000,000 credit line as five directors make way for lender nominees

    GeoVax can borrow up to $1,000,000 at 12% interest from Bowery Consulting Group, and it agreed to pursue a public offering of at least $5,000,000. The lender designated the new directors.

    GOVX
49. Oct 27, 2026Listings

    Enlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split

    Because Enlivex already did a reverse split within the past 12 months, it is not entitled to a 180-day period to regain compliance.

    ENLV
50. Oct 27, 2026Financings

    Endovia Health Sciences raises equity line ceiling to $135 million

    An addendum with C/M Capital Master Fund lifts the facility's maximum commitment from $35 million to $135 million. The filing does not say how much stock has been sold under it.

    EDVA
51. Oct 27, 2026Listings

    CDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares

    The November 12, 2026 meeting will vote on issuing stock under the Astor notes and warrants, and on reverse splits of up to 1-for-1,000. There were 9,322,805 shares outstanding on the October 23, 2026 record date.

    CDT
52. Oct 27, 2026Legal

    Beta Bionics discloses securities class action over iLet statements

    A purported stockholder sued Beta Bionics and certain executive officers in a California federal court in September. The company says a loss is not currently probable nor estimable.

    BBNX
53. Oct 27, 2026Distress

    Artiva drops AlloNK, cuts about 94% of staff and weighs strategic alternatives

    The company ended AlloNK development after two patient deaths and durability data that did not meet its threshold. It reported about $319.1 million in cash, cash equivalents and investments at September 30, 2026, a preliminary figure.

    ARTV
54. Oct 27, 2026Financings

    Aclaris Therapeutics prices $49,999,934 stock and pre-funded warrant offering

    Aclaris priced 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 more shares, $49,999,934 before costs, on the day it announced small Phase 1b results for its antibody ATI-052. The prospectus puts cash at approximately $204.6 million on September 30, 2026.

    ACRS
55. Oct 27, 2026Company Updates

    60 Degrees reports PCR-negative results in five babesiosis patients

    All five patients who finished the expanded access study reported improved outcomes and negative conventional PCR tests, and four of five were also negative on a highly sensitive test.

    SXTP
56. Oct 26, 2026Debt Financing

    West Pharmaceutical enters $750 million revolver and $200 million term loan

    Bank of America, N.A. is administrative agent under the new unsecured credit agreement. The company repaid $130.0 million under its 2019 credit agreement.

    WST
57. Oct 26, 2026Listings

    TScan Therapeutics asks stockholders to approve a reverse split of up to one-for-fifty

    TScan's board will set the reverse split ratio between one-for-two and one-for-fifty, and stockholders vote on November 20, 2026. Nasdaq's bid price deadline is February 23, 2027, and the stock closed at $0.2379 on October 12, 2026.

    TCRX
58. Oct 26, 2026Distress

    Supernus ends its UBS credit line ahead of the Indivior merger

    Supernus ended its UBS credit line on October 20, 2026, with nothing drawn and no penalty. The filing says the combined company is to enter a new senior secured facility at closing, but it gives no closing date and no terms.

    SUPN
59. Oct 26, 2026Mergers

    Skye Bioscience files preliminary proxy for its Redx Pharma acquisition

    Redx holders would own about 59.74% of the combined company and Skye holders about 5.38%, at an assumed exchange ratio of 0.0892. Skye also plans a reverse stock split, and its proxy warns that stockholders will vote without certainty about the combined company's Nasdaq listing.

    SKYE
60. Oct 26, 2026Listings

    Silexion shareholders back a 1-for-24 reverse split and more authorized shares

    Silexion shareholders approved a 500,000,000-share increase in authorized capital and a reverse split. The board chose 1-for-24 from a range of 1-for-15 to 1-for-25. Holders of about 18.6% of shares attended the reconvened meeting, which the articles treat as a quorum.

    SLXN
61. Oct 26, 2026Mergers

    Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger

    Rallybio's board declared an estimated $13.56 per share special cash distribution on October 25, 2026. Payment is conditioned on stockholder approval at a November 4, 2026 meeting, with closing expected November 6, 2026.

    RLYB
62. Oct 26, 2026Listings

    Onconetix sets a 1-for-10 reverse stock split for November 6

    The split cuts the share count to about 588,677 from roughly 5,886,774. The stock keeps trading on Nasdaq as ONCO under a new CUSIP.

    ONCO
63. Oct 26, 2026Financings

    First EQ504 dosing unlocks a $20 million private placement tranche for Equillium

    Equillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029.

    EQ
64. Oct 26, 2026Company Updates

    Aptevo says ten frontline AML patients on mipletamig reached stem cell transplant

    Ten patients with newly diagnosed AML advanced to transplant after treatment with mipletamig, venetoclax and azacitidine, according to Aptevo's October 26, 2026 release.

    APVO
65. Oct 26, 2026Financings

    Acumen Pharmaceuticals files a $500,000,000 shelf registration

    The S-3 covers common stock, preferred stock, debt securities and warrants, with pricing and terms to come in later prospectus supplements. Acumen's auditor included a going concern paragraph in its report on the 2025 financial statements.

    ABOS
66. Oct 26, 2026Listings

    AEON Biopharma seeks approval for a reverse split of up to 1-for-100

    AEON Biopharma asked stockholders to approve a reverse stock split of between 1-for-2 and 1-for-100, to be voted on December 15, 2026. The stock last sold at $0.24 on October 23, and NYSE American's cumulative ratio limit counts the company's 1-for-72 split of February 2025.

    AEON
67. Oct 23, 2026Financings

    Traws Pharma signs $50,000,000 stock purchase agreement with Roth Principal Investments

    Traws can sell up to $50,000,000 of new stock to Roth over 36 months, but no shares can be sold until the SEC declares a resale registration effective. Cash was $5.0 million on June 30, 2026, and cash used in operations was $18.2 million in 2025.

    TRAW
68. Oct 23, 2026Company Updates

    Neuphoria extends its rights agreement to October 27, 2027

    The board approved Amendment No. 1 to the rights agreement with Computershare, moving the final expiration date to the close of business on October 27, 2027.

    NEUP
69. Oct 23, 2026Listings

    Medicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter

    Nasdaq closed Medicus Pharma's bid price case on October 23, 2026, three days after a delisting letter. The 8-K does not say whether the company now meets the $5 million stockholders' equity standard Nasdaq cited.

    MDCX
70. Oct 23, 2026Listings

    Lunai Bioworks gets Nasdaq delisting notice and plans to leave the exchange

    Lunai Bioworks will not appeal a Nasdaq staff decision to delist its stock and plans to deregister with the SEC. Trading on Nasdaq is expected to be suspended on October 30, 2026.

    LNAI
71. Oct 23, 2026Legal

    Integra LifeSciences details New Jersey class action and two derivative suits in 10-Q

    The 2023 Pembroke Pines suit over FDA findings at the Boston plant is still being contested after a supplemental amended complaint. Two derivative suits are stayed behind it.

    IART
72. Oct 23, 2026Listings

    Citius Oncology gets Nasdaq extension to April 19, 2027 on bid price

    Citius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million.

    CTORCTXR
73. Oct 23, 2026Debt Financing

    China Resources Pharmaceutical issues RMB800 million third tranche of notes

    A wholly owned subsidiary completed the third 2026 tranche of medium term notes, RMB800 million at 1.45% per annum over three years.

    3320
74. Oct 23, 2026Mergers

    Bolt Biotherapeutics buys Prana Therapies and raises $120 million

    Bolt Biotherapeutics has agreed to acquire Prana Therapies in a stock-for-stock reverse merger and raise $120 million in a concurrent private placement. After the deal, Bolt's own holders are expected to own about 6.9% of the common stock, and the company says the cash lasts into 2028.

    BOLT
75. Oct 23, 2026Company Updates

    AquaBounty's preferred stock converts into 8,077,043 common shares

    On October 23, 2026, after its resale registration became effective, all Series A and Series B preferred shares converted into common stock, leaving 13,291,953 common shares outstanding.

    AQB
76. Oct 23, 2026Listings

    Akebia Therapeutics gets Nasdaq bid price notice, has until April 19, 2027

    Nasdaq says the stock closed below $1.00 for 30 consecutive business days. Cash fell from $184.8 million at year-end 2025 to $155.5 million at June 30, 2026, and the company says it could seek a reverse stock split.

    AKBA
77. Oct 22, 2026Financings

    United Therapeutics authorizes another $2 billion share repurchase

    The new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30.

    UTHR
78. Oct 22, 2026Financings

    Sagimet expects cash and $115 million offering to fund operations to mid-2029

    Sagimet's investor presentation says $257.6 million in cash, cash equivalents and marketable securities at June 30, 2026, plus a $115 million underwritten offering completed in September, should fund operations to mid-2029. The presentation does not name the underwriters.

    SGMT
79. Oct 22, 2026Listings

    Nuwellis sets one-for-nine reverse stock split effective October 26

    The split takes effect at 5:00 p.m. Eastern Time on October 26, 2026, and NUWE shares trade split-adjusted from October 27.

    NUWE
80. Oct 22, 2026Legal

    Medpace discloses plaintiff dropped Ohio securities class action over book-to-bill ratio

    Defendants: Medpace Holdings, August J. Troendle, Jesse J. Geiger and Kevin M. Brady. Plaintiff filed a voluntary dismissal without prejudice on October 12, and a derivative suit was also dropped.

    MEDP
81. Oct 22, 2026Debt Financing

    Glucotrack sells secured convertible notes and warrants, with Dawson James as placement agent

    The senior secured convertible notes carry a 22% original issue discount, 8% interest and a 9-month term. Dawson James Securities, Inc. is named as placement agent.

    GCTK
82. Oct 22, 2026Distress

    Fractyl cuts about 45% of staff and drops Rejuva gene therapy to fund Revita filing

    The company expects quarterly cash burn to fall by about half, to roughly $8 million, and says its cash lasts into the second quarter of 2027.

    GUTS
83. Oct 22, 2026Listings

    Enlivex announces 1-for-16 reverse share split effective October 27, 2026

    Issued shares will fall from 24,511,905 to about 1,531,995. The stock stays on the Nasdaq Capital Market under ENLV.

    ENLV
84. Oct 22, 2026Legal

    CSL faces shareholder class action over FY26 guidance and disclosure

    The suit, filed in the Supreme Court of Victoria, covers investors who bought CSL securities between February 2025 and May 2026. CSL denies liability and says it will defend the case.

    CSL
85. Oct 22, 2026Listings

    Azitra to carry out 1-for-10 reverse stock split on October 26

    Every 10 shares of common stock will combine into one share on NYSE American, with the stock trading on a split-adjusted basis from market open on October 26, 2026.

    AZTR
86. Oct 21, 2026Legal

    SomaLogic stockholder suit heads to 2027 trial without Standard BioTools; Palamedrix claim settled

    A Delaware suit naming Casdin Capital and SomaLogic directors is set for a March 2027 bench trial. SRS had claimed up to $17.5 million in Palamedrix milestones; that matter is resolved and the company paid Illumina $7.5 million on its indemnity.

    LAB
87. Oct 21, 2026Company Updates

    Genprex reports mouse research linking TUSC2 to healthy brain aging

    A peer-reviewed mouse study tied the TUSC2 gene, used in Genprex's REQORSA program, to protein balance and synaptic function in the hippocampus.

    GNPX
88. Oct 21, 2026Financings

    China SXT ends purchasers' right to buy up to $12 million more shares

    China SXT and the purchasers in its October 8, 2026 registered direct offering agreed to cancel, in full, a right to buy up to $12 million more shares. The company says the offering's securities already issued are not affected.

    SXTC
89. Oct 21, 2026Mergers

    Biotech reverse mergers reach highest count since 2021 as PIPEs return, J.P. Morgan says

    J.P. Morgan counted 27 reverse mergers worth $7.5 billion in the first nine months of 2026. Nineteen came with private placements, against three of 12 in 2025.

90. Oct 21, 2026Financings

    Arcus raises $250 million at $17.50 a share a day after kidney cancer data

    The offering priced below the $19.10 last reported sale price. Arcus says the money goes mainly to casdatifan, its HIF-2 alpha inhibitor now in two phase 3 programs.

    RCUS
91. Oct 21, 2026Listings

    Alaunos Therapeutics says $350.0 million financing restores Nasdaq equity compliance

    Alaunos told the SEC on October 21, 2026 that it believes its $350.0 million financing restored compliance with Nasdaq's $2,500,000 equity rule. The same filing says Nasdaq may not agree, and a November 10 hearing was still set.

    TCRT
92. Oct 20, 2026Financings

    Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross

    Surrozen sold 5,741,605 shares, pre-funded warrants and Series E warrants after FDA cleared its SZN-8141 IND application. It expects its cash, cash equivalents and marketable securities to last into 2029.

    SRZN
93. Oct 20, 2026Financings

    Surrozen closes $95.1 million second tranche of March 2025 private placement

    The second tranche brought in about $95.1 million gross, before placement agent fees, and the company expects cash to last into 2029. The first patient in its SZN-8141 trial is not expected to be dosed until the fourth quarter of 2026, after a rival Wnt drug met its primary endpoint in a Phase 2b/3 trial in the same eye disease.

    SRZN
94. Oct 20, 2026Company Updates

    Quoin publishes peer-reviewed paper on QRX003 in Netherton Syndrome

    The paper, published online on October 13, 2026, includes a pediatric compassionate-use case report. Quoin also described interim results from its Phase 2/3 study.

    QNRX
95. Oct 20, 2026Company Updates

    Premier Air Charter's chief financial officer resigns, CEO named interim

    Matt Aune resigned as chief financial officer on October 19, 2026, and the board named Sandra J. Bonar interim principal financial officer effective October 20, 2026.

    PREM
96. Oct 20, 2026Legal

    Lifecore reports July hearing on securities class action settlement

    Carew v. Lifecore Biomedical names the company and unnamed executive officers. The final approval hearing was held on July 28, 2026. A separate New York suit by 22NW Fund continues against the company.

    LFCR
97. Oct 20, 2026Financings

    Indaptus Therapeutics closes $24.0 million private placement of 20,338,974 shares

    Indaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million.

    INDP
98. Oct 20, 2026Legal

    Fifth Circuit vacates class certification in Filana securities class action

    The appeals court sent the Texas case back for new class certification proceedings. A $31.25 million settlement was filed in June, and Remi Barbier and Lindsay Burns, named in the 10-Q, are not parties to it.

    FLNA
99. Oct 20, 2026Financings

    Disc Medicine raises $450 million at $75 a share after phase 3 win

    The upsized offering funds a planned bitopertin launch. Disc says cash plus proceeds lasts into 2030 and had an estimated $682.8 million before the deal.

    IRON
100. Oct 20, 2026Financings

     BioAtla signs $40.0 million standby equity deal with Yorkville

     BioAtla can sell up to $40.0 million of stock to Yorkville over 36 months, but its cash was $1.5 million at June 30, 2026, and its prior $15.0 million line raised about $0.4 million.

     BCAB
101. Oct 20, 2026Financings

     Alpha Teknova launches stock offering, then prices 8,000,000 shares at $5.00

     The offering totals $40,000,000 at the public offering price, with $37,600,000 to Teknova before expenses. Underwriters have a 30-day option to buy up to 1,200,000 more shares.

     TKNO
102. Oct 19, 2026Legal

     Ultragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033

     The 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue.

     RARE
103. Oct 19, 2026Company Updates

     Two Polomar Health directors resign, leaving three on the board

     Alexandra Peterson and Gabrielle Toledano resigned effective October 14, 2026, and the board reduced its size from five to three. The board has not decided whether to fill the vacancies.

     PMHS
104. Oct 19, 2026Listings

     Silexion adjourns vote on 500 million new shares and reverse split to October 26

     The company says it needs both measures to protect its Nasdaq listing, with 14,473,292 shares already outstanding against 15,900,000 authorized. Shareholders rejected smaller versions in September.

     SLXN
105. Oct 19, 2026Financings

     OS Therapies gets $7.2 million gross from initial warrant inducement closing

     OS Therapies raised $7.2 million gross in the first closing of a warrant inducement, but the holders who exercised received new warrants for the same number of shares at $1.40, and the company reported only $205,035 in cash at June 30, 2026.

     OSTX
106. Oct 19, 2026Mergers

     Merck KGaA agrees to buy Silence Therapeutics for $20 per ADS to get PV drug divesiran

     The all-cash deal values Silence at about $1.1 billion in enterprise value, an 82% premium to its 30-day average price. Closing is expected in the first quarter of 2027.

     SLN
107. Oct 19, 2026Debt Financing

     Integra LifeSciences sells $450 million of 9.500% senior secured notes, refinances credit facility

     Integra refinanced a $1.3 billion revolver and a $775 million term loan with $450 million of 9.500% notes due 2033 and a $1.65 billion credit agreement, after reporting a 2025 net loss of $516.5 million.

     IART
108. Oct 19, 2026Distress

     EyePoint cuts about half its staff after second Duravyu wet AMD phase 3 miss

     Lucia missed its non-inferiority goal against Eylea. EyePoint will end both wet AMD trials early and put its cash behind two diabetic macular edema studies due in late 2027.

     EYPT
109. Oct 19, 2026Financings

     Dogwood Therapeutics agrees to sell $5 million of stock to top holder CK Life Sciences

     Dogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026.

     DWTX
110. Oct 19, 2026Financings

     Curis agrees to sell stock and warrants for about $8.5 million in gross proceeds

     Curis sold shares and pre-funded warrants at an effective $0.51 a share, with common warrants at $0.60. A.G.P./Alliance Global Partners, the lead placement agent, earns a 6.5% cash fee on the gross proceeds.

     CRIS
111. Oct 19, 2026Legal

     Curanex discloses two New York class actions tied to its August 2025 IPO

     Curanex Pharmaceuticals is a defendant, with underwriters Dominari Securities LLC, Pacific Century Securities, LLC and Revere Securities LLC, in two New York class actions over its August 2025 IPO. Both suits allege Securities Act violations in the offering documents.

     CURX
112. Oct 19, 2026Company Updates

     Cosmos Health expects fourth-quarter U.S. revenue of about $15 million

     Cosmos Health said active U.S. subscriptions reached 8,940 as of October 19, 2026. It expects fourth-quarter U.S. revenue of approximately $15 million and gross profit of approximately $10.5 million. The figures are preliminary and unaudited.

     COSM
113. Oct 19, 2026Legal

     Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000

     The drugmaker ends its Nucynta license and royalties with Grünenthal and gets certain patents assigned to it. Grünenthal has filed a motion to dismiss the New Jersey case.

     COLL
114. Oct 19, 2026Distress

     Collegium pays Grünenthal $17,000,000 to settle Nucynta suit and end license

     Collegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company.

     COLL
115. Oct 16, 2026Company Updates

     VivoSim amends Organovo lease, giving up part of its San Diego office

     Organovo, a VivoSim subsidiary, agreed on October 13, 2026 to vacate Suite 202 by February 28, 2027, extend Suite 100 through April 30, 2028 and receive a partial rent abatement.

     VIVS
116. Oct 16, 2026Financings

     Tenon Medical obtains investor waiver to increase at-the-market sales

     The investor waived limits that would have blocked a larger at-the-market offering, in exchange for a new warrant at $5.02 per share. WallachBeth Capital LLC also waived its rights under the sales agreement.

     TNON
117. Oct 16, 2026Mergers

     MiMedx and Sanara receive FTC Second Request on proposed merger

     The request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.

     MDXG
118. Oct 16, 2026Mergers

     MiMedx and Sanara MedTech receive FTC Second Request on merger

     The request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.

     MDXG
119. Oct 16, 2026Financings

     Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants

     The exchange leaves Maze with 53,931,889 shares of common stock outstanding as of October 16, 2026.

     MAZE
120. Oct 16, 2026Distress

     Fractyl shares fall 48% even as Revita meets six-month REMAIN-1 endpoint

     Patients kept about 80% of their tirzepatide weight loss after one Revita procedure versus 67% after sham. Fractyl plans a De Novo filing in late fourth quarter 2026.

     GUTS
121. Oct 16, 2026Debt Financing

     Clearmind Medicine to sell $2,000,000 of convertible notes for $1,800,000 in cash

     The sale draws on an agreement allowing up to $10,000,000 of convertible promissory notes. The company expects it to close on or before October 19, 2026.

     CMND
122. Oct 16, 2026Financings

     City Therapeutics raises $200 million in upsized IPO priced at $18

     The Cambridge RNAi developer sold 11.1 million shares at the midpoint of its range. Its lead drug, a Factor XI siRNA for blood clots, has more phase 1 data due in late 2026.

     CTYSLN
123. Oct 16, 2026Debt Financing

     China Resources Pharmaceutical unit issues RMB900 million corporate bonds

     A wholly owned subsidiary completed the second tranche of its 2026 corporate bonds in the PRC, RMB900 million at 1.48% per annum over three years.

     3320
124. Oct 16, 2026Financings

     Alector prices $75,030,000 stock offering at $2.05, above prior close

     Alector priced 36,600,000 shares at $2.05 for $75,030,000 gross. Its 2025 revenue fell to $21.0 million and cash used in operations was $184.0 million, against $59.9 million of cash on June 30, 2026.

     ALEC
125. Oct 15, 2026Company Updates

     Velocity Bioworks completes NMR feasibility test with LarmorBio

     Valion's CDMO unit finished an initial evaluation of LarmorBio's BioScan-NMR platform for continuous bioprocess monitoring.

     VBIO
126. Oct 15, 2026Legal

     Supernus inherits Sage securities class action, derivative suits and SEC subpoena

     Supernus (Nasdaq: SUPN) took on Sage's New York class action naming Barry Greene and Kimi Iguchi, three derivative suits against sixteen unnamed insiders, and an SEC subpoena. Supernus faces two merger suits of its own.

     SUPN
127. Oct 15, 2026Listings

     Sangamo's Nasdaq delisting becomes final as Chapter 11 case continues

     Nasdaq filed Form 25 on Oct. 7, ending a listing that began unravelling over the minimum bid price. The stock trades OTC as SGMOQ after Sangamo agreed to sell its Fabry program to PTC for $111 million in cash.

     SGMOQ
128. Oct 15, 2026Financings

     Recursion raises $200 million at $3.25 a share as Sanofi options first candidate

     The company says cash now lasts into 2029. Sanofi's option on an inflammatory disease molecule triggered a $10 million milestone.

     RXRX
129. Oct 15, 2026Mergers

     Rallybio holders to own 2.8% of the combined company in Avenzo reverse merger

     Rallybio's holders would keep 2.8% of the merged company, while Avenzo's holders would own 56.6% and investors in a $215.0 million financing 40.6%. Rallybio stockholders vote on the deal on November 4.

     RLYB
130. Oct 15, 2026Debt Financing

     Profusa issues $769,230.77 secured convertible note to Ascent Partners

     The note carries 7% interest, converts at $4.28 a share and matures in October 2027.

     PFSA
131. Oct 15, 2026Debt Financing

     OSR Health amends VXM01 license to allow up to $15,000,000 in convertible notes

     Under an amended license with BCM Europe AG, OSR Health can elect to take up to $15,000,000 of convertible notes in place of an equity purchase option.

     OSRH
132. Oct 15, 2026Listings

     Mustang Bio gets a second 180-day Nasdaq grace period to fix its bid price

     Nasdaq gave Mustang Bio until April 12, 2027 to lift its bid price to $1.00. The company has said it intends to do a reverse stock split if necessary.

     MBIO
133. Oct 15, 2026Legal

     Jasper Therapeutics faced Oct 15 hearing on motion to dismiss briquilimab class action

     Defendants: Jasper and unnamed current and former officers; derivative suits are captioned against Martell and others. A motion to dismiss was set for hearing October 15, and no ruling is reported.

     JSPR
134. Oct 15, 2026Financings

     Iambic Therapeutics prices IPO of 9,375,000 shares at $16.00

     The offering totals $150,000,000 before fees. The stock has been approved for listing on the Nasdaq Global Select Market under the symbol IAM.

     IAM
135. Oct 15, 2026Financings

     First Tracks Biotherapeutics agrees to sell 6,106,870 shares at $32.75, about $200 million

     The company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026.

     TRAX
136. Oct 15, 2026Financings

     Evofem Biosciences pushes Adjuvant note maturity to December 1, 2026

     Evofem moved the maturity of convertible notes held by Adjuvant to December 1, 2026, and removed some affirmative covenants. The 8-K gives no repayment plan, and the company's year-end cash was $578,000.

     EVFM
137. Oct 15, 2026Mergers

     Aditxt unit Ignite Proteomics and Copley Acquisition Corp end SPAC merger deal

     Aditxt's subsidiary Ignite Proteomics and the blank-check company Copley Acquisition Corp ended their June 2026 business combination agreement on October 9, 2026. Each side bears its own expenses, and the 8-K gives no reason for the termination.

     ADTX
138. Oct 15, 2026Company Updates

     Adial adjourns annual meeting again as Nasdaq approval is pending

     Adial reconvened its 2026 Annual Meeting on October 15, 2026 for four proposals and adjourned it a second time to October 26, 2026, while its Nasdaq listing application remains without approval.

     ADIL
139. Oct 15, 2026Legal

     Actinium securities class action dismissed with prejudice; plaintiffs file appeal

     The case names Actinium and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala and Sergio Giralt. Four derivative suits against directors and officers follow the same allegations.

     ATNM
140. Oct 15, 2026Financings

     ALX Oncology swaps 13,353,384 shares for pre-funded warrants with investors

     ALX Oncology's exchange trades 13,353,384 common shares for pre-funded warrants with a $0.001 exercise price, and the 8-K describes no cash payment to the company.

     ALXO
141. Oct 14, 2026Legal

     Xeris sues Torrent, Rising and others in New Jersey over generic Keveyis patent

     Xeris Biopharma's subsidiary filed two patent infringement suits on October 13 after a new Keveyis patent was granted. The 8-K names seven defendants.

     XERS
142. Oct 14, 2026Financings

     Vir Biotechnology agrees to sell Gilead 1,765,486 shares for about $25 million

     The stock purchase comes with a collaboration to engineer three T-cell engager candidates for solid tumors. Closing is subject to customary conditions.

     VIR
143. Oct 14, 2026Financings

     Ultragenyx agrees to transfer two priority review vouchers for $413 million

     The company will receive $210 million and $203 million in cash, subject to antitrust clearance. The NIH is owed 20% of the first sale.

     RARE
144. Oct 14, 2026Financings

     Silo Pharma issues 150,000 shares to buy software and intellectual property

     Silo Pharma agreed on October 13, 2026 to buy certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock. The shares are locked up for up to twelve months, and the 8-K names no underwriter or placement agent.

     SILO
145. Oct 14, 2026Listings

     Mannatech says it regained Nasdaq stockholders' equity compliance

     Mannatech said a Swiss holding company transaction and a pro forma tax adjustment put it back above Nasdaq's stockholders' equity minimum, subject to review and to Nasdaq's view.

     MTEX
146. Oct 14, 2026Distress

     Liquidia to pay net $175 million in global settlement with United Therapeutics

     The deal ends six lawsuits. Liquidia also owes $145.4 million in two installments due in 2027 and $60.3 million to other parties this month.

     LQDAUTHR
147. Oct 14, 2026Legal

     Liquidia settles all patent and trade secret litigation with United Therapeutics

     The 8-K lists a net $175.0 million payment to UTC, a further $145.4 million in installments, and a YUTREPIA label change removing PH-ILD. Three parties are also paid to end the RareGen case, and one of them is a related party.

     LQDAUTHR
148. Oct 14, 2026Company Updates

     Interpace Biosciences expects third quarter revenue of $10.1 million to $10.4 million

     The preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025.

     IDXG
149. Oct 14, 2026Listings

     Immutep Ltd regains Nasdaq bid price compliance after ADS ratio change

     Nasdaq confirmed on October 12, 2026 that the matter is closed. The company changed its ADS ratio from 10 to 200 ordinary shares effective September 28, 2026.

     IMM
150. Oct 14, 2026Mergers

     Eton Pharmaceuticals pays $10.0 million upfront for US rights to Aquestive's Libervant

     Milestones could add up to $47.5 million, plus royalties at a mid-teens percentage of net sales. The product has tentative FDA approval only, and Aquestive will be its exclusive manufacturer under a 20-year supply agreement.

     ETON
151. Oct 14, 2026Company Updates

     EMA grants orphan drug designation for QRX003 in peeling skin syndrome

     The designation is the eighth regulatory milestone for QRX003, according to the company. If QRX003 is approved in the EU, it would receive 10 years of market exclusivity.

     QNRX
152. Oct 14, 2026Company Updates

     Aptevo to present CD40 multispecific platform data at SITC 2026

     Aptevo will present its CD40-directed multispecific portfolio at the Society for Immunotherapy of Cancer annual meeting in Phoenix, November 4 to 8, 2026.

     APVO
153. Oct 14, 2026Mergers

     Aibotics completes purchase of PlayJamaica robotics and drone assets

     Aibotics signed an asset purchase agreement with PlayJamaica Limited on October 12, 2026, and completed the acquisition on October 14, issuing 22,500 shares of Series B Preferred Stock.

     AIBT
154. Oct 13, 2026Legal

     Weird Science demands $10 million to end Delaware Chancery suit and other claims against Lunai

     Lunai's 10-K says the Oct 7 demand covers all pending litigation. The Chancery case alleges breach of a 2018 investor rights agreement, and mediation has not been scheduled.

     LNAI
155. Oct 13, 2026Mergers

     Senti Biosciences adjourns annual meeting to seek more votes for merger proposal

     Senti adjourned its October 8, 2026 annual meeting without conducting any business to seek more votes for a merger proposal. The company reported $6.5 million of cash and cash equivalents at June 30, 2026, after using $43.4 million in operations in 2025.

     SNTI
156. Oct 13, 2026Company Updates

     Scienture expects preliminary third-quarter revenue of about $1.22 million

     Preliminary revenue rose 256% from the second quarter after the REZENOPY launch and higher Arbli wholesale unit sales. The figures are unaudited.

     SCNX
157. Oct 13, 2026Mergers

     Pulmatrix stockholders to vote October 26, 2026 on Eos SENOLYTIX merger

     Pulmatrix stockholders are due to vote October 26, 2026 on a merger with Eos SENOLYTIX, Inc., whose lead data so far are mouse studies. The filing gives no amount for the merger-associated financings it expects, and the company's cash was $2.2 million at June 30, 2026.

     PULM
158. Oct 13, 2026Company Updates

     Phio completes first commercial-scale cGMP batch of PH-762 drug substance

     The batch is a manufacturing milestone that supports the planned start of a Phase 2b trial in the first quarter of 2027. The company issued a press release announcing it on October 13, 2026.

     PHIO
159. Oct 13, 2026Company Updates

     MetaVia appoints Sarah Browne as chief medical officer

     Sarah Browne, M.D., joins MetaVia as Chief Medical Officer effective October 12, 2026, ahead of the fourth quarter 2026 topline readout from Part 3 of the DA-1726 Phase 1 trial.

     MTVA
160. Oct 13, 2026Mergers

     LogicMark completes merger, holders receive $1.31 a share in cash

     The merger with Langham Merger Sub took effect on October 13, 2026, and LogicMark is now a wholly owned subsidiary of Langham Project LLC.

     LGMK
161. Oct 13, 2026Listings

     CytoMed Therapeutics gets Nasdaq bid price notice, has until April 5, 2027

     Nasdaq said the ordinary shares closed below US$1.00 for 30 consecutive business days. The letter has no current effect on the listing or trading.

     GDTC
162. Oct 13, 2026Debt Financing

     CDT Equity gets $3,000,000 first tranche of $6,750,000 convertible note

     The first tranche brought in $3,000,000, with net proceeds of $2,869,850 after closing fees. The lender can convert at 70% of the lowest recent close, with a floor of $0.18354, and the company reported $747,000 of cash at June 30, 2026.

     CDT
163. Oct 13, 2026Company Updates

     Bluejay completes Toray manufacturing site ahead of deadline

     Bluejay Diagnostics said it finished establishing a Symphony cartridge manufacturing site under its amended Toray license, ahead of an October 23, 2026 deadline.

     BJDX
164. Oct 13, 2026Mergers

     Alaunos Therapeutics acquires Velaris, closes $350 million private placement

     Alaunos bought Velaris in a stock deal and closed a $350 million private placement led by Fairmount. Velaris has no product candidate tested in humans, and Alaunos had $124,000 in cash at June 30, 2026, according to its quarterly report.

     TCRT
165. Oct 13, 2026Debt Financing

     ADC Therapeutics agrees to $86.6 million PIPE and plans loan cut to $50.0 million

     ADC Therapeutics agreed to an $86.6 million private placement and to cut its senior loan to $50.0 million, and its royalty holder gave up a $150 million change-of-control payment. The changes depend on the placement closing, and expected cash at September 30, 2026 was $189.2 million, against $219.1 million at June 30.

     ADCT
166. Oct 9, 2026Financings

     Vaxcyte raises about $1.1 billion in stock and convertible notes after phase 3 win

     The company sold shares at $64 and $575 million of 1.50% notes due 2032, adding to $2.5 billion it held at the end of June.

     PCVX
167. Oct 9, 2026Debt Financing

     TuHURA Biosciences draws $650,000 more on Parkview credit line

     TuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million.

     HURA
168. Oct 9, 2026Financings

     TRex Bio prices IPO of 8,333,334 shares at $14.00 each

     TRex Bio priced 8,333,334 shares at $14.00 each, for $116,666,676 before underwriting fees. Eli Lilly, which paid the company a $55.0 million upfront in 2023, has indicated interest in buying shares, but the indication is not binding.

     TRXB
169. Oct 9, 2026Debt Financing

     SS Innovations issues $21,025,000.00 secured convertible note

     Growth Capital Partners, LLC is the lender. The note carries 8.75% interest, matures 36 months after the purchase price date and converts at 95% of a market price.

     SSII
170. Oct 9, 2026Financings

     Retension Pharmaceuticals prices IPO of 3,750,000 shares at $12.00

     The offering totals $45,000,000 before fees. The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt.

     RTSN
171. Oct 9, 2026Mergers

     Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5

     The amended deal, signed September 2, values Remix at $226.0 million against about $20.0 million for Passage Bio, with $100.0 million of concurrent financing. The final proxy was filed October 9.

     PASG
172. Oct 9, 2026Legal

     Lunai Bioworks cites its Delaware suit against Seven Points Capital in Nasdaq trading halt request

     Lunai's 8-K asks Nasdaq to suspend trading, citing records from its Delaware suit. A later 8-K says trading will be suspended on October 30 unless the company asks for a hearing, and it does not plan to ask.

     LNAI
173. Oct 9, 2026Debt Financing

     Integra LifeSciences prices $450,000,000 senior secured notes

     The 9.500% notes are due 2033 and will help refinance the company's existing credit facilities.

     IART
174. Oct 9, 2026Debt Financing

     Co-Diagnostics takes up to $3.1 million in secured convertible loans

     J.J. Astor & Co. is the lender. The initial note carries a $2.835 million principal amount, and the company says the proceeds will fund working capital.

     CODX
175. Oct 9, 2026Debt Financing

     Co-Diagnostics issues senior secured convertible note to J.J. Astor

     The note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027.

     CODX
176. Oct 9, 2026Listings

     Artelo Biosciences flags exposure to Nasdaq's new $5,000,000 market value rule

     Artelo was among about 180 Nasdaq companies first identified as below the new threshold. The company gives no market value figure, and the rule is on a temporary stay.

     ARTL
177. Oct 9, 2026Listings

     Alaunos Therapeutics gets Nasdaq delisting notice under $2,500,000 stockholders' equity rule

     Nasdaq staff told Alaunos on October 5, 2026 that its securities are subject to delisting under Listing Rule 5550(b)(1). The company plans to request a hearing and says it is working with a financial advisor on potential transactions.

     TCRT
178. Oct 8, 2026Debt Financing

     X4 Pharmaceuticals signs up to $150 million senior loan with K2 HealthVentures

     The first $80 million tranche repaid $75 million of principal and fees owed under the prior loan. Another $70 million may be available at X4's request, subject to K2HV approval.

     XFOR
179. Oct 8, 2026Debt Financing

     X4 Pharmaceuticals replaces loan with up to $150 million K2 facility

     The first $80 million tranche repaid the prior loan in full, including $75 million of principal.

     XFOR
180. Oct 8, 2026Mergers

     Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash

     Viatris agreed to buy Pacira for $36.50 a share in cash, an equity value of $1.65 billion, through a tender offer and a second-step merger. The release states no premium to the recent share price.

     PCRXVTRS
181. Oct 8, 2026Financings

     Valion Bio files $100,000,000 shelf with $5,000,000 at-the-market program

     Valion Bio filed a $100,000,000 shelf registration on October 7, 2026, and the same day agreed to sell 3i $50,000 of Series B preferred and warrants. The public float used for the shelf was based on a $7.75 price, while the last reported sale on October 5 was $2.48.

     VBIO
182. Oct 8, 2026Debt Financing

     Revolution Medicines borrows $250.0 million under Royalty Pharma loan

     Revolution Medicines borrowed $250.0 million on October 8, 2026, under a senior secured term loan with Royalty Pharma Development Funding, LLC. The loan carries a floating rate of three-month Term SOFR plus 5.75%.

     RVMD
183. Oct 8, 2026Mergers

     Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data

     Boundless Bio filed a Form S-4 on October 8, 2026 for its merger with private Serapha Bio. The filing estimates about 8.6737 Boundless shares for each Serapha share before a planned reverse split, and expects existing Boundless holders to own about 3.8% of the combined company.

     BOLD
184. Oct 8, 2026Listings

     Biodexa changes ADS ratio to 400 ordinary shares, a one-for-eight reverse ADS split

     The exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change.

     BDRX
185. Oct 8, 2026Financings

     Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share

     The deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate.

     RNA
186. Oct 8, 2026Financings

     AquaBounty to convert all preferred stock into 8,077,043 common shares

     AquaBounty agreed on October 7, 2026 that all Series A and Series B preferred stock will convert into 8,077,043 common shares by October 30, 2026 at the latest, with the resale shares to be registered.

     AQB
187. Oct 7, 2026Listings

     Redhill Biopharma gets 180 more days on Nasdaq bid price, to April 5, 2027

     Nasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025.

     RDHL
188. Oct 7, 2026Listings

     NexGel sets a 1-for-20 reverse stock split effective October 12, 2026

     Every 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP.

     NXGL
189. Oct 7, 2026Legal

     Neogen discloses appeal of dismissed Michigan securities suit and two related cases

     A federal court dismissed the Michigan class action with prejudice on August 10, 2026 and plaintiffs have appealed. A Minnesota Securities Act class action and a Michigan derivative suit remain pending.

     NEOG
190. Oct 7, 2026Listings

     Nasdaq files to remove Aditxt common stock from listing

     The Nasdaq Stock Market has filed a Form 25 to remove Aditxt's common stock from listing, dated October 7, 2026. The form does not say why Nasdaq acted, and the company reported $268,852 of cash at March 31, 2026.

     ADTX
191. Oct 7, 2026Listings

     Nasdaq files SEC notice to remove Sangamo Therapeutics stock from listing

     Nasdaq signed the Form 25 itself on October 6, 2026, and the form gives no reason. Sangamo's latest annual report warned it might cease operations, liquidate or seek bankruptcy protection.

     SGMOQ
192. Oct 7, 2026Mergers

     Jasper Therapeutics offers $0.324 per warrant to buy back up to 12,345,707 warrants

     Jasper Therapeutics will pay $0.324 in cash per warrant for up to 12,345,707 warrants, about $4.0 million if all are tendered, and the offer runs until November 6, 2026.

     JSPR
193. Oct 7, 2026Debt Financing

     FibroBiologics sells $1,200,000 convertible debenture to Peak One

     FibroBiologics sold a $1,200,000 convertible debenture to Peak One Opportunity Fund, L.P. for $1,020,000, an original issue discount of 15%. The debenture matures October 8, 2027 and converts only after a default, at $0.78 per share.

     FBLG
194. Oct 7, 2026Legal

     Envoy Medical ends Atlas SPAC redemption suit in Delaware with no payment

     Atlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants.

     COCH
195. Oct 7, 2026Company Updates

     Cosmos Health reports preliminary nine-month revenue of $54.3 million

     Cosmos Health said preliminary revenue for the nine months ended September 30, 2026 was approximately $54.3 million, up 19%. The company reaffirmed its outlook for full-year 2026 revenue of more than $90 million.

     COSM
196. Oct 7, 2026Debt Financing

     CERo agrees to sell operating unit to SRX Global

     CERo Therapeutics Holdings agreed on October 6, 2026 to sell its operating subsidiary to SRX Global Inc. The buyer would discharge the Consolidated Note, which had an outstanding principal balance of $8,249,643.77.

     CERO
197. Oct 7, 2026Company Updates

     BioRestorative appoints Donald J. Currie to its board

     The board appointed Donald J. Currie as a Class I director on October 7, 2026 to fill the seat left by Katharyn Field, and named him to two committees.

     BRTX
198. Oct 7, 2026Company Updates

     BioNexus signs exclusive Malaysian healthcare licence for CogniAI

     The licence is payable in BioNexus shares, and closing remains subject to technology delivery and approvals.

     BGLC
199. Oct 6, 2026Company Updates

     VivoSim Labs stockholders elect two directors and approve split range

     At its September 30, 2026 annual meeting, VivoSim Labs stockholders elected Keith Murphy and Adam Stern and approved a reverse stock split range of 1-to-5 to 1-to-20.

     VIVS
200. Oct 6, 2026Debt Financing

     Vaxcyte offers $500,000,000 of 1.50% convertible notes due 2032

     Vaxcyte is selling common stock and pre-funded warrants alongside $500,000,000 of convertible senior notes due 2032, a day after reporting Phase 3 data for VAX-31.

     PCVX
201. Oct 6, 2026Listings

     Universe Pharmaceuticals holders approve conditional 10-into-1 share consolidation

     A 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice.

     UPC
202. Oct 6, 2026Financings

     Telomir Pharmaceuticals sells about $5.6 million of common stock in PIPE

     Telomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million.

     TELO
203. Oct 6, 2026Company Updates

     Sonoma Pharmaceuticals adopts new Section 382 rights agreement

     The board replaced an expiring rights agreement with one meant to protect net operating loss carryforwards, with rights tied to holders of record on October 13, 2026.

     SNOA
204. Oct 6, 2026Debt Financing

     Rocket Pharmaceuticals secures credit facility of up to $150 million from Hercules

     Rocket Pharmaceuticals received $35 million at closing under a credit facility of up to $150 million with Hercules Capital. The company expects its cash, with that first draw, to fund operations into the third quarter of 2028, and it says more borrowing could extend that into 2029.

     RCKTHTGC
205. Oct 6, 2026Debt Financing

     Rocket Pharmaceuticals secures credit facility of up to $150 million

     Hercules Capital is the lender. Rocket received $35 million at closing, reported no revenue in 2025 or 2024, and held $283.7 million in cash and investments at June 30, 2026.

     RCKTHTGC
206. Oct 6, 2026Financings

     Range Impact issues 654,434 shares each to MRR and Wicks to end option deals

     Range Impact issued 654,434 shares each to MRR CNG and Wicks Building, priced at $0.764, to end two land option deals. Both buyers' $500,000 option fees were counted as the share price, and the 8-K names no adviser or placement agent for the issuances.

     RNGE
207. Oct 6, 2026Distress

     Premier Air Charter says lessors terminated its CJ3 aircraft leases

     The company did not cure asserted defaults, returned two Citation CJ3 aircraft on October 1, 2026, and lessors claim approximately $514,557 under the leases.

     PREM
208. Oct 6, 2026Debt Financing

     Nuo Therapeutics receives $325,000 second funding under loan

     Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028.

     AURX
209. Oct 6, 2026Company Updates

     NOMAD launches a 26-stop mobile power demonstration tour

     NOMAD Power Solutions began a tour of its Voyager battery systems on October 6, 2026. Three regional roadshows run through November 16, with stops in the Mountain West, Northeast and Southwest.

     NMAD
210. Oct 6, 2026Listings

     Kyntra Bio gets Nasdaq delisting determination, requests a hearing

     Nasdaq staff said Kyntra Bio had not shown compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. A hearing request keeps the stock trading for now.

     KYNB
211. Oct 6, 2026Company Updates

     Kairos Pharma reports positive interim Phase 2 data for ENV-105 in prostate cancer

     Kairos Pharma says median progression-free survival was 17.7 months with ENV-105 plus apalutamide, compared with 2 months on apalutamide alone, and has changed the trial to enroll patients earlier.

     KAPA
212. Oct 6, 2026Legal

     Inovio faces securities class action and five derivative suits over INO-3107 statements

     Inovio, CEO Jacqueline Shea and CFO Peter Kies are defendants in a Pennsylvania class action. Shea, Kies and seven directors are named in derivative suits. A lead plaintiff was appointed July 27, 2026.

     INO
213. Oct 6, 2026Mergers

     Hepion acquires Gravitas Life Sciences in a related party deal

     The purchase closed October 6, 2026 for $2,000,000 in cash and 25,000,000 shares, and four directors have ties to the seller's group.

     HEPA
214. Oct 6, 2026Company Updates

     Global Innovative Platforms appoints David R. Wells as fractional chief financial officer

     Wells takes the role effective October 1, 2026 under a services agreement with Atlas Bookkeeping, LLC, and becomes the company's principal financial and accounting officer.

     GIPL
215. Oct 6, 2026Distress

     Caribou explores strategic alternatives and ends its allogeneic CAR-T programs

     The Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs.

     CRBU
216. Oct 6, 2026Company Updates

     Bluejay reports SYMON-II baseline patient characteristics

     The preliminary analysis covers 777 evaluable patients with an overall 28-day mortality rate of approximately 18%. The company says the baseline data do not yet establish the test's performance.

     BJDX
217. Oct 6, 2026Mergers

     BeyondSpring sells BeyondSpring Ltd. for trial data rights instead of cash

     BeyondSpring Inc. completed the sale of BeyondSpring Ltd. to Biolin Investment Limited on September 30, 2026. No cash changed hands. The company received a license to China trial data, a funding commitment from the buyer, and a clawback, and it gave up control of SEED Therapeutics.

     BYSI
218. Oct 6, 2026Mergers

     BeyondSpring completes sale of subsidiary holding China unit Bulin for non-cash consideration

     BeyondSpring closed the sale of the holding company for its China unit, Bulin, on September 30, 2026. The buyer paid no cash at closing. It took on the China portion of the DUBLIN-4 Phase 3 trial in exchange, and BeyondSpring will receive the clinical data from that work.

     BYSI
219. Oct 6, 2026Mergers

     Adia Med agrees to sell 30% of Adia Labs to QCM Biologics for $1,500,000

     The buyer, run by David Konn, pays $1,000,000 in cash and signs a $500,000 note at 7% interest, secured by a pledge of the units.

     ADIA
220. Oct 6, 2026Company Updates

     60 Degrees outlines next steps after its babesiosis hospital study interim analysis

     At an October 6, 2026 webinar, the company said 30 patients were enrolled in its hospital study and that it plans to complete the current dataset and move to unblinding.

     SXTP
221. Oct 5, 2026Financings

     SeaStar Medical collects about $3.3 million from warrant exercises

     Holders exercised older warrants at a reduced $3.866 per share and received new warrants. H.C. Wainwright & Co., LLC acted as exclusive placement agent, and the offering closed on October 5, 2026.

     ICU
222. Oct 5, 2026Financings

     Immunome pays Bristol-Myers Squibb $20.0 million and 4,425,487 shares to end royalties

     Immunome paid Bristol-Myers Squibb $20.0 million and 4,425,487 shares under Amendment No. 4, which ends its milestone and royalty obligations. The 8-K names no underwriter or placement agent; at June 30, 2026 the company held $217.7 million in cash and equivalents plus $302.3 million in short-term investments.

     IMNM
223. Oct 4, 2026Debt Financing

     Profusa amends Ascent Partners convertible note terms

     Ascent Partners Fund LLC is the holder and collateral agent. The exhibit sets a $0.338 floor, a 150% share reserve and waivers on three later notes, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.

     PFSA
224. Oct 4, 2026Company Updates

     Apimeds unit MindWave signs AssureChain deal with BlockAssure

     MindWave will build, run and host an insurance network for BlockAssure and receive development fees plus 20% of the AssureCoin supply.

     APUS
225. Oct 2, 2026Legal

     Tonix gets Paragraph IV patent notice from Dr. Reddy's on generic TONMYA application

     Dr. Reddy's told Tonix on October 1, 2026 that it filed an ANDA for a generic version of TONMYA 2.8 mg sublingual tablets and certified that four Orange Book patents are invalid, unenforceable or not infringed. No lawsuit has been filed, and Tonix says it intends to enforce its rights.

     TNXP
226. Oct 2, 2026Financings

     Surrozen IND clearance sets up expected $95.1 million second private placement closing

     FDA clearance of the SZN-8141 IND satisfies the second closing milestone in Surrozen's March 2025 private placement, which is expected to bring about $95.1 million gross on or about October 20, 2026. First patient dosing is not expected until the fourth quarter of 2026, with initial data in the second half of 2027.

     SRZN
227. Oct 2, 2026Financings

     Sunshine Biopharma files for $7,000,000 unit offering, later priced at $0.55 per unit

     A preliminary prospectus dated October 2, 2026 set out a best efforts offering of units with Series D warrants. The deal was later priced to raise about $6.0 million before fees.

     SBFM
228. Oct 2, 2026Company Updates

     Silo Pharma buys Norsight software assets for a warrant

     Silo Pharma agreed on October 1, 2026, to acquire software, technology and intellectual property from Norsight Consulting in exchange for a warrant to buy 300,000 shares.

     SILO
229. Oct 2, 2026Legal

     Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters

     Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit.

     LNTH
230. Oct 2, 2026Listings

     Daré Bioscience gets Nasdaq notice for stock below $1.00

     Daré Bioscience has until March 29, 2027 to show a $1.00 closing bid price for 10 consecutive business days. A second 180-day period is possible only if it meets the other listing standards and says it will cure the shortfall, by a reverse split if needed. Its cash fell to $12.6 million by June 30, 2026.

     DARE
231. Oct 2, 2026Listings

     BeyondSpring gets Nasdaq notice after market value falls below $35 million

     BeyondSpring Inc. received a Nasdaq letter on September 29, 2026 saying its market value of listed securities has been below $35 million for 30 consecutive business days. It has until March 29, 2027 to regain compliance, and its shares keep trading in the meantime.

     BYSI
232. Oct 2, 2026Company Updates

     Aibotics agrees to acquire Empulser for Series C preferred stock

     The October 2, 2026 exchange agreement would give Aibotics all membership interests in Empulser Enterprises LLC in return for Series C Preferred Stock with a stated value of up to $22,000,000.

     AIBT
233. Oct 1, 2026Mergers

     SpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million

     The cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan.

     SGP4536BLCO
234. Oct 1, 2026Company Updates

     Scientific Industries signs CFO agreement and extends two others

     Zachary Rovinsky signed an employment agreement as chief financial officer, and the agreements of Helena Santos and John A. Moore were extended through September 30, 2027.

     SCND
235. Oct 1, 2026Mergers

     Mangoceuticals unit MangoRx IP gets $2.5 million commitment, receives $1.75 million

     Two strategic investors paid the first $1.75 million tranche for a 17.5% interest in MangoRx IP, a former subsidiary of Mangoceuticals. The other $750,000, for 7.5%, is due by November 28, 2026, and the company's cash had fallen to $228,688 by June 30.

     MGRX
236. Oct 1, 2026Listings

     Lantern Pharma gets Nasdaq notice over $35,000,000 market value rule

     Lantern has until March 24, 2027 to restore the $35,000,000 market value minimum after a Nasdaq notice dated September 25, 2026. Its 2025 net loss was $17.1 million.

     LTRN
237. Oct 1, 2026Mergers

     ENDRA amends merger agreement with ASP Isotopes and Renergen

     The October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes.

     NDRA
238. Oct 1, 2026Company Updates

     Azitra advances ATR-04 trial to Cohort 2 after safety review

     The safety review committee recommended moving to Cohort 2 after reviewing safety data from Cohort 1. About 24 patients are expected to enroll in the second cohort.

     AZTR
239. Oct 1, 2026Company Updates

     Aethlon stockholders approve 200,000,000 authorized common shares

     At an October 1, 2026 virtual annual meeting, stockholders also approved 100,000 more shares for the equity plan and 20,000,000 authorized preferred shares.

     AEMD
240. Oct 1, 2026Financings

     Adagio Medical converts $776,111 of notes into 4,978,869 shares

     A holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing.

     ADGM

September 2026

1. Sep 30, 2026Debt Financing

   iTonic Holdings extends maturity of bank loan to March 2027

   Beijing Rural Commercial Bank is the lender. A director gave an unsecured personal guarantee for the loan without consideration, and the company held $779,367 in cash and cash equivalents at June 30, 2026.

   ITOC
2. Sep 30, 2026Company Updates

   Valion and SKL complete oral mucosal Entolimod formulation

   Valion and Shear Kershman Laboratories finished formulation work on a needle-free Entolimod, with systemic exposure testing next.

   VBIO
3. Sep 30, 2026Listings

   Tevogen regains compliance with Nasdaq Global Market listing rules

   Nasdaq confirmed on September 29, 2026 that Tevogen meets the $50 million minimum market value of listed securities rule. The company had $1.1 million of cash at June 30, 2026, after cash used in operations of $12.3 million in 2025.

   TVGN
4. Sep 30, 2026Listings

   SciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half

   SciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern.

   SPRC
5. Sep 30, 2026Company Updates

   Q32 Bio reports Week 36 SIGNAL-AA Part B results for bempikibart

   Bempikibart showed a 35.3% mean reduction in SALT score at Week 36 in alopecia areata. The company intends to start a registration-directed program in the first half of 2027.

   QTTB
6. Sep 30, 2026Debt Financing

   Positron issues three promissory notes at 20% interest, with warrants

   The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share.

   POSC
7. Sep 30, 2026Distress

   Petros Pharmaceuticals assigns all assets to creditors and halts operations

   Petros Pharmaceuticals assigned all of its assets to PT Liquidation, LLC for the benefit of creditors on September 30, 2026, and says it has ceased substantially all operations. The executive chairman and two directors resigned the same day, and the Series A preferred stock must be redeemed immediately.

   PTPI
8. Sep 30, 2026Company Updates

   OSR Health chief scientific officer resigns, effective immediately

   Dr. Constance Hoefer gave notice on September 30, 2026, and her resignation took effect at once, the company reported in an 8-K filed October 2.

   OSRH
9. Sep 30, 2026Listings

   Nasdaq files to remove Abpro Holdings stock and warrants from listing

   Nasdaq filed a Form 25 notice dated 2026-09-30 to strike Abpro Holdings' Class A Common Stock and warrants from listing. The company had already received a delisting notice effective February 23, 2026, and its shares trade on the OTC Pink Limited Market.

   ABPO
10. Sep 30, 2026Listings

    Nasdaq files removal notice as Nutriband public warrants expire

    Nutriband's public warrants expired on September 30 without extension or repricing. Nasdaq filed a Form 25 to remove them. The company said its common stock is not affected.

    NTRB
11. Sep 30, 2026Financings

    NOMAD issues a $6.57 million secured note with a 9% rate

    NOMAD Power Solutions agreed to a secured note with a $6.57 million principal amount, for $6.0 million in gross proceeds. The note matures 12 months after its purchase price date and carries a 9% interest rate.

    NMAD
12. Sep 30, 2026Financings

    Lantern Pharma closes registered direct offering with about $4.0 million in gross proceeds

    Lantern sold 1,469,725 shares at $1.09 each plus pre-funded warrants for up to 2,200,000 shares. A concurrent private placement of warrants for up to 3,669,725 shares needs stockholder approval before exercise.

    LTRN
13. Sep 30, 2026Listings

    Evogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027

    Nasdaq has given Evogene until March 29, 2027 to lift its ordinary shares back above $1.00. The company says it may consider a reverse split. In 2025 it used $13.5 million in operations, and year-end cash was $13.0 million.

    EVGN
14. Sep 30, 2026Listings

    Clearmind Medicine to effect 1-for-8 reverse share split, trading from October 5, 2026

    Issued common shares will fall from 4,059,227 to 507,404, subject to fractional-share adjustments.

    CMND
15. Sep 30, 2026Mergers

    Chemomab amends domestication merger terms ahead of Scipher Medicine deal

    A technical amendment sets a formula-based exchange ratio for a combined company of 10,000,000 shares. A later amendment cut that number to 5,000,000.

    CMMB
16. Sep 30, 2026Financings

    CalciMedica files to sell up to $25,000,000 of stock through at-the-market program

    CalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first.

    CALC
17. Sep 30, 2026Financings

    BioStem Technologies prices $3 million private placement at $4.08 per share

    BioStem Technologies has agreed to issue 735,296 shares at $4.08 each in a private placement, with Series A and Series B warrants for the same number of shares at $3.83. The company expects gross proceeds of about $3 million, and about $5.6 million more if all the warrants are exercised for cash.

    BSEM
18. Sep 30, 2026Company Updates

    Apimeds names Eric Sherb chief financial officer

    Erick Frim resigned as interim chief financial officer on September 29, 2026, and the board appointed Eric Sherb effective October 1, 2026, at a base salary of $60,000 a year.

    APUS
19. Sep 30, 2026Company Updates

    AEON says FDA feedback may support a streamlined ABP-450 development path

    AEON Biopharma received official minutes from a Type 2b meeting with the FDA on its BOTOX biosimilar. It plans to file an IND for a comparative pharmacodynamic study in the fourth quarter of 2026.

    AEON
20. Sep 29, 2026Financings

    Pyxis Oncology prices $109,998,133 stock and warrant offering at $2.90

    Pyxis Oncology is selling 36,047,919 shares at $2.900 and pre-funded warrants, with common warrants at $3.50 that cannot be exercised until stockholders approve more authorized shares. Its auditor's report on the 2025 financial statements carries a going-concern warning.

    PYXS
21. Sep 29, 2026Company Updates

    Pelthos stockholders approve 2026 equity plan and elect eight directors

    The plan replaces the 2023 Equity Incentive Plan, as amended and restated, and took effect on approval at the September 29, 2026 annual meeting. Grant Thornton LLP was ratified as auditor for 2026.

    PTHS
22. Sep 29, 2026Debt Financing

    Odyssey Health extends two note maturities to January 2027

    Two notes held by LGH Investments, LLC and Peter J. D'Arruda now mature on January 31, 2027. All other terms stay the same, the filing says.

    ODYY
23. Sep 29, 2026Company Updates

    Moleculin completes enrollment in Part A of its MIRACLE trial

    The company reports 89 subjects enrolled, with two more in screening, and says it remains on track for a Part A readout in the first quarter of 2027.

    MBRX
24. Sep 29, 2026Distress

    Lunai Bioworks delays annual report, expects net loss of about $3.2 million

    The company, formerly Renovaro Inc., expects to file its Form 10-K for the year ended June 30, 2026 within the 15-day grace period. Its net loss for the prior year was about $178.0 million.

    LNAI
25. Sep 29, 2026Listings

    Liminatus Pharma regains Nasdaq compliance after 1-for-50 reverse split

    Nasdaq told the company on September 24, 2026 that its shares had closed above $1.00 for 13 straight trading days, closing the matter.

    LIMN
26. Sep 29, 2026Mergers

    Lexeo completes Mantle Therapeutics deal for $5,300,000 cash plus $3,000,000 in stock

    Lexeo paid $5,300,000 in cash and $3,000,000 in common stock upfront. Up to $12,000,000 in milestones and a $1,000,000 cash payment are not guaranteed.

    LXEO
27. Sep 29, 2026Listings

    Lakewood-Amedex holders approve share increase and reverse split authority

    Stockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty.

    LABT
28. Sep 29, 2026Financings

    Imunon agrees to swap $1,200,000 of Streeterville note for Series B preferred

    Imunon will exchange $1,200,000 of a Streeterville note for 120 Series B preferred shares that cannot convert into common stock but carry an 8% return. Cash and cash equivalents were $6.9 million at June 30, 2026.

    IMNN
29. Sep 29, 2026Financings

    Immix Biopharma prices $125 million stock offering at $11.00 a share

    The company is selling 11,363,637 shares through J.P. Morgan. Proceeds will fund development of its CAR-T candidate NXC-201.

    IMMX
30. Sep 29, 2026Financings

    Cuprina closes over-allotment of 648,373 shares at $1.15, raising offering to about $5,716,491

    Cuprina closed the sale of 648,373 more Class A shares at $1.15 after the underwriter exercised its over-allotment option in full. Total gross proceeds reached about $5,716,491, and R. F. Lafferty & Co., Inc. was the sole book-running manager.

    CUPR
31. Sep 29, 2026Financings

    BeyondSpring sets up at-the-market program for up to $11,942,800 in shares

    BeyondSpring has set up an at-the-market program through Citizens for up to 9,200,000 ordinary shares, capped at $11,942,800 by its public float limit. The prospectus supplement is dated September 29, 2026, and the same day the company agreed to sell its Chinese subsidiary to Biolin Investment Limited.

    BYSI
32. Sep 29, 2026Company Updates

    Alzamend Neuro presents lithium brain imaging results from phase 1/2a trial

    Slides filed with the SEC say the differences between AL001 and lithium carbonate were not statistically significant in the healthy cohort.

    ALZN
33. Sep 28, 2026Distress

    Zeo ScientifiX says it cannot file its eight-month transition report on time

    The Form 10-KT covers the eight months ended June 30, 2026. The company expects to file within the 15-day grace period.

    ZEOX
34. Sep 28, 2026Legal

    Unicycive discloses another securities class action over its OLC application

    Unicycive disclosed in an 8-K dated September 28, 2026 that a second securities class action was filed on September 3, 2026 against the company and certain of its officers over its oxylanthanum carbonate application. An earlier class action and two derivative suits are pending in the same federal court.

    UNCY
35. Sep 28, 2026Debt Financing

    TELA Bio gets lender consent to pause revenue covenant test

    The consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent.

    TELA
36. Sep 28, 2026Financings

    Silexion cuts warrant price to $0.2603 to raise about $0.84 million

    Holders exercising 3,216,928 existing warrants receive 6,433,856 new warrants that cannot be used until shareholders approve more authorized shares.

    SLXN
37. Sep 28, 2026Listings

    Polyrizon reports $8,410 thousand in cash at June 30, 2026

    Polyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months.

    PLRZ
38. Sep 28, 2026Mergers

    Lifecore Biomedical agrees to $6.28 a share cash sale to Webster Equity Partners

    The deal is valued at up to $663.7 million if performance milestones are met. Contingent value rights could lift total payout to $9.67 per share.

    LFCR
39. Sep 28, 2026Financings

    Jaguar Health issues 481,584 shares to cut Streeterville note by $3,400,000

    Jaguar issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 cut to a note first sold in 2021. The company reported about 1,945,542 shares outstanding as of September 25, 2026.

    JAGX
40. Sep 28, 2026Listings

    Gossamer Bio regains Nasdaq minimum bid price compliance

    Nasdaq closed the bid price matter on September 25, 2026, after an April notice. The 1-for-80 reverse split took effect on September 10, 2026, and the 2025 net loss was $170.4 million.

    GOSS
41. Sep 28, 2026Debt Financing

    Glucotrack amends terms of senior secured convertible note

    The amendment makes the floor price a hard limit and requires any make-whole payment to be made in cash. Glucotrack had $1.1 million in cash and cash equivalents at June 30, 2026.

    GCTK
42. Sep 28, 2026Debt Financing

    Celularity sells $11.01 million of secured convertible notes in deal of up to $25.0 million

    Celularity sold about $11.01 million of notes that convert at $1.50 a share, with warrants for about 4,037,000 shares. A second tranche of up to $10.0 million is available at the buyers' election through September 30, 2027.

    CELU
43. Sep 28, 2026Distress

    Advanced Biomed files late notice for annual report as audit is not complete

    Advanced Biomed told the SEC it could not file its annual report for the year ended June 30, 2026 on time because the audit was not finished. The notice does not name the auditor or explain the delay beyond that.

    ADVB
44. Sep 28, 2026Financings

    ADARx Pharmaceuticals closes IPO of 26,250,000 shares at $17.00 each

    ADARx Pharmaceuticals sold 26,250,000 shares at $17.00 in its IPO for about $446.3 million gross, and AbbVie bought 5,255,542 shares in a concurrent private placement worth about $89.3 million. The company had net losses of $46.4 million in 2024 and $73.1 million in 2025.

    ADRX
45. Sep 25, 2026Listings

    Silexion adds bid-price deficiency to pending Nasdaq panel review

    A Nasdaq hearings panel is already weighing a delisting over low shareholders' equity. The closing bid price has been below $1.00 for 30 consecutive business days.

    SLXN
46. Sep 25, 2026Listings

    Outlook Therapeutics gets a Nasdaq bid-price notice weeks after its drug's approval

    Nasdaq says OTLK closed under $1.00 for 30 straight business days. The company has until March 24, 2027 to cure, and its latest 10-Q carried a going-concern warning.

    OTLK
47. Sep 25, 2026Listings

    Matinas Biopharma effects one-for-fifteen reverse stock split

    The reverse split of Matinas BioPharma Holdings took effect at 12:01 a.m. Eastern Time on September 28, 2026. Every 15 shares of common stock became one share.

    MTNB
48. Sep 25, 2026Legal

    Jury awards Nektar $90 million in Lilly contract case; securities class action pending

    A federal jury found that Eli Lilly breached the implied covenant of good faith in a rezpegaldesleukin license with Nektar and awarded $90 million, according to an 8-K filed September 25, 2026. Nektar is also a defendant in a securities class action, Schramke v. Nektar Therapeutics, filed in March 2026.

    NKTR
49. Sep 25, 2026Listings

    Calidi Biotherapeutics receives NYSE American equity deficiency notice

    The notice, received September 21, 2026, says Calidi does not meet the exchange's stockholders' equity standard. The company must submit a compliance plan by October 21, 2026.

    CLDI
50. Sep 25, 2026Listings

    CDT Equity to do 1-for-25 reverse stock split on Nasdaq

    The split takes effect September 28, 2026, to keep the company in compliance with the Nasdaq bid-price rule, and trading on the split-adjusted basis starts September 29.

    CDT
51. Sep 25, 2026Distress

    America Great Health says it cannot file its annual report by September 30, 2026

    The company filed a late-filing notice for the year ended June 30, 2026. It says it has not been able to compile the financial data for its Form 10-K.

    AAGH
52. Sep 24, 2026Financings

    Viking raises $575 million in stock and convertible notes after maintenance data

    Viking sold shares at $35 and 2% notes due 2032 that convert at about $50.75. Both deals were upsized from $200 million each, and full exercise of the underwriters' options lifted gross proceeds to $575 million.

    VKTX
53. Sep 24, 2026Financings

    Nanobiotix reports €110.9 million cash after ~€86 million follow-on, runway into 2029

    The company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain.

    NANO
54. Sep 24, 2026Listings

    BGM Group announces 30-for-1 share consolidation, trading from October 1, 2026

    Class A shares outstanding will fall from 380,623,358 to 12,687,445 when the 30-for-1 consolidation takes effect on October 1, 2026. Shareholders approved it on September 5, 2026, and authorised share capital rises to US$15,090,000.

    BGM
55. Sep 24, 2026Company Updates

    Aptevo advances trispecific candidates toward scalable manufacturing

    Aptevo is optimizing several trispecific candidates for scalable manufacturing and expects IND-enabling studies for its lead candidate, APVO451, in the first half of 2027.

    APVO
56. Sep 23, 2026Mergers

    Zymeworks completes Theravance Biopharma acquisition, with $350 million in senior secured notes

    Zymeworks subsidiaries sold $350,000,000 of 8.25% senior secured notes due December 31, 2036 to an OMERS Private Capital affiliate, and former Theravance holders received contingent value rights that the filing calls highly speculative.

    ZYME
57. Sep 23, 2026Listings

    Xenetic files investor presentation on proposed transaction with Santersus

    The September 2026 deck's risk list includes a possible reverse stock split to meet Nasdaq listing requirements.

    XBIO
58. Sep 23, 2026Debt Financing

    Viking Therapeutics sells $225,000,000 of 2.00% convertible notes due 2032

    Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are the underwriters' representatives. The initial conversion price is about $50.75 a share, and the company sold 7,857,143 common shares at $35.00 in a separate offering the same day.

    VKTX
59. Sep 23, 2026Company Updates

    Valion names Dean Zikria interim CEO and changes board chair

    Board member Dean Zikria becomes interim chief executive officer, Thomas Jensen takes the board chair, and Lisa Wolf keeps her roles.

    VBIO
60. Sep 23, 2026Legal

    Sarepta faces securities class action and five derivative suits over Elevidys disclosures

    The class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026.

    SRPT
61. Sep 23, 2026Debt Financing

    QuidelOrtho amends credit agreement and resets covenant levels to 2029

    Bank of America, N.A. is administrative agent. The leverage and interest coverage tests now reset through the quarter ending September 30, 2029, and QuidelOrtho's cash and cash equivalents were $123.4 million at June 28, 2026.

    QDEL
62. Sep 23, 2026Debt Financing

    PROCEPT BioRobotics amends Canadian Imperial Bank term loan maturity

    The amendment extends the term loan maturity by one year, to the 72nd payment date after closing. PROCEPT BioRobotics paid a $26,000.00 extension fee.

    PRCT
63. Sep 23, 2026Financings

    Moleculin sells 888,400 shares through at-the-market program in September

    The sales raised $0.48 million, and anti-dilution terms cut the exercise price of the August 2026 Series I Warrants to $0.51.

    MBRX
64. Sep 23, 2026Financings

    MapLight resale registration for 13.2 million private-placement shares takes effect

    MapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales.

    MPLT
65. Sep 23, 2026Debt Financing

    Jazz Pharmaceuticals extends term loan to 2033, adds $273,310,355.18

    Bank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier.

    JAZZ
66. Sep 23, 2026Debt Financing

    IQVIA issues $2,000,000,000 of 6.375% senior notes due 2034

    The notes are governed by an indenture dated September 23, 2026, with U.S. Bank Trust Company, National Association, as trustee.

    IQV
67. Sep 23, 2026Mergers

    Glucotrack CEO outlines Lokahi priorities for LT-100 and the ai² platform

    In a strategic update dated September 23, 2026, Glucotrack and Lokahi Therapeutics said LT-100 is the immediate priority, with a clinical protocol submitted for regulatory review.

    GCTK
68. Sep 23, 2026Company Updates

    Evofem adds a second manufacturer for PHEXX

    Subject to regulatory approval, the new source is expected to reduce unit costs by 40% or more. Evofem expects to submit a supplemental NDA in mid-2027.

    EVFM
69. Sep 23, 2026Debt Financing

    Bayer places 2 billion euros of hybrid bonds

    Two tranches, with non-call periods of six and nine years, raise 2 billion euros for general corporate purposes.

    BAYN
70. Sep 23, 2026Distress

    Adagio Medical starts strategic review and cuts workforce

    The board opened a formal process to explore alternatives that may include an acquisition, merger or other transaction, and the company has set no timetable.

    ADGM
71. Sep 22, 2026Financings

    LeonaBio Series A warrants become exercisable at $6.35 a share

    LeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised.

    LONA
72. Sep 22, 2026Debt Financing

    Halozyme Therapeutics sells $1,500.0 million of 1.50% convertible notes

    The Bank of New York Mellon Trust Company, N.A. is trustee. The company used $187.5 million of the net proceeds on capped calls and expects to buy back older convertible notes, and its cash and cash equivalents were $163.1 million at June 30, 2026.

    HALO
73. Sep 22, 2026Company Updates

    FDA grants fast track designation for QRX003 in peeling skin syndrome

    The designation is the second Fast Track for QRX003, after Netherton Syndrome in March 2026. It follows an IND that the FDA cleared in July 2026.

    QNRX
74. Sep 22, 2026Financings

    Enlivex terminates private placement of 66,666,667 shares payable in RAIN tokens

    The agreement with the Rain Foundation was subject to shareholder approval. The company says it will not complete the placement or seek that approval.

    ENLV
75. Sep 22, 2026Legal

    Aytu BioPharma's Adzenys patent suit against Granules heads to a January 2027 trial

    Aytu (Nasdaq: AYTU) is the plaintiff against Granules Pharmaceuticals in Delaware, with trial moved to January 12, 2027. It is also a nominal plaintiff in a Section 16(b) suit against Armistice, now on appeal.

    AYTU
76. Sep 21, 2026Debt Financing

    TuHURA Biosciences draws another $650,000 on Parkview credit line

    Parkview Holdings One LLC is the lender. The $650,000 draw is small against $27.6 million of cash used in operations in 2025, and TuHURA reported $995,977 in cash and cash equivalents at June 30, 2026.

    HURA
77. Sep 21, 2026Listings

    Scinai Immunotherapeutics regains Nasdaq bid price compliance

    Nasdaq's September 18, 2026 letter says the ADSs closed at $1.00 or more for 19 consecutive business days. The matter is closed.

    SCNI
78. Sep 21, 2026Company Updates

    PTC completes acquisition of ST-920 Fabry gene therapy from Sangamo

    PTC says the rolling BLA for ST-920 is expected to be completed in the fourth quarter of 2026, with the goal of accelerated approval.

    PTCT
79. Sep 21, 2026Listings

    Jaguar Health completes 1-for-15 reverse split and removes old preferred series

    The company effected the reverse split on September 17, 2026, and filed a certificate removing the terms of fourteen older preferred stock series from its charter, leaving about 520,088 common shares outstanding.

    JAGX
80. Sep 21, 2026Debt Financing

    Insulet amends credit agreement, refinancing $475 million in term loans

    Morgan Stanley Senior Funding, Inc. is administrative agent. The margin on the refinanced term loans falls 0.25%, and cash and cash equivalents were $534.9 million at June 30, 2026, down from $716.1 million at the end of 2025.

    PODD
81. Sep 21, 2026Financings

    Iambic Therapeutics files for IPO, plans Nasdaq listing as IAM

    Iambic Therapeutics, Inc. filed a Form S-1 on September 21, 2026. The cover leaves the share count and price range blank.

    IAM
82. Sep 21, 2026Legal

    AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro

    AnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24.

    ANAB
83. Sep 18, 2026Distress

    Xenon pauses depression trial enrollment after psychosis reports, shares drop

    The company stopped enrolling in its phase 3 MDD and bipolar studies of azetukalner. Fierce Biotech reported the shares fell 26% pre-market the next day.

    XENE
84. Sep 18, 2026Company Updates

    Trafalgar International names Carlos Septién chief executive officer

    Porfirio Sanchez Talavera resigned as chief executive officer on September 18, 2026, and Carlos Septién, previously chief operating officer, took the post.

    GCAND
85. Sep 18, 2026Financings

    TRex Bio files for IPO as Eli Lilly signals interest in buying shares

    TRex Bio filed for a Nasdaq IPO on September 18, 2026. Eli Lilly, which signed a research collaboration with the company in 2023, has indicated interest in buying shares, but the indication is not binding and the price range and share count are still blank.

    TRXB
86. Sep 18, 2026Financings

    Retension Pharmaceuticals files for IPO, seeks Nasdaq listing as RTSN

    Retension Pharmaceuticals, a Falls Church, Virginia developer of a hypertension drug, filed a Form S-1 on September 18, 2026. The preliminary prospectus leaves the share count and price blank, and its 2025 financial statements have been restated.

    RTSN
87. Sep 18, 2026Financings

    Nasus Pharma sets up at-the-market program with BTIG for up to $8,500,000 of shares

    Nasus Pharma can sell up to $8,500,000 of shares through BTIG but is not obliged to. Its June 30, 2026 balance sheet held $11,904 thousand in cash, restricted cash and short-term deposits, and its prospectus supplement lists substantial doubt about going concern among its risks.

    NSRX
88. Sep 18, 2026Listings

    Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request

    Nasdaq staff says Moleculin is not eligible for a compliance period because it effected a 1-for-25 reverse stock split on December 1, 2025. The company plans to request a hearing, which stays any delisting action while it is pending.

    MBRX
89. Sep 18, 2026Listings

    InMed receives Nasdaq notice on minimum shareholders' equity

    Shareholders' equity of $1,075,007 in the 10-K for the year ended June 30, 2026 fell below the $2,500,000 Nasdaq minimum. The company has 45 calendar days to submit a plan.

    INM
90. Sep 18, 2026Listings

    Filana Therapeutics gets Nasdaq bid price notice, has until March 16, 2027

    Nasdaq gives Filana until March 16, 2027 to regain compliance. Cash and equivalents fell to $86.6 million at March 31, 2026, from $128.6 million at the end of 2024.

    FLNA
91. Sep 18, 2026Debt Financing

    Endovia closes $510,000 secured convertible note from C/M Capital

    C/M Capital Master Fund, LP is the investor. The $510,000 note converts at the lower of $1.75 and $0.01 above the closing price, and the company had $242,702 in cash and cash equivalents at June 30, 2026.

    EDVA
92. Sep 18, 2026Financings

    Electra Therapeutics prices IPO of 23,333,334 shares at $15.00, about $350 million

    Electra Therapeutics sold 23,333,334 shares at $15.00 in its initial public offering. The final prospectus repeats the auditor's going concern paragraph from the registration statement.

    ETRA
93. Sep 18, 2026Financings

    BioStem Technologies signs committed equity facility to sell up to $40,000,000 of stock to Roth

    BioStem (Nasdaq: BSEM) may sell shares to Roth Principal Investments over up to 36 months at a 3.0% or 5.0% discount to average price. The company pays a $400,000 cash commitment fee.

    BSEM
94. Sep 18, 2026Listings

    BeyondSpring gets Nasdaq minimum bid price notice, has until March 16, 2027

    Nasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180 calendar day compliance period that ends March 16, 2027.

    BYSI
95. Sep 18, 2026Financings

    Alaunos sells $1,120,000 of stock and warrants in registered direct offering

    Dawson James Securities is sole placement agent for the offering, priced at $1.46 per share under Nasdaq at-the-market rules.

    TCRT
96. Sep 17, 2026Listings

    Soligenix stockholders approve reverse split authority and share increase

    At its September 17, 2026 annual meeting, stockholders approved a reverse split at a ratio of 1-for-2 to 1-for-20 and raised authorized common shares from 75,000,000 to 125,000,000.

    SNGX
97. Sep 17, 2026Debt Financing

    Quantum BioPharma closes fourth debenture tranche of $100,000, cancels director warrants

    A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures.

    QNTM
98. Sep 17, 2026Listings

    Nasdaq to delist Aditxt common stock after June suspension

    The Nasdaq Stock Market said on September 17, 2026 that it will delist the common stock of Aditxt, Inc. The stock was suspended on June 25, 2026 and has not traded on Nasdaq since then.

    ADTX
99. Sep 17, 2026Mergers

    Impact BioMedical reports Zoar F-4 filing in business combination

    Zoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited.

    IBOPRPH
100. Sep 17, 2026Financings

     Halozyme prices upsized $1.3 billion convertible offering and retires older notes

     The 1.50% notes due 2033 convert at about $139.84 a share, a 27.5% premium to the Sept. 17 close. Part of the proceeds repurchases 2027 and 2028 notes and pays for capped calls.

     HALO
101. Sep 17, 2026Legal

     Aquestive faces securities class action and derivative suit over Anaphylm NDA statements

     Modica v. Aquestive names the company and chief executive Daniel Barber in New Jersey federal court. A derivative suit, Wilson v. Brown, is stayed behind it.

     AQST
102. Sep 17, 2026Mergers

     Aethlon to merge with North Immunology in an all-stock deal

     The deal comes with an oversubscribed $180 million private placement. Aethlon holders are expected to own about 4.75% of the combined company at closing, expected in the first quarter of 2027.

     AEMD
103. Sep 17, 2026Company Updates

     Adial stockholders approve equity plans and a larger share authorization

     Stockholders approved a 2017 plan amendment, a 2026 equity plan, a 2026 employee stock purchase plan and an increase in authorized shares to 500,000,000 at the September 17, 2026 meeting.

     ADIL
104. Sep 16, 2026Financings

     Xenetic Biosciences agrees to acquire Santersus AG in all-stock share exchange

     The deal needs Xenetic stockholder approval. Pro forma, current Xenetic holders would own approximately 15.0% and Santersus holders approximately 85.0%.

     XBIO
105. Sep 16, 2026Debt Financing

     Profusa sells senior secured convertible note to Ascent Partners Fund

     Ascent Partners Fund LLC bought the note as initial purchaser and also acts as collateral agent. The $384,615.38 note was sold for $350,000, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.

     PFSA
106. Sep 16, 2026Listings

     Pasithea warrants to expire on September 17, 2026

     Pasithea Therapeutics said its KTTAW warrants will expire on September 17, 2026 and stop trading on Nasdaq, while its common stock keeps trading as KTTA.

     KTTA
107. Sep 16, 2026Listings

     Matinas BioPharma sets one-for-fifteen reverse stock split

     The board approved a one-for-fifteen reverse split of the common stock, effective 12:01 a.m. Eastern Time on September 28, 2026, under the existing MTNB symbol.

     MTNB
108. Sep 16, 2026Debt Financing

     Halozyme plans $1.05 billion convertible notes offering

     Halozyme intends to offer $1.05 billion of convertible senior notes due 2033, with a 13-day option for up to $150 million more. Rate and conversion terms will be set at pricing, and the release names no bank.

     HALO
109. Sep 16, 2026Company Updates

     Co-Diagnostics and ReadyGo to evaluate blood testing for Ebola

     The companies will test whether ReadyGo's sample-preparation technology can work with the Co-Dx PCR platform on blood samples. Compatibility has not yet been established.

     CODX
110. Sep 16, 2026Listings

     Bone Biologics gets Nasdaq minimum bid price notice, has until March 9, 2027

     Nasdaq says the closing bid has been below $1 for 30 consecutive business days. The company completed a 1-for-6 reverse split in June 2025 and plans to seek approval for another at its next annual meeting.

     BBLG
111. Sep 16, 2026Company Updates

     Alaunos lowers stockholder meeting quorum to one-third of voting power

     The board adopted Second Amended and Restated By-Laws on September 16, 2026, effective immediately.

     TCRT
112. Sep 15, 2026Financings

     Tyra Biosciences prices $400 million offering of shares and pre-funded warrants at $22.03

     Tyra Biosciences priced 9,079,000 common shares and pre-funded warrants for 9,078,529 more, expecting about $400.0 million gross at $22.03 a share. The company had $73.8 million of cash at June 30, 2026, and a 2025 net loss of $119.9 million.

     TYRA
113. Sep 15, 2026Financings

     Jaguar Health swaps note and preferred shares for common stock

     Jaguar Health exchanged a convertible note and Series Q preferred shares for common stock in September 2026, and issued 535,000 common shares plus a pre-funded warrant to acquire the Napo Therapeutics shares of a minority holder.

     JAGX
114. Sep 15, 2026Legal

     Beta Bionics discloses securities class action filed September 4, 2026 over iLet statements

     A purported stockholder sued Beta Bionics and certain executive officers in federal court in California, alleging misstatements about iLet. The company says it intends to defend and that any loss is not currently probable or estimable.

     BBNX
115. Sep 14, 2026Debt Financing

     TuHURA Biosciences makes $650,000 draw on Parkview credit line

     TuHURA reported the draw in an 8-K dated September 17, 2026. Parkview Holdings One LLC is the lender, and cash and cash equivalents were $995,977 at June 30, 2026.

     HURA
116. Sep 14, 2026Distress

     Sionna Therapeutics cuts about 46% of workforce, sees cash into second half of 2029

     Sionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial.

     SION
117. Sep 14, 2026Company Updates

     Q32 Bio appoints José Trevejo as chief medical officer and Ellie Hershberger as chief development officer

     Both hires come as Q32 Bio prepares a registration-directed program for bempikibart in alopecia areata. The company plans to start it in the first half of 2027.

     QTTB
118. Sep 14, 2026Company Updates

     Phio reports PH-762 FDA submission and planned Phase 2b study

     Phio Pharmaceuticals said on September 14, 2026 that it reached a development milestone for PH-762, including the submission of materials to the FDA and a planned Phase 2b neoadjuvant study.

     PHIO
119. Sep 14, 2026Company Updates

     Onconetix provides $2.5 million bridge advance to Realbotix before acquisition

     The bridge facility provides up to $5,000,000 to Realbotix LLC, the target of a pending all-stock share exchange, with an initial advance of $2,500,000.

     ONCO
120. Sep 14, 2026Debt Financing

     MindWalk signs binding $30 million credit facility term sheet

     MindWalk Holdings signed a binding term sheet with Sanabil (Cayman) for a revolving credit facility of up to $30 million at a fixed 7.00% annual rate. The definitive agreement is not yet signed.

     HYFT
121. Sep 14, 2026Company Updates

     Glucotrack director resigns, citing possible conflict over merger terms

     Director Paul V. Goode resigned effective immediately after notifying the board on September 14, 2026, saying the merger agreement with Lokahi Therapeutics, Inc. could create a conflict of interest between the company and its subsidiary.

     GCTK
122. Sep 14, 2026Legal

     Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences

     Cardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit.

     CRDF
123. Sep 14, 2026Debt Financing

     CDT Equity issues $2,126,250 secured convertible note to J.J. Astor & Co.

     The note matures March 1, 2027 and is payable in 24 weekly installments of $88,593.75. The lender can convert at the greater of 70% of the lowest volume-weighted average price or a $0.05 floor.

     CDT
124. Sep 14, 2026Company Updates

     Biofrontera gets FDA approval for Ameluz in superficial basal cell carcinoma

     The company says Ameluz with the RhodoLED lamp is the first and only photodynamic therapy approved in the United States to treat a skin cancer. It plans a launch from late fourth quarter 2026 through first quarter 2027.

     BFRI
125. Sep 14, 2026Financings

     Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback

     All TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations.

     ASNDNOVO B
126. Sep 12, 2026Company Updates

     60 Degrees seeks FDA priority voucher for tafenoquine in babesiosis

     A September 12, 2026 submission asks FDA for a Commissioner's National Priority Voucher for an efficacy supplement to ARAKODA in babesiosis.

     SXTP
127. Sep 11, 2026Financings

     Tenon Medical announces warrant inducement for $2,872,338.58 gross

     Holders exercised 572,179 existing warrants for cash and received new warrants for 858,269 shares at $5.02 per share. WallachBeth Capital acted as financial advisor, and the closing was expected on or about September 14, 2026.

     TNON
128. Sep 11, 2026Financings

     Regentis reports $9.0 million cash after $6.5 million June private placement

     Regentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026.

     RGNT
129. Sep 11, 2026Debt Financing

     Glucotrack issues secured convertible notes and warrants in private placement

     The nine-month notes carry 8% interest and a 22% original issue discount, with Dawson James Securities, Inc. as placement agent and an exchange cap of 19.99%.

     GCTK
130. Sep 11, 2026Financings

     BioVie enters sales agreement for up to $6,464,341 of common stock

     BioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commission on gross proceeds.

     BIVI
131. Sep 11, 2026Legal

     Acadia derivative settlement gets preliminary approval as securities class action stays pending

     Nine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers.

     ACAD
132. Sep 10, 2026Mergers

     Tarsus Pharmaceuticals completes Alkeus acquisition with $270,000,000 in cash up front

     Tarsus paid $270,000,000 in cash and issued 2,908,692 shares at closing. Up to $350,000,000 in milestones and tiered revenue sharing on gildeuretinol sales remain to be paid.

     TARS
133. Sep 10, 2026Debt Financing

     Karyopharm gets forbearance after missed loan and note payments

     Lenders and noteholders agreed to forbear from enforcing remedies for a limited period. The forbearance period is set to end October 15, 2026 unless extended, and can end sooner on several triggers.

     KPTI
134. Sep 10, 2026Debt Financing

     Cerenome gets up to $20 million royalty-based facility from 3i, LP

     Cerenome, Inc. received initial funding under a senior secured facility of up to $20 million from 3i, LP, with royalty-based repayments. The company says its cash runway now reaches well into 2028.

     CNSY
135. Sep 10, 2026Company Updates

     Apimeds Pharmaceuticals adds Sungjoon Chae to board

     The appointment on September 10, 2026 followed a First Amendment to a settlement agreement that sets the board's interim makeup. Chae has been Co-Chief Executive Officer since May 4, 2026.

     APUS
136. Sep 9, 2026Debt Financing

     Tenon Medical repays convertible notes ahead of September 11 maturity

     Tenon repaid in full original issue discount senior convertible promissory notes with an aggregate principal balance of approximately $5.16 million, issued March 11, 2026. The release names no noteholder or agent.

     TNON
137. Sep 9, 2026Company Updates

     Rallybio CFO Jonathan Lieber moves to part-time employment

     Rallybio said Jonathan Lieber will move to part-time employment on September 15, 2026 and remain Chief Financial Officer. His employment ends at the closing of the pending Avenzo Therapeutics merger.

     RLYB
138. Sep 9, 2026Company Updates

     MetaVia reports DA-1726 tissue distribution data in preclinical study

     A preclinical study found DA-1726-derived radioactivity concentrated in adipose tissue and retained over time, which MetaVia says supports the waist circumference reduction seen in clinical studies.

     MTVA
139. Sep 9, 2026Financings

     Lexaria agrees to warrant inducement for approximately $5.9 million in gross proceeds

     Lexaria Bioscience cut the exercise price on 453,969 existing warrants to $12.92 a share, for about $5.9 million in gross proceeds. In return it issued two new warrant series, each for the same number of shares, at $12.67.

     LEXX
140. Sep 9, 2026Financings

     Lexaria agrees to warrant exercise at reduced $12.92 price, about $5.9 million

     The warrants will be exercised at $12.92 per share for gross proceeds of about $5.9 million, with H.C. Wainwright & Co. as exclusive placement agent. Holders receive new Series A and Series B warrants at $12.67.

     LEXX
141. Sep 9, 2026Company Updates

     Cocrystal doses last subject in CDI-988 norovirus challenge study

     Cocrystal Pharma said on September 9, 2026 that it dosed the last subject in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected in late 2026 or early 2027.

     COCP
142. Sep 8, 2026Listings

     iSpecimen gets until November 25, 2026 to meet Nasdaq equity rule

     The company plans a public offering of approximately $5 million, and its projections show stockholders' equity of approximately $5.1 million through June 30, 2027.

     ISPC
143. Sep 8, 2026Company Updates

     StimCell hires Stonegate Capital Markets as non-exclusive advisor

     The advisor will introduce investors and strategic partners for transactions the company approves, under an agreement effective August 24, 2026.

     STME
144. Sep 8, 2026Financings

     Protagonist authorizes $300 million share buyback after two drug approvals

     The peptide drug developer will fund repurchases from cash and royalty income. It held $849.5 million at June 30, before $275 million in Takeda payments due in the fourth quarter.

     PTGX
145. Sep 8, 2026Company Updates

     Lifeward investor deck lays out pipeline, reimbursement and Oramed platform

     A September 2026 investor presentation filed as Exhibit 99.1 sets out the company's product timeline, its Oramed-linked oral delivery program and its reported cash and revenue.

     LFWD
146. Sep 8, 2026Company Updates

     Kiora appoints Keith Lane as executive vice president of clinical development

     Kiora named Keith J. Lane, previously Chief Scientific Officer at Ora, Inc., to lead clinical development and regulatory affairs. The appointment supports the KIO-301 retinitis pigmentosa program.

     KPRX
147. Sep 8, 2026Financings

     Keros Therapeutics authorizes $5 million share buyback after $20 million Takeda milestone

     The board approved the program after Keros received a development milestone payment under its elritercept license with Takeda. The program does not oblige Keros to buy any shares.

     KROS
148. Sep 8, 2026Company Updates

     GRI Bio presents new Phase 2a data on GRI-0621 in IPF

     GRI Bio said new whole-blood, serum and flow cytometry data from its 35-patient Phase 2a study support nine mechanistic pillars for GRI-0621 in idiopathic pulmonary fibrosis.

     GRI
149. Sep 8, 2026Company Updates

     FDA grants rare pediatric disease designation for QRX003 in peeling skin syndrome

     The designation is the second Rare Pediatric Disease Designation for QRX003. Quoin said an approved application could qualify it for a priority review voucher.

     QNRX
150. Sep 8, 2026Distress

     Evommune drops EVO756 in atopic dermatitis after phase 2b misses all endpoints

     The 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans.

     EVMN
151. Sep 8, 2026Listings

     Can-Fite details 1-for-3,000 reverse split and ADS ratio change in 6-K

     A September 2026 report sets out a 1-for-3,000 reverse split of Can-Fite's ordinary shares in January 2026, and a change that cut each ADS from 300 ordinary shares to two. The company also lists the risk of failing NYSE American continued listing standards.

     CANF
152. Sep 8, 2026Company Updates

     Bluejay signs federal distribution partnership with Lovell Government Services

     Lovell will be Bluejay's exclusive distributor for federal procurement opportunities that favor veteran-owned small businesses, once its products receive FDA clearance or other required authorization.

     BJDX
153. Sep 8, 2026Financings

     60 Degrees presents its July financing and cash runway to investors

     A September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early October 2026.

     SXTP
154. Sep 4, 2026Listings

     iSpecimen agrees to buy Foldlab AI software assets for $4,500,000

     The deal pays $2,000,000 in cash, including milestone payments, and $2,500,000 in stock held in a five-year escrow.

     ISPC
155. Sep 4, 2026Listings

     XORTX Therapeutics files $2,500,000 paid promotion agreement with IR Agency

     The consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are promotional.

     XRTX
156. Sep 4, 2026Listings

     Quince Therapeutics (now IRulya Therapeutics) gets Nasdaq stockholders' equity deficiency notice

     Nasdaq told Quince Therapeutics its stockholders' equity was ($35,324,000), below the $10,000,000 minimum. The company has until October 15, 2026 to submit a compliance plan and has filed an initial listing application that would come with a name change.

     IRLAQNCX
157. Sep 4, 2026Financings

     Polyrizon closes $4.0 million registered direct offering and private placement at $12.00

     Polyrizon closed about $4.0 million from a registered direct offering and a concurrent private placement sold to one institutional investor, at $12.00 per unit. Aegis Capital Corp. acted as placement agent, and its fee took 8% of the registered portion.

     PLRZ
158. Sep 4, 2026Legal

     Nutriband says lawsuit over ended offering engagement remains in discovery

     Joseph Gunnar and Lucosky Brookman sued Nutriband, CEO Gareth Sheridan, President Serguei Melnik, Vitalie Botgros, TII Jet Services and Wolf Blitz in 2023 over a terminated offering engagement. Nutriband denies the claims and has counterclaimed.

     NTRB
159. Sep 4, 2026Financings

     Nutriband reports $3.42 million cash, says operations will fund the next year

     Nutriband says its operations will fund the next year and that going-concern doubt is gone, but revenue and spending both fell in the quarter and the company still burned cash.

     NTRB
160. Sep 4, 2026Listings

     Matinas BioPharma receives NYSE American stockholders' equity notice

     The exchange says stockholders' equity was $1.8 million at June 30, 2026, below the $2.0 million standard, and the listing continues under an accepted plan through October 2, 2027.

     MTNB
161. Sep 4, 2026Debt Financing

     Intellia Therapeutics gets up to $400 million term loan from OrbiMed

     Intellia Therapeutics will receive $75 million at closing under the facility. Up to $225 million more depends mainly on milestones for lonvo-z.

     NTLA
162. Sep 4, 2026Mergers

     Clearmind Medicine agrees to buy 51% of Charging Robotics for $2.5 million

     Clearmind will also lend Charging Robotics $1.5 million at 4% as a condition of closing, which is expected the week of September 7, 2026.

     CMND
163. Sep 4, 2026Company Updates

     BioRestorative's R&D vice president resigns and claims severance

     The company's board does not accept that the resignation was for good reason. The notice seeks about $1.29 million in cash severance under a disputed agreement.

     BRTX
164. Sep 4, 2026Financings

     ADARx Pharmaceuticals files for IPO, plans Nasdaq listing as ADRX

     ADARx Pharmaceuticals filed an S-1 for a Nasdaq IPO under ADRX, with five banks on the cover and the share count and price range left blank. Its net loss was $73,088 thousand in 2025, and it holds a $335.0 million upfront payment from AbbVie.

     ADRX
165. Sep 3, 2026Debt Financing

     Senti Biosciences unit sells $2.0 million in convertible notes to NSG

     The notes were issued under an April 27, 2026 purchase agreement, as amended on September 1, 2026. A separate $2.5 million equity commitment was signed the same day.

     SNTI
166. Sep 3, 2026Listings

     PRF Technologies reports $8,526 thousand in cash at June 30, 2026

     Cash rose to $8,526 thousand at June 30, 2026, from $3,125 thousand at year end, while the six-month loss was $2,942 thousand. Most of the cash came from a $10.0 million equity line that has since ended.

     PRFX
167. Sep 3, 2026Debt Financing

     Hepion Pharmaceuticals issues $500,000 secured convertible note to Gravitas

     The note bears 8% interest payable in kind and matures September 3, 2027. It converts at $0.04 per share after stockholders approve more authorized shares.

     HEPA
168. Sep 3, 2026Company Updates

     Aptevo reports 93% clinical benefit rate with mipletamig in TP53-mutated AML

     Thirteen of 14 evaluable TP53-mutated frontline AML patients treated with mipletamig, venetoclax and azacitidine had clinical benefit, according to Aptevo's September 3, 2026 release.

     APVO
169. Sep 2, 2026Debt Financing

     VolitionRx gets Lind waiver for ATM sales above $10 million

     Lind Global Asset Management XII waived defaults tied to at-the-market sales above the $10 million annual cap on notes issued in 2025 and 2026.

     VNRX
170. Sep 2, 2026Debt Financing

     TuHURA Biosciences borrows $1,500,000 under Parkview revolving facility

     The company borrowed $1,500,000 on September 2, 2026 under a loan agreement with Parkview Holdings One LLC. The facility allows up to $50 million and matures on April 21, 2031.

     HURA
171. Sep 2, 2026Distress

     TScan cuts 75% of staff and pauses phase 3 trial for lack of capital

     TScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days.

     TCRXAMGN
172. Sep 2, 2026Listings

     Quantum BioPharma applies to delist Class B shares from the CSE

     Quantum BioPharma has applied to delist its Class B shares from the Canadian Securities Exchange, with September 4, 2026 expected as the last trading day, subject to approval. The company's own release does not give the trading volumes behind the decision.

     QNTM
173. Sep 2, 2026Financings

     Immutep's FY2026 loss widens 29.1% after TACTI-004 lung cancer trial is discontinued

     Loss after tax attributable to owners was 79,304,563 for the year ended 30 June 2026, up from 61,434,165. Revenue included $14.6 million from licensing partner Dr Reddy's.

     IMM
174. Sep 2, 2026Listings

     BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split

     Nasdaq flagged a missing June-quarter 10-Q on Aug. 21. Days later the company announced a reverse split that cut its shares outstanding to about 1.38 million to fix a separate bid-price shortfall.

     BRTX
175. Sep 2, 2026Listings

     Anavex regains Nasdaq compliance after filing overdue 10-Qs on August 28, 2026

     Nasdaq says Anavex has regained compliance after filing overdue quarterly reports, but the release does not say why they were late.

     AVXL
176. Sep 1, 2026Debt Financing

     Profusa sells another senior secured convertible note to Ascent

     The note has a principal amount of $329,670.33 and was sold for $300,000.00, reflecting original issue discount. Ascent Partners Fund LLC is the initial purchaser.

     PFSA
177. Sep 1, 2026Debt Financing

     KPC gets registration for RMB1 billion medium term notes

     A non-wholly owned subsidiary of China Resources Pharmaceutical received a two-year registration for up to RMB1 billion of medium term notes.

     3320
178. Sep 1, 2026Mergers

     International Stem Cell completes sale of Lifeline Cell Technology to ATCC

     The sale closed September 1, 2026 at an adjusted price of $25,250,000, and the company filed unaudited pro forma statements showing its effect.

     ISCO
179. Sep 1, 2026Financings

     Intelligent Bio Solutions places up to $15 million with one investor

     The private placement brings about $5.0 million at closing, with a further $5 million tranche of warrants, and Ladenburg Thalmann & Co. Inc. acts as placement agent.

     INBS
180. Sep 1, 2026Listings

     Earth Science Tech holders approve reverse split authority for uplisting

     Shareholders approved authority for a reverse split tied to an uplisting, and a special committee to negotiate retiring the Series B preferred stock. The company's release reports no vote counts.

     ETST

August 2026

1. Aug 31, 2026Debt Financing

   PDS Biotechnology amends $6,000,000 promissory note

   PDS Biotechnology amended a $6,000,000 note with YA II PN, Ltd. to require weekly remittances from at-the-market sales and to apply other equity proceeds to a mandatory redemption payment.

   PDSB
2. Aug 31, 2026Company Updates

   Lifeward chief executive Mark Grant departs, Josh Hexter named interim

   Mark Grant leaves as president, chief executive and director effective August 31, 2026, and Josh Hexter becomes interim chief executive on September 1. Rami Aviram is named chief financial officer effective November 1, 2026.

   LFWD
3. Aug 31, 2026Debt Financing

   Kyntra Bio cuts royalty financing cap to $65 million

   Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., lowering the maximum payments and making a $42.6 million upfront payment.

   KYNB
4. Aug 31, 2026Debt Financing

   CDT Equity issues $541,620 senior secured convertible note to J.J. Astor

   The note was issued on August 31, 2026 and repaid in full on September 4, 2026. It came with warrants for 237,000 shares.

   CDT
5. Aug 31, 2026Debt Financing

   AIM ImmunoTech satisfies Streeterville note in full through share exchanges

   AIM ImmunoTech converted approximately $1,224,341 of a February 16, 2024 promissory note held by Streeterville Capital, LLC into 5,065,840 shares, and the note was satisfied in full as of September 3, 2026.

   AIM
6. Aug 28, 2026Company Updates

   Vyome names Jerry Leonard chief financial officer

   The board appointed Jerry Leonard as chief financial officer on August 27, 2026, effective September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, after interim CFO Robert Dickey gave notice of his resignation.

   HIND
7. Aug 28, 2026Distress

   Teva bids $57.5 million upfront for BioXcel's agitation drug in bankruptcy sale

   Teva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer.

   TEVA
8. Aug 28, 2026Financings

   Tenon Medical prices $3.0 million private placement with warrants

   Tenon Medical agreed to sell 597,610 shares, or pre-funded warrants, to an institutional investor, with warrants for up to 1,058,517 more shares. WallachBeth Capital LLC is the exclusive placement agent.

   TNON
9. Aug 28, 2026Listings

   Shuttle Pharmaceuticals gets Nasdaq deficiency notice over late Form 10-Q

   Nasdaq says Shuttle no longer meets Listing Rule 5250(c)(1) because its quarterly report for the period ended June 30, 2026 is late. A plan to regain compliance is due October 27, 2026.

   SHPH
10. Aug 28, 2026Financings

    Quoin Pharmaceuticals agrees to private placement with about $30.8 million upfront

    Quoin agreed to sell 6,305,300 ADSs or pre-funded warrants at $4.88 and warrants for up to 3,152,650 ADSs, for about $30.8 million at closing. The same day it reported interim results from six patients, and its 10-K carries a going-concern warning.

    QNRX
11. Aug 28, 2026Listings

    Oragenics receives NYSE American deficiency letter on equity

    NYSE American notified Oragenics on August 26, 2026 that it is not in compliance with two continued listing standards on stockholders' equity. The company has 45 days to submit a compliance plan and says it intends to do so.

    OGEN
12. Aug 28, 2026Debt Financing

    Moderna sells $3.0 billion of zero-coupon convertible notes after upsized pricing

    The notes convert at about $210.58 a share, 47.5% above the August 27 close, and proceeds may fund the oncology business.

    MRNA
13. Aug 28, 2026Debt Financing

    InSilico Medicine plans US$305 million convertible bond sale

    The company agreed on August 27, 2026 to issue convertible bonds with an initial conversion price of HK$58.07 per share.

    3696
14. Aug 28, 2026Listings

    Glucotrack effects 1-for-15 reverse stock split

    The reverse split took effect August 28, 2026, with trading on a split-adjusted basis from August 31, 2026, and shares outstanding were reduced from 11,972,157 to approximately 798,144.

    GCTK
15. Aug 28, 2026Financings

    Electra Therapeutics files for IPO, plans Nasdaq listing as ETRA

    Electra Therapeutics filed a Form S-1 on August 28, 2026, and the cover leaves the share count and price range blank. Its auditor's report includes a going concern paragraph, and the company says its cash may not cover the next 12 months.

    ETRA
16. Aug 28, 2026Listings

    ENvue Medical announces 1-for-12 reverse stock split effective September 1

    Each 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the Nasdaq Capital Market on September 1, 2026, under the FEED symbol.

    FEED
17. Aug 28, 2026Listings

    China SXT cuts pre-paid share purchase floor price back to $0.20 from $16.00

    The July 3, 2026 agreement allows pre-paid purchases of up to $31,500,000 before an original issue discount. The August 27 amendment restores the $0.20 floor after a 1-for-80 share consolidation had raised it to $16.00.

    SXTC
18. Aug 28, 2026Financings

    Can-Fite files $100,000,000 shelf with at-the-market program of up to $1,065,000

    Can-Fite BioPharma's shelf sets a ceiling of $100,000,000, but the at-the-market sales agreement with H.C. Wainwright & Co., LLC covers only $1,065,000, a limit set by its public float.

    CANF
19. Aug 28, 2026Financings

    BioLineRx raises $3.75M at $2.78 per ADS with 1.5x warrant coverage

    BioLineRx sold 1,348,921 ADSs at $2.78 each and issued warrants on 2,023,382 more ADSs. It also amended older warrants on 277,273 ADSs and cut its at-the-market facility to zero.

    BLRX
20. Aug 28, 2026Company Updates

    Aprea Therapeutics reports expanded patent portfolio for WEE1 and ATR programs

    Aprea said it holds 28 issued and 30 pending patents for its precision oncology programs, with the WEE1 family of applications expiring in 2047 if granted.

    APRE
21. Aug 27, 2026Listings

    Valion sets 1-for-25 reverse stock split to regain Nasdaq compliance

    The split takes effect August 31, 2026 under the same VBIO symbol, and the company says it aims to meet the Nasdaq minimum bid price rule.

    VBIO
22. Aug 27, 2026Listings

    Senti Biosciences gets two Nasdaq notices, on bid price and a $3.4M equity deficit

    Nasdaq flagged Senti's sub-$1 share price and a stockholders' deficit below the $2.5 million minimum. The bid-price clock runs to Feb. 23, 2027; the equity plan is due Oct. 11.

    SNTI
23. Aug 27, 2026Debt Financing

    Pharmaron agrees to issue RMB2,180 million convertible bonds

    Pharmaron Beijing signed an agreement on August 26, 2026 for convertible bonds with an initial conversion price of HK$36.08 per H share.

    300759
24. Aug 27, 2026Financings

    Optimi Health sets up equity line to sell up to US$100 million of shares to Seven Knots

    Optimi can sell shares to Seven Knots, LLC at its discretion, up to US$2 million per draw. It issued a US$1.5 million convertible note as a commitment fee.

    OPTI
25. Aug 27, 2026Listings

    OSR Health hearing before Nasdaq Panel set for September 29

    The Nasdaq Hearings Panel scheduled OSR Health's hearing for September 29, 2026, while trading in its securities remains suspended under the company's own filing.

    OSRH
26. Aug 27, 2026Debt Financing

    Moderna plans $2.0 billion convertible notes private placement

    Moderna said it intends to sell $2.0 billion of notes due 2032, with an option for up to $300.0 million more. It would also enter capped call transactions to reduce potential dilution.

    MRNA
27. Aug 27, 2026Financings

    Jazz prices $1.1 billion of exchangeable notes and repurchases $225 million of shares

    The 1.875% notes due 2032 carry an exchange price of about $355.24, a 42.5% premium to the Aug. 26 close. The offering was upsized from $1.0 billion.

    JAZZ
28. Aug 27, 2026Mergers

    Cyclerion (now Korsana Biosciences) shareholders approve merger issuance and 1-for-7 reverse split

    Shareholders backed the Korsana merger share issuance and change of control on August 26, 2026. The combined company expects to trade on Nasdaq as KRSA from September 9, 2026; a Cayman redomestication failed.

    KRSA
29. Aug 27, 2026Debt Financing

    CERo Therapeutics consolidates older notes into secured SRX Global loan

    The note combines earlier notes and lets SRX advance up to $6,000,000 in total at 10% interest. Principal and interest are due October 15, 2026.

    CERO
30. Aug 27, 2026Distress

    BioXcel files Chapter 11 with Teva as $57.5 million stalking horse bidder

    BioXcel filed Chapter 11 on Aug 27 with Teva's $57.5 million upfront bid as the floor for a court auction. That upfront sum is below the company's $107,152 thousand of total debt at June 30.

    BTAITEVA
31. Aug 27, 2026Listings

    Artelo Biosciences sets 1-for-9 reverse split, trading from August 31, 2026

    Artelo will combine every nine shares of common stock into one, with split-adjusted trading beginning August 31, 2026, and about 547,774 shares outstanding afterward.

    ARTL
32. Aug 26, 2026Financings

    Turn sells $1.35 million of stock to existing investors at $10.00 a share

    A Form D filed August 26, 2026 reports $1,650,000 sold to eight investors, while the August 14 agreements covered $1.35 million. The shares carry registration rights.

    TTRX
33. Aug 26, 2026Company Updates

    Nuwellis investor presentation cites 20% first-half revenue growth

    The August 2026 deck says first-half revenue rose 20% and that cash runway extends through 2Q27.

    NUWE
34. Aug 26, 2026Financings

    LeonaBio enrolls 500th subject in Phase 3 ELAINE-3 trial

    LeonaBio said it enrolled the 500th subject in its ELAINE-3 trial of lasofoxifene, an announcement that also sets a date used in the exercise terms of its Series A warrants.

    LONA
35. Aug 26, 2026Debt Financing

    Jazz plans $1.0 billion exchangeable notes offering with share buyback

    Jazz Investments I Limited plans to sell $1.0 billion of exchangeable notes due 2032. Jazz also expects to buy back up to $225.0 million of its ordinary shares from note purchasers.

    JAZZ
36. Aug 26, 2026Listings

    Interpace Biosciences sets 1-for-5 reverse stock split to support Nasdaq bid

    The split takes effect August 27, 2026 and reduces outstanding shares from approximately 27.7 million to approximately 5.5 million, aimed at Nasdaq's minimum bid price requirement.

    IDXG
37. Aug 26, 2026Financings

    Immatics agrees to sell shares and warrants at $8.69 in $150 million offering

    Immatics agreed to sell 12,945,916 ordinary shares at $8.69, plus pre-funded warrants for 4,315,304 shares, for expected gross proceeds of $150 million. Its 2025 net loss was €196.4 million, after net income of €15.2 million in 2024.

    IMTX
38. Aug 25, 2026Distress

    PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy

    PTC Therapeutics will pay $111 million upfront and up to $100 million more in milestones for ST-920, subject to approval by the bankruptcy court.

    PTCT
39. Aug 25, 2026Distress

    PDS Biotechnology to cut about 36% of workforce, removes Chief Operating Officer

    PDS Biotechnology approved a reduction in force on August 6, 2026 and estimates a one-time charge of approximately $842,000. It also ended Stephan Toutain's role as Chief Operating Officer.

    PDSB
40. Aug 25, 2026Company Updates

    Miles Suk steps down as Abpro Holdings chairman but stays on the board

    Abpro Holdings said Miles Suk resigned as chairman of its board effective August 25, 2026. The board will appoint a successor chair at its next regularly scheduled meeting.

    ABPO
41. Aug 25, 2026Financings

    Hepion sells 8,000,000 shares and warrants in a $400,000 private placement

    The agreements are dated August 25, 2026, and priced at $0.05 per share. The filing names no underwriter or placement agent.

    HEPA
42. Aug 25, 2026Listings

    Ensysce gets Nasdaq bid price extension to February 2027

    Nasdaq extended the Ensysce Biosciences bid price deadline to February 22, 2027, and said the company must meet initial listing criteria after its Cy Biopharma acquisition.

    ENSC
43. Aug 24, 2026Financings

    Skye Bioscience signs equity line with Redmile affiliate for up to $22,000,000

    Skye Bioscience's equity line with a Redmile affiliate covers up to $22,000,000 and requires purchases of up to $2,000,000 a month once it starts. The line is reduced if the PIPE exceeds $103,000,000 and falls away at $125,000,000.

    SKYE
44. Aug 24, 2026Listings

    Longeveron does a 1-for-10 reverse split to meet Nasdaq's $1 bid minimum

    The split took effect Aug. 26 and cut Class A shares to about 3.04 million. Three weeks later the company reported that its HLHS trial missed its primary endpoint.

    LGVN
45. Aug 24, 2026Debt Financing

    BioXcel takes $1,250,000 in additional term loans from its lenders

    The amendment also lowers the minimum cash liquidity covenant to $250,000 and sets an August 31, 2026 deadline for a transaction acceptable to the lenders.

    BTAI
46. Aug 24, 2026Financings

    Arbutus Biopharma starts tender offer for up to US$230 million of its shares

    Arbutus filed a Schedule TO on August 24, 2026 to start an issuer tender offer for up to US$230 million of its common shares, paid in cash. The filing points to an Offer to Purchase dated the same day, and it does not state the start or expiry dates in its own text.

    ABUS
47. Aug 21, 2026Listings

    VivoSim Labs receives Nasdaq bid price notice with February 2027 deadline

    Nasdaq staff said VivoSim Labs has until February 16, 2027 to show a closing bid price of at least $1 for ten consecutive business days, and the company is weighing a reverse split.

    VIVS
48. Aug 21, 2026Financings

    Veradermics CEO, technical chief and two large holders sell shares in August

    Insiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales.

    MANE
49. Aug 21, 2026Listings

    Pasithea receives Nasdaq extension to regain bid price compliance

    Nasdaq granted Pasithea Therapeutics 180 more days, to February 16, 2027, to regain the $1.00 minimum closing bid price required for continued listing.

    KTTA
50. Aug 21, 2026Financings

    Oruka Therapeutics files $1,000,000,000 shelf with $500,000,000 sales program

    TD Cowen is the sales agent for up to $500,000,000 of common stock under a sales agreement that sits inside a $1,000,000,000 shelf. The filing puts the outstanding count at 61,069,887 shares on June 30, 2026.

    ORKA
51. Aug 21, 2026Debt Financing

    Nexalin issues $1,170,000.00 promissory note to Streeterville Capital

    The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC.

    NXL
52. Aug 21, 2026Company Updates

    NexGel names Brian Kieser interim CEO and forms a strategic review committee

    Brian Kieser became interim chief executive on August 21, 2026, as Adam Levy left the role. A special committee will review non-core assets, liquidity and the company's long-term strategic direction.

    NXGL
53. Aug 21, 2026Financings

    Moleculin lifts ATM to $19.7M weeks after a $9.3M deal with 3x warrants

    Moleculin can now sell up to $19,700,000 under its at-the-market program, weeks after a July deal with warrants on 37,130,001 shares. The trial figures it cited are blinded and preliminary, drawn from 62 patients.

    MBRX
54. Aug 21, 2026Listings

    Kairos Pharma sets 1-for-7 reverse stock split effective September 1, 2026

    Split-adjusted shares will trade under the existing KAPA symbol at market open on September 1, 2026, and the company says the split is meant to help it keep its NYSE American listing.

    KAPA
55. Aug 21, 2026Debt Financing

    Imugene amends CVI convertible notes and issues new warrants

    A$2.1 million of existing notes is redeemed and replaced by new zero-coupon notes, and the remaining notes amortise in five instalments.

    IMU
56. Aug 21, 2026Financings

    Gossamer Bio private placement has $150 million committed, $25.0 million at first closing

    Gossamer Bio's private placement of up to $250 million opens with $25.0 million at a first closing. A $125.0 million second closing depends on FDA acceptance of its seralutinib filing, and warrants that could add about $100.0 million depend on FDA approval.

    GOSS
57. Aug 21, 2026Listings

    Estrella Immunopharma gets Nasdaq minimum bid price notice, has until February 16, 2027 to comply

    Nasdaq notified Estrella on August 17, 2026 that its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance. Its year-end 2025 cash was $1.4 million.

    ESLA
58. Aug 21, 2026Mergers

    Elutia completes SimpliDerm business sale to Cellution Biologics, receives $7.7 million

    The August 17, 2026 closing leaves the price open to an inventory adjustment and up to $3 million in contingent payments. Elutia says it will focus on NXT-41x and believes it has funding through the first full year of its commercial launch in 2028.

    ELUT
59. Aug 21, 2026Listings

    Citius Pharmaceuticals gets Nasdaq extension to February 8, 2027 on bid price

    Nasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance.

    CTXRCTOR
60. Aug 21, 2026Debt Financing

    BCAL Diagnostics details convertible note draws under its $10 million facility

    After raising $3.1 million by February, BCAL drew further notes and plans more, which use up its Listing Rule 7.1 capacity.

    BDX
61. Aug 21, 2026Listings

    Azitra regains NYSE American continued listing compliance

    NYSE Regulation's August 19, 2026 letter says the company resolved deficiencies under two continued listing standards. A new lapse within 12 months could bring faster action.

    AZTR
62. Aug 21, 2026Mergers

    Arbutus plans US$230 million Dutch auction tender offer for its shares

    Arbutus said on August 21, 2026 that it plans a modified Dutch auction tender offer for up to US$230 million of its common shares at US$5.00 to US$5.75 each, funded from cash on hand. The offer has not started, and the company says it needs exemptive relief in Canada and the United States first.

    ABUS
63. Aug 21, 2026Listings

    Adial Pharmaceuticals gets Nasdaq stockholders' equity notice, plan due October 2, 2026

    Nasdaq told Adial on August 18, 2026 that it no longer meets the $2,500,000 stockholders' equity requirement. The company says it anticipates regaining compliance once holders approve conversion of its Series A Non-Voting Convertible Preferred Stock.

    ADIL
64. Aug 20, 2026Financings

    UroGen signs option deal with IntraGel and agrees to invest up to $7,000,000

    UroGen gets an option on IntraGel's TumoCure for advanced head and neck cancer and agrees to invest up to $7,000,000 in IntraGel's equity. The 8-K gives no clinical data, no option fee and no exercise deadline.

    URGN
65. Aug 20, 2026Company Updates

    Protagenic reports FDA pre-IND feedback on PT00114 for generalized anxiety disorder

    The FDA raised no objection to the planned Phase 1 design and identified no clinical hold issues. Protagenic plans to submit the IND before the end of 2026.

    PTIX
66. Aug 20, 2026Listings

    Profusa reports Q2 2026 results and progress on G3 option

    Profusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026.

    PFSA
67. Aug 20, 2026Listings

    Curanex regains Nasdaq bid-price compliance after 1-for-20 reverse split

    Curanex's 1-for-20 reverse split took effect on August 20, 2026. Nasdaq closed its bid-price matter on September 3, after the stock traded at or above $1.00 for ten consecutive business days.

    CURX
68. Aug 20, 2026Company Updates

    Adaptin Bio opens enrollment in Phase 1 trial of APTN-101 for glioblastoma

    Adaptin Bio said on August 20, 2026 that enrollment has opened for a Phase 1 study of APTN-101 in patients with glioblastoma. The study is being conducted with Duke University and expects to enroll up to 15 adults.

    APTN
69. Aug 20, 2026Legal

    Abbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million

    Abbott Laboratories, a defendant in numerous NEC lawsuits, agreed to resolve the Gill case, where a jury awarded $495 million, and claims for about 2,000 other infants. About 1,700 lawsuits remain pending.

    ABT
70. Aug 19, 2026Financings

    TuHURA Biosciences, Inc. stockholders approve 1,878,287 loan fee shares for Parkview

    TuHURA Biosciences' stockholders approved on August 18, 2026 the issue of 1,878,287 shares to its lender, Parkview Holdings One LLC, as a fee for a $50 million revolving credit facility. The company's cash stood at $995,977 on June 30, 2026, according to its quarterly report.

    HURA
71. Aug 19, 2026Listings

    Skye Bioscience gets Nasdaq notice: stockholders' equity was ($497,307)

    Nasdaq said on August 18, 2026 that Skye Bioscience's stockholders' equity was a deficit of $497,307 at June 30, 2026, below the $2,500,000 minimum. The company has until October 2, 2026 to submit a plan to regain compliance.

    SKYE
72. Aug 19, 2026Listings

    OSR Health receives Nasdaq delisting determination, will request hearing

    Nasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on August 26, 2026.

    OSRH
73. Aug 19, 2026Listings

    Mereo BioPharma gets second Nasdaq bid price period, to February 16, 2027

    Nasdaq said on August 18, 2026 that the ADSs are still below $1.00 but the company is eligible for 180 more calendar days.

    MREO
74. Aug 19, 2026Legal

    Mereo BioPharma faces securities class action naming its CEO and chief scientific officer

    Dodge v. Mereo Biopharma Group PLC (1:26-cv-988) was filed Feb. 4, 2026 in the Southern District of New York. The lead plaintiff filed an amended complaint on July 13, 2026.

    MREO
75. Aug 19, 2026Company Updates

    Kiora licenses KIO-301 rights in South Korea to Chong Kun Dang

    Kiora will receive a $1 million upfront payment from Chong Kun Dang for KIO-301 rights in South Korea. Kiora says its partners will coordinate a single global Phase 3 trial in retinitis pigmentosa.

    KPRX
76. Aug 19, 2026Company Updates

    Jaguar Health reports second quarter 2026 net loss of $12.7 million

    Net loss attributable to common stockholders was $12.7 million for the quarter ended June 30, 2026, as U.S. revenue from its two main prescription products now flows to licensee Future Pak under a January 2026 agreement.

    JAGX
77. Aug 19, 2026Company Updates

    Intelligent Bio Solutions reports fiscal 2026 revenue of $4,215,175

    Revenue rose 38% and gross margin reached 48.63%, and the company says its FDA 510(k) submission remains on track for the second half of calendar 2026.

    INBS
78. Aug 19, 2026Financings

    Innate Pharma files subscription agreement for new shares at €1.70 each

    Innate Pharma is issuing new shares at a fixed €1.70 each through Stifel and BTIG. Year-end cash fell to €28.1 million at December 31, 2025, from €66.4 million a year earlier.

    IPH
79. Aug 19, 2026Company Updates

    Hepion appoints James Liddy as a director

    The board approved the appointment on August 19, 2026, effective immediately. The filing says no arrangements tie his selection to any other person.

    HEPA
80. Aug 19, 2026Company Updates

    Cosmos Health reports second-quarter 2026 revenue of $18.99 million

    Revenue rose 28.8% and total liabilities fell 13.3% from year-end 2025, the company said.

    COSM
81. Aug 19, 2026Company Updates

    Apimeds Pharmaceuticals takes assignment of Apitox rights

    Under an agreement dated August 19, 2026, FreeT Inc. assigned to Apimeds Pharmaceuticals a set of Apitox rights, including 100% of the Korean medicine clinic market and a 25% royalty entitlement on U.S. proceeds.

    APUS
82. Aug 18, 2026Company Updates

    Silo Pharma issues 165,000 shares for software and domain names

    Silo agreed on August 18, 2026 to buy software, technology and domain names from Parkview Consulting LLC, paying with shares subject to a lock-up of up to twelve months.

    SILO
83. Aug 18, 2026Financings

    SciSparc unit NeuroThera Labs completes C$5.4 million private placements

    SciSparc put in C$2.7 million, half the total, and says it will hold approximately 44.6% of NeuroThera afterward. NeuroThera plans to use the money for general working capital.

    SPRCNTLX
84. Aug 18, 2026Legal

    Outlook Therapeutics faces securities class action and stayed derivative suit over LYTENAVA BLA

    The New Jersey court dismissed the second amended complaint in part on Dec. 23, 2025, and plaintiffs refiled. Outlook and certain unnamed officers are defendants; a Delaware derivative suit is stayed.

    OTLK
85. Aug 18, 2026Listings

    Liminatus Pharma sets 1-for-50 reverse stock split to meet Nasdaq minimum bid price requirement

    Liminatus will cut its shares 50 to 1 at the close of trading on August 20, 2026. The Nasdaq Panel now requires a $1.00 closing bid for ten consecutive trading days by September 3, after notices on market value and bid price.

    LIMN
86. Aug 18, 2026Debt Financing

    ICON plc issues $2.15 billion of senior unsecured notes

    The notes mature in 2029, 2031 and 2036 and carry rates of 5.064%, 5.421% and 5.995%. Proceeds repaid term loans, a bridge facility and 2027 secured notes.

    ICLR
87. Aug 18, 2026Company Updates

    Genprex signs CDMO deal to scale up diabetes gene therapy manufacturing

    The contract manufacturer will make drug product for IND-enabling preclinical studies and future clinical trials of the company's AAV-based diabetes gene therapy.

    GNPX
88. Aug 18, 2026Company Updates

    Cocrystal appoints Carol L. Brosgart to its board of directors

    Cocrystal Pharma's board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately, according to a Form 8-K filed August 18, 2026.

    COCP
89. Aug 18, 2026Listings

    BullFrog AI granted Nasdaq second compliance period for bid price

    Nasdaq gave BullFrog AI until February 8, 2027 to regain the $1.00 minimum bid price. Stockholders approved a reverse stock split at a ratio of not less than 1-to-2 and not more than 1-to-15.

    BFRG
90. Aug 18, 2026Debt Financing

    Baxter raises note tender offer cap to $600 million after early results

    Holders tendered $756,712,000 of the 2.539% notes due 2032 by the early tender time. The offer cap rose from $500 million to $600 million.

    BAX
91. Aug 18, 2026Financings

    Amylyx Pharmaceuticals launches $350,000,000 common stock offering

    Amylyx's final supplement prices 14,090,000 shares at $35.500 for $500,195,000 before costs, above the $350,000,000 in the first filing. The company announced Phase 3 topline results the same day.

    AMLX
92. Aug 17, 2026Listings

    XORTX reports $994,045 in cash and a going-concern note for first half of 2026

    XORTX ended June 30, 2026 with $994,045 in cash after a $5,000,000 public offering, and the going-concern note stays. Operations used $3,768,993 in the six months.

    XRTX
93. Aug 17, 2026Company Updates

    Revelation grants CEO and CFO restricted stock tied to market value

    James Rolke and Chester Zygmont each received restricted stock awards that vest in four tranches tied to market capitalization milestones of $30 million to $120 million.

    REVB
94. Aug 17, 2026Distress

    Outlook Therapeutics files NT 10-Q for June quarter, cites finance staff turnover

    Outlook says it cannot file its quarterly report on time because of its size, finance department turnover and work on a public offering that closed on August 14, 2026. It has a going concern warning in its last annual report.

    OTLK
95. Aug 17, 2026Listings

    Lexaria Bioscience regains Nasdaq bid price compliance, hearing cancelled

    The Hearings Advisor told the company on August 17, 2026 that staff confirmed compliance with Listing Rule 5550(a)(2), and the requested hearing was cancelled.

    LEXX
96. Aug 17, 2026Mergers

    Fulcrum Therapeutics agrees to all-stock merger with Slate Medicines

    Fulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers.

    FULC
97. Aug 17, 2026Mergers

    ENDRA reports second quarter 2026 results and merger progress

    ENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quarter of 2026.

    NDRAASPI
98. Aug 17, 2026Financings

    Dermata agrees to $3.4 million private placement with warrants

    Dermata Therapeutics agreed to sell 2,293,608 shares, or pre-funded warrants, at $1.46 per share, with Series E and Series F warrants attached. Gross proceeds are expected to be about $3.4 million before offering expenses.

    DRMA
99. Aug 17, 2026Debt Financing

    Coherus Oncology takes $55,000,000 senior secured term loan to refinance debt

    Innovatus Life Sciences Lending Fund I, LP, is collateral agent on a loan that replaces an existing term loan and runs to August 2031, with interest-only payments for an initial 36 months.

    CHRS
100. Aug 17, 2026Financings

     Bright Minds Biosciences reports C$307,828,515 cash after public offering

     Cash and cash equivalents reached CAD 307,828,515 at June 30, 2026, after a January 2026 public offering at US$90 a share. Over the nine months the company used CAD 23,402,489 in operations and reported no revenue.

     DRUG
101. Aug 14, 2026Company Updates

     Vycor Medical reports second quarter 2026 results

     Revenue for the three months ended June 30, 2026 was $418,264, a decrease of 16% from the 2025 period. The company said most of the decline came from international markets.

     VYCO
102. Aug 14, 2026Legal

     Vistagen faces securities class action and two derivative suits over PALISADE-3 trial statements

     A Northern District of California class action names Vistagen, CEO Shawn Singh and COO Joshua Prince. Two derivative suits are stayed behind it, and a separate pro se case was dismissed with prejudice on August 12.

     VTGN
103. Aug 14, 2026Debt Financing

     Trinity Biotech amends Perceptive term loan, adding about $2.5 million

     The amendment provides approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest, for a total investment of approximately $7.0 million.

     TRIB
104. Aug 14, 2026Company Updates

     Traws Pharma reports Q2 2026 results and updated MHRA timeline

     Traws reports $5.0 million in cash at June 30, 2026, and says existing cash plus expected at-the-market proceeds fund planned operations into the first quarter of 2027.

     TRAW
105. Aug 14, 2026Listings

     Skye Bioscience outlines Redx Pharma deal in August 14, 2026 investor deck

     Skye Bioscience's investor deck describes a U.K. scheme of arrangement to combine with Redx Pharma, a concurrent financing totaling $125 million, and a contingent value right for former Skye holders. The deck says Skye is discontinuing its CBeyond trial of nimacimab.

     SKYE
106. Aug 14, 2026Distress

     Silexion had $2.2 million in cash at June 30 and flags going-concern doubt

     Management said cash would last through the fourth quarter of 2026. The company has leaned on at-the-market sales and small offerings, and a Nasdaq delisting notice followed on August 18.

     SLXN
107. Aug 14, 2026Debt Financing

     Senti Biosciences unit sells $4.0 million of convertible notes to Celadon

     The notes were issued under an April 27, 2026 purchase agreement. The filing also ties the company to a potential merger with a contingent value right that could pay up to $60.0 million in cash.

     SNTI
108. Aug 14, 2026Legal

     Scilex loses ZTlido patent appeal as Federal Circuit affirms non-infringement ruling for Aveva

     The Federal Circuit affirmed on Aug. 4, 2026 that Aveva's generic does not infringe Scilex's ZTlido patents. Defendants were Aveva Drug Delivery Systems, Apotex Corp. and Apotex, Inc.

     SCLX
109. Aug 14, 2026Legal

     Scilex and Semnur named in Sorrento equity holders' suit, now stayed in a California federal court

     Mevi et al. v. Ji et al. names Scilex, Semnur and others not listed in the 10-Q. The court stayed the case on June 25, 2026; Scilex's filings do not identify the other defendants.

     SCLX
110. Aug 14, 2026Company Updates

     Scienture reports second quarter 2026 revenue of $343,639

     Revenue rose from $56,325 in the first quarter, gross margin was approximately 97.7% and the net loss narrowed to about $2.8 million. The company began commercial launch of REZENOPY during the quarter.

     SCNX
111. Aug 14, 2026Company Updates

     Retractable Technologies reports second-quarter net sales of $7.2 million

     Net sales fell from $10.4 million a year earlier, and the quarter's net income of $2.8 million includes a $6.4 million gain on the sale of equity securities.

     RVP
112. Aug 14, 2026Company Updates

     Quoin reports second quarter 2026 results and QRX003 progress

     Quoin said it had about $10.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, and that it expects that position to fund operations into 2027.

     QNRX
113. Aug 14, 2026Distress

     ProtoKinetix files late-filing notice for its June 30, 2026 quarterly report

     The notice also says its 2025 Form 10-K and its March 31, 2026 Form 10-Q have not been filed. The company cites delays in finishing its financial statements and an auditor review.

     PKTX
114. Aug 14, 2026Company Updates

     PAVmed reports second quarter 2026 results and Lucid coverage policy

     Lucid Diagnostics recognized $1.5 million in EsoGuard revenue in the second quarter, and PAVmed reported cash of $3.8 million at June 30, 2026.

     PAVMLUCD
115. Aug 14, 2026Distress

     Nutra Pharma files late-filing notice for its June 30, 2026 quarterly report

     Nutra Pharma filed a Form 12b-25 notice on August 14, 2026, saying its quarterly report for the period ended June 30, 2026 would be late. Its cash at December 31, 2025 was $12,181.

     NPHC
116. Aug 14, 2026Legal

     Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion

     A Securities Act suit in New York names Neumora, certain executive officers and certain underwriters. Defendants' reply on their motion to dismiss the second amended complaint is due August 24, 2026.

     NMRA
117. Aug 14, 2026Company Updates

     Lifeward reports second quarter 2026 revenue up 16% to $6.6 million

     Lifeward reported a net loss of $11.5 million for the quarter and said a July 6, 2026 financing could provide up to $11.2 million in growth capital.

     LFWD
118. Aug 14, 2026Company Updates

     LeonaBio reports second quarter 2026 results and ELAINE-3 update

     LeonaBio reported cash, cash equivalents and investments of $51.1 million at June 30, 2026, and said it has enrolled 495 patients in its Phase 3 ELAINE-3 trial.

     LONA
119. Aug 14, 2026Financings

     InflaRx registers up to $65,000,000 more in shares for sales program

     Sales run through Leerink Partners under an agreement dated June 28, 2024. The commission is up to 3.0% of gross proceeds.

     IFRX
120. Aug 14, 2026Legal

     HCW Biologics faces December jury trial in Florida mechanics lien foreclosure case

     BE&K Building Group sued HCW Biologics, Cogent Bank and subcontractors in Broward County over unpaid renovation invoices. Fisk Electric's suit was consolidated, and Cogent Bank has demanded the liens be cleared.

     HCWB
121. Aug 14, 2026Legal

     GT Biopharma sued by four convertible note holders over undelivered conversion shares

     GT Biopharma is the only defendant named in New York suits by Z-One, Silberfein, DiPietro and the Werthman Trust. Z-One's claims were dismissed and appealed. The other three are in settlement talks.

     GTBP
122. Aug 14, 2026Legal

     Exicure's class action and derivative suits end with court-approved settlements

     Exicure's securities class action and its shareholder derivative suits are over, according to a quarterly report filed August 14, 2026. The class action settled for $5.625 million, funded by insurers, and the derivative suits were dismissed in June 2026 after court approval.

     XCUR
123. Aug 14, 2026Company Updates

     Enveric reports second quarter 2026 net loss of $3.0 million

     The company reported cash-on-hand of $8.3 million as of June 30, 2026, and an update on its lead candidate EB-003 ahead of an IND submission.

     ENVB
124. Aug 14, 2026Financings

     Daré prices $6.0M registered direct with warrants on twice the shares

     Daré Bioscience sold 4.38M shares at $1.37 and gave buyers two warrant series covering 8.76M more, while Nasdaq reviews its listing and cash runs into Q4.

     DARE
125. Aug 14, 2026Distress

     Curanex flags going-concern doubt with $2.94 million in cash at June 30

     Curanex says its cash will not last twelve months, a reversal of the no-doubt finding in its first-quarter report. Prepaid research payments have so far held cash use well below its losses.

     CURX
126. Aug 14, 2026Legal

     Capricor discloses new securities class action and derivative suit as FDA date slips

     Defendants: Capricor and unnamed officers in the new July 30 class action, and Capricor and CEO Linda Marbán in the 2025 one. The FDA also moved the deramiocel date to November 22, 2026.

     CAPR
127. Aug 14, 2026Listings

     CASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote

     CASI Pharmaceuticals had $3.8 million of cash at June 30, 2026, after its ordinary shares left Nasdaq and began quoting on the OTCQB. Its first-half release says recurring operating losses have raised substantial doubt about its ability to continue as a going concern.

     CASIF
128. Aug 14, 2026Company Updates

     BioForce Nanosciences names interim CEO, adds general counsel and advisers

     An August 14, 2026 filing lists officers, directors and advisory board members, including Richard Kaiser as interim chief executive officer and Scott Mager as general counsel and director.

     BFNH
129. Aug 14, 2026Financings

     Adlai Nortye reports US$231.9 million cash after two 2026 private placements

     Adlai Nortye reports $231.9 million in cash and short-term investments at June 30, 2026, up from $8.1 million six months earlier, after two private placements of $140 million and $150 million before fees, and it has de-prioritized AN4005 as a monotherapy.

     ANL
130. Aug 14, 2026Listings

     Adagio Medical receives Nasdaq notice on stockholders' equity

     The company reported stockholders' equity of negative $415,000 at June 30, 2026, below Nasdaq's $2,500,000 minimum, and must submit a compliance plan by September 28, 2026.

     ADGM
131. Aug 13, 2026Financings

     Turn issues 579,664 shares as GEM exercises warrant on a cashless basis

     The warrant covered 1,192,207 shares at $5.03. Because GEM used the cashless option, Turn received no cash and issued fewer shares than the warrant allowed it to buy.

     TTRX
132. Aug 13, 2026Company Updates

     Tenon Medical reports second quarter 2026 revenue of $1.3 million

     Revenue rose 127% from a year earlier and gross margin reached 64%. Cash was $1.7 million at June 30, 2026, before a $4.2 million offering that closed on July 1.

     TNON
133. Aug 13, 2026Financings

     Silexion raises $2.5 million in public offering of shares and warrants at $0.65

     The best-efforts deal closed August 13, 2026. Silexion also converted $750,001 of debt owed to its former SPAC sponsor into shares at the offering price.

     SLXN
134. Aug 13, 2026Listings

     Satellos reports $47,251 thousand net equity proceeds in first half of 2026

     Cash and short-term investments stood at $7,393 thousand and $54,446 thousand at June 30, 2026. The shares were consolidated twelve-for-one in January.

     MSCL
135. Aug 13, 2026Distress

     Sangamo bankruptcy auction brings in $163.55 million from PTC and Lilly

     Winning bids yield about $163.55 million in cash at closing and up to $100 million in milestones. Every sale still needs court approval, and the company is still selling other assets.

     SGMOQLLY
136. Aug 13, 2026Distress

     Regen Biopharma files late-filing notice for its June 30, 2026 quarterly report

     Regen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date.

     RGBP
137. Aug 13, 2026Financings

     ProQR reports $59.2 million June financing and €117.1 million cash

     ProQR raised about $59.2 million in June, through a $50.0 million underwritten registered direct offering and a $9.2 million private placement to Eli Lilly and Company. The release names no underwriter, and says cash of €117.1 million covers runway into mid-2028.

     PRQR
138. Aug 13, 2026Debt Financing

     Positron arranges $2,000,000 line of credit at 12% from investor George Ortiz

     The note matures on August 13, 2028 and bears fixed interest at 12%. Cash is payable only on demand after maturity or while an event of default continues.

     POSC
139. Aug 13, 2026Distress

     Polaryx reports $11.5 million cash, funding into early 2027 and going-concern doubt

     The company says its cash lasts through the first quarter of 2027 and it will need more capital after that. SOTERIA is due to start in the second half of 2026.

     PLYX
140. Aug 13, 2026Distress

     Pelthos Therapeutics says first-quarter 2026 financials can no longer be relied on, will restate

     Pelthos Therapeutics said on August 13, 2026 that its first-quarter 2026 financial statements can no longer be relied on. The restatement adds $14.8 million to the accumulated deficit, and the company reports a material weakness in its controls over convertible debt.

     PTHS
141. Aug 13, 2026Debt Financing

     OPKO issues $125,000,000 in additional senior secured notes

     The notes mature in July 2044 and are secured by royalty payments that EirGen Pharma Limited receives on mazdutide. HCR Injection SPV, LLC serves as agent.

     OPK
142. Aug 13, 2026Company Updates

     Nuwellis reports 14% second-quarter revenue growth and 76% gross margin

     Net sales were $2.0 million in the quarter, and the company says recent financings extend its cash runway through the second quarter of 2027.

     NUWE
143. Aug 13, 2026Financings

     NervGen reports C$86,789,698 cash after May 2026 public offering

     NervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units.

     NGEN
144. Aug 13, 2026Company Updates

     MiNK reports second quarter 2026 results and early trial observations

     MiNK said its cash and cash equivalents were $8.8 million as of June 30, 2026, and its second quarter net loss was $3.1 million. The company also reported Day 28 observations from its randomized Phase 2 trial in acute lung injury.

     INKT
145. Aug 13, 2026Financings

     MapLight reports $351.3 million in cash and investments, sees funding through 2028

     MapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $150.0 million at $11.38 a share. Six-month operating cash use was $96.0 million.

     MPLT
146. Aug 13, 2026Financings

     MapLight agrees $150 million private placement of shares and pre-funded warrants

     MapLight agreed to sell 9,197,887 voting shares at $11.38 and pre-funded warrants for 3,983,168 more shares, for about $150.0 million gross before fees.

     MPLT
147. Aug 13, 2026Company Updates

     Lifeloc reports second-quarter 2026 revenue up 10%

     Net revenue rose to $2.445 million for the quarter ended June 30, 2026, and the company said it is targeting a limited commercial launch of SpinDetect in the first quarter of 2027.

     LCTC
148. Aug 13, 2026Legal

     Kyntra Bio accrues $7.0 million for indemnity tied to SEC case against ex-CMO

     Kyntra Bio, formerly FibroGen, says it must advance legal costs for an SEC case against its former chief medical officer and may have to cover some costs and judgments. It had accrued about $7.0 million for those obligations at June 30, 2026, up from an amount it called not material three months earlier.

     KYNB
149. Aug 13, 2026Legal

     Gossamer Bio faces securities class action; lead plaintiff named, amended complaint due Aug. 10

     Kinnamon v. Gossamer Bio names the company and unnamed executive officers and directors over a June 16, 2025 to February 20, 2026 class period. The 10-Q gives no loss estimate.

     GOSS
150. Aug 13, 2026Legal

     Fate Therapeutics faces securities class action and three derivative suits over Janssen disclosures

     The 10-Q says Fate and unnamed officers are defendants in a Southern District of California class action. The derivative suits are captioned against Wolchko; board lists come from Fate's 2023 and 2026 proxies.

     FATE
151. Aug 13, 2026Company Updates

     Equillium expects EQ504 Phase 1 start in Q4 2026 and cash into 2029

     Equillium reported a second-quarter net loss of $4.7 million and cash and cash equivalents of $57.2 million at June 30, 2026, which it says can fund planned operations into 2029.

     EQ
152. Aug 13, 2026Financings

     Ensysce completes Cy Biopharma acquisition with $38.6 million placements

     Ensysce Biosciences said the Cy Biopharma acquisition closed on August 6, 2026, with private placement financings of $38.6 million and cash runway into late 2027.

     ENSC
153. Aug 13, 2026Company Updates

     Dogwood reports second quarter 2026 results and Halneuron update

     Dogwood reported a second quarter net loss of $11.5 million, including a $6.7 million non-cash impairment, and $9.6 million in cash that it says funds operations through the Phase 2b readout.

     DWTX
154. Aug 13, 2026Legal

     Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit over MYQORZO

     Cytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia.

     CYTK
155. Aug 13, 2026Legal

     CorMedix faces DefenCath securities class action as derivative settlement heads to a hearing

     The class action names CorMedix and six officers, including Khoso Baluch. A settlement of derivative suits naming 12 individuals had a final approval hearing set for September 23, 2026.

     CRMD
156. Aug 13, 2026Company Updates

     Co-Diagnostics reports second quarter 2026 results and flu and RSV test submission

     The net loss was $6.3 million, or $1.46 per share, and cash and cash equivalents were $3.6 million at June 30, 2026. The company said it submitted a 510(k) for its flu A/B and RSV test.

     CODX
157. Aug 13, 2026Legal

     Calidi faces suits from two former finance staff and an investor's securities fraud claim

     Calidi, director and ex-CEO Allan Camaisa and ex-officer Ms. Pizarro are defendants in San Diego employment suits. Investor Yian Zeng's federal case against Calidi had a summary judgment hearing set for Aug 24, 2026.

     CLDI
158. Aug 13, 2026Financings

     Bluejay reports Q2 2026 results and $9.6 million in cash

     The company says its June 2026 private placement brought in about $7.6 million in net proceeds and that its cash should fund operations through the second quarter of 2027.

     BJDX
159. Aug 13, 2026Company Updates

     Biofrontera reports second-quarter 2026 net product revenue of $12.0 million

     Net product revenue rose 32.9% from a year earlier, and gross margin reached 80%. The net loss was $0.6 million, compared with $5.3 million in the prior-year quarter.

     BFRI
160. Aug 13, 2026Legal

     BioVie securities class certified in Nevada; three derivative suits stayed

     The 10-K says the court certified the class on June 18, 2026 in In re BioVie Inc. Securities Litigation. BioVie and unnamed officers are defendants; insurance carries a $2 million deductible.

     BIVI
161. Aug 13, 2026Financings

     Aptevo Therapeutics closes warrant inducement and private placement for about $4.5 million

     Aptevo Therapeutics (Nasdaq: APVO) closed deals that cut warrant exercise prices to $4.03 per share and sold shares or pre-funded warrants in a private placement. Roth Capital Partners was placement agent.

     APVO
162. Aug 13, 2026Legal

     Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending

     Alumis (Nasdaq: ALMS) inherited Boukadoum v. Acelyrin in its May 2025 merger. The filing names ACELYRIN and unnamed officers and directors; ACELYRIN's 2024 signers are listed.

     ALMS
163. Aug 13, 2026Company Updates

     Aethlon reports first-quarter fiscal 2027 results and third-cohort dosing

     The company reported cash of approximately $4.9 million at June 30, 2026, after raising about $4.0 million in gross proceeds after quarter-end, and operating expenses down 11.9%.

     AEMD
164. Aug 13, 2026Legal

     ARS Pharmaceuticals faces securities class action over neffy insurance coverage timeline

     A stockholder sued the company and unnamed current and former officers in the Southern District of California on August 5, 2026. A pharmacy filed a separate fax-advertising class action in July.

     SPRY
165. Aug 13, 2026Legal

     ARS Pharmaceuticals details Aptar trade secret suit and its own antitrust claim over neffy parts

     AptarGroup and Aptar France sued ARS Pharmaceuticals and ARS Pharmaceuticals Operations in March 2025. The company's separate antitrust suit against AptarGroup was moved to New York in July 2026.

     SPRY
166. Aug 12, 2026Company Updates

     iSpecimen signs $2,000,000 investor relations consulting agreement

     IR Agency LLC will provide news distribution for up to ten releases over a three-month term, and the fee is fully earned on receipt.

     ISPC
167. Aug 12, 2026Financings

     Vogenx prices IPO of 6,250,000 shares at $13.00 on Nasdaq

     Vogenx priced 6,250,000 shares at $13.00, for $81,250,000 before underwriting discounts. The prospectus shows $251 thousand of cash at March 31, 2026 and a going-concern warning.

     VOGX
168. Aug 12, 2026Distress

     Turn Therapeutics ends June with $10.3 million and a going-concern warning

     Management says June 30 cash covers GX-03 work in atopic dermatitis into the third quarter of 2027, but the 10-Q also raises substantial doubt that Turn can continue as a going concern.

     TTRX
169. Aug 12, 2026Legal

     Spero says SEC closed its investigation without action against it; two ex-executives settled

     The SEC fined former CEO Ankit Mahadevia $112,500 and former CFO Satyavrat Shukla $75,000 in a settled January 2026 order. Spero's letter of Jan 20, 2026 says the SEC does not intend to recommend action against it.

     SPRO
170. Aug 12, 2026Debt Financing

     Profusa issues $714,285.72 senior secured convertible note

     The note has a $650,000.00 purchase price and matures in August 2027. The filing names no placement agent or advisor.

     PFSA
171. Aug 12, 2026Financings

     Pharvaris reports €318 million cash after $132.3 million offering

     Pharvaris reported €318 million of cash at June 30, 2026, after a $132.3 million underwritten offering it closed in May. The company says the money extends its runway into 2028, while its quarterly loss reached €47.8 million and its key pivotal trial has yet to report.

     PHVS
172. Aug 12, 2026Distress

     PTC named winning bidder for Sangamo's Fabry gene therapy ST-920

     PTC says the ST-920 rolling BLA will be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 if the acquisition closes.

     PTCT
173. Aug 12, 2026Company Updates

     Mannatech reports second quarter 2026 net income of $1.0 million

     Net sales rose to $26.7 million for the quarter ended June 30, 2026, and the company reported net income after a net loss a year earlier.

     MTEX
174. Aug 12, 2026Financings

     Lakefront Biotherapeutics reports 241,904 shares bought back under EUR 50 million program

     Repurchases run no later than December 31, 2026. The company expects year-end 2026 cash and financial investments of EUR 1.975 billion to EUR 2.050 billion, including the buyback.

     LKFT
175. Aug 12, 2026Legal

     Inovio's supply-contract suit against VGXI and GeneOne is set for trial in October 2026

     Inovio sued VGXI, Inc. and GeneOne Life Science, Inc. in a Pennsylvania state court in 2020 over a supply agreement. The defendants counterclaimed. A seven-day trial was scheduled to begin October 13, 2026.

     INO
176. Aug 12, 2026Legal

     Humacyte securities suit over Symvess safety enters discovery; four derivative suits pending

     The North Carolina class action names Humacyte and certain officers. Derivative suits name current or former directors and officers, and Ayabudge LLC in two cases. Product safety claims survived dismissal.

     HUMA
177. Aug 12, 2026Financings

     ENvue Medical agrees to a $50 million committed equity facility

     The company can sell up to $50.0 million of common stock to one institutional investor, and the same day it amended a Series H preferred stock agreement with that investor.

     FEED
178. Aug 12, 2026Mergers

     Bio Green Med reports second-quarter results and updates Future NRG deal

     Net loss was $0.4 million for the quarter ended June 30, 2026, while the company advances a share exchange that would make Future NRG Sdn. Bhd. a wholly owned subsidiary.

     BGMS
179. Aug 12, 2026Legal

     Atara Biotherapeutics faces securities class action over tab-cel ALLELE study statements

     Kuang v. Atara, filed in Central District of California, names the company and unnamed current and former officers. An amended complaint came on August 10, and defendants must respond by October 9.

     ATRA
180. Aug 12, 2026Company Updates

     Aprea reports second-quarter 2026 results and $41.2 million in cash

     Aprea Therapeutics reported a net loss of $3.6 million for the quarter ended June 30, 2026, and said its cash should last into the first quarter of 2028. The company is also expanding enrollment in its lead WEE1 inhibitor trial.

     APRE
181. Aug 12, 2026Legal

     Alto Neuroscience IPO securities class action dismissed with leave to amend

     A federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed.

     ANRO
182. Aug 12, 2026Debt Financing

     Alkermes amends term loan credit agreement, cutting interest spreads

     JPMorgan Chase Bank, N.A. is administrative agent. The amendment cuts the spread on term loan A by 0.75% and on term loan B by 0.50%.

     ALKS
183. Aug 12, 2026Debt Financing

     Agenus extends Ocean 1181 loan maturity to November 2029

     The loan principal stays at $24,750,000 and the rate stays at 13.0%. The $247,500 extension fee is paid half in cash and half in shares.

     AGEN
184. Aug 12, 2026Company Updates

     Aditxt completes sale of Pearsanta to MDNA Holdings

     Aditxt, Inc. said that on August 12, 2026 MDNA Holdings Inc. acquired substantially all of the outstanding shares of its majority-owned subsidiary, Pearsanta, Inc. Pearsanta agreed to pay Aditxt royalties on Net Revenue and two milestone payments of $250,000 each.

     ADTX
185. Aug 12, 2026Company Updates

     AEON reports second-quarter 2026 results and a $15.3 million financing

     AEON Biopharma reported $3.4 million in cash at June 30, 2026, and said upfront proceeds from its July offering extend its runway into the first quarter of 2027. The company also regained NYSE American compliance on August 3, 2026.

     AEON
186. Aug 11, 2026Financings

     Veradermics reports $819.9 million in cash and securities, sees funding into 2030

     Veradermics reported $819.9 million in cash and securities at June 30 and says the money lasts into 2030. That runway depends on Phase 3 readouts, the first of them due in the second half of 2026.

     MANE
187. Aug 11, 2026Company Updates

     Theriva Biologics doses first VIRAGE2 patients and reports cash into Q1 2027

     The NYSE American company reported $11.3 million of cash at June 30, 2026, after first patients were dosed in a Phase 2a trial of more frequent VCN-01 dosing in pancreatic cancer.

     TOVX
188. Aug 11, 2026Legal

     TherapeuticsMD's Mayne Pharma suit is stayed; IMVEXXY patent cases against Teva and Sun continue

     TherapeuticsMD (Nasdaq: TXMD) sued Mayne Pharma LLC in Delaware over net working capital allowances and faces a countersuit. Teva and Sun Pharma are defendants in New Jersey patent cases over generic IMVEXXY.

     TXMD
189. Aug 11, 2026Legal

     Taysha derivative suit over 2023 private placement faces termination motion

     Stockholders sued in Delaware Chancery over the August 2023 private placement. A special litigation committee moved on March 3, 2026 to end the case, and the lead plaintiff does not oppose.

     TSHA
190. Aug 11, 2026Financings

     Tango Therapeutics files for up to $400,000,000 at-the-market stock program

     Tango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination.

     TNGX
191. Aug 11, 2026Financings

     Silence Therapeutics raises $175 million after divesiran phase 2 win

     The upsized offering priced at $13.50 per ADS a day after the SANRECO results, adding to $72.1 million in cash at the end of June.

     SLN
192. Aug 11, 2026Legal

     Kyverna faces IPO securities class action and consolidated derivative suit

     Kyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated.

     KYTX
193. Aug 11, 2026Company Updates

     Intensity Therapeutics reports Q2 2026 results and trial updates

     Cash and cash equivalents were $9.5 million at June 30, 2026. The company began activities to resume enrollment in its INVINCIBLE-3 study and restarted treatment in INVINCIBLE-4.

     INTS
194. Aug 11, 2026Legal

     Gain Therapeutics and CEO Gene Mack sued in Delaware over warrant exercise price

     Warrant holder Andrew Schwartzberg seeks more than $3.1 million from Gain and Gene Mack for breach of contract, fraudulent inducement and promissory estoppel. Gain's 10-Q reports going concern doubt.

     GANX
195. Aug 11, 2026Legal

     Erasca faces securities class action and ERAS-0015 derivative suit

     Erasca (Nasdaq: ERAS) is named in a June class action in San Diego federal court. An August derivative suit names its current directors and CFO. The 10-Q names no officers in the class action.

     ERAS
196. Aug 11, 2026Debt Financing

     Enlivex amends $21.0 million Lind note and resets conversion price

     Enlivex deleted a market capitalization default from its Lind note and revised conversion and prepayment terms. Outstanding principal rose to $19.2 million.

     ENLV
197. Aug 11, 2026Listings

     Eloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting

     The company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028.

     ELOX
198. Aug 11, 2026Company Updates

     Dermata reports second-quarter 2026 results and $4.4 million in cash

     Dermata Therapeutics reported $4.4 million in cash and cash equivalents at June 30, 2026, and said it expects to launch Tome Foundational Treatment on August 25, 2026. Cash is expected to fund operations into the fourth quarter of 2026.

     DRMA
199. Aug 11, 2026Company Updates

     Bolt Biotherapeutics reports second-quarter results and cash into 2027

     The company had $18.1 million in cash, cash equivalents and marketable securities on June 30, 2026. It expects to report initial clinical data from its lead antibody conjugate, BDC-4182, with its third-quarter results.

     BOLT
200. Aug 11, 2026Legal

     Bicara and Biocon face Y-Trap inventorship suit over ficerafusp alfa patents

     Y-Trap, Inc. sued Bicara Therapeutics and Biocon Ltd in Massachusetts federal court in October 2024. Discovery is ongoing, and a patent office review Bicara requested was instituted on July 15, 2026.

     BCAX
201. Aug 11, 2026Distress

     Aura Biosciences cuts about 20% of workforce, expects cash runway into 2029

     The company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients.

     AURA
202. Aug 11, 2026Financings

     Absci cash rises to $201 million after June raise; Lilly invests $40 million

     The company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody.

     ABSI
203. Aug 11, 2026Financings

     AbCellera launches $200,000,000 share offering, then prices it at $9.75

     A later announcement prices 17,435,897 common shares and pre-funded warrants for 3,076,926 shares, for expected gross proceeds of about $200.0 million. The offering is expected to close on August 14, 2026.

     ABCL
204. Aug 10, 2026Listings

     Wave Life Sciences Ltd. (now Wave Life Sciences, Inc.) files Form 15 to end SEC reporting

     The notice lists one holder of record of the ordinary shares and is dated August 7, 2026. Wave Life Sciences Ltd. reported a net loss of $204.4 million for 2025.

     WVE
205. Aug 10, 2026Legal

     Veru faces securities class action and five derivative suits over sabizabulin statements

     Veru, Chairman and CEO Mitchell Steiner and CFO Michele Greco are defendants in a Florida class action. Five derivative suits name seven officers and directors. Veru says it cannot estimate losses.

     VERU
206. Aug 10, 2026Legal

     Veru faces fraud and warranty suit from the buyer of its FC2 business

     Clear Future, Inc. sued Veru Inc. in Delaware Superior Court after buying the FC2 female condom business for $18.0 million in cash. Veru is the defendant named in the 10-Q and says it cannot estimate losses.

     VERU
207. Aug 10, 2026Legal

     Sana Biotechnology securities class action is stayed after second amended complaint

     The Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed.

     SANA
208. Aug 10, 2026Legal

     Rocket Pharmaceuticals faces securities class action and derivative suit over Danon trial

     Ho and Yankov complaints named Rocket, CEO Gaurav Shah and former CFO Aaron Ondrey. Rocket's motion to dismiss the consolidated complaint is pending, and a derivative suit is stayed.

     RCKT
209. Aug 10, 2026Company Updates

     Palisade Bio reports second quarter 2026 results and Phase 2 plans for PALI-2108

     The company reported a net loss of $10.6 million for the quarter and cash of $125.2 million at June 30, 2026. It expects to start the Phase 2 ASCENTRA-UC trial in the second half of 2026.

     PALI
210. Aug 10, 2026Debt Financing

     OS Therapies sells up to $10,000,000 of senior secured convertible notes

     The first closing on August 10, 2026 covered $5,000,000 of units, including a bridge note conversion, and the second tranche is optional for each purchaser.

     OSTX
211. Aug 10, 2026Legal

     MoonLake faces securities class action over sonelokimab; motion to dismiss pending

     The Peters suit names MoonLake and its chief executive, chief financial and chief scientific officers. The class period runs March 10, 2024 through September 29, 2025.

     MLTX
212. Aug 10, 2026Legal

     Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery

     Vreeland v. Metagenomi names the company, unnamed officers and directors under Section 11. The court partly denied dismissal on March 24, 2026; the S-1 shows who signed.

     MGX
213. Aug 10, 2026Listings

     Lakewood-Amedex Biotherapeutics sets vote on share increase to 100,000,000 and reverse split

     Holders will vote on September 22, 2026 on raising authorized common stock from 12,500,000 shares and on a reverse split of up to 1-for-20.

     LABT
214. Aug 10, 2026Company Updates

     Interpace Biosciences reports second quarter revenue of $9.1 million

     Revenue was $9.1 million, down slightly from the prior-year quarter as reported, while income from continuing operations was $0.3 million and thyroid revenue rose 9%.

     IDXG
215. Aug 10, 2026Financings

     Cogent Biosciences files for up to $400,000,000 at-the-market stock sales

     Guggenheim Securities may act as agent or principal and is entitled to a 3.0% commission. The last reported sale price on August 7, 2026 was $42.39 per share, and the supplement puts dilution to new buyers at $37.68 per share.

     COGT
216. Aug 10, 2026Company Updates

     Bionano reports second quarter 2026 revenue of $8.2 million

     Consumables revenue rose 31%, and the company completed the retirement of its senior secured convertible debentures.

     BNGO
217. Aug 10, 2026Debt Financing

     BioXcel amends Oaktree credit agreement, sets August 21 deadline

     Oaktree Fund Administration, LLC is administrative agent. The amendment requires definitive transaction agreements by August 21, 2026 and sets the minimum liquidity amount at $3,000,000 from August 10, 2026.

     BTAI
218. Aug 10, 2026Legal

     Axsome resolves all Sunosi patent suits; Symbravo case against Apotex continues

     Axsome's 10-Q says it has settled with every current Sunosi ANDA filer, the last being Aurobindo on June 2, 2026. Its Symbravo patent suit against Apotex Inc. is in fact discovery.

     AXSM
219. Aug 10, 2026Legal

     Axsome derivative suit dismissed in Delaware; New York case awaits ruling on motion

     Stockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed.

     AXSM
220. Aug 10, 2026Debt Financing

     Aspire closes $30.0 million cash acquisition and enters $22.5 million revolver

     The senior secured revolving credit facility will help fund the cash price for Dura Driver Control Systems, along with cash on hand. The release names no lender.

     ASBP
221. Aug 10, 2026Distress

     Anavex Life Sciences says it cannot file its June quarter report on time

     The company cites a special committee's review of matters tied to the April 30, 2026 termination of its chief executive. Its quarterly report for the period ended March 31, 2026 is also listed as not filed.

     AVXL
222. Aug 10, 2026Distress

     Anavex Life Sciences files NT 10-Q, says June quarter report is late amid special committee review

     Anavex (Nasdaq: AVXL) cannot file its 10-Q for the quarter ended June 30, 2026 on time. The company also lists its 10-Q for the quarter ended March 31, 2026 as not yet filed.

     AVXL
223. Aug 10, 2026Company Updates

     Adial expects CEO and CFO to leave after its September annual meeting

     Adial anticipates that Cary Claiborne and Vinay Shah will leave after stockholders approve the proposals at the annual meeting, and that Matthew Davidson will become president and chief executive officer.

     ADIL
224. Aug 7, 2026Legal

     aTyr Pharma moves to dismiss amended class action over efzofitimod statements

     Defendants: aTyr Pharma, CEO Sanjay Shukla and, since May, CFO Jill M. Broadfoot. The July 17 motion to dismiss targets the amended complaint; aTyr committed on August 7 to cut 60% of staff.

     ATYR
225. Aug 7, 2026Debt Financing

     TuHURA Biosciences draws $650,000 more on its Parkview credit line

     The draw is part of a revolving credit facility of up to $50 million with Parkview Holdings One LLC that matures in April 2031.

     HURA
226. Aug 7, 2026Company Updates

     OSR Health says Nasdaq did not endorse its loyalty CVR program

     The company said a July 31 statement should not be read as Nasdaq approval of the Shareholder Loyalty CVR Program, and the August 14, 2026 record date is unchanged.

     OSRH
227. Aug 7, 2026Legal

     Natera appeals Guardant false advertising judgment after $292.5 million verdict

     A jury found Natera liable in November 2024 in the Northern District of California. Final judgment came in June 2026 and Natera is appealing to the Ninth Circuit.

     NTRA
228. Aug 7, 2026Company Updates

     Minerva Neurosciences reports second quarter 2026 results and C19 trial progress

     Minerva reported GAAP net income of $17.5 million for the quarter, driven by a non-cash warrant gain, and cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026.

     NERV
229. Aug 7, 2026Legal

     Merck faces securities class action over Gardasil demand in China, with derivative suits stayed

     Cronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees.

     MRK
230. Aug 7, 2026Financings

     Latigo Biotherapeutics prices IPO of 19,200,000 shares at $18.00

     The offering totals $345,600,000 before underwriting discounts, and the company's auditors have raised going-concern doubt.

     LTGO
231. Aug 7, 2026Company Updates

     Kiora reports second quarter 2026 results and cash runway into late 2028

     Kiora ended the quarter with about $16.8 million in cash and short-term investments. The company also reported a private placement for up to $24.0 million, with $5.0 million received upfront.

     KPRX
232. Aug 7, 2026Financings

     Glucotrack amends White Lion equity line with commitment shares

     Glucotrack amended its July 14, 2026 common stock purchase agreement with White Lion Capital, LLC, agreeing to issue 2,505,513 commitment shares and to pay a true-up amount if the commitment fee price falls below the minimum price.

     GCTK
233. Aug 7, 2026Financings

     Corbus Pharmaceuticals sets up sales program for up to $127,500,000

     Corbus can sell up to $127,500,000 of common stock through Jefferies LLC, which earns a fixed 3% commission on each share. At the $9.40 price the filing uses, new buyers would see $2.46 a share of immediate dilution.

     CRBP
234. Aug 7, 2026Legal

     CervoMed discloses ex-CEO's 2014 suit, narrowed in March, with trial set for October

     Paul Feller sued RestorGenex, Pro Sports & Entertainment, ProElite and Stratus Media Group, GmbH in Los Angeles. The court dismissed some claims on March 26, 2026. CervoMed says it is defending itself vigorously.

     CRVO
235. Aug 7, 2026Financings

     BlossomHill prices IPO of 9,375,000 shares at $16.00, $150,000,000 in total

     BlossomHill priced 9,375,000 shares at $16.00 for $150,000,000 before costs, with delivery expected on or about August 10, 2026. The auditor's report on the 2025 financial statements includes a going-concern paragraph.

     BLSM
236. Aug 7, 2026Company Updates

     BioRestorative suspends orders and shipments of two biocosmeceutical lines

     The company paused its ExoCR and BioX products on August 7, 2026 while it reviews documentation, sourcing and regulatory status. It has not decided to discontinue them.

     BRTX
237. Aug 7, 2026Listings

     Aptorum Group (now Niki BioSolutions) regains Nasdaq bid price compliance

     Nasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls.

     NIKI
238. Aug 7, 2026Legal

     Agenus securities class action dismissed, plaintiff appeals; SEC closes investigation

     The District of Massachusetts dismissed In re Agenus Inc. Securities Litigation on March 24, 2026. The lead plaintiff appealed to the First Circuit, where briefing began in June. Derivative suits remain stayed.

     AGEN
239. Aug 7, 2026Legal

     ANI loses post-trial motions in CG Oncology royalty case and defends Acella suit

     A Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25.

     ANIPCGON
240. Aug 7, 2026Legal

     ANI and Novitium face two generic drug patent suits and antitrust counterclaims in a third

     Orphalan sued Novitium, and Xeris and Strongbridge sued Novitium and ANI. In a Harmony patent case against AET and Sandoz entities, the defendants counterclaim against Harmony and Novitium.

     ANIP
241. Aug 6, 2026Financings

     iSpecimen prices $5 million public offering at $1.30 per share

     E.F. Hutton & Co. is the exclusive placement agent, and the offering is expected to close on August 7, 2026.

     ISPC
242. Aug 6, 2026Listings

     Zhengye Biotechnology regains Nasdaq bid price compliance

     Nasdaq's August 5, 2026 letter says the Class A ordinary shares closed at $1.00 or more for ten straight business days. The shares stay on the Nasdaq Capital Market.

     ZYBT
243. Aug 6, 2026Company Updates

     VivoSim Labs reports regained equity compliance after July cash events

     VivoSim Labs said Nasdaq told it on August 4, 2026 that it met the $2.5M stockholders' equity minimum, after a $5.0 million milestone payment, an escrow release and a $4.0 million financing in July.

     VIVS
244. Aug 6, 2026Legal

     Viatris faces Indore plant securities class action and derivative suits in two federal courts

     Viatris (Nasdaq: VTRS) and unnamed current and former officers are defendants in a Pennsylvania class action over Indore disclosures. Derivative suits name officers and directors in Pennsylvania and Delaware.

     VTRS
245. Aug 6, 2026Legal

     Verrica agrees in principle to settle 2022 securities class action over YCANTH

     Defendants: Verrica and unnamed current and former officers and directors. A July term sheet would end a case certified in March; Verrica accrued $4.0 million and needs court approval.

     VRCA
246. Aug 6, 2026Company Updates

     Theriva doses first patient in VIRAGE2 pancreatic cancer trial

     The Phase 2a study will test more frequent repeated dosing of VCN-01 with standard chemotherapy in first-line metastatic pancreatic cancer.

     TOVX
247. Aug 6, 2026Financings

     Tarsus agrees to buy Alkeus for $270,000,000 in cash and $180,000,000 in stock

     The merger agreement signed July 31, 2026 also provides milestone payments of up to $350,000,000. Closing needs Hart-Scott-Rodino clearance, and Tarsus expects to complete the deal in 2026.

     TARS
248. Aug 6, 2026Financings

     SpyGlass ends June with $234.2 million and says cash lasts through 2028

     Second-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that.

     SGPGKOS
249. Aug 6, 2026Financings

     Solid Biosciences adds sales program of up to $200,000,000 with Jefferies

     Solid Biosciences filed a prospectus supplement for up to $200,000,000 of at-the-market stock sales through Jefferies, replacing a prior $85,000,000 program. The filing says buyers would face dilution of about $4.30 per share at an assumed $8.73 price.

     SLDB
250. Aug 6, 2026Financings

     Scholar Rock files new $200 million at-the-market stock program

     The Jefferies program replaces a November 2025 prospectus and has raised about $257.7 million in net proceeds to date. The filing came the day the company reported second-quarter results.

     SRRK
251. Aug 6, 2026Financings

     Roivant posts $290.6M quarterly loss, $3.9B cash, and keeps buying back stock

     The holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end.

     ROIV
252. Aug 6, 2026Company Updates

     Revelation reports second quarter 2026 results and cash into early 2027

     Revelation reported a net loss of $3.3 million for the quarter and $11.5 million in cash at June 30, 2026, which it says can fund operations through the first quarter of 2027.

     REVB
253. Aug 6, 2026Legal

     Relay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay

     Hayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss.

     RLAY
254. Aug 6, 2026Financings

     Relay Therapeutics adds $212,978,049 to at-the-market stock program

     Relay Therapeutics amended its stock sales agreement on August 6, 2026 to add $212,978,049 of at-the-market sales, raising the program to $462,978,049. The prospectus puts immediate dilution at $14.22 a share for investors who buy in the offering.

     RLAY
255. Aug 6, 2026Legal

     Puma's malpractice suit against former law firm waits on North Carolina Supreme Court

     Puma is suing Hedrick Gardner Kincheloe & Garofalo, L.L.P. and attorney David L. Levy over its defense in the Eshelman case. The Court of Appeals revived the claim on Sept. 3, 2025.

     PBYI
256. Aug 6, 2026Legal

     PepGen reports its securities class action and shareholder demand are over

     The 10-Q says the Karam suit against PepGen, its CEO and its CFO was voluntarily dismissed on Nov. 18, 2025. The filing does not name the officers; the 2023 annual report shows McArthur and Donnelly.

     PEPG
257. Aug 6, 2026Financings

     Oculis reports CHF 47,775 thousand from at-the-market share sales in first half

     Oculis sold 2,250,000 shares under its ATM program for CHF 47,775 thousand in the first half of 2026. Cash and cash equivalents fell to CHF 61,614 thousand at June 30, 2026.

     OCS
258. Aug 6, 2026Legal

     Ocugen awaits Third Circuit ruling in dismissed securities suit as derivative suits remain stayed

     The 10-Q says the defendants in the Pennsylvania class action are the company and "certain of its agents" and names none. Derivative suits in two courts are stayed, and a Delaware class action over the charter was dismissed as moot.

     OCGN
259. Aug 6, 2026Company Updates

     MetaVia reports second quarter 2026 net loss of $5.3 million

     MetaVia reported a net loss of $5.3 million for the quarter ended June 30, 2026, with cash and cash equivalents of $12.6 million, and said all active Part 3 patients reached their highest planned doses.

     MTVA
260. Aug 6, 2026Legal

     Iovance faces securities class action and three derivative suits over 2025 revenue forecast

     Iovance (Nasdaq: IOVA) and unnamed officers are defendants in a California class action over 2025 revenue guidance. Derivative suits against Frederick Vogt, Jean-Marc Bellemin and others are stayed. Iovance has moved to dismiss.

     IOVA
261. Aug 6, 2026Legal

     Iovance defends two Delaware derivative suits over director pay and a 2024 stock offering

     Iovance (Nasdaq: IOVA) is a nominal defendant in two Court of Chancery suits against its directors. A 2020 pay suit is consolidated and a 2024 offering suit is in motion-to-dismiss briefing.

     IOVA
262. Aug 6, 2026Legal

     Intellia says court dismissed securities class action; director pay and patent suits continue

     A Massachusetts court fully granted dismissal of the Gonzalez suit against Intellia (Nasdaq: NTLA) and unnamed officers on June 18, 2026. A Delaware suit against directors and BlueAllele's patent suit remain open.

     NTLA
263. Aug 6, 2026Company Updates

     IN8bio reports second quarter 2026 results and glioblastoma survival data

     IN8bio reported cash of $18.0 million at June 30, 2026 and a net loss of $4.8 million for the quarter, along with updates on its glioblastoma and gamma-delta T cell engager programs.

     INAB
264. Aug 6, 2026Debt Financing

     ICON plc subsidiary prices senior notes to repay bridge and term loans

     ICON plc said its subsidiary priced three series of senior unsecured notes. Proceeds are meant to repay its bridge facility, senior secured term loans and 2027 notes.

     ICLR
265. Aug 6, 2026Legal

     Gilead cites August 2026 ruling in HIV drug injury suits with about 23,000 active plaintiffs

     The 10-Q names Gilead as defendant, with no co-defendants listed, in a putative class action and product liability suits over Viread, Truvada, Atripla, Complera and Stribild. A federal bellwether trial is set for March 2027.

     GILD
266. Aug 6, 2026Legal

     Gilead HIV antitrust appeal awaits ruling after October 2025 argument; Aetna trial set for 2027

     Gilead, Bristol-Myers Squibb, Johnson & Johnson and Teva are defendants in consolidated federal suits over HIV drugs. Gilead paid $525 million in 2023 to settle with the direct purchaser class and retailer opt-out plaintiffs.

     GILD
267. Aug 6, 2026Financings

     GH Research reports $111.2 million net proceeds from April 2026 share offering

     The April offering sold 6,527,779 shares at $18.00. The interim report does not name the underwriters, and the six-month loss rose to $34,113 thousand.

     GHRS
268. Aug 6, 2026Legal

     Federal Circuit affirms invalidity of Puma-licensed patents in Tagrisso suit against AstraZeneca

     The Federal Circuit affirmed on July 9, 2026 that the asserted patent claims are invalid. Wyeth, the Pfizer subsidiary and co-plaintiff, had won a $107.5 million jury award against AstraZeneca Pharmaceuticals LP and AstraZeneca AB.

     PBYI
269. Aug 6, 2026Mergers

     Ensysce Biosciences buys Cy Biopharma, agrees to two-tranche private placement of Series C stock

     Ensysce completed its acquisition of Cy Biopharma on August 5, 2026 and agreed to a Series C private placement of about $43 million in two tranches. After the deal, Cy's former holders would own about 73.86% of Ensysce on a fully diluted basis, and the second tranche depends on a clinical milestone.

     ENSC
270. Aug 6, 2026Financings

     Celldex holds $717.6 million before phase 3 readout; CFO Sam Martin to retire

     An April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027.

     CLDX
271. Aug 6, 2026Financings

     Braveheart Bio prices IPO of 21,250,000 shares at $18.00

     Braveheart Bio's final prospectus, dated August 5, 2026, prices 21,250,000 shares at $18.00 each. Net proceeds are estimated at $351.2 million, and the company's accumulated deficit was $80.3 million at March 31, 2026.

     BRVE
272. Aug 6, 2026Company Updates

     BioVie reports topline results from Phase 2 SUNRISE-PD trial in Parkinson's disease

     BioVie said bezisterim met its prespecified endpoints in early-stage Parkinson's disease, with improved blood inflammatory markers and better composite clinical outcomes than placebo.

     BIVI
273. Aug 6, 2026Financings

     Artiva Biotherapeutics files $400,000,000 shelf with $100,000,000 ATM program

     The at-the-market program would run through Leerink Partners as sales agent. The company's stock last sold at $11.59 per share on August 5, 2026.

     ARTV
274. Aug 6, 2026Legal

     Ardelyx securities suit over Xphozah ends after appeal is withdrawn

     Yarborough v. Ardelyx named the company and executives Michael Raab, Susan Rodriguez, Laura Williams and Elizabeth Grammer. The First Circuit appeal was dismissed on March 26, 2026.

     ARDX
275. Aug 6, 2026Legal

     Arcturus sues AbbVie and Capstan over trade secrets, and Capstan counterclaims

     Arcturus filed in the Southern District of California on September 23, 2025. Capstan Therapeutics answered with counterclaims against the company and two employees, and no trial date is set.

     ARCT
276. Aug 6, 2026Company Updates

     AquaBounty widens Ohio strategic review to power infrastructure

     AquaBounty said on August 6, 2026 that its review of the Pioneer, Ohio property now covers power infrastructure and energy development, alongside its aquaculture sale talks.

     AQB
277. Aug 6, 2026Financings

     AgomAb Therapeutics NV reports €252.0 million cash after $208 million IPO

     Cash of €252.0 million compares with a six-month net loss of €31.0 million and €29,917 thousand used in operating activities. The release gives no efficacy figures for either of the two drugs.

     AGMB
278. Aug 5, 2026Listings

     Vistagen gets 180-day Nasdaq extension, until February 1, 2027, on minimum bid price rule

     Nasdaq gave Vistagen until February 1, 2027 to restore a $1.00 minimum bid, while its 10-K says its lead Phase 3 study missed the primary endpoint. It used $42.1 million in operations in its last fiscal year.

     VTGN
279. Aug 5, 2026Legal

     Revolution Medicines reports final judgment in Delaware suit over EQRx merger

     The Court of Chancery dismissed Nemeth v. Casdin with prejudice on June 18, 2026 after a settlement. Revolution was named only as successor to EQRx, alongside its director Alexis Borisy and others.

     RVMD
280. Aug 5, 2026Legal

     Recursion and its lab landlord remain in Utah court over lease construction claims

     Industry Office SLC sued Recursion in 2023 for breach of contract; Recursion counterclaimed for breach and fraudulent misrepresentation. Both sides are in discovery. An Exscientia class action ended in December 2025.

     RXRX
281. Aug 5, 2026Company Updates

     Q32 Bio reports Q2 2026 net loss of $8.9 million and $106.3 million cash

     The company reported positive 36-week topline results for bempikibart and completed a $200.0 million public offering in July 2026.

     QTTB
282. Aug 5, 2026Legal

     Perrigo faces New York securities class action over infant formula statements

     The 10-Q names Perrigo, CFO Eduardo Bezerra and former CEOs Patrick Lockwood-Taylor and Murray Kessler in French v. Perrigo. A Teamsters pension fund is lead plaintiff and filed an amended complaint on May 1, 2026.

     PRGO
283. Aug 5, 2026Legal

     Mirum sues Sandoz, Hetero, Biophore and Zydus in Delaware over generic Livmarli; trial set for 2028

     Mirum, Satiogen and Shire Human Genetic Therapies are plaintiffs in four consolidated cases. A 30-month FDA stay runs through March 29, 2029, and the Markman hearing is April 21, 2027.

     MIRM
284. Aug 5, 2026Legal

     Geron faces Rytelo securities class action and four derivative suits

     Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss.

     GERN
285. Aug 5, 2026Listings

     Genprex regains Nasdaq bid price compliance, panel oversight runs to December 7

     Nasdaq's Hearings Panel confirmed on August 4, 2026 that Genprex regained the $1.00 minimum bid price, but the panel keeps jurisdiction until December 7, 2026.

     GNPX
286. Aug 5, 2026Mergers

     Eton Pharmaceuticals licenses ASN-001 from Auson for $3.0 million upfront

     Eton (Nasdaq: ETON) signed a license agreement for ASN-001, a late-stage infantile hemangioma gel. It owes milestone payments after FDA approval and tiered royalties of 10% to 15% on net sales.

     ETON
287. Aug 5, 2026Distress

     Emergent BioSolutions posts $180.2 million Q2 loss, cuts about 90 roles

     A $191.3 million non-cash impairment charge drove the loss. The company expects annualized savings of approximately $40 million from the restructuring.

     EBS
288. Aug 5, 2026Company Updates

     Dermata sets August 25, 2026 sale date for Tome Foundational Treatment

     Dermata Therapeutics expects its first commercial product, Tome Foundational Treatment, to be available for sale starting August 25, 2026. The set of four once-weekly treatments sells for $178, about $45 per treatment.

     DRMA
289. Aug 5, 2026Legal

     Context Therapeutics closes Delaware suit over three-year director terms; $850,000 fee paid

     The Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000.

     CNTX
290. Aug 5, 2026Legal

     BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO

     BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible.

     BCRX
291. Aug 5, 2026Legal

     BioAge faces Ninth Circuit appeal of dismissed IPO securities class action

     BioAge Labs' 10-Q says a federal court dismissed the IPO securities class action with prejudice on March 2, 2026, and the plaintiff has appealed to the Ninth Circuit. The defendants are BioAge, its directors and certain officers, and the filings do not name the officers.

     BIOA
292. Aug 5, 2026Listings

     Aura Biosciences holders approve raising authorized shares to 500,000,000

     Authorized common shares rise from 150,000,000. The August 5, 2026 special meeting also approved an amendment to the 2021 Stock Option and Incentive Plan.

     AURA
293. Aug 5, 2026Financings

     Attovia Therapeutics prices IPO of 17,000,000 shares at $17.00

     The offering totals $289,000,000 before fees. The shares have been approved for listing on the Nasdaq Global Market as ATTO.

     ATTO
294. Aug 5, 2026Financings

     Arcus ends last TIGIT phase 3 as Gilead gives up its three board seats

     Arcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of 2028.

     RCUSGILDAZN
295. Aug 5, 2026Legal

     Amgen's ChemoCentryx securities class action settlement gets preliminary approval

     Homyk v. ChemoCentryx named ChemoCentryx and its CEO over TAVNEOS statements. A California federal court preliminarily approved a class settlement on June 12, 2026; final hearing is October 29.

     AMGN
296. Aug 5, 2026Legal

     Amgen agrees to settle Roofers securities class action over IRS tax disclosures

     Amgen, CEO Robert Bradway and CFO Peter Griffith agreed to settle the New York class action, subject to court approval. Derivative suits against directors are stayed.

     AMGN
297. Aug 5, 2026Legal

     Acadia awaits Federal Circuit ruling in Nuplazid patent suits; Zydus trial set for Nov. 2

     Acadia is the plaintiff against Aurobindo, MSN, Teva and Zydus entities. A June 2025 judgment for Acadia is on appeal, and a new Zydus case goes to trial November 2, 2026.

     ACAD
298. Aug 4, 2026Financings

     Tyra Biosciences sold full $150,000,000 under sales program, raises limit to $250,000,000

     Tyra Biosciences has sold the full $150,000,000 under its May 2025 at-the-market agreement and has raised the ceiling to $250,000,000. The filing also shows a 2025 net loss of $119.9 million and cash used in operations of $95.1 million.

     TYRA
299. Aug 4, 2026Legal

     OnKure says plaintiffs have not pursued two New York suits over its Reneo merger proxy

     Thomas and Kent v. Reneo name Reneo and unnamed individual defendants. The 10-Q says plaintiffs have not pursued the claims; the 2024 proxy lists Reneo's board.

     OKUR
300. Aug 4, 2026Financings

     OnKure files $100,000,000 at-the-market stock sale supplement

     The company says it is no longer subject to a Form S-3 sales limit. It had not sold any Class A shares under the program as of August 4, 2026.

     OKUR
301. Aug 4, 2026Legal

     Niagen Bioscience details consumer class actions, Thorne suit and Elysium fee appeal

     Niagen and its ChromaDex subsidiary are sued in two consumer class actions and a Thorne patent case. A Federal Circuit ruling on a $9.2 million fee award to Elysium is pending.

     NAGE
302. Aug 4, 2026Debt Financing

     Glucotrack adds $3,500,000 to secured convertible bridge financing

     Glucotrack issued follow-on senior secured convertible notes with a $4,487,179 face amount and sold pre-funded warrants in an interim private placement.

     GCTK
303. Aug 4, 2026Company Updates

     Faeth Therapeutics reports $186.4 million in cash and securities after Sensei combination

     Faeth reported a net loss of $16.0 million for the quarter ended June 30, 2026, and said topline data from its Phase 2 PIK-201 trial in endometrial cancer are expected by year-end.

     FTH
304. Aug 4, 2026Financings

     CAMP4 completes second closing of private placement for $50.1 million gross proceeds

     CAMP4 Therapeutics sold 10,756,498 shares and pre-funded warrants for 21,925,368 shares on August 3, 2026, after the trigger for the second closing was satisfied.

     CAMP
305. Aug 4, 2026Distress

     Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges

     Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million.

     BIO
306. Aug 4, 2026Legal

     Arrowhead still defending Ionis patent suit over plozasiran after Delaware case was dismissed

     Ionis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025.

     ARWR
307. Aug 4, 2026Financings

     60 Degrees Pharmaceuticals closes private placement for about $1.0 million gross proceeds

     60 Degrees sold shares at $1.74 for approximately $1.0 million gross, with H.C. Wainwright & Co. as exclusive placement agent, after its annual report carried a going-concern warning.

     SXTP
308. Aug 3, 2026Legal

     Supernus faces January 2027 APOKYN antitrust trial; related insurance suits pending

     Sage Chemical and TruPharma sued Supernus, Britannia, US WorldMeds and others in Delaware. Four individuals were dismissed in 2024. Insurance coverage suits tied to an unnamed Delaware action are open.

     SUPN
309. Aug 3, 2026Debt Financing

     Supernus and Indivior plan merger backed by $650 million Citibank loan

     Supernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026.

     SUPNINDV
310. Aug 3, 2026Financings

     Stoke Therapeutics files new $200,000,000 at-the-market stock program

     Stoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million.

     STOK
311. Aug 3, 2026Company Updates

     QHSLab reports second-quarter 2026 revenue up 40.1%

     Total revenue rose 40.1% to $847,490 in the quarter ended June 30, 2026, and ISP revenue rose 86.4%, the company said in unaudited results.

     USAQ
312. Aug 3, 2026Legal

     Ocular Therapeutix faces EyePoint defamation suit; injunction ruling still pending

     EyePoint, Inc. sued Ocular in Massachusetts state court on March 20, 2026 over alleged false statements about DURAVYU. The court denied a restraining order on April 13 and has not ruled on a preliminary injunction.

     OCUL
313. Aug 3, 2026Mergers

     LogicMark agrees to $1.31 per share cash merger with Langham Project

     The agreement dated July 31, 2026 would convert LogicMark into a wholly owned subsidiary of Langham Project, LLC, subject to a shareholder vote and other conditions.

     LGMK
314. Aug 3, 2026Distress

     Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea

     Kuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders.

     LSTA
315. Aug 3, 2026Legal

     Krystal Biotech sued in Delaware over inventorship of two KB407 cystic fibrosis patents

     Jonathan Forman says he conceived of inventions claimed in two U.S. patents and was wrongly left off as an inventor. Krystal is the named defendant and says the claims are without merit.

     KRYS
316. Aug 3, 2026Legal

     Krystal Biotech reports DOJ subpoenas on VYJUVEK testing program, director pay suit settlement

     The company and certain employees received Justice Department subpoenas in early 2025. A Delaware derivative suit over non-employee director pay has a fairness hearing set for September 14, 2026.

     KRYS
317. Aug 3, 2026Financings

     Cocrystal sells $5 million of stock to OPKO Health

     OPKO Health, a longtime shareholder, buys 5,474,053 shares at $0.9134 each in a private placement with no warrants attached.

     COCPOPK
318. Aug 3, 2026Debt Financing

     Autolus issues first $75 million under up to $250 million Perceptive facility

     Autolus issued an initial $75 million of notes to Perceptive Advisors on July 30, 2026 under a five-year, interest-only credit facility of up to $250 million. The company's outlook for cash into the second quarter of 2028 counts the first two tranches totaling $100 million.

     AUTL
319. Aug 3, 2026Financings

     Autolus issues $75.0 million of notes under up to $250.0 million Perceptive facility

     The senior secured notes mature July 30, 2031. Perceptive also received a warrant for up to 3,500,000 American Depositary Shares at $1.9314 each.

     AUTL
320. Aug 3, 2026Debt Financing

     Amneal reprices $2.039 billion term loan and adds $45.2 million

     Amneal's subsidiary converted $2.039 billion of term loans into new loans with a lower interest margin and added a $45.2 million term loan. The company estimates about $12 million of annual cash interest savings, and the maturity stays at August 1, 2032.

     AMRX
321. Aug 3, 2026Financings

     Alzamend Neuro sells $7.5 million of Series D preferred to affiliate Ault Lending

     The agreement allows up to $25 million of Series D convertible preferred stock, and the first tranche closed July 31, 2026.

     ALZN
322. Aug 3, 2026Listings

     AEON regains NYSE American compliance after July offering

     NYSE Regulation confirmed that AEON resolved the stockholders' equity deficiencies it had reported, after an offering that closed on July 15, 2026. The company expects the below-compliance indicator to be removed from its trading symbol.

     AEON

July 2026

1. Jul 31, 2026Debt Financing

   ProPhase Labs issues $2,085,000 senior secured convertible note

   ProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027.

   PRPH
2. Jul 31, 2026Listings

   PDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January 26, 2027

   Nasdaq said PDS Biotechnology's common stock closed below $1.00 for 30 consecutive business days. The letter has no immediate effect on its Nasdaq Capital Market listing, and the company names a reverse stock split as one option.

   PDSB
3. Jul 31, 2026Legal

   Organon faces securities class action over dividend statements and a merger proxy suit

   Teamsters Local 710 leads a consolidated New Jersey class action against Organon and unnamed officers. Two derivative suits are stayed, and a July 6 suit against the board and Sun Pharma entities challenges the merger proxy.

   OGN
4. Jul 31, 2026Financings

   Nuwellis prices $3.4 million registered direct offering at $2.59 a share

   Ladenburg Thalmann & Co. Inc. is the exclusive placement agent, and the deal includes warrants to buy up to 1,310,890 shares.

   NUWE
5. Jul 31, 2026Financings

   Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note

   Northwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000.

   NWBO
6. Jul 31, 2026Company Updates

   Nasdaq tells OSR Health its loyalty CVR program will not adjust price

   In a verbal communication, Nasdaq said the Shareholder Loyalty CVR program will not trigger a mechanical price adjustment, OSR Health said on July 31, 2026.

   OSRH
7. Jul 31, 2026Listings

   Mira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027

   Nasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million.

   MIRA
8. Jul 31, 2026Financings

   Hepion closes $3,055,000 private placement with matching warrants

   Agreements dated July 31, 2026 cover 61,100,000 shares at $0.05 per share. The offering closed on August 3, 2026, and the filing names no underwriter.

   HEPA
9. Jul 31, 2026Listings

   Evogene calls September 4 meeting on director slates, share capital and reverse split

   Evogene's board backs its own seven-person slate over a rival four-person slate at a September 4 meeting, and asks for 120,000,000 more authorized shares and a reverse split of 1-for-2 to 1-for-15. Year-end cash fell to $13.0 million in 2025.

   EVGN
10. Jul 31, 2026Financings

    Co-Diagnostics warrant inducement expected to raise about $2.67 million

    Holders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent.

    CODX
11. Jul 31, 2026Debt Financing

    CDT Equity raises J.J. Astor note to $2,266,650 at 19% interest

    CDT Equity and J.J. Astor & Co. signed a second amendment on July 31, 2026 that raised the note's principal to $2,266,650 at 19% interest. Weekly installments of $104,187.65 start August 19, 2026, and the lender may convert part of the balance into common stock.

    CDT
12. Jul 31, 2026Debt Financing

    BioXcel amends Oaktree credit agreement and defers payment

    BioXcel's Eleventh Amendment moves a $9,016,914.47 payment to August 31, 2026, lowers the minimum liquidity amount to $6,250,000 and requires definitive transaction agreements by August 10, 2026.

    BTAI
13. Jul 31, 2026Financings

    Apnimed prices IPO of 12,000,000 shares at $16.00

    Apnimed priced 12,000,000 shares at $16.00 for $192,000,000 before fees. The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus.

    APMD
14. Jul 31, 2026Debt Financing

    Aiforia signs EUR 20 million venture debt with EIB

    The binding agreement with the European Investment Bank has three tranches and covenants tied to management changes.

15. Jul 31, 2026Listings

    Aethlon effects 1-for-5 reverse stock split effective July 31

    The split takes effect at 10:00 a.m. Eastern Time on July 31, 2026, and shares are expected to trade split-adjusted on August 4, 2026 under AEMD.

    AEMD
16. Jul 30, 2026Company Updates

    PTC raises 2026 product revenue guidance after second quarter

    PTC reported second quarter 2026 total revenue of $361 million, including $239 million of product revenue, and raised full-year product revenue guidance to $850 to $950 million.

    PTCT
17. Jul 30, 2026Financings

    Novo Holdings cuts MapLight stake below 5% after July 30 share sales

    The Danish investor sold 1.6 million shares in open-market trades at $12.00 to $15.00 and reported 2,086,622 shares left, about 4.9%.

    MPLT
18. Jul 30, 2026Listings

    Nasdaq panel grants Genprex an exception on the $1.00 bid price rule

    The panel's July 29, 2026 decision lets Genprex stay listed on the Nasdaq Capital Market while it keeps a closing bid of at least $1.00 each trading day until December 7, 2026.

    GNPX
19. Jul 30, 2026Listings

    Lexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule

    Shares outstanding will drop from 24,787,446 to 1,652,518. The company expects to seek a Nasdaq hearing if it gets a delisting notice.

    LEXX
20. Jul 30, 2026Legal

    Bristol Myers Squibb sues seven generic drugmakers in Delaware over Camzyos patents

    Bristol Myers Squibb's 10-Q says it sued seven generic drugmakers in the U.S. District Court for the District of Delaware over Camzyos patents. The defendants are Aurobindo, Zenara, Micro Labs, Dr. Reddy's, Annora, Apotex and MSN. The filing gives no case numbers, filing dates or rulings.

    BMY
21. Jul 30, 2026Legal

    Bristol Myers Squibb details Texas Plavix suit, Arkansas 340B complaint and Celgene settlement

    Bristol Myers Squibb's 10-Q says the company and certain Sanofi entities are defendants in a Texas state suit over Plavix labeling, sales and promotion. Arkansas has sued BMS over 340B contract pharmacy policies, and a Celgene securities class action settled with final approval in May 2026.

    BMY
22. Jul 30, 2026Legal

    Baxter's Hillrom unit faces Linet antitrust suit, a bed-buyer appeal and two DOJ requests

    Linet Americas sued Hill-Rom Holdings, Hill-Rom Company and Hill-Rom Services in 2021. A dismissed class action is on appeal, and a DOJ demand and subpoena remain open.

    BAX
23. Jul 30, 2026Legal

    Baxter faces two securities class actions and a derivative suit over Novum LVP statements

    Suits in Illinois federal court allege misleading statements about Baxter's Novum LVP pump. The 10-Q names Baxter and unnamed officers; the derivative captions name Jose E. Almeida.

    BAX
24. Jul 30, 2026Debt Financing

    Annexon secures credit facility of up to $200 million from Oxford Finance

    Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval.

    ANNX
25. Jul 30, 2026Listings

    Alterity reports A$37.3 million cash after 1-for-50 share consolidation

    The quarterly cash flow report also shows an A$3,982,992 tax incentive refund and says the company is evaluating strategic and funding alternatives.

    ATH
26. Jul 29, 2026Company Updates

    Vector BioSource agrees to buy four blood collection centers

    FOXO subsidiary Vector BioSource, Inc. signed a definitive agreement to acquire four U.S. blood collection centers from Grifols Bio Supplies, Inc. The company expects the deal to close in the third or fourth quarter of 2026.

    FOXO
27. Jul 29, 2026Listings

    Traws Pharma receives Nasdaq notice on $1.00 minimum bid price

    Nasdaq says Traws has until January 25, 2027 to regain compliance with the minimum bid price requirement, and that its listing remains fully effective for now.

    TRAW
28. Jul 29, 2026Mergers

    Trafalgar adds three new officers and three incoming directors

    The board of The Greater Cannabis Company, Inc. named Carlos Septién, Michelle Cervantes Vivanco and Ernesto Gómez Berjón on July 29, 2026, and they join the board after a notice period.

    GCAND
29. Jul 29, 2026Mergers

    Synlogic to merge with Caldera Therapeutics in all-stock deal

    The combined company would operate as Caldera Therapeutics. A concurrent private placement of approximately $278 million is expected to close alongside the merger, which is expected to close by early 2027.

    SYBX
30. Jul 29, 2026Financings

    RA Capital exchanges 18,030,000 Inhibikase Therapeutics shares for a pre-funded warrant

    On July 29, 2026, RA Capital Healthcare Fund exchanged 18,030,000 Inhibikase common shares for a pre-funded warrant on the same number of shares. The warrant carries a 9.99% ownership limit, and the filing does not say why the exchange was made.

    IKT
31. Jul 29, 2026Mergers

    Processa acquires Vidya Therapeutics with $200 million placement

    Processa said it acquired Vidya Therapeutics, whose lead asset is the BTK inhibitor VT-7208, alongside a concurrent private placement of approximately $200 million.

    PCSA
32. Jul 29, 2026Financings

    LB Pharmaceuticals agrees to $150 million private placement at $34.94 a share

    The company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year.

    LBRX
33. Jul 29, 2026Financings

    Inventiva says cash covers operations to end of Q2 2027 after June financings

    Inventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months.

    IVA
34. Jul 29, 2026Financings

    HCW Biologics prices $1.6 million private placement with insiders and a stockholder

    The company agreed to sell 618,682 units at $2.585 per unit, including shares to its founder, chairman and an officer, and the common warrants need stockholder approval.

    HCWB
35. Jul 29, 2026Company Updates

    Glucotrack unit advances LT-100 toward single-injection dosing

    Lokahi Therapeutics, a wholly owned subsidiary of Glucotrack, said nonclinical results support testing one subcutaneous injection in place of up to 15 intradermal injections, with clinical evaluation possibly starting in the fourth quarter of 2026.

    GCTK
36. Jul 29, 2026Listings

    Earth Science Tech to ask holders for advisory vote on reverse split for uplisting

    Earth Science Tech's board wants a non-binding stockholder signal on a reverse split to meet the bid price test for an uplisting. The company says it is not currently a listed issuer, and the proxy's notice gives no split ratio.

    ETST
37. Jul 29, 2026Financings

    Dyne Therapeutics has $898.5 million in cash and a runway into 2028 after July offering

    The company sold 21,045,000 shares at $20.50 in July and expanded a loan facility to $400 million as it prepares a possible Duchenne launch.

    DYN
38. Jul 29, 2026Debt Financing

    China Resources Pharmaceutical issues RMB1 billion second tranche of notes

    A wholly owned subsidiary completed the second 2026 tranche of medium term notes, RMB1 billion at 1.52% per annum over three years.

    3320
39. Jul 29, 2026Listings

    Celularity gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027 to comply

    Celularity (Nasdaq: CELU) was told on July 23, 2026 that its Class A common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its listing, the company says.

    CELU
40. Jul 29, 2026Debt Financing

    Accuray gets lender waiver of defaults under financing agreement

    Accuray's lenders waived two defaults under its financing agreement, and the same amendment exchanges converted debt for preferred shares and penny warrants, subject to shareholder approval.

    ARAY
41. Jul 28, 2026Debt Financing

    TuHURA Biosciences draws $1,500,000 on its Parkview revolving credit facility

    TuHURA Biosciences borrowed $1,500,000 more under its $50 million revolving facility with Parkview Holdings One LLC. The filing gives no interest rate for the draw and flags conflicts of interest tied to the lender.

    HURA
42. Jul 28, 2026Financings

    Onconetix sells $30,249,600 of Series F preferred in PIPE financing

    The securities purchase agreement covers 37,812 shares of Series F convertible preferred stock with an initial conversion price of $0.9767 per share.

    ONCO
43. Jul 28, 2026Debt Financing

    Grifols refinances all 2027 maturities with about €3 billion term loan

    Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June.

    GRF
44. Jul 28, 2026Financings

    Entera Bio closes $275.0 million private placement at $2.04 a share

    BVF Partners-affiliated funds are among the buyers and gain the right to name two directors. Entera says it will use the money to support a Phase 3 study of EB613.

    ENTX
45. Jul 28, 2026Company Updates

    BioNexus advances VitaGuard rollout in Southeast Asia

    After a working visit to China, BioNexus says it is preparing the VitaGuard platform for ten licensed Southeast Asian markets.

    BGLC
46. Jul 28, 2026Listings

    BGM Group regains Nasdaq compliance after filing its late 20-F

    BGM Group filed the annual report for the year ended September 30, 2025 on July 21, 2026, and Nasdaq said the filing cured the lapse on July 24. The same report shows a net loss of $19.9 million, up from $1.4 million.

    BGM
47. Jul 28, 2026Debt Financing

    American Shared Hospital Services signs forbearance with Fifth Third Bank

    A third amendment to the credit agreement with Fifth Third Bank, National Association, sets a standstill period that runs to June 30, 2027.

    AMS
48. Jul 28, 2026Legal

    Alkermes sues Teva, Apotex and MSN over proposed generic Lybalvi

    Two Alkermes subsidiaries filed Hatch-Waxman patent suits in New Jersey and Delaware against Teva Pharmaceuticals, Apotex and MSN entities. FDA approval of each generic application is stayed for up to 30 months.

    ALKS
49. Jul 28, 2026Legal

    Alkermes faces direct-purchaser antitrust class action over Vivitrol patent

    Value Drug Company sued Alkermes, Inc. and Alkermes Pharma Ireland Limited in Massachusetts in October 2025. A December 2025 motion to dismiss is the latest step the 10-Q reports.

    ALKS
50. Jul 27, 2026Financings

    Scribe Therapeutics prices IPO of 8,580,000 shares at $15.00

    Scribe sold 8,580,000 shares at $15.00 with a going concern warning in its prospectus. The company had $49.7 million in cash and marketable securities at March 31, 2026, against $40.5 million in outstanding indebtedness.

    SCTX
51. Jul 27, 2026Debt Financing

    Profusa expects about $7 million convertible note alongside diagnostics deal

    Profusa signed a non-binding term sheet to acquire a private diagnostics company that it says had about $111 million of 2025 revenue. The deal would come with an estimated $7 million convertible note at a 7% rate and a 9% original issue discount.

    PFSA
52. Jul 27, 2026Listings

    Calidi Biotherapeutics effects 1-for-16 reverse stock split

    The split became effective July 30, 2026, and the common stock began trading split-adjusted on July 31 under the existing CLDI symbol.

    CLDI
53. Jul 27, 2026Debt Financing

    BiomX extends $1,250,000 note to November 1, 2026

    BiomX extended a $1,250,000 promissory note held by Water IO Ltd. to November 1, 2026, after a $250,000 payment. The remaining principal is due in four monthly installments of $250,000, and accrued interest is to be settled in 800,000 shares of common stock if approvals arrive.

54. Jul 27, 2026Company Updates

    Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone

    Aptevo filed a patent application covering a Nectin-4 x PD-L1 dual-targeting backbone that it says could support radiopharmaceuticals, T-cell engagers and other immune-based approaches.

    APVO
55. Jul 24, 2026Listings

    VivoSim Labs gets Nasdaq equity notice and cites July warrant exercises

    Nasdaq said VivoSim Labs no longer met the $2,500,000 stockholders' equity minimum on July 20, 2026, and the company said its equity exceeded $2.5 million after July transactions.

    VIVS
56. Jul 24, 2026Listings

    Standard BioTools gets Nasdaq minimum bid price notice, has until January 19, 2027

    Nasdaq told Standard BioTools on July 22, 2026 that its shares closed below $1.00 for 30 days. The company has until January 19, 2027 to regain compliance, and its own filing says it cannot be sure it will.

    LAB
57. Jul 24, 2026Listings

    Oncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027

    Nasdaq told Oncolytics its stock closed below $1.00 for 30 consecutive business days. The letter does not change the listing for now, but the company's annual report says its $5.2 million of cash cannot fund planned operations for 12 months, and that doubt about its ability to continue as a going concern is substantial.

    ONCY
58. Jul 24, 2026Financings

    MannKind closes $50.0 million private placement led by Frazier Life Sciences

    MannKind sold 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88. The company names a $45.0 million contingent value rights payment, triggered by an FDA approval, among the uses of the money.

    MNKD
59. Jul 24, 2026Listings

    FibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price, plans appeal

    Nasdaq staff says the bid price closed below $1.00 for 30 consecutive business days and that FibroBiologics gets no 180-day compliance period after a reverse stock split. The company intends to request a hearing.

    FBLG
60. Jul 24, 2026Financings

    BTIG terminates Matinas at-the-market sales agreement

    BTIG, LLC ended the 2020 at-the-market sales agreement with Matinas BioPharma, effective July 23, 2026, and the company says it owes no termination penalties.

    MTNB
61. Jul 24, 2026Listings

    Apimeds Pharmaceuticals reverse stock split took effect July 24

    The one-for-ten split took effect on July 24, 2026, and the stock trades on NYSE American under APUS on a split-adjusted basis, with par value cut to $0.001.

    APUS
62. Jul 23, 2026Distress

    Summit files $380 million stock program as 10-Q flags going concern doubt

    Cash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM.

    SMMT
63. Jul 23, 2026Legal

    Summit Therapeutics derivative suit over $520 million Duggan notes ends in voluntary dismissal

    Rainaldi Revocable Trust sued certain current and former Summit directors in Delaware Chancery in 2025, with Summit a nominal defendant. The parties stipulated to dismissal on May 27, 2026.

    SMMT
64. Jul 23, 2026Financings

    Radiopharm Theranostics sets $9,300,000 ATM limit, prices $4,050,001.36 ADS sale

    Radiopharm amended its at-the-market program to $9,300,000 on July 23, 2026. The next day it announced a $4.1 million registered direct offering at $3.16 per ADS, below the $4.29 last sale price on July 21.

    RAD
65. Jul 23, 2026Company Updates

    NexGel signs a new employment agreement with CEO Adam Levy

    The July 23, 2026 agreement sets a $375,000 base salary, EBITDA-linked bonus tiers and an option grant of 160,000 shares at $0.647 per share.

    NXGL
66. Jul 23, 2026Mergers

    Neuphoria and Scancell agree to all-share merger with up to $89 million financing

    Scancell will acquire Neuphoria in an all-share deal that would create a combined company listed on Nasdaq, alongside a financing of up to $89 million.

    NEUPSCLP
67. Jul 23, 2026Company Updates

    Bone Biologics completes $3.0 million private placement with warrants

    A single healthcare-focused institutional investor bought the shares. The company says the financing extends its runway through Q2 2027, and warrants could add up to about $6.0 million more if exercised for cash.

    BBLG
68. Jul 23, 2026Financings

    AEON reports partial over-allotment exercise in July offering

    The underwriters bought 4,696,102 additional shares on July 23, 2026, for about $1.5 million in gross proceeds. Lake Street Capital Markets, LLC acted as representative of the underwriters.

    AEON
69. Jul 22, 2026Company Updates

    Kairos Pharma announces Bayer collaboration to test ENV-105 with XOFIGO

    The collaboration will evaluate ENV-105 with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer involving bone, and the company cites a $570M to $1.3B addressable global market.

    KAPA
70. Jul 22, 2026Distress

    First Choice Healthcare amends deal for Florida pharmacy companies

    The amended agreement sets a maximum price of $21,306,000 for companies bought from seller Gary C. Bernard, M.D., and it depends on a related business combination that has not closed.

    FCHS
71. Jul 22, 2026Debt Financing

    China Resources Pharmaceutical issues RMB1 billion medium term notes

    A wholly owned subsidiary completed the first tranche of its 2026 medium term notes on 21 July 2026, at 1.53% per annum over 3 years.

    3320
72. Jul 22, 2026Financings

    China Pharma prices $5 million registered direct offering

    China Pharma Holdings, Inc. priced a registered direct offering of 2.5 million common shares at $2 per share, for gross proceeds of $5 million before placement agent fees and other expenses. FT Global Capital, Inc. is the exclusive placement agent.

    CPHI
73. Jul 21, 2026Listings

    XTL Biopharmaceuticals regains Nasdaq compliance, faces one-year panel monitor

    Nasdaq staff confirmed on July 20, 2026 that XTL meets four listing rules. Another equity shortfall within the year would lead to a delist determination.

    XTLB
74. Jul 21, 2026Company Updates

    Phio adds dermatologist R. Todd Plott to its board

    Phio Pharmaceuticals increased its board to six members and appointed R. Todd Plott, M.D., effective July 20, 2026, to serve until the 2026 annual meeting of stockholders.

    PHIO
75. Jul 21, 2026Company Updates

    Bluejay completes SYMON-II enrollment of 750 patients ahead of plan

    Preliminary observations show an approximately 17% 28-day mortality rate in the enrolled population. The company expects to complete data cleaning, statistical analysis and clinical reporting over the coming months.

    BJDX
76. Jul 20, 2026Financings

    Sunshine Biopharma sets up $4,000,000 at-the-market stock sale with Aegis Capital

    Sunshine Biopharma Inc. signed an at-the-market sales agreement with Aegis Capital Corp. under which it may sell up to $4,000,000 of common stock, with Aegis as exclusive sales agent.

    SBFM
77. Jul 20, 2026Listings

    Rockwell Medical regains Nasdaq bid price compliance, matter closed

    Nasdaq told Rockwell Medical on July 16, 2026 that the company had regained compliance with the $1.00 minimum bid price, and closed the matter. The 8-K does not give the closing prices behind that finding.

    RMTI
78. Jul 20, 2026Financings

    OKYO Pharma files annual report, cites $22 million offering and $20.6 million cash

    The company says it raised approximately $25 million in the fiscal year ended March 31, 2026. It says its cash funds the planned Phase 3 trial of urcosimod.

    OKYO
79. Jul 20, 2026Company Updates

    60 Degrees describes its babesiosis plan and a 2028 profitability target

    A July 2026 corporate presentation says the company targets profitability in 2028, based on malaria prevention sales and a supplemental indication for babesiosis.

    SXTP
80. Jul 17, 2026Debt Financing

    Xeris completes note exchange and conversion; no 2028 convertible notes remain

    Holders swapped about $23 million of 8.00% notes for about 5.0 million shares and about $23 million in cash. A separate holder converted $10.5 million of notes into about 3.6 million shares.

    XERS
81. Jul 17, 2026Financings

    Latigo Biotherapeutics files for IPO, plans Nasdaq listing as LTGO

    Latigo Biotherapeutics, Inc. filed a Form S-1 on July 17, 2026. The filing leaves the share count and price range blank, and the auditors have raised going-concern doubt.

    LTGO
82. Jul 17, 2026Debt Financing

    Healthy Extracts issues $258,750 promissory note to Labrys Fund II

    Healthy Extracts Inc. issued a one-year promissory note with a principal amount of $258,750 to LABRYS FUND II, L.P. under an agreement dated July 17, 2026. The company received a net amount of $225,000, minus expenses.

    HYEX
83. Jul 17, 2026Listings

    Daré Bioscience gets Nasdaq notice on stockholders' equity, plans hearing

    Nasdaq told Daré Bioscience (Nasdaq: DARE) on July 13, 2026 that it no longer meets Listing Rule 5550(b). The company intends to request a hearing, which would stay delisting while the panel decides.

    DARE
84. Jul 17, 2026Company Updates

    Damora completes move from Delaware to the Cayman Islands

    Damora Therapeutics completed its redomestication effective July 16, 2026. Its ordinary shares trade on Nasdaq under a new CUSIP from July 20, 2026.

    DMRA
85. Jul 17, 2026Financings

    BlossomHill Therapeutics files for IPO, plans Nasdaq listing as BLSM

    BlossomHill's S-1 leaves the share count, the price range and the proceeds blank. The prospectus also says the auditor's report on the 2025 financial statements carries a going-concern paragraph.

    BLSM
86. Jul 16, 2026Financings

    VivoSim Labs prices $4.0 million private placement with $0.85 warrants

    VivoSim Labs agreed to sell 4,705,883 shares and warrants to one healthcare investor, with A.G.P./Alliance Global Partners as sole placement agent.

    VIVS
87. Jul 16, 2026Company Updates

    Raphael Pharmaceutical chairman and CFO resign; Uri Tadelis named CFO

    Ajay Kumar Dhadha resigned as chairman effective June 30, 2026. Guy Ofir resigned as chief financial officer and general counsel effective July 16, 2026, and the company appointed Uri Tadelis as CFO.

    RAPH
88. Jul 16, 2026Financings

    REGENXBIO prices $100 million stock offering at $9.00 a share

    REGENXBIO launched a $100 million stock offering on July 16, 2026 at $9.00 a share, below the $11.20 close. Its own preliminary estimate puts cash, cash equivalents and marketable securities at about $105.5 million on June 30, down from $150.5 million on March 31.

    RGNX
89. Jul 16, 2026Debt Financing

    Inhibrx expands Oxford Finance facility to $500.0 million

    Inhibrx's Oxford Finance facility now totals up to $500.0 million. The company funded $100.0 million at signing, and up to $225.0 million more depends on the lenders' discretion.

    INBX
90. Jul 16, 2026Debt Financing

    Inhibrx expands Oxford Finance credit facility to up to $500.0 million

    A second amendment adds a tranche of up to $325.0 million, of which $100.0 million was funded at signing. The lenders received warrants for 21,457 shares at $93.21 per share.

    INBX
91. Jul 16, 2026Financings

    Helus Pharma (Cybin Inc.) closes US$50 million share offering at US$4.85

    Helus Pharma sold 10,309,280 shares at US$4.85 in an underwritten offering that closed on June 25, 2026. The proceeds are meant partly for a Phase 3 depression program whose data are not due until the fourth quarter.

    HELP
92. Jul 16, 2026Listings

    CDT Equity to do 1-for-10 reverse stock split effective July 17

    The split takes effect July 17, 2026 and trades on a split-adjusted basis from July 20, reducing outstanding shares to approximately 631,077.

    CDT
93. Jul 16, 2026Financings

    Bio-Path sells small Regulation A lots and hires a strategic advisor

    Bio-Path reports two small share sales under its Regulation A offering and an advisory engagement to find a buyer, partner or licensor.

    BPTH
94. Jul 16, 2026Distress

    Arbutus expects to return up to approximately $230M to shareholders

    Arbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026.

    ABUSROIV
95. Jul 16, 2026Debt Financing

    Aditxt amends secured note purchase deal at Ignite Proteomics

    Aditxt signed Amendment No. 2 to its secured note purchase agreement with Ignite Proteomics investors on July 16, 2026. The amendment adds an investor, cancels one note and issues two new notes, and leaves the total senior secured principal unchanged.

    ADTX
96. Jul 15, 2026Financings

    Vogenx files for IPO, plans Nasdaq Capital Market listing as VOGX

    Vogenx filed a Form S-1 on July 15, 2026 for an initial public offering with the share count and price still blank. The filing reports $251 thousand of cash on March 31, 2026, and its financial statements carry going-concern doubt.

    VOGX
97. Jul 15, 2026Mergers

    Senti Biosciences signs merger agreement with Celadon affiliate, with CVRs tied to SENTI-202

    Senti Biosciences agreed on July 14, 2026 to move most of its business, including lead candidate SENTI-202, to an affiliate of its largest stockholder. Holders would receive contingent value rights worth up to $60 million that pay only if milestones are met, while the company used $43.4 million in operations in 2025.

    SNTI
98. Jul 15, 2026Financings

    ProQR registers resale of up to 3,030,303 shares for a selling shareholder

    ProQR is registering 3,030,303 shares for resale by a holder the prospectus calls Ginkgo, issued in April 2026 under a share purchase agreement tied to a services contract. ProQR receives none of the proceeds, and the prospectus gives no per-share price for the shares.

    PRQR
99. Jul 15, 2026Debt Financing

    Prestige Brands sells $400.0 million of 6.250% senior notes due 2034

    Prestige Brands, a subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due 2034. The 8-K names no placement agent, underwriter or advisor and does not say how the proceeds will be used. The parent's annual report says Walmart and Amazon were its only customers above 10% of gross revenues during 2026.

    PBH
100. Jul 15, 2026Company Updates

     Polomar Health names Douglas Beck chief financial officer

     Douglas Beck became chief financial officer and treasurer effective July 15, 2026, and serves as principal financial and accounting officer. He is a licensed certified public accountant.

     PMHS
101. Jul 15, 2026Debt Financing

     Neurotech secures $3.15 million secured loan

     The loan is secured against refundable R&D tax incentive offsets for FY2026 and FY2027 and will help fund Phase III studies in ASD.

102. Jul 15, 2026Debt Financing

     Medincell secures €28 million in non-dilutive loans

     The €28 million of bank loans has a five-year maturity and no covenants, and €20 million of the EIB facility is being repaid early, though the remaining EIB balance still comes due in July 2028.

     MEDCL
103. Jul 15, 2026Company Updates

     Kairos Pharma reports interim Phase 1 safety data for ENV-105 in lung cancer

     The company reports no serious adverse events, defined as Grade 3 or higher, in 13 patients treated with ENV-105 and osimertinib, and says the safety profile supports progression toward an early efficacy readout.

     KAPA
104. Jul 15, 2026Company Updates

     Ensysce chief operating officer Jeffrey Millard resigns

     Ensysce Biosciences disclosed in an 8-K that Jeffrey Millard resigned as chief operating officer, effective July 10, 2026, with no reason or successor given.

     ENSC
105. Jul 15, 2026Financings

     Braveheart Bio files for IPO, plans Nasdaq Global Market listing as BRVE

     Braveheart Bio, Inc. filed a Form S-1 on July 15, 2026 for an initial public offering on The Nasdaq Global Market under the symbol BRVE. The preliminary prospectus leaves the share count and price blank, and names Goldman Sachs & Co. LLC and Jefferies as joint bookrunners.

     BRVE
106. Jul 15, 2026Debt Financing

     Bayer places 5 billion U.S. dollars of bonds in five tranches

     Bayer US Finance LLC issues the notes, guaranteed by Bayer AG, with maturities between 5 and 30 years.

     BAYN
107. Jul 15, 2026Company Updates

     Azitra reports ex vivo skin data for its filaggrin cosmetic ingredient

     Two ex vivo human skin studies of ATR-COSF showed deeper protein penetration and higher skin elasticity, according to a July 15, 2026 release. A human study is planned next.

     AZTR
108. Jul 14, 2026Financings

     Q32 Bio enters underwriting agreement for public offering at $18.25 per share

     Morgan Stanley, Jefferies, Cantor Fitzgerald and Oppenheimer are the representatives of the underwriters. The offering is expected to close on July 16, 2026.

     QTTB
109. Jul 14, 2026Mergers

     NextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement

     NextCure (Nasdaq: NXTC) agreed to an all-stock merger with Avere Therapeutics. The 8-K puts pre-merger Avere holders at about 98.11% of the combined company, which would take the Avere Therapeutics name.

     NXTC
110. Jul 14, 2026Listings

     Genprex plans a 1-for-22 reverse stock split effective July 16

     The split, approved by the board on July 2, 2026, moves shares outstanding from 11,108,577 to approximately 504,936, and the company released an investor presentation the same day.

     GNPX
111. Jul 14, 2026Debt Financing

     CERo Therapeutics expands SRX Global convertible note to $2,085,200

     CERo Therapeutics expanded its convertible note with SRX Global to $2,085,200. The note carries 10% interest, matures May 28, 2027, and converts at the lesser of $0.05 and 80% of recent trading lows.

     CERO
112. Jul 14, 2026Financings

     Attovia Therapeutics files for IPO, plans Nasdaq listing as ATTO

     Attovia Therapeutics, Inc. filed a Form S-1 on July 14, 2026. The cover leaves the share count and price range blank.

     ATTO
113. Jul 14, 2026Listings

     Apollomics regains Nasdaq compliance on $35 million market value rule

     Nasdaq said on July 8, 2026 that the matter is closed. The company had been notified of the shortfall on June 18, 2026.

     APLM
114. Jul 13, 2026Mergers

     Matinas plans GH Power combination and sells MAT2203 to Azurity

     Matinas BioPharma agreed to combine with GH Power in a business combination expected to close in the fourth quarter of 2026, and to sell its MAT2203 and LNC business to Azurity Pharmaceuticals for $4.0 million upfront.

     MTNB
115. Jul 13, 2026Financings

     Erasca launches $500,000,000 stock offering, then prices 31,428,572 shares at $17.50

     Erasca's final terms are 31,428,572 shares at $17.50, a total of $550,000,010.00, above the $500,000,000 first announced. Its two clinical-stage programs are early, and the annual report shows a net loss of $124.5 million for 2025.

     ERAS
116. Jul 13, 2026Financings

     Cumberland Pharmaceuticals declares $1.50 special dividend, authorizes $5 million buyback

     Cumberland will pay a $1.50 special dividend and has authorized up to $5 million of buybacks. The board acted after the Apotex sale produced more net cash than the company had projected.

     CPIX
117. Jul 13, 2026Listings

     Apimeds Pharmaceuticals sets reverse split date of July 24

     The company said on July 13, 2026 that its one-for-ten reverse split would take effect on July 24, after a March 2026 target passed without a filing.

     APUS
118. Jul 13, 2026Financings

     AEON prices upsized $13.75 million offering with milestone warrants

     The offering was priced at $0.3221 per share and accompanying warrants. Lake Street Capital Markets, LLC is sole bookrunner, and Laidlaw & Company (UK) Ltd. is lead manager.

     AEON
119. Jul 10, 2026Financings

     Traws Pharma sets $5,575,709 at-the-market sales limit with Citizens JMP

     Citizens JMP Securities, LLC may sell up to $5,575,709 of Traws common stock under a July 10, 2026 prospectus supplement, the amount the company's current baby shelf limit allows.

     TRAW
120. Jul 10, 2026Financings

     Silo prices up to $11.7 million private placement

     Silo agreed to sell 619,965 shares and warrants at $6.452 per share, with H.C. Wainwright & Co. as exclusive placement agent. The company expects about $4 million upfront.

     SILO
121. Jul 10, 2026Company Updates

     Revelation adopts stockholder rights plan with a 10% trigger

     The board adopted a rights plan on July 10, 2026 and declared a dividend of one right per share, payable to stockholders of record on July 21, 2026.

     REVB
122. Jul 10, 2026Financings

     Niagen Bioscience sets up $50,000,000 share sales program

     Canaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible book value at $0.97 a share against a $3.37 reference price.

     NAGE
123. Jul 10, 2026Company Updates

     NOMAD Power Solutions raises Voyager energy storage by up to 56%

     The third-generation Voyager series raises standard usable storage to 2.025 MWh on the Eagle and Falcon and to 1.0 MWh on the Hawk, with power ratings and footprint unchanged.

     NMAD
124. Jul 10, 2026Debt Financing

     Kestra Medical draws $75.0 million from up to $200.0 million term loan

     Kestra Medical drew $75.0 million from a facility of up to $200.0 million. The Tranche A loan funded on July 10, 2026, and repaid a prior loan from Perceptive Credit Holdings IV, LP.

     KMTS
125. Jul 10, 2026Company Updates

     International Stem Cell agrees to sell Lifeline Cell Technology for $25.0 million

     The buyer is American Type Culture Collection, Inc., and the company expects the sale to close in the third fiscal quarter of 2026, subject to closing conditions.

     ISCO
126. Jul 10, 2026Financings

     Cue Biopharma agrees to $50.0 million private placement led by Cormorant

     Cue will sell 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for gross proceeds of about $50.0 million. Cormorant Asset Management led. The 8-K also reports RSU grants to officers and directors.

     CUE
127. Jul 10, 2026Financings

     Cue Biopharma agrees to $50.0 million private placement at $33.21 a share

     Cue Biopharma is selling 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for about $50.0 million in gross proceeds. Its release says the lead candidate is advancing toward Phase 1, while its annual report calls that candidate preclinical.

     CUE
128. Jul 10, 2026Company Updates

     Calidi Biotherapeutics signs new San Diego lease

     The company signed a 44-month lease for Suite 120 at 5580 Morehouse Drive and agreed to terminate its existing lease, effective September 30, 2026.

     CLDI
129. Jul 10, 2026Financings

     Apnimed files for IPO, plans Nasdaq Global Market listing as APMD

     Apnimed, Inc. filed a Form S-1 with a preliminary prospectus dated July 10, 2026. The cover leaves the share count and price range blank, and the company has no approved drug yet.

     APMD
130. Jul 10, 2026Debt Financing

     Anika Therapeutics amends $50.0 million Bank of America revolving credit line

     Anika Therapeutics signed a fifth amendment to its Bank of America revolving credit line, now maturing July 10, 2031. The filing names no amount drawn, and the line carries a first-priority lien on most of the company's assets.

     ANIK
131. Jul 9, 2026Company Updates

     MetaVia completes dose titration in Phase 1 Part 3 study of DA-1726

     All active patients in both Part 3 cohorts of the DA-1726 obesity study reached target doses of 48 mg and 64 mg, and topline data remains on track for the fourth quarter of 2026.

     MTVA
132. Jul 9, 2026Listings

     ENDRA regains Nasdaq stockholders' equity compliance

     Nasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor.

     NDRA
133. Jul 9, 2026Financings

     Bone Biologics closes private placement of pre-funded warrants, about $2.7 million net

     Bone Biologics sold pre-funded warrants for 2,112,677 shares at a combined $1.419 each, with Series F and G warrants at $1.42, through H.C. Wainwright & Co. Net proceeds were about $2.7 million, and the 10-K carries a going-concern warning.

     BBLG
134. Jul 8, 2026Company Updates

     ZyVersa director resigns as company explores cost cuts

     ZyVersa said a director has resigned and that it is considering cost reductions, pay cuts for two officers and possible sales of its VAR 200 or IC 100 candidates while it seeks to raise capital.

     ZVSA
135. Jul 8, 2026Debt Financing

     Kyverna amends $150 million Oxford Finance loan facility

     Kyverna extended availability of $15.0 million in remaining Term A Loans to December 31, 2026, for a $187,500 upfront fee. Further changes to the facility apply only if the company draws the full $15.0 million.

     KYTX
136. Jul 8, 2026Legal

     Evommune CFO agrees to return $10,160 short-swing profit after July share purchase

     Evommune's chief financial officer disclosed a purchase that matches a May sale under the short-swing rule, and agreed to pay the company $10,160.

     EVMN
137. Jul 8, 2026Debt Financing

     Evofem Biosciences issues $706,304 subordinated note to HUB Cyber Security

     Evofem issued a $706,304 subordinated note to HUB Cyber Security, Ltd. The 12% note matures eleven months after July 8, 2026, and accrues a $2,000 weekly monitoring fee plus a one-time administration fee of $14,126.

     EVFM
138. Jul 8, 2026Company Updates

     BioRestorative's CEO and CFO resign and claim severance; a new CEO is named

     Two executives gave notice on July 13, 2026 and asserted about $2.85 million in aggregate cash severance. The board does not accept the claims, and it named Katharyn Field chief executive officer.

     BRTX
139. Jul 8, 2026Listings

     AquaBounty's board declines reverse stock split for now

     AquaBounty's board decided on July 6, 2026 not to carry out a reverse split of 1-for-5 to 1-for-20 that stockholders approved, and that authority expires July 31, 2026.

     AQB
140. Jul 7, 2026Company Updates

     Theriva receives Spanish authorization for VIRAGE2 trial

     Spain's AEMPS cleared the Phase 2a study of more frequent VCN-01 dosing in first-line metastatic pancreatic cancer.

     TOVX
141. Jul 7, 2026Financings

     Semnur signs binding term sheet for a $100 million investment from iHolding

     Semnur, a majority-owned subsidiary of Scilex, said iHolding Group LLP would buy $100,000,000 of newly issued common stock at an expected $10.00 per share. The proposal remains subject to due diligence and definitive agreements.

     SMNR
142. Jul 7, 2026Financings

     MeiraGTx agrees to up to $400 million Oberland Capital investment, $135 million initially

     MeiraGTx will receive up to $400 million from Oberland Capital, starting with $135 million that includes $125 million of royalty funding and a $10 million equity investment. The release does not state the cap multiple on the royalties or the price of the new shares.

     MGTX
143. Jul 7, 2026Mergers

     MacroGenics completes sale of manufacturing operations to Bora for $122.5 million

     Bora Pharmaceuticals took over MacroGenics' Rockville manufacturing site and hired about 140 former employees. The $122.5 million price is before fees, and the 8-K says extra post-closing payments may not be earned or received.

     MGNX
144. Jul 7, 2026Mergers

     MacroGenics completes sale of CDMO manufacturing business to Bora for $122.5 million

     Bora Pharmaceuticals and Bora Biologics USA paid $122.5 million, before transaction fees and expenses, for MacroGenics' GMP manufacturing operations. The sale closed effective June 30, 2026 and is subject to post-closing adjustments.

     MGNX
145. Jul 6, 2026Debt Financing

     Prestige Consumer Healthcare draws $95.0 million term loan to fund LaCorium acquisition

     The company's subsidiary drew $95,000,000 on July 1, 2026. The 8-K also notes a $400,000,000 private offering of senior unsecured notes due 2034 whose pricing a July 6, 2026 press release announced.

     PBH
146. Jul 6, 2026Company Updates

     Polomar Health reconstitutes its board and amends the equity plan

     Four directors were elected effective July 1, 2026, George Hornig became executive chairman and Terrence M. Tierney became interim chief executive officer. The annual evergreen increase falls from 10% to 3%.

     PMHS
147. Jul 6, 2026Listings

     Oragenics names John Spencer CFO and reports annual meeting votes

     Oragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026. The company's June 29, 2026 annual meeting included a vote on authority for a reverse stock split of one-for-two to one-for-fifty.

     OGEN
148. Jul 6, 2026Debt Financing

     Nuvation Bio's convertible notes offering reaches $287.5 million after greenshoe

     Nuvation Bio's underwriters exercised in full an option for $37.5 million more of 0.75% convertible senior notes due 2032, lifting the offering to $287.5 million. Net proceeds are estimated at $277.6 million, and the capped calls bought with them cost about $2.2 million.

     NUVB
149. Jul 6, 2026Debt Financing

     Nuvation Bio issues $37.5 million more convertible notes, offering totals $287.5 million

     Nuvation Bio issued $37.5 million more of its 0.75% convertible senior notes due 2032 on July 6, 2026, after underwriters exercised their option in full. The offering now totals $287.5 million, with estimated net proceeds of about $277.6 million, and the notes can be settled in cash, shares or both at the company's choice.

     NUVB
150. Jul 6, 2026Financings

     MindWalk added to Russell 3000E Index, then files $250,000,000 shelf

     The index change took effect after the U.S. market close on June 26, 2026. A Form F-3 filed on July 13, 2026 replaces an older shelf and includes a $50,000,000 at-the-market program.

     HYFT
151. Jul 6, 2026Financings

     IGC Pharma issues shares to two officers at $0.27 to settle $1,154,210 owed to them

     The CEO and the principal financial officer paid for the shares by cancelling amounts the company owed them, including personal cash advances. IGC Pharma paid no cash.

     IGC
152. Jul 6, 2026Listings

     Gelteq closes second debt tranche, receiving $2.5 million net of discount

     Shareholders approved the second tranche on June 18, 2026, and the investor now holds a $2.875 million note convertible at 93% of recent trading prices.

     GELS
153. Jul 6, 2026Listings

     FOXO CEO gives mid-year 2026 update and says uplisting is under consideration

     In a letter to shareholders, CEO Seamus Lagan reported first quarter 2026 net revenues of about $5.1 million, completed a 1:3,000 reverse stock split, and said FOXO is considering an uplisting to a recognized exchange before the end of 2026.

     FOXO
154. Jul 6, 2026Debt Financing

     Cynata takes $600,000 loan secured against R&D TI rebate

     The $600,000 loan is secured against an expected R&D tax rebate of approximately $1.7m and the company's assets, and falls due by 30 September 2026 unless extended.

     CYP
155. Jul 6, 2026Listings

     COSCIENS Biopharma files Form 15 to end SEC reporting duties

     The July 6, 2026 notice lists approximately 153 holders of record of its common shares.

     CSCI
156. Jul 6, 2026Debt Financing

     BioXcel amends its credit agreement and forms a strategic process committee

     The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date.

     BTAIQ
157. Jul 6, 2026Debt Financing

     Aspira Women's Health takes $1,050,000 secured subordinated loan

     Aspira Women's Health signed a $1,050,000 secured subordinated note with Agile Lending, LLC as lead lender. The note matures January 26, 2027, and the company will use it to refinance an earlier January loan.

     AWHL
158. Jul 6, 2026Financings

     Aethlon prices $4.0 million follow-on offering at $0.7101 per share

     Maxim Group LLC is sole placement agent for 5,633,009 shares or pre-funded warrants, each sold with a warrant for the same number of shares.

     AEMD
159. Jul 2, 2026Financings

     Scribe Therapeutics files for IPO, plans Nasdaq listing as SCTX

     Scribe Therapeutics filed an S-1 on July 2, 2026 with blank share and price terms. Management and its auditor have raised substantial doubt about its ability to continue as a going concern.

     SCTX
160. Jul 2, 2026Financings

     Pyxis Oncology agrees to sell about $50 million of stock and warrants in private placement

     Pyxis Oncology agreed to sell 19,600,153 shares at $2.551 and warrants at $3.289 to investors led by BVF Partners L.P. The press release says the upfront money extends cash into the second quarter of 2027, while the company's annual report carried a going-concern warning and said cash would fund operations only into the fourth quarter of 2026.

     PYXS
161. Jul 2, 2026Debt Financing

     Omeros expects to close $16.0 million note repurchase, agrees to $14.5 million more

     Omeros expects to close a $16.0 million principal repurchase of its 9.50% convertible notes due 2029, and agreed to buy up to $14.5 million more. The repurchases would leave about $40.3 million of notes outstanding, and the company may replace the cash with debt that is not convertible into equity.

     OMER
162. Jul 2, 2026Financings

     MetaVia files prospectus supplement for up to $4,000,000 in share sales

     MetaVia filed a prospectus supplement for up to $4,000,000 of common stock under its at-the-market sales agreement with Ladenburg Thalmann & Co. Inc., dated November 6, 2025.

     MTVA
163. Jul 2, 2026Mergers

     LIXTE completes merger with NOMAD Transportable Power Systems

     LIXTE is issuing 2,992,041 common shares and 50,366.07 Series D preferred shares to NOMAD stockholders, and has changed its name to NOMAD Power Solutions effective July 3, 2026.

     NMAD
164. Jul 2, 2026Distress

     Integrated BioPharma extends PNC revolving credit line to April 14, 2027

     The $4,000,000.00 PNC line now runs to April 14, 2027, and a new Convertible ELOC of up to $250,000.00 replaces a matured $500,000.00 equipment note.

     INBP
165. Jul 2, 2026Financings

     Enanta Pharmaceuticals files for up to $75,000,000 at-the-market stock sales

     The company signed an Open Market Sale Agreement with Jefferies LLC on July 2, 2026. Jefferies is entitled to a commission of up to 3.0% of gross sales.

     ENTA
166. Jul 2, 2026Financings

     Creative Medical Technology gets $4.5 million from warrant exercise at reduced $1.60 price

     Holders of warrants for 2,790,340 shares exercised after the price fell from $2.86 to $1.60 and received new warrants for 5,580,680 shares. Roth Capital Partners acted as financial advisor.

     CELZ
167. Jul 2, 2026Company Updates

     CNS Pharmaceuticals lays out oncology and neurology asset search

     The July 2026 investor presentation describes a formal asset search after a $22.5 million financing and a leadership rebuild.

     CNSP
168. Jul 2, 2026Debt Financing

     Ardelyx draws $50.0 million Term F Loan under SLR Investment Corp. loan agreement, maturing 2030

     Ardelyx received the funds on June 29, 2026 under its 2022 loan and security agreement. The loan bears interest of 4.55% plus the greater of 1-month SOFR or 3.5%, with interest-only payments until July 1, 2030.

     ARDX
169. Jul 1, 2026Debt Financing

     Viatris closes ¥40,000,000,000 unsecured term loan with Mizuho Bank

     Viatris signed a ¥40,000,000,000 senior unsecured term loan with Mizuho Bank, Ltd. as administrative agent. The proceeds may repay a 2021 loan of the same size, and the company reported a net loss of $3.51 billion for 2025.

     VTRS
170. Jul 1, 2026Company Updates

     Hepion adds two directors, including the son of its interim CEO

     Danina Fisher and Gary S. Stetz, II joined the board on July 1, 2026. The filing notes that Mr. Stetz is the son of Gary Stetz, the interim chief executive.

     HEPA
171. Jul 1, 2026Debt Financing

     Fresenius issues €1 billion in dual-tranche bonds

     Two €500 million tranches, due in 2031 and 2034, will fund general corporate purposes, including refinancing.

     FRE
172. Jul 1, 2026Listings

     FOXO completes 1-for-3,000 reverse stock split

     The reverse split of FOXO's Class A common stock took effect at 4:01 p.m. ET on June 30, 2026. Shares trade on a split-adjusted basis under the temporary symbol FOXOD until the symbol reverts to FOXO on or about July 20, 2026.

     FOXO
173. Jul 1, 2026Mergers

     Cumberland Pharmaceuticals closes $100 million branded-product deal with Apotex

     Apotex paid $100 million in cash to close the branded-products deal after shareholders approved it. Cumberland now says it will focus on ifetroban, but its release gives no trial figures for any of the programs.

     CPIX
174. Jul 1, 2026Mergers

     Cumberland Pharmaceuticals closes $100 million asset sale to Apotex affiliates

     Cumberland sold six branded products for $100 million in cash and repaid about $5.3 million owed to Pinnacle Bank. It kept ifetroban, whose data so far come from early-stage studies, and its filings do not split out revenue for the products it sold.

     CPIX
175. Jul 1, 2026Financings

     Cadrenal Therapeutics raises $3.0 million in private placement priced at-the-market

     Cadrenal (Nasdaq: CVKD) received gross proceeds of approximately $3.0 million from one institutional investor. Warrants could add about $5.8 million if exercised in full for cash, the company says.

     CVKD
176. Jul 1, 2026Financings

     BridgeBio raises up to $1 billion in convertible preferred from Sixth Street, KKR unit

     The 7% preferred converts at $137.79 a share and is aimed at supporting present and upcoming launches. $933.9 million was funded at close.

     BBIO
177. Jul 1, 2026Company Updates

     BioForce Nanosciences receives Nevada oil and gas lease assignment pending federal approval

     A July 1, 2026 filing says the company received an assignment of eleven federal leases covering approximately 19,957 acres in Nye County, Nevada, subject to Bureau of Land Management approval.

     BFNH
178. Jul 1, 2026Debt Financing

     Alvotech secures $75 million term loan from GoldenTree funds

     Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025.

     ALVO

June 2026

1. Jun 30, 2026Debt Financing

   TuHURA Biosciences borrows $1,900,000 more under Parkview credit line

   TuHURA Biosciences drew an additional $1,900,000 under its revolving credit facility with Parkview Holdings One LLC. The facility matures April 21, 2031 and allows up to $50 million in borrowing, and the filing does not describe its interest rate or collateral.

   HURA
2. Jun 30, 2026Financings

   Tenon Medical prices $4.2 million public offering with warrants

   The offering is priced at $0.38 per share and common warrants. WallachBeth Capital LLC is the sole placement agent, and part of the proceeds will repay convertible notes.

   TNON
3. Jun 30, 2026Debt Financing

   OS Therapies signs $10 million secured convertible note with Leonite Fund

   The company calls it a line of credit backed by UK tax credits. It drew $1.6 million first, mainly for OST-HER2 manufacturing.

   OSTX
4. Jun 30, 2026Company Updates

   Moleculin calls first-45-patient MIRACLE results positive but gives no figures

   The company says both Annamycin arms showed favorable efficacy trends against the control arm in relapsed or refractory AML, on a full intent-to-treat basis.

   MBRX
5. Jun 30, 2026Debt Financing

   Lifeward amends senior secured convertible notes tied to Oramed

   The notes carry 8.0% interest and a $5.40 conversion price. The second tranche depends on ReWalk sales growth or a share price of $13.80 or higher.

   LFWD
6. Jun 30, 2026Listings

   HCW Biologics regains Nasdaq bid price compliance, faces monitor until June 17, 2027

   A Nasdaq Hearings Panel found HCW Biologics (Nasdaq: HCWB) back in compliance with the minimum bid price rule. The company faces a mandatory panel monitor and will effect a one-for-six reverse stock split on June 30, 2026.

   HCWB
7. Jun 30, 2026Company Updates

   Cosmos Health authorizes share repurchase of up to $5 million

   The program expires December 31, 2026 and may be renewed at the company's discretion.

   COSM
8. Jun 30, 2026Debt Financing

   CDT Equity closes second tranche of its $1,460,000 convertible loan

   J.J. Astor & Co. is the lender on a senior secured convertible note with a principal amount of $1,971,000, amended on June 30, 2026. The company receives $1,460,000 in two tranches, and repays the loan in weekly installments of $82,125 starting July 10, 2026.

   CDT
9. Jun 30, 2026Debt Financing

   Bespoke Extracts extends senior secured notes to August 14, 2026

   The amendment moves the maturity of $410,000 in notes from June 30 to August 14, 2026, raises the rate to 17% from July 1 and requires extension shares.

   BSPK
10. Jun 30, 2026Company Updates

    Aptevo receives $1.5 million grant to advance APVO451

    Aptevo was awarded a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, its nectin-4-targeted trispecific candidate.

    APVO
11. Jun 30, 2026Financings

    Abivax launches $600,000,000 offering of American Depositary Shares

    Abivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results.

    ABVX
12. Jun 29, 2026Mergers

    Zymeworks agrees to buy Theravance Biopharma for $17 per share, about $929 million

    Zymeworks will pay $17.00 per share in cash, financed mainly by a $350 million non-recourse note from OMERS Life Sciences. The release says 75% of the YUPELRI profit-share cash flows are assigned to OMERS to service the note.

    ZYME
13. Jun 29, 2026Company Updates

    Trafalgar Asset Management gains voting control and cancels company debt

    Trafalgar Asset Management, LLC bought all the Series A and Series B preferred stock on June 29, 2026, and certain company debts were settled and canceled the same day.

    GCAND
14. Jun 29, 2026Listings

    Rockwell Medical sets 1-for-10 reverse stock split for July 1, 2026

    Rockwell Medical's one-for-ten reverse split takes effect at 12:01 a.m. Eastern Time on July 1, 2026. The certificate was filed June 24, and the company says fractional shares will be paid in cash at the June 30 closing price, adjusted by the company.

    RMTI
15. Jun 29, 2026Debt Financing

    Celularity takes $1,000,000 secured loan from Barach family trust

    Celularity signed a $1,000,000 secured loan with the Philip & Daniele Barach Family Trust at 4.0%. The loan matures at the earlier of 30 days after closing or receipt of certain financing proceeds, and it rises to 18.0% after a default.

    CELU
16. Jun 29, 2026Financings

    BioCryst to close Birmingham discovery center, cuts 2026 spending outlook

    The HAE drugmaker will stop internal drug discovery and look outside for new programs. A later 8-K/A put severance at $6.2 million to $7.5 million, and a state WARN notice listed 47 jobs at the site.

    BCRX
17. Jun 29, 2026Debt Financing

    Ardelyx draws $50.0 million term loan from SLR Investment Corp.

    Ardelyx drew a $50.0 million Term F Loan from SLR Investment Corp. on June 29, 2026. The loan matures July 1, 2030 at 4.55% plus the greater of 1-month SOFR or 3.5%, and in a default the agent can reach the company's cash.

    ARDX
18. Jun 29, 2026Company Updates

    Alaunos reports body-fat-adjusted liver weight analysis for ALN1003

    Alaunos says a body-fat-adjusted analysis of liver weight in a 48-day mouse study supports further preclinical work on ALN1003.

    TCRT
19. Jun 29, 2026Debt Financing

    Agenus extends maturity of $5.09 million in notes

    Agenus pushed back the maturity of $5.09 million of 2015 notes by eight months, to February 18, 2027, and extended the expiration of earlier warrants to June 25, 2031. The filing does not describe new cash from the deal.

    AGEN
20. Jun 26, 2026Financings

    Soligenix adds $2,500,000 to its at-the-market sales agreement

    Soligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,500,000.

    SNGX
21. Jun 26, 2026Debt Financing

    Shoulder Innovations takes $15.0 million Stifel term loan, repays Trinity

    Shoulder Innovations signed a $15.0 million senior secured term loan with Stifel Bank on June 26, 2026, and used it to repay Trinity Capital. The $30.0 million asset-based revolver was undrawn at closing.

    SI
22. Jun 26, 2026Listings

    Matinas BioPharma receives NYSE American equity notice, plan accepted

    NYSE American says Matinas BioPharma fell short of two stockholders' equity standards and accepted its compliance plan, with a plan period through October 2, 2027.

    MTNB
23. Jun 26, 2026Debt Financing

    China Resources Pharmaceutical unit issues RMB2 billion corporate bonds

    A non-wholly owned subsidiary completed the third tranche of its 2026 corporate bonds, RMB2 billion at 1.59% per annum over three years.

    3320
24. Jun 25, 2026Debt Financing

    Nuvation Bio proposes $200.0 million convertible notes offering

    Nuvation Bio plans $200.0 million of notes due 2032 and expects to use the proceeds to repay its senior secured loan and pay for capped calls. The rate and conversion price are not set until pricing.

    NUVB
25. Jun 25, 2026Debt Financing

    Ligand Pharmaceuticals completes $700.0 million 0.00% convertible senior notes offering

    Ligand closed $700.0 million of 0.00% convertible senior notes due 2031 after the initial purchasers exercised their option in full. Net proceeds were approximately $678.2 million, with about $72.9 million going to note hedges and approximately $60 million to a share repurchase. The initial conversion price is approximately $334.27 per share.

    LGND
26. Jun 25, 2026Debt Financing

    Disc Medicine draws $30,000,000 and extends Hercules loan draw periods

    A First Amendment to the Hercules loan splits the remaining $50,000,000 tranche and extends later draw deadlines into 2027 and 2028.

    IRON
27. Jun 25, 2026Financings

    Cellectis shareholders approve share-issuance authorizations, including an ATM program

    Voting results filed June 25, 2026 show resolutions 13 to 24 carried with 95.25% to 99.73% of votes cast. Resolution 30, a savings-plan share issue, drew 14.81% support, yet the filing labels it carried.

    ALCLS
28. Jun 25, 2026Financings

    AquaBounty sells $2,250,000 of Series B preferred stock

    The private placement closed June 25, 2026, with Univest Securities, LLC as placement agent. The shares carry an 18.0% annual dividend and a $1.03 conversion price.

    AQB
29. Jun 25, 2026Debt Financing

    ALX Oncology closes up to $50,000,000 HSBC term loan facility

    ALX Oncology borrowed $10,000,000 at closing from HSBC Ventures USA and used it to refinance its Oxford Finance and Silicon Valley Bank loan. The facility can reach $50,000,000, but $10,000,000 of that is uncommitted and the rest depends on draw dates and milestones.

    ALXO
30. Jun 24, 2026Company Updates

    Revelation amends CEO and CFO employment agreements and bylaws

    The amended agreements raise change-in-control severance and set a three-year initial term, and the board amended the bylaws on proxy nominations, the definition of Cause and emergency succession.

    REVB
31. Jun 24, 2026Financings

    CalciMedica agrees to private placement with expected upfront gross proceeds of about $15.0 million

    Investors agreed to buy 18,673,429 units at $0.8033 or $0.8032. Series A and B warrants could add up to approximately $34 million if fully exercised for cash. Closing is expected on or about June 25, 2026.

    CALC
32. Jun 24, 2026Financings

    Absci raises $100 million at $7.41 a share with Eli Lilly among buyers

    The offering followed interim phase 1 data for ABS-201. Proceeds fund the antibody's hair loss and endometriosis programs.

    ABSI
33. Jun 24, 2026Debt Financing

    4D Molecular Therapeutics signs up to $200.0 million Hercules loan

    Hercules Capital, Inc. is the lender on senior secured term loans that mature in 2031, and most of the money is milestone-based or at the lender's discretion. The filing does not say how the company will use the proceeds.

    FDMT
34. Jun 23, 2026Debt Financing

    Sangamo files Chapter 11 with DIP financing from Northridge ATM

    Sangamo filed for Chapter 11 in Delaware on June 23, 2026 and seeks court approval of DIP financing from Northridge ATM, LLC. Eli Lilly and Astellas have signed stalking horse bids for its assets.

    SGMOQ
35. Jun 23, 2026Listings

    Nuwellis to effect one-for-thirty-five reverse stock split on June 25

    The split takes effect at 5:00 p.m. Eastern Time on June 25, 2026, and NUWE shares trade split-adjusted from June 26.

    NUWE
36. Jun 23, 2026Company Updates

    FDA conditionally accepts QYLEKI as the brand name for QRX003

    The FDA conditionally accepted QYLEKI as the proposed brand name for QRX003 in Netherton Syndrome, and the company says a pivotal Phase 3 study is expected to start in the second half of 2026.

    QNRX
37. Jun 23, 2026Company Updates

    Calidi Biotherapeutics appoints Corsee Sanders to board

    Dr. Corsee Sanders, a former Genentech/Roche and Celgene executive, joined the board as an independent director effective June 17, 2026.

    CLDILEGNRARE
38. Jun 23, 2026Debt Financing

    CalciMedica pushes Avenue loan maturity to 2029 and cuts warrant price

    Avenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00.

    CALC
39. Jun 23, 2026Debt Financing

    CERo Therapeutics amends $1,413,600 promissory note with SRX Health

    CERo Therapeutics amended a note with SRX Health Solutions, Inc. that converts into common stock at a price set by recent trading. The maximum is $1,413,600, of which $663,600 was funded on June 23, 2026.

    CERO
40. Jun 23, 2026Distress

    Boundless Bio signs merger agreement with Serapha Bio, cuts workforce by approximately 75%

    Boundless Bio agreed to an all-stock merger with privately held Serapha Bio and said it would cut about 75% of its workforce. After closing, Boundless holders would own about 3.69% of the combined company, and most of the early data behind the deal come from a trial in Shanghai.

    BOLD
41. Jun 22, 2026Financings

    uniQure launches $150,000,000 offering, then prices an upsized $225 million sale

    uniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch.

    QURE
42. Jun 22, 2026Company Updates

    Traws Pharma prepares updated MHRA data package for third quarter

    Traws says MHRA feedback has led it to add preclinical safety information to the tivoxavir marboxil data package, which it expects to resubmit in the third quarter of 2026.

    TRAW
43. Jun 22, 2026Listings

    Provectus holders authorize reverse split of between 1-for-10 and 1-for-50

    Provectus holders authorized a reverse split of between 1-for-10 and 1-for-50, with the ratio left to the board, and a matching cut in authorized shares. The company had $251,291 of cash at December 31, 2025, and its net loss widened to $5.4 million.

    PVCT
44. Jun 22, 2026Debt Financing

    NeoGenomics completes $316.25 million convertible notes offering

    NeoGenomics completed $316.25 million of 0.75% convertible senior notes due 2032 under an indenture with U.S. Bank Trust Company, National Association, as trustee. It used about $28.7 million of the proceeds on capped calls.

    NEO
45. Jun 22, 2026Debt Financing

    Ligand plans $550 million of convertible notes due 2031

    Ligand plans a private offering of $550.0 million of notes due 2031 to fund note hedges, a repurchase of up to $75 million of stock and general purposes, including a pending deal for Xoma Royalty Corporation.

    LGND
46. Jun 22, 2026Company Updates

    Genprex receives Canadian notice of allowance for REQORSA combination patent

    The Canadian Intellectual Property Office issued a notice of allowance for a patent covering REQORSA with PD-1 or PD-L1 antibodies in lung cancer.

    GNPX
47. Jun 22, 2026Legal

    Former SPAC sponsor sues Silexion in Tel Aviv over note conversions

    Defendants: Silexion, chairman and CEO Ilan Hadar, and CFO Mirit Horenshtein Hadar. Moringa Sponsor disputes how Silexion converted part of a $3,433 thousand note into shares and alternatively demands cash; Silexion says it complied with the note.

    SLXN
48. Jun 22, 2026Listings

    Eledon holders approve raising authorized common shares to 450,000,000

    The annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026.

    ELDN
49. Jun 22, 2026Financings

    Definium launches $500 million offering, then prices 20,588,236 shares at $34.00

    Definium sold 20,588,236 common shares at $34.00, or $700,000,024 before discounts, on the same day it reported that its Emerge depression trial met its primary endpoint. The prospectus supplement names eight underwriters, and its underwriting terms name no counsel.

    DFTX
50. Jun 22, 2026Listings

    CytomX holders approve 600,000,000 authorized shares and larger equity plans

    Stockholders voted on June 17, 2026 to raise authorized common stock from 300,000,000 to 600,000,000 shares. The 8-K does not say what the company plans to do with the extra shares.

    CTMX
51. Jun 22, 2026Debt Financing

    BetterLife closes CAD $2,000,000 convertible debenture financing

    BetterLife Pharma closed a CAD $2,000,000 convertible debenture on June 22, 2026, and a director and insider subscribed for the full amount. The conversion price compares with $0.07 per unit in an April 2026 private placement.

    BETR
52. Jun 22, 2026Listings

    Allogene holders approve 800,000,000 shares; files ATM supplement for up to $135.0 million

    Stockholders approved raising authorized common stock from 400,000,000 to 800,000,000 at the June 18, 2026 meeting; 345,024,351 shares were outstanding on the April 20 record date. A sales supplement filed June 22 covers up to $135.0 million of stock sales through TD Securities (U.S.A.) LLC.

    ALLO
53. Jun 22, 2026Financings

    Allogene Therapeutics registers up to $135,000,000 in share sales via TD Cowen

    The sales agreement dates to 2019 and was amended in 2022 and 2023. TD Cowen can receive up to 3.0% of gross proceeds, and the prospectus lists 100,200,000 shares issued in April at $2.00 a share.

    ALLO
54. Jun 22, 2026Listings

    Akebia stockholders approve raising authorized common shares to 500,000,000

    Stockholders approved raising authorized common stock from 350,000,000 to 500,000,000 at a June 17, 2026 meeting, with 88,853,129 votes against. The 8-K does not say how many shares are outstanding or planned for issue.

    AKBA
55. Jun 22, 2026Debt Financing

    Aditxt adds $769,230.77 in senior secured convertible notes

    Aditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The filing does not name the investors.

    ADTX
56. Jun 18, 2026Listings

    Xencor holders approve 4,000,000-share increase to 2023 equity plan

    The annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor.

    XNCR
57. Jun 18, 2026Debt Financing

    Viatris completes €650,000,000 public offering of 4.250% senior notes due 2033

    Viatris completed a €650,000,000 offering of 4.250% senior notes due 2033 on June 17, 2026. The proceeds first repay June revolver borrowings used to pay off $1.675 billion of 2026 notes, and the company reported a 2025 net loss of $3.51 billion. The 8-K names no underwriter.

    VTRS
58. Jun 18, 2026Company Updates

    Sonoma Pharmaceuticals lifts at-the-market offering ceiling to $3,641,703

    A prospectus supplement filed June 18, 2026 raises the aggregate offering price under the company's sales agreement with Ladenburg Thalmann to $3,641,703.

    SNOA
59. Jun 18, 2026Listings

    Silo Pharma regains Nasdaq minimum bid price compliance

    Nasdaq told Silo it regained compliance with the minimum closing bid price requirement as of June 17, 2026, and the matter is now closed.

    SILO
60. Jun 18, 2026Distress

    SL Science closes Horizon Space Acquisition II deal, files shell company report

    SL Science Holding completed its merger with Horizon Space Acquisition II on June 12, 2026. Its shell company report says its three product candidates are still in preclinical testing, and that its financial statements carry a going-concern warning.

    SLBT
61. Jun 18, 2026Financings

    Redhill Biopharma signs $6 million private placement, up to $19.4 million with warrants

    Redhill Biopharma agreed on June 18, 2026 to sell 8,571,429 ADSs at $0.70 each with two series of warrants. The upfront money is about $6 million, and the warrants add about $13.4 million only if they are exercised for cash, which the company says is not assured.

    RDHL
62. Jun 18, 2026Company Updates

    Petros names Robert Weinstein chief accounting officer

    Petros appointed Robert Weinstein as chief accounting officer and principal financial officer on June 18, 2026, the day it separated Mitchell Arnold from his finance roles.

    PTPI
63. Jun 18, 2026Debt Financing

    PTC Therapeutics closes $550,000,000 convertible notes offering

    PTC Therapeutics sold $550,000,000 of 0.0% convertible senior notes due 2031 through Morgan Stanley & Co. LLC as representative of the initial purchasers. The initial conversion price is about $107.48 a share.

    PTCT
64. Jun 18, 2026Financings

    PRF Technologies signs $15.0 million equity line with Yorkville

    The Standby Equity Purchase Agreement lets PRF sell up to $15.0 million of shares over 36 months at 97% of recent prices. Its 2026 going-concern paragraph and $3.1 million year-end cash sit beside the new line.

    PRFX
65. Jun 18, 2026Company Updates

    LIXTE to lend $6.5 million to NOMAD before the acquisition closes

    The loan funds long-lead components and working capital ahead of an acquisition that the companies expect to close on or about July 1, 2026.

    NMAD
66. Jun 18, 2026Company Updates

    Kiora reports preclinical epilepsy data for ion channel modulator KIO-300

    KIO-300 significantly suppressed seizure-associated activity in an ex vivo mouse temporal lobe epilepsy model, Kiora said. The poster was presented at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026.

    KPRX
67. Jun 18, 2026Financings

    Kardigan prices IPO of 25,000,000 shares at $16.00

    Kardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern.

    KARD
68. Jun 18, 2026Financings

    Iovance Biotherapeutics files automatic shelf with $89,650,167 ATM supplement

    The sale agreement supplement covers up to $89,650,167 of stock sold through Jefferies. Iovance's last reported sale price was $3.93 on June 17, 2026, and its 2025 net loss was $391.0 million.

    IOVA
69. Jun 18, 2026Company Updates

    GRI Bio receives FDA orphan drug designation for GRI-0621 in IPF

    The FDA granted orphan drug designation to GRI-0621 for idiopathic pulmonary fibrosis, a designation that could bring seven years of U.S. market exclusivity if the drug is approved.

    GRI
70. Jun 18, 2026Listings

    Dyadic International gets Nasdaq delisting notice over bid price, plans hearing

    Nasdaq started a process that could lead to delisting after Dyadic missed the June 17, 2026 deadline to meet the $1.00 minimum bid price. The company plans to request a hearing, and the request automatically stays any delisting action until the panel decides.

    DYAI
71. Jun 17, 2026Mergers

    Rigel completes vepdegestrant license from Arvinas and Pfizer, pays $70.0 million

    Rigel paid the licensors a one-time upfront payment of $70.0 million after the antitrust waiting period ended early. The 8-K describes no milestones, royalties or clinical details for the drug.

    RIGL
72. Jun 17, 2026Mergers

    Rigel Pharmaceuticals completes vepdegestrant license, pays $70.0 million upfront

    The license for VEPPANU (vepdegestrant) became effective after the Hart-Scott-Rodino waiting period ended early. Rigel paid the licensors, Arvinas and Pfizer, a one-time upfront payment of $70.0 million.

    RIGL
73. Jun 17, 2026Company Updates

    ProtoKinetix names Keith Brunt president and adds two directors

    ProtoKinetix appointed Keith Brunt as a director and president and added Michael Jones and Jason Lamp to its board on June 17, 2026, after a March 31, 2026 resignation.

    PKTX
74. Jun 17, 2026Debt Financing

    Omeros agrees to repurchase up to $16.0 million of convertible notes

    Omeros agreed to repurchase up to about $16.0 million of 9.50% convertible notes due 2029 for a total of up to about $34.0 million. The final price depends on the stock's trading in an averaging period that began June 18, 2026.

    OMER
75. Jun 17, 2026Financings

    Legend Biotech launches $225,000,000 ADS offering, then prices 7,700,000 ADSs at $29.35

    The offering totals $225,995,000 before underwriting discounts. Underwriters hold a 30-day option for 1,155,000 more ADSs, and closing was expected on June 23, 2026. The shares priced below the last sale price of $33.52.

    LEGN
76. Jun 17, 2026Listings

    Lakewood-Amedex Biotherapeutics sets 1-for-10 reverse split, trading June 22, 2026

    Outstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT.

    LABT
77. Jun 17, 2026Debt Financing

    Jaguar Health amends Streeterville and Uptown royalty deals and extends a note to October

    Jaguar Health's monthly royalty minimums of $750,000.00 now start October 1, 2026 under both royalty interests, and a Streeterville note matures October 1, 2026 instead of July 1. Streeterville also received common stock for Series Q preferred shares.

    JAGX
78. Jun 17, 2026Debt Financing

    Gossamer Bio completes exchange of 2027 convertible notes into secured notes

    Gossamer Bio's exchange of 2027 convertible notes drew $181,052,000 of tenders, and $18,948,000 of the old notes remain outstanding under a supplemental indenture that strips most covenants. The new notes are secured first-lien debt.

    GOSS
79. Jun 17, 2026Company Updates

    Azitra pauses its Netherton trial and moves capital to cosmetics and proteins

    In a letter to shareholders issued June 17, 2026, CEO Francisco Salva said the company will redirect funds from ATR-12 enrollment to a filaggrin cosmetic ingredient and recombinant protein work.

    AZTR
80. Jun 17, 2026Company Updates

    Aspira Women's Health names interim CEO after Buhle exit

    Chairman John Fraser takes over as interim chief executive effective June 17, 2026, while the board searches for a permanent CEO. Terms of Michael Buhle's separation agreement are not yet final.

    AWHL
81. Jun 17, 2026Debt Financing

    Adaptive Biotechnologies prices upsized $300 million convertible notes

    Adaptive Biotechnologies priced $300 million of 0% convertible senior notes due 2031, upsized from $250 million. J. Wood Capital Advisors LLC, its financial advisor on the offering, agreed to purchase about $10 million of shares.

    ADPT
82. Jun 16, 2026Mergers

    Prestige Consumer Healthcare closes $1.045 billion Breathe Right acquisition, signs new term loan

    Prestige Consumer Healthcare (NYSE: PBH) completed the Breathe Right purchase for $1.045 billion in cash and entered a Term Loan Credit Agreement. It also raised its asset-based revolver commitments to $225 million.

    PBH
83. Jun 16, 2026Company Updates

    Nuwellis appoints Mike McCormick as chief executive officer

    John Erb steps back from the executive role and remains Chairman of the Board, and the new chief executive takes over on June 30, 2026.

    NUWE
84. Jun 16, 2026Debt Financing

    Dyne Therapeutics draws $50.0 million more under Hercules facility

    Dyne Therapeutics' Hercules facility now totals up to $400.0 million, with $200.0 million outstanding after a $50.0 million draw on June 16, 2026. Hercules Capital, Inc. is administrative agent and collateral agent for the lenders.

    DYN
85. Jun 15, 2026Distress

    enGene cuts about 50% of workforce, reports $285.2 million in cash

    The bladder cancer gene therapy developer stopped enrollment in three study cohorts to conserve cash. It plans to start its BLA filing in the second half of 2026.

    ENGN
86. Jun 15, 2026Distress

    enGene Therapeutics cuts workforce by about 50% in restructuring to preserve cash

    enGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand.

    ENGN
87. Jun 15, 2026Listings

    Rockwell Medical holders approve reverse stock split amendment

    Holders cast 16,993,038 votes for the reverse split and 6,597,036 against it at the June 12, 2026 annual meeting. The 8-K reports the result but gives no split ratio and no effective date.

    RMTI
88. Jun 15, 2026Distress

    Polomar Health ends its Altanine merger and a patent license

    Polomar and Altanine terminated their merger agreement as of June 12, 2026, and ended a related patent license. Polomar has until September 7, 2026, to sell remaining inventory under that license.

    PMHS
89. Jun 15, 2026Debt Financing

    PDS Biotechnology closes $6,000,000 note with YA II PN

    PDS Biotechnology's $6,000,000 note carries a 10% rate, a warrant for 2,158,274 shares and a twelve-month term. Yorkville Securities, an affiliate of the investor, is one of two sales agents for a $50,000,000 at-the-market program.

    PDSB
90. Jun 15, 2026Distress

    Neumora to cut workforce about 35% and end navacaprant after Phase 3 studies miss endpoints

    Neumora Therapeutics is ending development of navacaprant after its two Phase 3 KOASTAL trials in major depressive disorder missed statistical significance. It cut about 35% of its workforce and amended a loan with K2 HealthVentures, and it says its cash will last into the third quarter of 2027.

    NMRA
91. Jun 15, 2026Company Updates

    Lifeloc completes SpinDetect disk tooling and sets a staged rollout

    Lifeloc completed production tooling for its SpinDetect test disks, commissioned a cleanroom, and expects a commercial launch in late 2026 or early 2027.

    LCTC
92. Jun 15, 2026Company Updates

    Global Innovative Platforms updates shareholders on studies, board and partners

    The June 2026 letter reports an eight-month heartworm study begun April 1, 2026, a FINRA application submitted June 12, 2026, and a collaboration paying approximately $15,000 to $18,000 a month.

    GIPL
93. Jun 15, 2026Financings

    Alvotech launches $125 million share sale, then prices 22,666,667 shares at $3.750

    Alvotech priced 22,666,667 shares at $3.750, below its $4.24 Nasdaq close on June 15, and a private placement of 17,826,666 shares to European investors is set to add about $66.85 million.

    ALVO
94. Jun 15, 2026Debt Financing

    Adaptive Biotechnologies plans $250 million of convertible notes

    Adaptive Biotechnologies plans a $250 million offering of convertible senior notes due 2031 and expects to use up to $25 million of the proceeds to repurchase common stock. The interest rate and conversion terms will be set only at pricing.

    ADPT
95. Jun 15, 2026Listings

    AIM ImmunoTech regains NYSE American stockholders' equity compliance

    The NYSE American said on June 12, 2026 that AIM had resolved its stockholders' equity deficiencies after a series of share sales and warrant exercises in May and June.

    AIM
96. Jun 12, 2026Debt Financing

    Viatris offers €650,000,000 of 4.250% senior notes due 2033

    Viatris is offering €650,000,000 of 4.250% senior notes due 2033 to repay revolving credit borrowings drawn to retire its 2026 notes. Its 2025 net loss was $3.51 billion.

    VTRS
97. Jun 12, 2026Company Updates

    Traws Pharma defers TXM challenge study after negative MHRA review

    Traws says a negative review by the UK regulator has deferred its planned Phase 2a influenza challenge study, and that it is advancing backup influenza compounds.

    TRAW
98. Jun 12, 2026Listings

    Soligenix gets Nasdaq minimum bid price notice, ends HyBryte program

    Nasdaq told Soligenix on June 10, 2026 that its stock has closed below the $1.00 minimum bid price, and the company has until December 7, 2026 to regain compliance. Its board then ended the HyBryte development program, after an interim analysis in a Phase 3 trial recommended stopping it for futility.

    SNGX
99. Jun 12, 2026Mergers

    Rocket Pharmaceuticals closes $180 million sale of priority review voucher

    Rocket received $180.0 million in gross proceeds from a large pharmaceutical company. It says pro forma cash of approximately $322.6 million should fund operations into the second quarter of 2028.

    RCKT
100. Jun 12, 2026Listings

     Nasdaq staff says Genprex is not eligible for a bid price compliance period

     A June 10, 2026 Nasdaq letter said Genprex would be delisted unless it requested a hearing, because its stock closed under $1.00 for 30 consecutive business days and it had a reverse split on October 21, 2025.

     GNPX
101. Jun 12, 2026Distress

     Lipella's bankruptcy court approves sale of substantially all assets

     A bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026.

     LIPO
102. Jun 12, 2026Listings

     Cuprina Holdings regains Nasdaq compliance, July 7, 2026 hearing cancelled

     Cuprina said Nasdaq staff told its hearings department the bid price shortfall was cured, and a July 7, 2026 panel hearing was cancelled. The release does not say what moved the share price, and year-end cash was $2.4 million against cash used in operations of $7.1 million.

     CUPR
103. Jun 12, 2026Debt Financing

     Clearmind sells $1,000,000 of convertible notes at 90% of principal

     Clearmind Medicine will issue $1,000,000 of convertible notes for $900,000 in cash, under a one-time exception to its own $2,500,000 quarterly limit. The agreement also amends the conversion price and sets a $1.875 floor price per share.

     CMND
104. Jun 12, 2026Listings

     Celularity gets Nasdaq notice on market value of listed securities, has until December 7, 2026

     Nasdaq told Celularity on June 9, 2026 that its market value of listed securities was below the $35 million minimum for 30 consecutive business days. The notice does not delist the stock.

     CELU
105. Jun 12, 2026Listings

     BioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales

     Nasdaq granted BioCardia until October 7, 2026 to regain compliance. The company says at-the-market sales with H.C. Wainwright & Co. brought net proceeds of $4.9 million and that it believes equity now exceeds $2.5 million.

     BCDA
106. Jun 12, 2026Listings

     Annexon holders approve raising authorized common shares to 500,000,000

     Annexon's stockholders approved raising authorized common stock from 300,000,000 to 500,000,000 shares on June 11, 2026, with 8,795,454 abstentions and no reason given for the increase.

     ANNX
107. Jun 12, 2026Listings

     Adagio Medical gets Nasdaq bid price notice, has until December 9

     The company's common stock traded below $1.00 for 30 consecutive business days, and it has 180 calendar days to regain compliance.

     ADGM
108. Jun 11, 2026Debt Financing

     Xeris exchanges $23 million of 2028 convertible notes for cash and stock

     Xeris will retire about $23 million of its 8.00% convertible notes due 2028 for about $23 million in cash plus common stock, with Morgan Stanley as placement agent. About $10.5 million of the notes will remain outstanding.

     XERS
109. Jun 11, 2026Mergers

     Veraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11

     Veraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million.

     VRXA
110. Jun 11, 2026Company Updates

     Theriva reports Phase 1 head and neck cancer results in journal

     Clinical Cancer Research published the Phase 1 study of VCN-01 with durvalumab in patients whose cancer was refractory to immunotherapy.

     TOVX
111. Jun 11, 2026Financings

     Parabilis Medicines closes private placement of 4,166,666 shares to Regeneron alongside IPO

     Parabilis Medicines (Nasdaq: PBLS) sold shares to Regeneron at 90% of the $20.00 IPO price under a Stock Purchase Agreement dated June 9, 2026. The placement closed June 11, 2026.

     PBLS
112. Jun 11, 2026Debt Financing

     IQVIA issues €950,000,000 of 4.625% senior notes due 2033

     IQVIA's €950,000,000 of 4.625% senior notes due 2033 are governed by a June 11, 2026 indenture with U.S. Bank Trust Company, National Association as trustee. Its 2025 net income of $1.36 billion was slightly below 2024.

     IQV
113. Jun 11, 2026Financings

     Enliven Therapeutics launches $250,000,000 offering, then prices upsized sale at $37.50

     The final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June 15, 2026.

     ELVN
114. Jun 11, 2026Debt Financing

     CDT Equity repays legacy notes and signs $1,460,000 JJ Astor loan

     CDT Equity agreed to pay off its Alliance Global Partners and Ascent Partners loans and signed a loan of up to $1,460,000 with JJ Astor & Co, which it says is now its only loan facility. Its 2025 net loss was $39.2 million.

     CDT
115. Jun 11, 2026Mergers

     Adial acquires Azora Therapeutics and announces up to $64 million financing

     The deal adds AT177, a colon-targeted AhR agonist for ulcerative colitis, to Adial's pipeline, with about $32 million in initial gross proceeds and up to $32 million more tied to Phase 1 initiation.

     ADIL
116. Jun 10, 2026Listings

     Voyager Therapeutics holders approve doubling common stock to 240,000,000 shares

     Voyager Therapeutics' stockholders approved on June 9, 2026 an increase in authorized common stock from 120,000,000 to 240,000,000 shares, and in total authorized capital stock from 125,000,000 to 245,000,000. The 8-K gives no reason for the increase.

     VYGR
117. Jun 10, 2026Listings

     Solid Biosciences holders approve doubling authorized shares to 480,000,000

     Solid Biosciences stockholders voted at the June 10, 2026 annual meeting to double authorized common stock to 480,000,000 shares. The vote drew 893,360 votes against, and the say-on-pay vote drew 6,203,634 against.

     SLDB
118. Jun 10, 2026Debt Financing

     Precision BioSciences extends Banc of California term loan

     Precision BioSciences has moved the maturity of its Banc of California term loan from June 30, 2027 to December 31, 2029. The company used $65.8 million in operations in 2025 and ended 2024 with $85.9 million in cash and cash equivalents.

     DTIL
119. Jun 10, 2026Financings

     Parabilis Medicines prices IPO of 33,500,000 shares at $20.00, $670,000,000 in total

     Parabilis Medicines priced 33,500,000 shares at $20.00 each, and Regeneron agreed to buy $75.0 million of stock at 90% of the IPO price, as the company's net loss reached $145,889 thousand in 2025.

     PBLS
120. Jun 10, 2026Company Updates

     Palisade Bio adds Jordan Zwick to its board and raises authorized shares

     The annual meeting on June 10, 2026 approved raising authorized common stock from 300,000,000 to 450,000,000 shares. Stockholders also approved two amended equity plans.

     PALI
121. Jun 10, 2026Debt Financing

     BioRestorative sets up $1,000,000 revolving loan from Bowery Group

     BioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million.

     BRTXNUWEISPC
122. Jun 10, 2026Financings

     Bio Green Med sells 1,103,338 shares to foreign investors for $794,403

     The sale at $0.72 per share closed on June 10, 2026 under Regulation S, and the filing names no underwriter, placement agent or financial advisor.

     BGMS
123. Jun 10, 2026Listings

     Aptorum Group (now Niki BioSolutions) shareholders approve DiamiR merger

     Shareholders of both companies approved the all-stock merger on June 9, 2026. The release gives no exchange ratio, and the company's 2025 research spending was $352,879, down from $2.2 million.

     NIKI
124. Jun 10, 2026Company Updates

     Aethlon Medical reports fiscal 2026 results and enters third cohort

     Aethlon Medical reported a net loss of $7.2 million for the fiscal year ended March 31, 2026, and said its Australian oncology study has entered its third and final dosing cohort.

     AEMD
125. Jun 9, 2026Listings

     Relay Therapeutics holders approve raising authorized shares to 450,000,000

     Common stock authorized rises from 300,000,000 shares. Relay filed the amendment in Delaware on June 9, 2026.

     RLAY
126. Jun 9, 2026Listings

     Jasper Therapeutics receives Nasdaq minimum bid price notice, has until November 30, 2026

     Nasdaq notified Jasper (JSPR) on June 3, 2026 that its voting common stock closed below $1.00 for thirty consecutive business days. The notice has no immediate effect on trading; a reverse stock split is among the options named.

     JSPR
127. Jun 9, 2026Debt Financing

     Idorsia takes up to CHF 250 million senior secured term loan

     The first CHF 150 million tranche will refinance the existing New Money Facility, of which CHF 105 million has been drawn.

     IDIA
128. Jun 9, 2026Financings

     Enveric files $2,425,000 at-the-market offering supplement with H.C. Wainwright

     The prospectus supplement adds $2,425,000 of common stock to an at-the-market agreement with H.C. Wainwright & Co., LLC, following $4,483,711.04 already sold under it.

     ENVB
129. Jun 9, 2026Company Updates

     Cocrystal names James Sapirstein chief executive officer

     An 8-K filed June 9, 2026 sets out the offer letter for the new chief executive, who replaces two co-chief executives.

     COCP
130. Jun 9, 2026Listings

     Bluejay stockholders approve reverse split authority

     Stockholders approved a reverse split at a fixed ratio between 1-for-2 and 1-for-20, but the board has no present intention to carry it out in the next 12 months.

     BJDX
131. Jun 9, 2026Financings

     BGM Group closes US$12,000,000 private placement of 200,000,000 shares and warrants

     BGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000. The private placement closed on June 8, 2026.

     BGM
132. Jun 9, 2026Mergers

     Aditxt signs deal to take Ignite Proteomics public at $150 million value

     Aditxt, Inc. signed a definitive business combination agreement for Ignite Proteomics, LLC, its 100%-owned subsidiary, at an implied equity value of approximately $150 million. Ignite would become an independent public company through a newly formed holding company.

     ADTX
133. Jun 8, 2026Listings

     aTyr Pharma gets 180 more days from Nasdaq to meet $1.00 minimum bid price

     Nasdaq gave aTyr Pharma until November 30, 2026 to regain the $1.00 minimum bid price, and the company says it may use a reverse stock split. Its lead drug missed the primary endpoint of its Phase 3 trial in September 2025.

     ATYR
134. Jun 8, 2026Debt Financing

     Vivos Therapeutics issues convertible note of up to $5,000,000

     Vivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed.

     VVOS
135. Jun 8, 2026Listings

     Savara holders approve doubling authorized shares to 600,000,000

     Savara stockholders approved doubling authorized common stock to 600,000,000 shares. The 8-K gives no reason for the increase, and it also reports a new CFO and COO effective July 15, 2026, after the current CFO resigns for health reasons.

     SVRA
136. Jun 8, 2026Company Updates

     PTC director Alethia Young steps down and stays on as an advisor

     Alethia Young resigned from the PTC Therapeutics board effective June 8, 2026, and will remain an advisor under a consulting agreement running through June 8, 2027.

     PTCT
137. Jun 8, 2026Financings

     Nuwellis closes $6.0 million public offering priced at $0.30 a share

     Ladenburg Thalmann & Co. Inc. was sole book-running manager, and the deal included Series C warrants for up to 60,000,000 shares.

     NUWE
138. Jun 8, 2026Listings

     MetaVia shareholders approve reverse split range of 1-for-5 to 1-for-22

     At its June 8, 2026 annual meeting, MetaVia stockholders approved a reverse split of 5 to 22 shares into one, with the ratio left to the board, and 200,000 more shares for the equity plan.

     MTVA
139. Jun 8, 2026Debt Financing

     Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan

     Celcuity issued $575,000,000 of 0.250% convertible senior notes due 2032 on June 8, 2026, with net proceeds of approximately $557.0 million. It repaid its loan agreement in full the same day.

     CELC
140. Jun 8, 2026Financings

     BioNTech starts buyback of up to USD 1.0 billion of ADSs, running to May 6, 2027

     BioNTech is buying back American Depositary Shares worth up to USD 1.0 billion, with the buyback period running from June 8, 2026 to May 6, 2027. The program rests on a May 17, 2024 shareholder authorization capped at 24.9 million shares, and a credit institution the company has mandated runs the purchases.

     BNTX
141. Jun 5, 2026Company Updates

     Theriva special meeting fails to reach quorum on warrant approval

     Too few shares were present for the June 5, 2026 special meeting on share issuance for warrants, and the company must call another meeting.

     TOVX
142. Jun 5, 2026Financings

     Solid Biosciences updates resale prospectus to add selling stockholders

     Solid Biosciences filed a prospectus supplement on June 5, 2026 that adds holders who bought shares from existing selling stockholders. Several holders in the table are offering their entire stake, and the company says it does not know when or in what amounts they will sell.

     SLDB
143. Jun 5, 2026Company Updates

     Petros grants 7,000,000 restricted shares to directors and officers

     The board approved restricted share awards on June 5, 2026, to the chairman, two directors and the president and chief commercial officer.

     PTPI
144. Jun 5, 2026Company Updates

     OSR Health postpones 2026 annual meeting, no new date set

     The board postponed the annual stockholder meeting that had been scheduled for June 18, 2026, and said it has not yet set a new date.

     OSRH
145. Jun 5, 2026Debt Financing

     Inotiv enters $65.5 million DIP credit agreement after Chapter 11 filing

     Inotiv's $65.5 million debtor-in-possession facility includes $25,000,000 of new money and rolls up $40,521,753.47 of prepetition bridge loans into superpriority term loans. Both tranches pay interest in kind at Adjusted Term SOFR plus 11.5%.

146. Jun 5, 2026Debt Financing

     IGC Pharma extends $12,000,000 bank credit facility with O-Bank

     IGC Pharma has extended its $12,000,000 bank facility with O-Bank, and the facility fee rises from $48,000 to $60,000. The filing gives no amount drawn and no interest rate.

     IGC
147. Jun 5, 2026Debt Financing

     Cerus takes up to $65.0 million secured term loan from MidCap

     Cerus has restated its two MidCap credit agreements, borrowing a first $35.0 million on a term loan that can reach $65.0 million. Its revolver had $29.9 million outstanding at closing, and the term loan is priced at Term SOFR plus 5.50%.

     CERS
148. Jun 5, 2026Financings

     Aspira Women's Health closes $1.485 million private placement

     The June 5, 2026 deal sold 3,300,000 shares at $0.45 each, with warrants to buy up to 4,455,000 more shares. The filing names no underwriter or placement agent.

     AWHL
149. Jun 4, 2026Financings

     Valneva registers resale of up to 31,787,634 ordinary shares by selling holders

     Valneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale.

     VLA
150. Jun 4, 2026Listings

     Trevi Therapeutics holders approve doubling authorized shares to 400,000,000

     Trevi stockholders voted to double authorized common stock to 400,000,000 shares and to add 8,000,000 shares to the stock incentive plan. The lead cough drug has no Phase 3 results yet, and the 2025 net loss was $42.8 million.

     TRVI
151. Jun 4, 2026Debt Financing

     Syndax agrees to sell $250.0 million of 2.25% convertible notes due 2031

     Syndax estimates net proceeds of about $243 million from the notes after the placement agent's fees and expenses. The 2.25% notes mature on June 15, 2031, and the conversion price is about $24.76 per share.

     SNDX
152. Jun 4, 2026Debt Financing

     Syndax agrees to $250.0 million private placement of 2.25% convertible notes

     Syndax Pharmaceuticals agreed on June 3, 2026 to issue $250.0 million of 2.25% convertible notes due 2031 in a private placement, with about $243 million of net proceeds expected. J. Wood Capital Advisors LLC is the sole placement agent, and the company's 2025 net loss was $285.4 million.

     SNDX
153. Jun 4, 2026Listings

     OnKure Therapeutics holders approve equity plan adding 3,231,638 shares

     The amended 2024 plan also drops a cap on its annual share increase. The vote came at the June 3, 2026 annual meeting.

     OKUR
154. Jun 4, 2026Debt Financing

     Luye Pharma to issue US$180,000,000 bonds due 2031

     Luye Pharma plans US$180,000,000 of 5.25% convertible bonds due 2031 and a concurrent repurchase of its 6.25% convertible bonds due 2028 at US$1,031.25 per US$1,000 of principal. The announcement says the two transactions may or may not complete.

     2186
155. Jun 4, 2026Company Updates

     Kairos Pharma signs CL-741 term sheet and lists milestones for 2026

     Kairos Pharma has signed a term sheet to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor, from privately held Celyn Therapeutics, Inc., and has listed the milestones it expects for the rest of 2026.

     KAPA
156. Jun 4, 2026Debt Financing

     IMUNON to raise $10 million through preferred stock and secured notes

     IMUNON has sold $10 million of preferred stock and two secured notes to Streeterville Capital, with half placed in a collateral account, to fund its Phase 3 OVATION 3 trial. The company used $13.9 million in operations in 2025.

     IMNN
157. Jun 4, 2026Distress

     Fulcrum Therapeutics to cut workforce by approximately 85%, reviews strategic alternatives

     The restructuring follows the discontinuation of pociredir for sickle cell disease and carries expected charges of approximately $4.2 million. Leerink Partners LLC is advising the board.

     FULC
158. Jun 4, 2026Mergers

     Bio Green Med agrees to all-stock deal to acquire Future NRG

     A Business Combination Agreement would make Future NRG Sdn. Bhd., a Malaysian medical waste treatment company, a wholly owned subsidiary of Bio Green Med Solution, with closing expected in the fourth quarter of 2026.

     BGMS
159. Jun 4, 2026Company Updates

     AIM ImmunoTech releases video segment on Ebola and Ampligen

     The company said on June 4, 2026 that its virtual investor video discusses Ampligen's Ebola research, and that an updated Ebola-focused presentation is available on its website.

     AIM
160. Jun 3, 2026Mergers

     REGENXBIO starts stock option exchange offer for non-executive employees

     REGENXBIO opened an option exchange offer for non-executive employees on June 3, 2026, after stockholders approved it. Stockholders rejected a similar program for executives, and the company's 2025 annual report says the year's $193.9 million net loss and a going-concern doubt sit alongside $240.9 million of cash.

     RGNX
161. Jun 3, 2026Mergers

     REGENXBIO starts stock option exchange for non-executive employees

     REGENXBIO started a stock option exchange for non-executive employees on June 3, 2026, after stockholders approved it at the May 29 annual meeting. Stockholders rejected a similar exchange for executives, with 21,021,531 votes against to 14,097,815 for.

     RGNX
162. Jun 3, 2026Company Updates

     Minerva stockholders approve charter changes on officer liability and forum

     At its June 3, 2026 annual meeting, Minerva's stockholders approved two charter amendments, and the board adopted amended bylaws the same day.

     NERV
163. Jun 3, 2026Financings

     Mineralys prices $150 million stock offering at $26.50 to fund Tanabe royalty buyback

     Mineralys sold 5,660,378 shares at $26.50, below the $28.85 last sale on June 2, 2026. The proceeds fund part of a $200.0 million upfront payment to buy back a royalty owed to Tanabe Pharma Corporation.

     MLYS
164. Jun 3, 2026Debt Financing

     Helix BioPharma closes C$3,673,000 convertible debenture placement

     The unsecured debentures carry 25.00% simple interest, mature 14 months after closing and can convert at C$1.42 per share.

     HBP
165. Jun 3, 2026Debt Financing

     Gossamer Bio exchanges $181,052,000 of 2027 convertible notes

     Gossamer Bio says holders of 90.526% of its 2027 convertible notes tendered early, and the company expects to issue $65,174,000 of new 7.50% secured convertible notes due 2030 at early settlement. The exchange also strips most covenants from the old indenture.

     GOSS
166. Jun 3, 2026Debt Financing

     FONAR closes merger with $20 million term loan and $15 million revolver

     FONAR's merger closed on June 3, 2026, and the company is now a wholly owned subsidiary of FONAR, LLC. As a borrower and guarantor under a new OceanFirst Bank credit agreement, it is bound by a $20 million term loan facility and a $15 million revolving facility secured by substantially all assets.

167. Jun 3, 2026Company Updates

     Cocrystal appoints James Sapirstein as chief executive officer

     The antiviral developer names a former biopharma chief executive with 23 product launches to lead the company, effective immediately.

     COCP
168. Jun 3, 2026Debt Financing

     Celcuity proposes $400,000,000 convertible notes, then prices $500,000,000 at 0.250%

     The notes mature on August 1, 2032, carry an initial conversion price of approximately $124.53 a share, and will repay the Oxford Finance and Innovatus loan in full. The last reported sale price on June 2, 2026 was $91.42.

     CELC
169. Jun 3, 2026Debt Financing

     Celcuity prices upsized $500,000,000 convertible notes offering

     Celcuity priced $500,000,000 of 0.250% convertible senior notes due 2032, upsized from $400,000,000, with a 30-day option for $75,000,000 more. The company plans to use the proceeds first to repay its Oxford Finance loan.

     CELC
170. Jun 3, 2026Debt Financing

     CONMED agrees to buy back 2.250% convertible notes due 2027 for cash

     CONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show.

     CNMD
171. Jun 3, 2026Financings

     BriaCell closes best efforts offering of 1,449,300 shares at $3.25, raising $4.71 million gross

     BriaCell sold 1,449,300 common shares at $3.25 in a best efforts offering for gross proceeds of $4.71 million. ThinkEquity LLC was sole placement agent, with a 7.5% cash fee and warrants for 72,465 shares, and the company's 10-K carries a going-concern warning.

     BCTX
172. Jun 3, 2026Debt Financing

     Aditxt issues senior secured convertible notes with 35% discount

     Aditxt has issued senior secured convertible notes that combine about $725,000 in new cash with earlier notes consolidated into them, at a 35% original issue discount. The company held $268,852 in cash at March 31, 2026.

     ADTX
173. Jun 2, 2026Debt Financing

     Sensus Healthcare signs $15,000,000 revolving note with City National Bank of Florida

     City National Bank of Florida will lend up to $15,000,000 under a revolving note that matures June 5, 2027.

     SRTS
174. Jun 2, 2026Debt Financing

     Mineralys signs up to $500.0 million senior secured term loan

     Mineralys can draw $100.0 million at closing on a $500.0 million loan, while the next $150.0 million depends on FDA approval of lorundrostat, and it owes Tanabe a $200.0 million cash payment.

     MLYS
175. Jun 2, 2026Debt Financing

     Maravai LifeSciences signs $150.0 million term loan and $30.0 million revolver

     A new credit agreement refinances a 2020 facility, with BSP Agency, LLC as administrative and collateral agent.

     MRVI
176. Jun 2, 2026Debt Financing

     Inotiv plans $326 million debt cut through prepackaged Chapter 11

     Inotiv's prepackaged Chapter 11 plan would cut about $326 million of funded debt, convert a substantial portion of it into equity and cancel existing equity interests.

177. Jun 2, 2026Legal

     Delaware court holds Heron CINVANTI patent claims invalid; Heron plans appeal

     The court ruled June 1, 2026 in Heron's patent suit against Azurity Pharmaceuticals and Slayback Pharma entities. Heron says it will appeal to the Federal Circuit and that the ruling does not affect a prior settlement.

     HRTX
178. Jun 2, 2026Company Updates

     Bluejay announces U.S. manufacturing partnership with Argonaut

     The strategic partnership with Argonaut Manufacturing Services aims to build U.S.-based manufacturing for the Symphony platform and reduce reliance on overseas sourcing.

     BJDX
179. Jun 1, 2026Debt Financing

     Teleflex prices $500.0 million of 5.875% senior notes due 2032

     Teleflex will use the proceeds, with cash on hand, to redeem its outstanding 4.625% Senior Notes due 2027. The notes are being sold in a private offering.

     TFX
180. Jun 1, 2026Listings

     Silo Pharma completes 1-for-15 reverse stock split

     The Nevada certificate took effect on June 2, 2026, and shares began trading split-adjusted on Nasdaq on June 3. The ticker stays SILO under a new CUSIP number.

     SILO
181. Jun 1, 2026Debt Financing

     Nutriband extends $5 million related-party credit line tied to Kindeva work

     Nutriband amended its $5 million credit line with TII Jet Services, a lender in Portugal. Advances carry 7% interest and may be used only for work with Kindeva toward the fentanyl NDA.

     NTRB
182. Jun 1, 2026Distress

     Fulcrum Therapeutics drops pociredir and starts strategic review after FDA feedback

     Fulcrum ends pociredir, its lead sickle cell program, after FDA concerns about malignancy risk, and sets no timeline for its strategic review. It reported $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026.

     FULC
183. Jun 1, 2026Debt Financing

     Clearmind to issue $1,500,000 in convertible promissory notes

     The notes carry a $1,500,000 principal amount and a cash purchase price of 90% of principal. The sale falls under an investor agreement amended in April 2026.

     CMND

May 2026

1. May 29, 2026Debt Financing

   Nuo Therapeutics closes $675,000 interim loan at 12% interest

   Five lenders, including a director and a holder of more than 5% of the stock, joined the interim tranche. The notes pay 12% interest in warrants rather than cash and mature December 31, 2028.

   AURX
2. May 29, 2026Listings

   Enveric stockholders vote on reverse split range and larger authorized share count

   The 8-K reports the May 28, 2026 annual meeting vote counts, including a reverse split ratio of 1-for-5 to 1-for-15 set at the Board's discretion.

   ENVB
3. May 29, 2026Debt Financing

   China Resources Pharmaceutical plans RMB5 billion medium term notes

   A wholly owned subsidiary received registration for up to RMB5 billion of medium term notes, valid for two years, with no issue announced yet.

   3320
4. May 29, 2026Legal

   Cardiff Oncology disputes Nerviano's termination of 2017 license agreement

   Nerviano Medical Sciences told Cardiff on May 27, 2026 it was ending the License Agreement over a patent inventorship dispute. Cardiff, which sued NMS as defendant on May 19, says the notice is legally ineffective.

   CRDF
5. May 29, 2026Financings

   Calidi Biotherapeutics amends warrant for up to 17,391,304 shares at $0.23, adds stockholder vote

   Calidi Biotherapeutics replaced a May 6 warrant for up to 17,391,304 shares at $0.23 with one that cannot be exercised until stockholders approve it. The minimum vesting amount doubles to $1,000,000 and the vesting deadline moves to September 30, 2026.

   CLDI
6. May 29, 2026Distress

   American Shared Hospital Services discloses lender default notice

   Fifth Third Bank's May 29, 2026 notice cites four specified events of default under the credit agreement and raises the interest rate to the default rate.

   AMS
7. May 28, 2026Company Updates

   Vyome reports first quarter 2026 results and an in-licensing agreement

   Vyome reported a net loss attributable to common shareholders of approximately $963,000 for the quarter ended March 31, 2026, and cash of approximately $8.8 million, while announcing an in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise.

   HIND
8. May 28, 2026Financings

   Soligenix adds $2,956,000 to its at-the-market sales agreement

   Soligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,956,000.

   SNGX
9. May 28, 2026Financings

   Sol-Gel says $33.1 million March offering and $52.8 million balance fund it into 2028

   Sol-Gel's first-quarter 2026 report shows $52.8 million in cash and securities at March 31 after a March offering of about $33.1 million, with revenue of $0.1 million and a net loss of $3.7 million. The company says the funds support operations into 2028.

   SLGL
10. May 28, 2026Listings

    Silexion completes 1-for-10 reverse split, its third since late 2024

    Silexion's 1-for-10 reverse share split took effect after the close of trading on May 28, 2026, and the company's warrants were repriced ten-fold with it. By autumn the company was asking shareholders for another split.

    SLXN
11. May 28, 2026Debt Financing

    Royalty Pharma signs new $1.8 billion revolving credit facility maturing in 2031

    Royalty Pharma signed a $1.8 billion unsecured revolving credit facility maturing May 22, 2031, and repaid its 2021 facility in full. The covenants cap funded debt at 4.00 times Adjusted EBITDA, and the exhibit names a different borrower from the 8-K.

    RPRX
12. May 28, 2026Financings

    Polaryx closes $10 million private placement with about 35 investors

    Prices ran from $3.70 to $4.10 a share depending on commitment size. MStone Partners, the largest holder, bought $360,000 of stock.

    PLYX
13. May 28, 2026Company Updates

    Pelthos CEO to present at Jefferies Global Healthcare Conference on June 4, 2026

    Scott Plesha will present and hold one-on-one investor meetings in New York. The company furnished its May 28, 2026 press release and a company presentation.

    PTHS
14. May 28, 2026Listings

    Nasdaq council upholds Abpro Holdings delisting; OTC Pink quotation expected

    Abpro Holdings said Nasdaq's Listing and Hearing Review Council reaffirmed the panel's decision to delist its common stock and public warrants.

    ABPO
15. May 28, 2026Debt Financing

    Medline sells $1,250.0 million and $750.0 million in senior secured notes

    Medline issued $1,250.0 million of 2031 notes and $750.0 million of 2033 notes, then refinanced part of its 2030 term loan into an approximately $2,750.0 million loan due 2033. The new debt is secured on substantially all assets.

    MDLN
16. May 28, 2026Company Updates

    FOXO licenses its epigenetics technology to LongevityFP

    FOXO Technologies and LongevityFP Technologies, LLC signed an exclusive license on May 28, 2026. LongevityFP will pay a royalty of three percent of its net revenues, capped at $1.3 million.

    FOXO
17. May 28, 2026Financings

    ENDRA expects $3.8 million from private placement of stock and warrants

    ENDRA agreed on May 27, 2026 to sell 578,387 shares or prefunded warrants, with common warrants for up to 1,156,774 shares, through sole placement agent Lucid Capital Markets, LLC.

    NDRA
18. May 28, 2026Debt Financing

    CERo Therapeutics issues $937,500 convertible note to SRX Health Solutions

    The note was sold for $750,000 and bears 10% interest, with conversion at the lesser of $0.05 or a discount to recent trading prices.

    CERO
19. May 28, 2026Listings

    CDT Equity gets Nasdaq notice over late first-quarter 10-Q

    The company did not file its quarterly report for the period ended March 31, 2026 on time, and it has until July 20, 2026 to submit a plan to regain compliance.

    CDT
20. May 27, 2026Company Updates

    Traws Pharma unveils dual-strike antiviral aimed at hantavirus and Ebola

    Traws says a proprietary combination antiviral may have activity against hantavirus, Ebola and Lassa, and that it plans to work with the U.S. CDC and regional regulators in Africa.

    TRAW
21. May 27, 2026Debt Financing

    Teleflex enters new credit agreement with JPMorgan Chase as agent

    The credit agreement names JPMorgan Chase Bank, N.A. as administrative agent. The company's Form 8-K describes a revolver and two term loan facilities that refinance its earlier agreement.

    TFX
22. May 27, 2026Listings

    SINTX Technologies gets Nasdaq stockholders' equity deficiency notice, plan due July 6, 2026

    SINTX Technologies received a Nasdaq notice on May 22, 2026 that its stockholders' equity, about $904,000 at March 31, 2026, is below the $2.5 million minimum. It has until July 6, 2026 to submit a plan to regain compliance, and its 2025 annual report carries a going-concern paragraph.

    SINT
23. May 27, 2026Company Updates

    OSR Health agrees to buy VXM01 assets from Vaximm for $30,000,000

    The $30,000,000 price is due in full on completion of a Phase 2 study of VXM01, and the company may make voluntary partial payments before then.

    OSRH
24. May 27, 2026Listings

    Nasdaq letter says Aditxt falls below $2,500,000 equity minimum

    Aditxt, Inc. received a Nasdaq letter on May 27, 2026 citing stockholders' equity of $(35,174,386) for the period ended March 31, 2026. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 11, 2026.

    ADTX
25. May 27, 2026Financings

    Minerva sets up $75 million at-the-market stock sale with Leerink Partners

    Minerva signed a sales agreement with Leerink Partners LLC for up to $75.0 million of common stock, and its filing also says the roluperidone Phase 3 relapse phase now runs 52 weeks.

    NERV
26. May 27, 2026Company Updates

    MetaVia reports DA-1726 mean weight reduction of 9.1% at 48 mg

    In a late-breaking poster at the EASL Congress 2026, the company reported a 9.1% mean body-weight reduction at Day 54 in the 48 mg cohort, with no serious adverse events up to that dose.

    MTVA
27. May 27, 2026Debt Financing

    Medicus Pharma closes secured notes with Streeterville Capital

    The lender paid $12 million at closing and deposited $10 million in a subsidiary's account under a deposit account control agreement. The notes carry monthly cash redemptions and trigger-based increases.

    MDCX
28. May 27, 2026Listings

    Dermata shareholders approve warrant repricing and larger equity plan

    At its May 27, 2026 annual meeting, Dermata Therapeutics shareholders approved raising the share reserve of its 2021 equity plan to 402,214 shares and repricing warrants for up to 120,734 shares. Three Class II directors were elected.

    DRMA
29. May 27, 2026Debt Financing

    CONMED amends JPMorgan credit agreement to add a delayed draw term loan

    The first omnibus amendment adds Term A-2 commitments of $450,000,000 under the company's existing credit agreement, with JPMorgan Chase Bank, N.A. as administrative agent.

    CNMD
30. May 27, 2026Debt Financing

    Biophytis changes Hexagon bond facility to make it revolving

    Biophytis amended its straight bond financing with Hexagon Capital Fund a second time, making the facility revolving and reducing its cost.

    ALBPS
31. May 27, 2026Company Updates

    BioRestorative files Lance Alstodt's employment agreement terms

    The agreement, dated May 27, 2026, sets a three-year initial term and a bonus of up to 50% of salary. Severance equals two times salary plus bonus if he is terminated without cause or resigns for good reason.

    BRTX
32. May 27, 2026Financings

    Aptevo and Niowave launch 50/50 radiopharmaceutical collaboration

    Aptevo and Niowave agreed to a 50/50 collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment at closing.

    APVO
33. May 26, 2026Debt Financing

    TuHURA takes first $1,700,000 draw on Parkview revolving credit facility

    The $50 million revolving facility from Parkview Holdings One LLC matures in April 2031. The company expects to use the first draw for general corporate purposes.

    HURA
34. May 26, 2026Company Updates

    Scienture CFO resigns and Narasimhan Mani named interim CFO

    Eric Sherb resigned as chief financial officer on May 26, 2026. Dr. Narasimhan Mani, already a director and Co-Chief Executive Officer, took the interim role the same day.

    SCNX
35. May 26, 2026Financings

    Kardigan files for IPO, plans Nasdaq Global Market listing as KARD

    Kardigan filed an S-1 for an IPO that would list on the Nasdaq Global Market as KARD. The filing leaves the share count and price range blank, reports $287.1 million of cash and investments, and still says there is substantial doubt about its ability to continue as a going concern.

    KARD
36. May 26, 2026Company Updates

    Genprex reports ASCO abstract on Trop-2 and PTEN biomarkers for REQORSA

    A Genprex-supported abstract at the 2026 ASCO Annual Meeting linked Trop-2 and PTEN protein levels to progression-free survival in non-small cell lung cancer, but not in small cell lung cancer.

    GNPX
37. May 26, 2026Company Updates

    Cocrystal reports pan-viral inhibitors active against hantavirus and influenza

    The company says its novel direct-acting antivirals show pan-viral activity in early in vitro work against hantavirus, bunyavirus and influenza.

    COCP
38. May 26, 2026Debt Financing

    Cartesian Therapeutics signs term loan of up to $150.0 million with K2 HealthVentures

    Cartesian drew $50.0 million at closing under a senior secured loan that can reach $150.0 million, with the lenders able to convert up to $15.0 million into common stock at $8.2526 a share. The loan carries a minimum cash covenant starting April 1, 2027, and the 8-K does not name the individual lenders.

    RNAC
39. May 26, 2026Company Updates

    Bio-Path cancels planned reverse split and approves treasury plan

    The company canceled a previously approved 1-30 reverse split and its board approved a digital asset treasury and a share of a court judgment held by its chief executive.

    BPTH
40. May 26, 2026Company Updates

    Aspira Women's Health expands Cleveland Clinic collaboration on AI diagnostics

    The master collaboration and license agreement covers biomarker discovery, validation and analytical models for women's health diagnostics. The release states no financial terms.

    AWHL
41. May 26, 2026Company Updates

    Alaunos combines two ALN1003 mouse studies into one preclinical readout

    Alaunos says early, non-GLP mouse data for ALN1003 span weight, insulin resistance, adipose signaling and liver pathology.

    TCRT
42. May 22, 2026Listings

    TransCode Therapeutics gets Nasdaq stockholders' equity deficiency notice

    Nasdaq told TransCode on May 19, 2026 that its stockholders' equity of $1,251,427 is below the $2,500,000 minimum. The company has until July 3, 2026 to submit a plan to regain compliance, and its equity had been $10,335,466 at December 31, 2025.

    RNAZ
43. May 22, 2026Listings

    Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap

    Tempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning.

    TPST
44. May 22, 2026Legal

    SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027

    Defendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027.

    SGPGKOS
45. May 22, 2026Financings

    FOXO settles J.H. Darbie fees and seeks a reverse stock split

    FOXO settled amounts owed to J.H. Darbie & Co., Inc. with preferred stock and $175,000 in installments. Its majority holder approved a reverse split at a ratio of 1:1,000 to 1:10,000.

    FOXO
46. May 22, 2026Listings

    Ensysce receives Nasdaq notice on stockholders' equity requirement

    Nasdaq said Ensysce Biosciences must submit a plan by July 6, 2026, to regain compliance with its $2.5 million stockholders' equity requirement, or face delisting.

    ENSC
47. May 22, 2026Debt Financing

    Cartesian Therapeutics signs up to $150.0 million senior secured term loans

    The loans carry a variable rate of at least 8.95% and mature on June 1, 2030. Only the first $50.0 million was funded at closing, and the two later tranches depend on milestones.

    RNAC
48. May 21, 2026Financings

    HCW Biologics prices about $4.0 million private placement with E.F. Hutton as agent

    The company priced 2,846,975 units at $1.405 each to a group of healthcare investors, and the warrants are exercisable at $1.28 per share.

    HCWB
49. May 21, 2026Company Updates

    Cosmos Health reports first-quarter 2026 revenue of $17.93 million

    Revenue rose 30.7% and total liabilities fell 9.6% in the quarter, and the company said its momentum continued into the second quarter.

    COSM
50. May 20, 2026Debt Financing

    Senti Biosciences issues $10.0 million senior secured convertible notes

    Celadon Partners SPV 24 bought the notes, and Acquiom Agency Services LLC was named collateral agent.

    SNTI
51. May 20, 2026Financings

    Purple Biotech files $200,000,000 replacement shelf, ATM limited to $824,331

    The F-3 caps the Wainwright ATM at $824,331 because the public float is below $75.0 million. The filing puts the float at $4.9 million, and the ADS last traded at $3.78 on May 18, 2026.

    PPBT
52. May 20, 2026Financings

    Optimi Health prices US IPO of 2,400,000 shares at US$6.25

    The offering totals US$15,000,000 before fees. Optimi has been approved to list on the Nasdaq Capital Market under the symbol OPTH.

    OPTI
53. May 19, 2026Financings

    Regencell Bioscience agrees to $20.0 million registered direct offering at $20.30 a share

    Regencell Bioscience agreed on May 19, 2026 to sell 985,222 ordinary shares at $20.30 each in a registered direct offering, about $20.0 million gross. Univest Securities, LLC is the sole placement agent and is also buying shares for its own account.

    RGC
54. May 19, 2026Financings

    Parabilis Medicines files for IPO; Regeneron agrees to buy about $75.0 million of stock

    Parabilis Medicines filed its IPO registration on May 19, 2026, with a $75.0 million Regeneron private placement tied to a collaboration, while its net loss grew to $145,889 thousand in 2025.

    PBLS
55. May 19, 2026Listings

    Onconetix to effect 1-for-10 reverse stock split on May 21, 2026

    The Board fixed the ratio under a stockholder authority approved April 30, 2026, to help keep the stock above Nasdaq's $1.00 minimum bid price.

    ONCO
56. May 19, 2026Listings

    Larimar Therapeutics holders approve raising authorized shares to 215,000,000

    Authorized common stock rises from 115,000,000 to 215,000,000 shares, against 103,882,937 shares outstanding at the March 25, 2026 record date.

    LRMR
57. May 19, 2026Mergers

    InMed agrees to all-stock merger with Mentari Therapeutics

    InMed and privately held Mentari Therapeutics signed a definitive merger agreement, alongside a concurrent US$290 million private placement for the combined company.

    INM
58. May 19, 2026Listings

    Clearmind Medicine announces 1-for-10 reverse split, effective May 21, 2026

    The split is part of the company's plan to regain compliance with Nasdaq's minimum bid price rule. Issued shares fall from 10,190,337 to about 1,019,033.

    CMND
59. May 19, 2026Debt Financing

    AIM ImmunoTech pushes Streeterville note maturity to June 2027

    The note is now due June 30, 2027. The balance is about $1.68 million after the amendment and the extension fee.

    AIM
60. May 18, 2026Financings

    Sunshine Biopharma prices $6.0 million public offering of units and Series C warrants

    The reasonable best efforts offering of 12,000,000 common units at $0.50 per unit is expected to close on or about May 19, 2026, with Aegis Capital Corp. as exclusive placement agent.

    SBFM
61. May 18, 2026Company Updates

    Scienture reports Q1 2026 revenue of $56 thousand and a 95.6% gross margin

    Revenue rose 449% from a year earlier on more Arbli orders. The company also reported $11.0 million of non-dilutive debt financing.

    SCNX
62. May 18, 2026Listings

    Palatin Technologies to move stock listing from NYSE American to Nasdaq Capital Market

    Palatin will switch from NYSE American to the Nasdaq Capital Market, with its last NYSE American trading day on May 28, 2026. The move needs no shareholder action, but the company's annual report carries a going-concern warning.

    PTN
63. May 18, 2026Listings

    NervGen reports $16.6 million cash and investments after Nasdaq listing

    NervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding.

    NGEN
64. May 18, 2026Company Updates

    MetaVia to present three late-breaking abstracts at ADA 2026

    Three posters, one on DA-1726 and two on vanoglipel, were accepted for the American Diabetes Association Scientific Sessions in New Orleans, June 5 to 8, 2026.

    MTVA
65. May 18, 2026Debt Financing

    Gossamer Bio launches exchange offer for 5.00% convertible notes

    The offer would swap $200 million of 2027 notes for new 7.50% secured convertible notes due 2030, plus shares or prefunded warrants.

    GOSS
66. May 18, 2026Company Updates

    Evofem reports first quarter 2026 net loss of $5.5 million

    Net sales were $0.9 million, up from $0.8 million a year earlier. The CEO said the company looks forward to non-dilutive capital from ex-U.S. partnerships in 2026.

    EVFM
67. May 18, 2026Debt Financing

    Assertio's $23.50 cash merger would give 2027 convertible noteholders repurchase rights

    The merger with Zydus Worldwide DMCC would let noteholders require repurchase at 100% of principal plus accrued interest. Parent waived the requirement that Assertio launch a note offer.

68. May 18, 2026Company Updates

    Alaunos reports updated ALN1003 mouse data on insulin and liver markers

    Alaunos reported non-GLP mouse data for ALN1003 on insulin resistance, adipose signaling and liver histology, and said its cash runway extends into the second quarter of 2026.

    TCRT
69. May 18, 2026Distress

    Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment

    Akari Therapeutics says its quarterly report for the period ended March 31, 2026 will be late, partly because of work on an upcoming public offering. It also expects a material non-cash impairment charge, and its March 2026 annual report carried a going-concern paragraph.

    AKTX
70. May 15, 2026Debt Financing

    WuXi AppTec agrees to issue RMB6,780 million convertible bonds

    WuXi AppTec signed a subscription agreement on May 14, 2026 for bonds with an initial conversion price of HK$153.00 per H share.

    603259
71. May 15, 2026Company Updates

    Vycor Medical reports first quarter 2026 results

    Revenue for the three months ended March 31, 2026 was $458,540, an increase of $22,162, or 5%, over the 2025 period. The company said most of the growth came from international markets.

    VYCO
72. May 15, 2026Company Updates

    Traws Pharma reports Q1 2026 net loss of $7.1 million and financing

    Traws reports a net loss of $7.1 million for the quarter ended March 31, 2026, and says its private financing of up to $60 million supports operations into the first quarter of 2027.

    TRAW
73. May 15, 2026Listings

    Skye Bioscience gets Nasdaq notice: stockholders' equity of $9,011,804 is below $10,000,000 minimum

    Nasdaq says Skye's stockholders' equity of $9,011,804, reported for the quarter ended March 31, 2026, is below the $10,000,000 Global Market minimum. The company has until June 29, 2026 to submit a plan.

    SKYE
74. May 15, 2026Distress

    Scilex files NT 10-Q late filing notice, expects first quarter 10-Q by May 20, 2026

    Scilex Holding Company says it needs more time to finish its first-quarter 2026 financial statements, including the consolidation of Vivasor Holding Company, and expects to file by May 20, 2026. Its 2025 annual report carries a going-concern warning and an accumulated deficit of about $921.8 million.

    SCLX
75. May 15, 2026Company Updates

    Retractable Technologies reports first-quarter net sales of $7.2 million

    Net sales fell from $8.3 million a year earlier, the operating loss widened to $6.2 million, and the company cut its workforce by approximately 16% in April.

    RVP
76. May 15, 2026Listings

    Rani Therapeutics gets Nasdaq minimum bid price notice, CFO Svai Sanford to resign

    Rani Therapeutics (Nasdaq: RANI) has until November 9, 2026, to regain bid price compliance. It also reported cash, cash equivalents and marketable securities of $43.4 million and a first quarter net loss of $8.0 million.

    RANI
77. May 15, 2026Distress

    Polomar Health waives Altanine merger conditions and amends CEO pact

    A May 11, 2026 consent and waiver letter sets aside several closing conditions and requires updated audited financial statements. A May 12 amendment cuts the chief executive's base salary to $19,000 a month.

    PMHS
78. May 15, 2026Company Updates

    Pelthos changes auditor and sets out separation terms for former CFO

    Pelthos dismissed CBIZ CPAs P.C. and engaged Grant Thornton LLP for 2026. The filing names Francis Knuettel II, whose separation agreement provides 12 months of base salary, or $430,000.00.

    PTHS
79. May 15, 2026Company Updates

    PAVmed reports first quarter 2026 results and simpler capital structure

    PAVmed ended the first quarter with $6.5 million in cash, and Lucid Diagnostics' underwritten offering netted about $17 million.

    PAVM
80. May 15, 2026Distress

    Oramed Pharmaceuticals files NT 10-Q, says March 31, 2026 quarterly report will be late

    Oramed Pharmaceuticals says it needs more time to finish the financial statements for the quarter ended March 31, 2026, and expects to file within five calendar days of the due date. Its 2025 annual report showed a $7,675,000 Scilex note due March 31, 2026, and going-concern warnings at two companies it has invested in.

    ORMP
81. May 15, 2026Distress

    OS Therapies files NT 10-Q, says first-quarter report will be late after slower financial close

    OS Therapies will miss the May 15, 2026 deadline for its first-quarter 10-Q and says it expects to file within the five-day extension. The filing comes from a company whose annual report, filed March 31, 2026, carries a going-concern warning and reports $269,830 of cash at year-end.

    OSTX
82. May 15, 2026Company Updates

    MiNK starts randomized Phase 2 trial in acute lung injury

    MiNK reported first quarter 2026 results and said cash and cash equivalents were approximately $9.5 million at March 31, 2026. Preliminary data from the trial are expected in the second half of 2026.

    INKTIBRX
83. May 15, 2026Company Updates

    Lifeloc reports first quarter 2026 results and SpinDetect milestone

    Net revenue rose 1% to $2.294 million and the quarterly net loss narrowed. The company said production tooling for its SpinDetect drug analyzer is complete and first article disks have been delivered.

    LCTC
84. May 15, 2026Mergers

    Healthy Extracts acquires Adli Gummies, which does business as Imaraïs Beauty

    Healthy Extracts Inc. acquired 100% of Adli Gummies Inc. under an agreement dated May 15, 2026. It issued secured promissory notes of $165,000 and $629,000 and shares equal to approximately 17.76% of its outstanding common stock.

    HYEX
85. May 15, 2026Distress

    Exicure files NT 10-Q late filing notice, expects $1,827,911 first quarter net loss

    Exicure says it needs more time to finish its quarterly report and expects a net loss of approximately $1,827,911 for the quarter. Cash fell to about $2,504,054 by March 31, 2026, and its 10-K already carried a going-concern warning.

    XCUR
86. May 15, 2026Company Updates

    Enveric reports first quarter 2026 net loss of $1.6 million

    The company reported cash-on-hand of $4.9 million at March 31, 2026, and a cash balance of approximately $10.3 million as of May 15, 2026.

    ENVB
87. May 15, 2026Company Updates

    Ensysce reports first quarter 2026 results and starts strategic review

    Ensysce Biosciences reported first quarter 2026 results, said its PF614-301 Phase 3 trial reached 50% of its interim enrollment target, and began a review of strategic alternatives.

    ENSC
88. May 15, 2026Listings

    Enlivex gets Nasdaq bid price notice, has until November 9, 2026

    Nasdaq said the ordinary shares closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing or trading.

    ENLV
89. May 15, 2026Company Updates

    Emmaus reports lower first-quarter revenue and a wider net loss

    Net revenues fell to $2.0 million as U.S. sales dropped 33%. The company reported a net loss of $3.3 million and cash of $1.1 million at March 31, 2026.

    EMMA
90. May 15, 2026Mergers

    Cumberland Pharmaceuticals files proxy for $100 million asset sale to Apotex

    Cumberland would receive $100 million in cash from Apotex and keep its ifetroban programs. Because Tennessee law may treat the sale as a sale of substantially all of its assets, shareholders are asked to approve it.

    CPIX
91. May 15, 2026Financings

    Conexeu Sciences issues 4,342,648 shares on warrant exercises for about $1,963,967

    Warrant holders paid approximately $1,963,967 in gross proceeds on May 12, 2026 under an incentive program. The company also raised its stockholder meeting quorum to one-third to match Nasdaq rules.

    CNXU
92. May 15, 2026Company Updates

    BioXcel reports first quarter 2026 results and engages MTS Health Partners

    The company said the FDA accepted its IGALMI at-home sNDA with a November 14, 2026 PDUFA date, and that it is reviewing strategic options. First quarter net loss was $12.7 million.

    BTAIQ
93. May 15, 2026Distress

    Apimeds Pharmaceuticals US files NT 10-Q, says quarterly report for March 31, 2026 will be late

    Apimeds (APUS) says it needs more time to finalize financial statements for the quarter ended March 31, 2026 and expects to file within a five-calendar-day extension. Its latest 10-K carries a going concern paragraph.

    APUS
94. May 15, 2026Distress

    ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026

    ABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period.

    ABVC
95. May 14, 2026Financings

    Zymeworks authorizes $125.0 million share repurchase program, ends 2025 program

    The earlier program bought back shares at an average price of $24.36 for $102.3 million. Zymeworks had about 73.0 million common shares outstanding as of May 13, 2026.

    ZYME
96. May 14, 2026Debt Financing

    Senti Biosciences signs up to $40 million in convertible note financing

    An affiliate of Celadon Partners SPV 24 may buy notes in two tranches. The first tranche is $10 million and is expected to close in May.

    SNTI
97. May 14, 2026Listings

    Preferred stock removed from Nasdaq as Bio Green Med reports first-quarter results

    The 6% Convertible Exchangeable Preferred Stock, under the symbol BGMSP, stopped trading in March. The common stock, BGMS, remains listed, and first-quarter product revenue was $0.8 million.

    BGMS
98. May 14, 2026Company Updates

    Pelthos issues first-quarter 2026 results release and posts company presentation

    The company furnished a press release summarizing results for the three months ended March 31, 2026, with an update on operations. The 8-K body does not repeat the figures in that release.

    PTHS
99. May 14, 2026Debt Financing

    Ocugen closes $130.0 million of 6.75% convertible notes

    The notes include the full exercise of a $15.0 million over-allotment option. Ocugen used approximately $32.7 million of the proceeds to repay its Avenue loan.

    OCGN
100. May 14, 2026Debt Financing

     Inotiv amends credit agreement with $40.0 million bridge facility

     Inotiv borrowed $27.5 million under the bridge facility and used it to repay its revolving loans, which were then terminated. The amendment also excludes some covenant tests and adds strategic alternatives milestones.

101. May 14, 2026Company Updates

     HCW Biologics reports first-quarter 2026 net income on Trimmune license

     The company reported $6.5 million in revenue and net income of $3.5 million for the quarter ended March 31, 2026, and it still states substantial doubt about going concern.

     HCWB
102. May 14, 2026Debt Financing

     Gilead sells senior notes due 2028 through 2034 in public offering

     Gilead sold four series of senior notes due 2028 through 2034 in a public offering, with coupons from 4.250% to 4.900%. Barclays, BofA Securities and Citigroup Global Markets are the representatives of the underwriters.

     GILD
103. May 14, 2026Company Updates

     Genprex reports preclinical diabetes gene therapy data at ASGCT

     Research collaborators presented data showing the company's Pdx1 and MafA gene therapy reversed hyperglycemia in a type 2 diabetes mouse model at the 2026 ASGCT Annual Meeting in Boston.

     GNPX
104. May 14, 2026Company Updates

     GRI Bio reports first-quarter 2026 results and new GRI-0621 data

     GRI Bio reported approximately $11.0 million in cash as of March 31, 2026, and added analyses from its Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis.

     GRI
105. May 14, 2026Company Updates

     Dogwood reports first quarter 2026 results and SP16 IND approval

     Dogwood reported a first quarter net loss of $5.0 million and cash on hand of $13.2 million, which it says runs into the fourth quarter of 2026.

     DWTX
106. May 14, 2026Listings

     Cuprina shareholders approve share consolidation and higher Class B voting rights

     Cuprina holders approved a share consolidation, raised Class B votes from 10 to 100 per share and allowed share issues of 20% or more of Class A shares. About 2.79% of the Class A votes were represented at the meeting.

     CUPR
107. May 14, 2026Company Updates

     Co-Diagnostics reports first quarter 2026 results and $8.2 million in cash

     The net loss was $9.1 million, or $4.06 per share, and cash and cash equivalents were $8.2 million at March 31, 2026. The company said enrollment in its upper respiratory test studies is complete.

     CODX
108. May 14, 2026Distress

     Cell Source's delayed 10-Q shows $1,240 in cash and $11.1 million of past-due notes

     Cell Source, an OTC Pink company, signed a 10-Q on May 14, 2026 for the quarter ended March 31, 2025. It reports $1,240 of cash, a going-concern warning, and notes past due, while it prepares a Nasdaq uplisting.

     CLCS
109. May 14, 2026Company Updates

     Calidi reports first quarter 2026 results and CLD-401 progress

     Calidi reported a first quarter net loss of $4.4 million, a $1.0 million cut in general and administrative expenses and a CLD-401 IND goal of year end 2026.

     CLDI
110. May 14, 2026Company Updates

     Biofrontera reports first-quarter 2026 results and regains Nasdaq bid price compliance

     Revenue rose about 17% to $10.1 million in the first quarter. Nasdaq confirmed on May 6, 2026 that the company had regained compliance with its minimum bid price requirement.

     BFRI
111. May 14, 2026Listings

     Aditxt plans 1-for-27 reverse stock split effective May 18

     Aditxt, Inc. said it will effect a 1-for-27 reverse split of its common stock at the opening of trading on May 18, 2026. The company says the split is primarily intended to bring it into compliance with Nasdaq's minimum bid price requirement.

     ADTX
112. May 14, 2026Company Updates

     AIM ImmunoTech posts KOL segment on Ampligen in pancreatic cancer

     The company said the on-demand segment features an Erasmus MC surgeon who discusses named patient program results and interim data from the ongoing Phase 2 trial.

     AIM
113. May 13, 2026Financings

     Whitehawk Therapeutics agrees to $87.5 million private placement of stock and warrants

     Whitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing.

     WHWK
114. May 13, 2026Debt Financing

     Spruce Biosciences details its $50.0 million Avenue Capital loan facility

     Avenue Capital Management II, L.P. is the lender under a term loan facility signed January 7, 2026. The first $15.0 million tranche funded after closing.

     SPRB
115. May 13, 2026Company Updates

     Onconetix reports Q1 2026 progress at Proteomedix

     The Swiss unit added two peer-reviewed papers, began enrolling in a U.S. validation study with Labcorp and kept expanding sales in Europe. The release does not report quarterly revenue or cash.

     ONCO
116. May 13, 2026Listings

     LogicMark revenue rises 24% in first quarter 2026

     Revenue reached $3.2 million and gross margin 69.6%, while the operating loss narrowed to $1.5 million and cash and investments totaled $7.5 million.

     LGMK
117. May 13, 2026Company Updates

     Intelligent Bio Solutions reports fiscal third quarter revenue up 46%

     Total revenue reached $1.06 million for the quarter ended March 31, 2026, and nine-month revenue reached $3.07 million, up 39% year over year.

     INBS
118. May 13, 2026Company Updates

     Equillium names Snehal Naik chief development officer and reports Q1 2026 results

     Equillium said cash and cash equivalents were $61.3 million at March 31, 2026, following a $35 million private placement with RA Capital Management completed in March 2026.

     EQ
119. May 13, 2026Financings

     Dermata reports first-quarter 2026 results and $2.0 million in ATM proceeds

     Dermata Therapeutics said its at-the-market facility produced $2.0 million of net proceeds in the first quarter of 2026. Cash was $6.9 million at March 31, 2026, and the company expects its resources to fund operations into the first quarter of 2027.

     DRMA
120. May 13, 2026Company Updates

     Bionano reports first quarter 2026 revenue of $6.7 million

     Consumables revenue grew 20%, and the company guided to full-year 2026 revenue of $30 to $33 million.

     BNGO
121. May 13, 2026Debt Financing

     BiomX sets up $2,000,000 credit line from Mandragola with 12% notes

     Mandragola Ltd is the lender under a credit line that issues 12% convertible promissory notes for each advance. Mandragola also received a five-year warrant.

122. May 13, 2026Debt Financing

     Armata Pharmaceuticals takes $25 million secured loan from Innoviva

     The 14.0% term loan matures in January 2029 and is secured by substantially all of the company's assets. The lender is a subsidiary of Innoviva, which the filing describes as a principal shareholder.

     ARMP
123. May 13, 2026Debt Financing

     Armata Pharmaceuticals signs $25 million secured loan with Innoviva at 14.0%

     The term loan from Innoviva Strategic Opportunities LLC matures January 11, 2029 and is secured by substantially all company assets. Armata reported about $4.8 million of unrestricted cash and cash equivalents at March 31, 2026.

     ARMP
124. May 13, 2026Company Updates

     Aptevo completes CEO transition and secures $60 million equity line

     Aptevo says its RAINIER trial of mipletamig remains on track for Phase 2 dose selection by year end, and that a $60 million standby equity purchase agreement extends its access to capital.

     APVO
125. May 13, 2026Company Updates

     Aprea reports first-quarter 2026 results and $46.5 million in cash

     Aprea said its $30 million private placement closed on March 31, 2026, and reported $46.5 million in cash at March 31, 2026, with runway into the first quarter of 2028. The company also described two partial responses in its Phase 1 trial of APR-1051.

     APRE
126. May 13, 2026Financings

     Allogene cites $200.4 million gross proceeds from April offering, runway to 2029

     Allogene had $266.9 million in cash and investments at March 31, 2026, after an April offering with $200.4 million gross proceeds. Its first-quarter net loss was $42.6 million, and its key ALPHA3 comparison rests on 12 patients per arm.

     ALLO
127. May 12, 2026Company Updates

     TherapeuticsMD reports first quarter 2026 results and strategic review

     The royalty company reported net income from continuing operations of $103 thousand and cash of $8.4 million as of March 31, 2026, and said it still evaluates strategic alternatives.

     TXMD
128. May 12, 2026Debt Financing

     Tempus AI completes $460.0 million convertible notes offering

     The notes carry no regular interest and mature May 15, 2032, after the initial purchasers exercised their option in full.

     TEM
129. May 12, 2026Company Updates

     Palisade Bio reports first quarter 2026 results and $132.6 million in cash

     The company reported cash and cash equivalents of $132.6 million at March 31, 2026. It said the Phase 2 ulcerative colitis trial of PALI-2108 is expected to start in the third quarter of 2026.

     PALI
130. May 12, 2026Company Updates

     Nuwellis reports 26% first-quarter revenue growth and 70.1% gross margin

     Net sales were $2.4 million, and the company reported about $2.2 million of cash and no debt at March 31, 2026.

     NUWE
131. May 12, 2026Debt Financing

     Mirum proposes $600.0 million convertible notes offering

     Mirum plans to sell $600.0 million of convertible senior notes due 2032, with an option for up to $90.0 million more. Part of the proceeds would go toward exchanges of its 2029 notes.

     MIRM
132. May 12, 2026Debt Financing

     Mirum prices $600 million of 0% convertible notes and refinances 2029 debt

     The notes carry no interest and convert at about $138.94 a share, a 30% premium to the May 12 price. Mirum swapped $237.2 million of 4% notes due 2029 for cash and shares.

     MIRM
133. May 12, 2026Company Updates

     Interpace Biosciences reports first quarter revenue of $9.0 million

     Revenue was $9.0 million, down 22% from the prior-year quarter as reported and up 14% on a pro forma basis, and the company reaffirmed its 2026 thyroid growth guidance.

     IDXG
134. May 12, 2026Financings

     Fractyl posts first-quarter profit on warrant revaluation as cash falls to $63 million

     A $30.1 million gain on warrant liabilities turned a $20.8 million operating loss into $9.2 million of net income.

     GUTS
135. May 12, 2026Debt Financing

     FOXO exchanges Series A preferred for senior unsecured notes

     Two institutional holders swapped Series A preferred stock for non-convertible notes of $5,307,096.94 and $2,467,988.34, due May 12, 2027.

     FOXO
136. May 12, 2026Mergers

     Collegium completes AZSTARYS purchase for about $650 million, raises 2026 guidance

     Collegium paid about $650 million in cash for AZSTARYS, using $350 million of its own cash and a $300 million loan draw. Corium Therapeutics may receive up to $135 million more if milestones are met.

     COLL
137. May 12, 2026Mergers

     Collegium completes $650 million AZSTARYS acquisition, funded with cash and $300 million term loan

     Collegium paid about $650 million in cash for AZSTARYS, using about $350 million of cash on hand and a $300 million delayed draw term loan. Two senior executives are leaving, and the company may pay up to $135 million more if AZSTARYS hits milestones.

     COLL
138. May 12, 2026Company Updates

     Bolt Biotherapeutics reports first-quarter results and $23.9 million in cash

     The company said its cash should fund operations into 2027, including completion of the dose escalation part of the BDC-4182 study. It expects initial clinical data in the third quarter of 2026.

     BOLT
139. May 12, 2026Debt Financing

     Aquestive enters $150 million debt facility with Oaktree

     The facility refinances Aquestive's existing debt. It starts with $55.0 million at signing and adds tranches tied to FDA approval and sales milestones.

     AQST
140. May 11, 2026Financings

     Viridian raises $394 million in convertible notes and stock, repays Hercules loan

     The company sold $250 million of 1.75% notes due 2032 and shares at $17.00 ahead of its first approval. It used part of the money to pay off about $55.1 million of term debt.

     VRDN
141. May 11, 2026Debt Financing

     Travere sells $525 million of 2032 convertible notes to buy back $221 million of 2029 notes

     The 0.50% notes would lift convertible principal to $619.9 million but cut the coupon. Travere said it would spend about $350.9 million to repurchase part of the older debt.

     TVTX
142. May 11, 2026Listings

     SciSparc gets conditional Nasdaq compliance letter on stockholders' equity

     Nasdaq staff said on May 7, 2026 that SciSparc now meets the $2,500,000 stockholders' equity standard, but the letter is conditional. Delisting is possible if the company's next periodic report does not show compliance.

     SPRC
143. May 11, 2026Listings

     PureTech Health PLC files Form 25 to delist its ADSs from Nasdaq

     The filing, dated May 11, 2026, relies on the SEC rule for a voluntary withdrawal by the issuer. It covers American Depositary Shares, each representing 10 ordinary shares.

     PRTC
144. May 11, 2026Financings

     Odyssey Therapeutics sells 1,388,889 shares to TPG affiliate at $18.00 in private placement

     The private placement closed alongside Odyssey's initial public offering. The Share Purchase Agreement is dated May 7, 2026 and names five placement agents.

     ODTX
145. May 11, 2026Debt Financing

     NexGel issues $1,000,000 convertible note to new director Brian J. Kieser

     The unsecured note converts at $0.60 a share and goes to Brian J. Kieser, a new director who runs Sequence LifeScience. Sequence bought $5,500,000 of notes in an earlier April financing.

     NXGL
146. May 11, 2026Company Updates

     MetaVia to present DA-1726 data as a late-breaking poster at EASL 2026

     A late-breaking abstract on the obesity candidate DA-1726 was accepted for a poster at the EASL Congress 2026 in Barcelona, scheduled for May 27, 2026.

     MTVA
147. May 11, 2026Company Updates

     Functional Brands lowers Series C preferred conversion price to $0.1636

     The company agreed with all Series C holders to reset the conversion price to $0.1636 per share, the market price at signing.

     MEHA
148. May 11, 2026Financings

     Conexeu Sciences registers 9,481,123 shares for resale ahead of planned Nasdaq listing

     The prospectus registers resale shares only, so the company gets no proceeds from those sales. It expects Nasdaq trading on or about May 21, 2026, and its own financials carry going-concern doubt.

     CNXU
149. May 11, 2026Mergers

     Aurinia completes Kezar Life Sciences acquisition after tender offer at $6.955 per share plus CVR

     Aurinia said on May 11, 2026 that it completed its acquisition of Kezar Life Sciences. Holders received $6.955 in cash plus one contingent value right per share, after a tender offer in which 5,927,580 Kezar shares, about 80.24% of those outstanding, were validly tendered.

     AUPH
150. May 11, 2026Financings

     ArriVent BioPharma files for up to $250,000,000 in at-the-market stock sales

     ArriVent BioPharma, Inc. filed a prospectus supplement on May 11, 2026 under its existing sales agreement with Jefferies LLC. The last reported sale price was $29.50 per share on May 8, 2026.

     AVBP
151. May 11, 2026Distress

     Anavex Life Sciences files late-filing notice for 10-Q after CEO termination

     Anavex Life Sciences told the SEC on May 11, 2026 that it cannot file its first-quarter 10-Q on time. The delay follows the April 30 termination of CEO Christopher Missling, and the company says the review of that termination may take longer than it expects.

     AVXL
152. May 11, 2026Company Updates

     Adial reports first quarter 2026 results and an AD04 business update

     Cash was $4.6 million at March 31, 2026, and Adial says it can fund operating expenses into the second half of 2026 on its committed development plans.

     ADIL
153. May 8, 2026Listings

     iSpecimen prices $2.5 million private placement at $5.12 per share

     E.F. Hutton & Co. is the exclusive placement agent, and the company expects the offering to close on or about May 11, 2026.

     ISPC
154. May 8, 2026Financings

     Nektar Therapeutics sets up $150,000,000 at-the-market stock program

     Nektar will sell up to $150 million of stock through Guggenheim Securities and H.C. Wainwright at a 3.0% commission. The company used $208.5 million in operations in 2025, and its Phase 3 spending is set to rise.

     NKTR
155. May 8, 2026Debt Financing

     Lifeloc borrows $500,000 from its Chairman and CFO

     Lifeloc Technologies entered into a $500,000 promissory note with Vern Kornelsen, its Chief Financial Officer and Chairman of the Board. The note carries 10.5% interest and is secured by its Wheat Ridge office and most of its assets.

     LCTC
156. May 8, 2026Company Updates

     Kiora reports first quarter 2026 results and runway into late 2028

     Kiora ended the first quarter with $13.9 million in cash and short-term investments. It raised an additional $5.0 million in gross proceeds from a strategic equity investment after quarter end.

     KPRX
157. May 8, 2026Listings

     Humacyte gets Nasdaq minimum bid price deficiency notice, has until November 2, 2026

     Nasdaq told Humacyte on May 4, 2026 that its common stock closed below $1.00 for 30 consecutive business days. The company has until November 2, 2026 to regain compliance, and the notice has no immediate effect on its listing.

     HUMA
158. May 8, 2026Financings

     Artiva Biotherapeutics prices $300.0 million offering of shares and warrants

     Artiva Biotherapeutics agreed to sell 23,871,526 shares at $11.52 each, plus pre-funded warrants for 2,170,138 shares. The company's last reported sale price was $12.52 on May 7, 2026.

     ARTV
159. May 7, 2026Financings

     Structure Therapeutics raises its at-the-market limit to $400,000,000

     Leerink Partners LLC and Cantor Fitzgerald & Co. are the sales agents. About $58.5 million of ADSs had already been sold, leaving $341,478,784 of capacity after the supplement.

     GPCR
160. May 7, 2026Company Updates

     Revelation Biosciences reports first quarter 2026 net loss of $3.0 million

     Cash stood at $14.1 million on March 31, 2026, which the company says covers operations through the first quarter of 2027.

     REVB
161. May 7, 2026Company Updates

     Quoin reports first quarter 2026 results and FDA meeting outcome

     Quoin said an FDA Type C meeting indicated a single Phase 3 study may be sufficient for U.S. approval of QRX003, and reported approximately $14 million in cash as of March 31, 2026.

     QNRX
162. May 7, 2026Company Updates

     PTC raises 2026 product revenue guidance after first quarter

     PTC reported first quarter 2026 total revenue of $273 million and a net loss of $2.8 million, and raised full-year product revenue guidance to $750 to $850 million.

     PTCT
163. May 7, 2026Company Updates

     Oragenics signs letter of intent to license CardioDialysis for TBI

     Oragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years.

     OGENSIGY
164. May 7, 2026Company Updates

     LeonaBio reports first quarter 2026 results and ELAINE-3 amendment

     LeonaBio said it is increasing the ELAINE-3 sample size to up to 600 participants and expects to start a Phase 2 ALS study for ATH-1105 in the second half of 2026.

     LONA
165. May 7, 2026Company Updates

     Intensity Therapeutics reports Q1 2026 results and enrollment plans

     Cash and cash equivalents were $10.2 million at March 31, 2026. The company plans to resume enrollment in INVINCIBLE-3 at a limited number of U.S. sites by the third quarter of 2026.

     INTS
166. May 7, 2026Company Updates

     IN8bio reports first quarter 2026 results and glioblastoma survival updates

     IN8bio reported cash of $21.9 million at March 31, 2026 and a net loss of $5.1 million for the quarter, and it described updated glioblastoma data and its INB-619 engager program.

     INAB
167. May 7, 2026Debt Financing

     Gelteq agrees to up to $3.5 million in convertible note financing

     An institutional investor will fund up to $3.5 million in two tranches. The first note carries 7% interest, matures in eighteen months and converts at a price that cannot fall below $0.50.

     GELS
168. May 7, 2026Financings

     Celldex closes $345 million raise and guides to funding through 2028

     First-quarter cash was $451.5 million before the April offering. Celldex then expected phase 3 hives data in the fourth quarter of 2026.

     CLDX
169. May 7, 2026Legal

     Capricor sues Nippon Shinyaku and NS Pharma over Deramiocel U.S. distribution agreement

     Capricor Therapeutics filed a complaint in New Jersey seeking to rescind its January 24, 2022 distribution agreement and asking for a preliminary injunction. The FDA target action date for Deramiocel is August 22, 2026.

     CAPR
170. May 7, 2026Company Updates

     Bluejay gives first quarter 2026 corporate update

     About 680 patients were enrolled in SYMON-II as of May 5, 2026, toward a target of 750, and the company reported a first-quarter net loss of approximately $1.9 million.

     BJDX
171. May 7, 2026Distress

     Arcturus Therapeutics reports $213.4 million in cash, sees runway past Q2 2028

     Operating expenses fell to $31.0 million from $46.2 million, but revenue fell by $27.3 million and the net loss was approximately $27.0 million.

     ARCT
172. May 7, 2026Financings

     AIM ImmunoTech arranges warrant inducement through Ladenburg Thalmann

     Existing holders agreed to exercise warrants at $0.48 a share in exchange for new Class H warrants, with gross proceeds of approximately $4.20 million if all existing warrants are exercised.

     AIM
173. May 6, 2026Debt Financing

     Viridian completes $250,000,000 convertible notes offering

     Viridian's $250,000,000 offering of 1.75% convertible senior notes due 2032 includes the full $25.0 million over-allotment option. A concurrent sale of 7,352,942 shares was priced at $17.00 a share.

     VRDN
174. May 6, 2026Financings

     TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million

     First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases.

     TGTX
175. May 6, 2026Financings

     InflaRx prices $150,000,000 share offering at $2.00 and closes it a day later

     InflaRx N.V. sold 75,000,000 ordinary shares in an underwritten offering led by Guggenheim Securities. The offering closed on May 7, 2026.

     IFRX
176. May 6, 2026Company Updates

     InMed reports third quarter results and a $3.0 million net loss

     InMed reported a net loss of $3.0 million for the quarter ended March 31, 2026, and cash, cash equivalents and short-term investments of $5.2 million, as it winds down its commercial operations.

     INM
177. May 6, 2026Debt Financing

     Citius Oncology prices $11.5 million warrant inducement and signs Avenue term loan

     Citius Oncology signed a warrant inducement worth about $11.5 million and a loan of up to $25.0 million with Avenue. Existing warrants are repriced to $0.90, and the new warrants and conversion rights add to the share count.

     CTOR
178. May 6, 2026Debt Financing

     Citius Oncology announces up to $36.5 million in loan and warrant financing

     Citius Oncology signed a loan of up to $25 million with an Avenue Capital fund and expects about $11.5 million gross from a warrant exercise. Only $10 million of the loan funds at closing, and the new warrants cannot be exercised until stockholders approve the shares.

     CTOR
179. May 6, 2026Company Updates

     Aptevo reports 87% clinical benefit in frontline AML through Cohort 5

     Aptevo says mipletamig data from 31 evaluable frontline AML patients show continued activity, and that the RAINIER trial has entered its final dose-optimization stage.

     APVO
180. May 5, 2026Debt Financing

     Travere proposes $400 million convertible notes offering

     Travere plans to sell $400 million of convertible senior notes due 2032, with an option for up to $60 million more. It intends to use part of the proceeds to repurchase 2029 notes for cash.

     TVTX
181. May 5, 2026Company Updates

     Theriva reports Q1 2026 results and FDA agreement on Phase 3 design

     The company reported cash of $14.4 million at March 31, 2026, a runway into Q1 2027, and FDA general agreement on a pivotal Phase 3 design for VCN-01.

     TOVX
182. May 5, 2026Company Updates

     Q32 Bio reports Q1 2026 results and first patient dosed in Part B extension

     Cash and cash equivalents were $50.8 million at March 31, 2026. The company received $14.2 million of at-the-market proceeds after the quarter ended.

     QTTB
183. May 5, 2026Debt Financing

     Ocugen plans $115 million convertible senior notes offering

     Ocugen plans $115 million of 6.75% convertible senior notes due 2034, with an option that takes the total to $130 million. Proceeds include $32.7 million to retire Avenue debt at 12.5%.

     OCGN
184. May 5, 2026Company Updates

     Minerva reports first quarter 2026 results and starts its Phase 3 trial

     The company reported a GAAP net loss of $125.4 million for the quarter, including a $109.4 million non-cash warrant charge, and said the first patient was screened in March.

     NERV
185. May 5, 2026Financings

     Exelixis authorizes another $750 million buyback as first-quarter revenue hits $610.8 million

     The new program runs through Dec. 31, 2027. First-quarter net product revenue was $555.0 million and 2026 guidance was left unchanged.

     EXEL
186. May 5, 2026Company Updates

     Apimeds Pharmaceuticals appoints Sungjoon Chae co-chief executive

     Apimeds named Sungjoon Chae Co-Chief Executive Officer on May 4, 2026 on a stockholder's nomination. The Form 8-K, dated May 5, 2026, describes his background as an architect and urban designer.

     APUS
187. May 4, 2026Company Updates

     Pasithea names Kartik Krishnan chief medical officer

     Kartik Krishnan, M.D., Ph.D., became chief medical officer on May 1, 2026, and will oversee clinical development and medical strategy for PAS-004.

     KTTA
188. May 4, 2026Mergers

     Lisata and Kuva Labs delay tender offer start to May 29, Kuva to pay up to $1.1 million of expenses

     Lisata and Kuva Labs signed an amendment and waiver on May 3, 2026 that moves the tender offer start from April 13, 2026 to May 29, 2026. Kuva will pay up to $1.1 million of Lisata's expenses until the offer starts, and the offer is $5.00 in cash plus a $1.00 contingent value right.

     LSTA
189. May 4, 2026Debt Financing

     Lexicon signs up to $100 million loan with Hercules Capital

     Lexicon signed a loan of up to $100 million from Hercules in three tranches. The first $55 million was funded at closing, and Hercules receives warrants at $1.59 a share.

     LXRX
190. May 4, 2026Mergers

     Gyre Therapeutics completes all-stock acquisition of Cullgen valued at about $300 million

     Gyre closed its merger with Cullgen on May 4, 2026. Cullgen holders get Gyre common and Series B preferred stock, and Cullgen's former CEO Ying Luo becomes Gyre's CEO.

     GYRE
191. May 4, 2026Financings

     CNS Pharmaceuticals agrees to about $22.5 million private placement with pre-funded warrants

     CNS Pharmaceuticals priced a private placement of common stock at $2.30 per share and pre-funded warrants at $2.299, for approximately $22.5 million gross. Most of the shares are pre-funded warrants for 9,143,479 shares. Closing is expected May 5, 2026. A director resigned and a new one was named.

     CNSP
192. May 4, 2026Mergers

     Aura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price

     Aura Biosciences agreed to buy back up to 6,922,870 shares from Matrix Capital at $5.64, the price of an equity offering it announced on May 4, 2026. The buyback comes out of the offering's proceeds, and the company put preliminary cash at $114.7 million as of March 31, 2026.

     AURA
193. May 3, 2026Mergers

     Rallybio to receive $50,000,000 fee after Candid ends merger

     Candid terminated its merger agreement with Rallybio on May 3, 2026, and entered into a Permitted Alternative Agreement with UCB S.A. Rallybio intends to withdraw its Form S-4 registration statement.

     RLYB
194. May 1, 2026Financings

     Veradermics raises about $472 million in $100-a-share follow-on and warrant sale

     Veradermics closed an underwritten sale of 3,843,790 shares at $100.00 and a $30.0 million private placement of pre-funded warrants on May 1. Its pivotal hair-loss trials are still running against $70.0 million of annual losses.

     MANE
195. May 1, 2026Mergers

     Shuttle Pharmaceuticals agrees to merge with United Dogecoin

     The merger is backed by an $11 million private placement that Shuttle expected to close on May 4, 2026.

     SHPH
196. May 1, 2026Mergers

     Senti Biosciences agrees to sell $10.0 million of secured convertible notes to Celadon affiliate

     Senti Biosciences agreed to sell up to $40.0 million of secured convertible notes to an affiliate of its largest stockholder. If the notes are not converted, the company must pay 200% of principal in cash at maturity, and the second tranche depends on a related deal that could pay up to $60.0 million.

     SNTI
197. May 1, 2026Financings

     Seaport Therapeutics prices IPO of 14,160,000 shares at $18.00

     The offering totals $254,880,000 before fees, and Seaport expects net proceeds of about $233.9 million. Entities affiliated with General Atlantic, a holder of more than 5% of the stock, have indicated interest in up to $50 million of shares, which is not binding.

     SPTX
198. May 1, 2026Financings

     Regentis Biomaterials files to sell 3,333,334 shares at an assumed $3.00

     Regentis Biomaterials Ltd. filed a Form F-1 on May 1, 2026 for a firm commitment offering through ThinkEquity. The $3.00 price is the April 28, 2026 NYSE American close.

     RGNT
199. May 1, 2026Financings

     Hemab Therapeutics Holdings prices $301,500,000 IPO at $18.00 per share

     The company priced 16,750,000 shares at $18.00 each, with delivery expected on or about May 4, 2026. It had net losses of $63.9 million in 2025 and no approved products.

     COAG
200. May 1, 2026Financings

     Cue Biopharma licenses Ascendant-221 from Ascendant Health, to pay $15.0 million upfront

     Cue Biopharma agreed to pay a $15.0 million upfront for rights to Ascendant-221, an anti-IgE antibody still in a Phase 2 study run by the licensor's affiliate, and to issue pre-funded warrants for up to 551,724 shares. Milestones could reach $676.5 million, and the company's own release cites a current going concern determination.

     CUE
201. May 1, 2026Debt Financing

     CERo sells convertible note with $500,000 face value to Keystone

     CERo Therapeutics Holdings issued a convertible promissory note to Keystone Capital Partners, LLC on April 27, 2026, with a purchase price of $400,000 and a principal face value of $500,000.

     CERO
202. May 1, 2026Debt Financing

     Alphatec signs $175.0 million term loan and $125.0 million revolver

     JPMorgan Chase Bank, N.A. is administrative agent on the $175.0 million term loan A and the $125.0 million revolver, which repaid older credit agreements.

     ATEC

April 2026

1. Apr 30, 2026Distress

   XTL Biopharmaceuticals cannot file its 2025 Form 20-F, citing subsidiary liquidation

   The company says it lacks operational and financial data for its subsidiary The Social Proxy Ltd., which is in liquidation proceedings.

   XTLB
2. Apr 30, 2026Financings

   Valneva prices €37 million private placement of shares with attached warrants

   Valneva agreed on April 29, 2026 to sell 15,893,817 new shares, each with a warrant, for €37 million. The warrants could add about €47 million if every one is exercised, at €2.96 each.

   VLA
3. Apr 30, 2026Distress

   Tiziana Life Sciences files late-filing notice for its 2025 annual report on Form 20-F

   The company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date.

   TLSA
4. Apr 30, 2026Listings

   Rockwell Medical to put reverse stock split to a vote at June 12, 2026 meeting

   DEK:Rockwell Medical's proxy asks holders to approve a reverse split at a virtual meeting on June 12, 2026. Approval needs a majority of the votes cast, and the company's 2025 net loss was $5.3 million.

   RMTI
5. Apr 30, 2026Mergers

   Perrigo completes sale of Dermacosmetics business to Karo for €305.6 million in cash

   Perrigo (NYSE: PRGO) received €305.6 million at closing and may get up to €27.0 million more over three years. The company says net proceeds will be used primarily to reduce debt.

   PRGO
6. Apr 30, 2026Debt Financing

   PDS Biotechnology agrees to sell $6,000,000 promissory note

   The 10% note matures in twelve months and is sold to YA II PN, LTD. for $5,760,000. It comes with a warrant for 2,158,274 shares at $1.1824 a share.

   PDSB
7. Apr 30, 2026Listings

   Enveric corrects reverse split maximum in proxy materials to 1-for-15

   A proxy supplement corrects a typographical error that showed a 1-for-50 maximum on the proxy card and notice before the May 28, 2026 annual meeting.

   ENVB
8. Apr 30, 2026Company Updates

   Cocrystal presents CDI-988 norovirus data at ICAR 2026

   The company says the first cohort of its Phase 1b norovirus challenge study is fully enrolled, with prevention and treatment cohorts to follow.

   COCP
9. Apr 30, 2026Debt Financing

   Clearmind amends convertible note deal, leaving $10 million available

   The amendment raises the subscription amount so that $10,000,000 of capacity remains for future convertible promissory notes.

   CMND
10. Apr 30, 2026Financings

    Avalyn Pharma prices IPO of 16,666,667 shares at $18.00

    The offering totals $300,000,006 before fees. The shares have been approved for listing on the Nasdaq Global Select Market as AVLN.

    AVLN
11. Apr 30, 2026Distress

    Addex Therapeutics files late-filing notice for its 2025 annual report on Form 20-F

    Addex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business.

    ADXN
12. Apr 29, 2026Listings

    PureTech to delist ADSs from Nasdaq and keep its primary London listing

    PureTech will delist its American Depositary Shares from Nasdaq and keep its London listing. The Form 25 is expected around May 11, 2026, with the last Nasdaq trading day around May 20, and the company plans to deregister with the SEC afterward.

    PRTC
13. Apr 29, 2026Company Updates

    OSR Health licenses VXM01 to BCM Europe for up to $815 million

    BCM Europe, the company's largest shareholder, holds an exclusive global license and has pledged its entire stake as collateral for milestone payments of up to $815 million.

    OSRH
14. Apr 29, 2026Distress

    Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F

    The company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date.

    MENS
15. Apr 29, 2026Listings

    CorMedix asks holders to ratify past changes to preferred stock terms

    CorMedix wants stockholders to ratify earlier changes to its Series E and Series C-3 preferred stock, and to let preferred holders alone approve future changes to those terms.

    CRMD
16. Apr 29, 2026Distress

    Autolus Therapeutics to cut about 13% of workforce, expects about $8 million in charges

    Autolus will cut about 13% of its workforce and expects about $8 million in severance and related charges, with savings of about $15 million a year from 2027. It reiterated 2026 AUCATZYL revenue guidance of $120 million to $135 million, while its 10-K reports a 2025 net loss of $287.5 million and cash used in operations of $283.6 million.

    AUTL
17. Apr 29, 2026Distress

    Autolus Therapeutics cuts about 13% of staff, targets $15 million in annual savings

    The company expects about $8 million in restructuring charges and continues to expect its cash to fund operations into the fourth quarter of 2027.

    AUTL
18. Apr 28, 2026Company Updates

    Soligenix FLASH 2 trial recommended to halt for futility

    After an interim efficacy analysis, the Data Monitoring Committee recommended stopping the Phase 3 HyBryte trial for futility, and Soligenix says it has approximately $5.9 million of cash.

    SNGX
19. Apr 28, 2026Listings

    InflaRx regains Nasdaq bid price compliance

    Nasdaq's notice dated April 27, 2026 says the ordinary shares closed at $1.00 or more for 10 consecutive business days. The matter is closed.

    IFRX
20. Apr 28, 2026Listings

    Citius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026

    Nasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until October 19, 2026 to cure, while its auditor has flagged going-concern doubt and its parent funds most operations.

    CTOR
21. Apr 28, 2026Mergers

    Avalo Therapeutics agrees to pay $2.25 million for option on $15 million AlmataBio milestone

    Avalo can pay $5.125 million in cash or stock within 90 days instead of $15 million owed when a Phase 3 trial doses its first patient. If it does not, the milestone amount becomes $12.75 million.

    AVTX
22. Apr 27, 2026Debt Financing

    Scienture closes $8 million note purchase with Streeterville Capital

    The April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent.

    SCNX
23. Apr 27, 2026Mergers

    Organon agrees to be acquired by Sun Pharma for $14.00 per share in cash

    Organon agreed on April 26, 2026 to be bought by Sun Pharma for $14.00 a share in cash, a 103% premium to an April 9 close set before a media report. The company's enterprise value is $11.75 billion, and it carries $8.6 billion of debt.

    OGN
24. Apr 27, 2026Mergers

    Ligand Pharmaceuticals signs merger agreement to acquire XOMA Royalty for $39.00 per share in cash

    Ligand will pay about $739 million in equity value for XOMA Royalty, plus a contingent value right tied to litigation. The deal needs a XOMA Royalty stockholder vote and is expected to close in the third quarter of 2026.

    LGND
25. Apr 27, 2026Financings

    Intellia Therapeutics proposes $150,000,000 stock offering, prices it at $10.75

    Intellia filed to sell $150 million of common stock on April 27, 2026 and priced 16,744,187 shares at $10.75 on April 28. Its preliminary cash at March 31 was $517.2 million, and its risk factors say the FDA has lifted a clinical hold on the nex-z Phase 3 trials.

    NTLA
26. Apr 27, 2026Financings

    InMed cuts exercise price on preferred investment options to $0.80

    InMed agreed to amend the exercise prices on preferred investment options held by Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC to $0.80 per share.

    INM
27. Apr 27, 2026Company Updates

    Evofem signs exclusive SOLOSEC distribution deal for sub-Saharan Africa

    Clovis Davis Pharmaceuticals will lead distribution, promotion, marketing and sales of SOLOSEC in the territory. The release is dated April 27, 2026.

    EVFM
28. Apr 26, 2026Company Updates

    Aspira Women's Health names John Strahley chief financial officer

    John Strahley joins as a fractional CFO and chief accounting officer effective April 27, 2026, on a $167,000 base salary, after the consulting arrangement with Brian Hungerford ended.

    AWHL
29. Apr 24, 2026Listings

    iSpecimen plans 1-for-40 reverse stock split effective April 27, 2026

    After the split, the company's 52,639,796 shares become 1,316,032 shares, and the stock trades split-adjusted from April 28, 2026.

    ISPC
30. Apr 24, 2026Mergers

    Telomir Pharmaceuticals completes acquisition of TELI Pharmaceuticals for 34,389,710 shares

    Telomir acquired 100% of TELI on April 22, 2026 and now holds the global rights to Telomir-1. Bayshore Trust contributed $1 million at closing and entered an option to pay up to $4 million more if milestones are met.

    TELO
31. Apr 24, 2026Company Updates

    Onconetix directors Oakley and Meier resign; Dorf named chairman

    Josh Epstein joined the board on April 23, 2026 and chairs its Nominating and Corporate Governance Committee. The 8-K says neither resignation involved a disagreement with management.

    ONCO
32. Apr 24, 2026Financings

    Citius Pharmaceuticals prices $5 million registered direct offering at $0.985

    Citius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern.

    CTXRCTOR
33. Apr 23, 2026Financings

    Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares

    The company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning.

    LABT
34. Apr 22, 2026Listings

    Tevogen Bio Holdings (now Tevogen Inc.) gets two Nasdaq deficiency notices on market value

    Tevogen received two Nasdaq notices in April 2026 saying it no longer meets the $50 million listed-securities market value requirement or the $15 million publicly held shares requirement. It has until October 13 and October 14, 2026 to regain compliance with each.

    TVGN
35. Apr 22, 2026Financings

    Maze Therapeutics prices $150 million stock and pre-funded warrant offering

    Maze Therapeutics, Inc. is selling 5,540,000 shares at $23.50 each and pre-funded warrants for 850,000 shares. Leerink Partners LLC is sole underwriter, and dilution to new investors is $14.40 per share.

    MAZE
36. Apr 22, 2026Mergers

    Galera and Obsidian Therapeutics merger moves forward with Gazelle Parent S-4

    Gazelle Parent, Inc. filed the registration statement on April 22, 2026. Galera has agreed to sell Series C preferred stock for about $350.0 million, less certain Obsidian financing proceeds, before the mergers close.

    OBX
37. Apr 22, 2026Listings

    Cue Biopharma sets 1-for-30 reverse stock split for April 23, 2026

    Cue Biopharma's 1-for-30 reverse split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. The company says it is meant to restore compliance with Nasdaq's minimum bid price, and its filing still carries a going-concern determination.

    CUE
38. Apr 22, 2026Listings

    Apimeds Pharmaceuticals gets NYSE American late filing notice for 2025 Form 10-K

    NYSE Regulation told Apimeds Pharmaceuticals US on April 17, 2026 that it had not filed its 2025 annual report on time. The company has until October 15, 2026 to file, its stock carries a ".LF" tag, and a trading halt that began April 2 is still in effect.

    APUS
39. Apr 22, 2026Financings

    Amneal agrees to acquire Kashiv BioSciences for $375,000,000 in cash and 28,942,108 shares

    Amneal will pay $375 million in cash and issue 28,942,108 shares to buy Kashiv BioSciences, and some sellers are affiliates of the Amneal Group. Up to $350 million more depends on US regulatory milestones for Kashiv products.

    AMRX
40. Apr 22, 2026Financings

    Altimmune launches stock and warrant offering, later prices it at $3.00

    Altimmune sold 64,250,000 shares at $3.00 with a warrant for each share, against a last reported sale price of $3.47 on April 22, 2026.

    ALT
41. Apr 21, 2026Financings

    Oruka Therapeutics substitutes selling stockholder in resale prospectus

    SILV Fund Ltd. replaces Point72 Associates, LLC for 531,670 shares. The resale prospectus still covers up to 39,425,806 shares, against 49,542,691 outstanding on February 28, 2026.

    ORKA
42. Apr 21, 2026Distress

    Lilly to end Rigel ocadusertib license effective June 15, 2026

    Eli Lilly gave notice on April 16, 2026 that it is terminating its license for ocadusertib, a RIPK1 inhibitor, effective June 15, 2026. Rigel expects to regain full rights and does not expect future milestones or royalties under the agreement.

    RIGL
43. Apr 21, 2026Financings

    Hepion raises $700,000 in a common stock private placement

    The agreements dated April 21, 2026 cover 17,500,000 shares at $0.04 per share, and the offering closed the same day. The filing names no underwriter or placement agent.

    HEPA
44. Apr 21, 2026Distress

    CASI Pharmaceuticals says 2025 Form 20-F is late, expects going-concern doubt

    CASI Pharmaceuticals filed a Form NT 20-F on April 21, 2026, saying its annual report on Form 20-F for 2025 will be late because its U.S. GAAP financial statements are not yet available. It expects that report to say there remains substantial doubt about its ability to continue as a going concern.

    CASIF
45. Apr 20, 2026Financings

    Spruce Biosciences announces proposed underwritten public offering

    Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are joint book-running managers, with Jones and Craig-Hallum as co-managers.

    SPRB
46. Apr 20, 2026Distress

    Semnur terminates two share purchase agreements tied to its 2025 merger

    Semnur ended a private placement agreement with JW Capital Securities Limited and a share purchase agreement with Biconomy PTE. Ltd. Neither agreement had produced any issued shares.

    SMNR
47. Apr 20, 2026Financings

    Kailera Therapeutics completes IPO with $718.8 million in gross proceeds at $16.00 a share

    Kailera Therapeutics (Nasdaq: KLRA) sold 44,921,875 shares in its initial public offering, including the underwriters' full option. A restated charter set up a classified board and exclusive forum rules.

    KLRA
48. Apr 20, 2026Debt Financing

    IGC Pharma sells promissory notes to FirstFire and Vanquish Funding for $307,000 and $207,000

    The notes mature in 2027 and carry 12% interest. They can convert into common stock at 75% of the lowest trading price in the prior ten trading days, and only after an event of default.

    IGC
49. Apr 20, 2026Mergers

    First Tracks Biotherapeutics begins Nasdaq trading as TRAX with $180 million in cash

    The company was spun off from AnaptysBio, Inc. on April 20, 2026. It says it has a two-year cash runway.

    TRAX
50. Apr 20, 2026Mergers

    First Tracks Biotherapeutics begins Nasdaq trading after AnaptysBio spin-off

    First Tracks Biotherapeutics began trading on Nasdaq as AnaptysBio completed the spin-off. The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks.

    TRAX
51. Apr 20, 2026Financings

    Daré Bioscience closes sale of 20,000 units in Regulation A preferred stock and warrant offering

    Daré issued 20,000 Investor Units at $5.00 each, with one Series A Convertible Preferred share and two warrants per unit. The offering is for up to 4,854,000 units, and the company's auditor has raised going concern doubt.

    DARE
52. Apr 20, 2026Mergers

    AnaptysBio completes spin-off of First Tracks Biotherapeutics, keeps royalty business

    AnaptysBio completed the spin-off of First Tracks Biotherapeutics on April 20, 2026, one share for every share held on April 6. AnaptysBio keeps the royalty business and gives a range of $140-$145 million for its net cash, while the press release calls the spin-off taxable and cites an EBIT margin it does not reconcile to GAAP.

    ANAB
53. Apr 20, 2026Mergers

    AnaptysBio completes spin-off of First Tracks Biotherapeutics

    Shareholders received one First Tracks share for each AnaptysBio share held on April 6, 2026. AnaptysBio now manages two royalty collaborations and starts with about $140-$145 million in net cash.

    ANABTRAX
54. Apr 20, 2026Financings

    AN2 Therapeutics sets up $80,000,000 share sales program with Jefferies

    AN2 Therapeutics filed an $80,000,000 prospectus supplement dated April 20, 2026 for sales through Jefferies LLC, which will be deemed an underwriter, earns up to 3.0% of gross proceeds and is under no obligation to sell any set amount.

    ANTX
55. Apr 17, 2026Company Updates

    Theriva to present VIRAGE trial biomarker data at AACR 2026

    A poster on April 20, 2026 will report tumor response, biomarker and subgroup analyses from the VIRAGE Phase 2b trial of VCN-01.

    TOVX
56. Apr 17, 2026Financings

    Odyssey Therapeutics files for IPO, plans Nasdaq Capital Market listing as ODTX

    Odyssey Therapeutics, Inc. filed a Form S-1 on April 17, 2026. The cover leaves the share count and price range blank.

    ODTX
57. Apr 17, 2026Financings

    Kailera Therapeutics prices IPO of 39,062,500 shares at $16.00

    The offering totals $625,000,000 before fees. Existing stockholders have indicated interest in buying up to approximately $225 million of shares.

    KLRA
58. Apr 17, 2026Debt Financing

    Emergent BioSolutions draws $150 million OrbiMed term loan, repays prior credit agreement

    The Credit Agreement also provides a $75 million delayed draw term loan, available for 24 months. Interest is Term SOFR plus 6.25% per annum, with a 3.00% floor.

    EBS
59. Apr 17, 2026Debt Financing

    Emergent BioSolutions closes $150 million term loan with OrbiMed, cuts ABL revolver to $50 million

    Emergent drew a $150 million term loan with OrbiMed as administrative agent and repaid its prior credit agreement. Interest is Term SOFR plus 6.25%, with a 3.00% floor, and the loan matures as late as April 16, 2031. The asset-based revolver falls from $100 million to $50 million.

    EBS
60. Apr 17, 2026Financings

    Alamar Biosciences prices IPO of 11,250,000 shares at $17.00 each

    Alamar priced 11,250,000 shares at $17.00 each, and the underwriters later exercised their option in full, bringing gross proceeds to about $219.9 million.

    ALMR
61. Apr 16, 2026Financings

    Trevi Therapeutics prices $150 million stock offering at $13.00 per share

    Trevi sold 11,600,000 shares at $13.00 each, about $150 million, below the $14.54 last sale on April 16, 2026. Its two pivotal Phase 3 trials for Haduvio are not due to report until the second half of 2027 and the first half of 2028.

    TRVI
62. Apr 16, 2026Company Updates

    Oncotelic reports $249.0 million 2025 profit that is a non-cash joint venture gain

    The result reflects a non-cash increase of approximately $365.4 million in the fair value of the company's GMP Biotechnology investment, partly offset by a tax provision.

    OTLC
63. Apr 16, 2026Mergers

    MeiraGTx buys XLRP gene therapy rights from Janssen for $25,000,000 upfront

    MeiraGTx also agreed to a one-time $50,000,000 contingent payment and mid-teens royalties starting on or after July 1, 2029. The 8-K also reports an amendment with Hologen.

    MGTX
64. Apr 16, 2026Mergers

    MeiraGTx agrees to buy bota-vec from Johnson & Johnson for $25 million upfront

    MeiraGTx will pay Johnson & Johnson $25 million in cash upfront for bota-vec, a gene therapy whose Phase 3 primary endpoint did not reach statistical significance. The company plans filings in the U.S., EU and Japan, with a potential launch in 2027.

    MGTX
65. Apr 16, 2026Financings

    Enveric announces up to $13.9 million private placement priced at-the-market

    The company agreed to sell 2,222,223 shares at $2.25 per share with warrants, for about $5 million upfront, with H.C. Wainwright & Co. as placement agent.

    ENVB
66. Apr 16, 2026Company Updates

    Emmaus appoints Henry Du to its board and audit committee

    Henry H. Du, a certified public accountant and interim chief financial officer of Alpha Cognition, fills the board seat left by the resignation of Jon Kuwahara.

    EMMAACOG
67. Apr 16, 2026Listings

    Altimmune holders approve doubling authorized shares to 400,000,000

    Shareholders approved raising authorized common stock from 200,000,000 to 400,000,000 shares, against 130,105,177 shares outstanding at the March 13, 2026 record date.

    ALT
68. Apr 16, 2026Financings

    Acurx Pharmaceuticals prices $2.5 million registered direct offering with warrants

    Acurx agreed to sell 816,068 shares at $3.03 and pre-funded warrants for 9,017 shares, plus Series H warrants at $2.78 in a concurrent private placement. H.C. Wainwright & Co., LLC is the placement agent, and the 10-K says existing resources will not fund operations for at least 12 months.

    ACXP
69. Apr 16, 2026Financings

    Achieve Life Sciences agrees to $180 million private placement; CEO Richard Stewart to step down

    Achieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026.

    ACHV
70. Apr 15, 2026Mergers

    Wave Life Sciences plans to move its parent company from Singapore to Delaware

    Wave Life Sciences said on April 15, 2026 that its board approved moving the parent company from Singapore to Delaware. Shares would be exchanged one for one, and the company expects the change in mid-2026, subject to shareholder and Singapore High Court approval.

    WVE
71. Apr 15, 2026Company Updates

    Traws Pharma reports 2025 results and completes up to $60 million PIPE

    Traws says a $10 million upfront private placement, with up to $50 million more in warrants, supports operations into the first quarter of 2027, including a planned challenge trial of tivoxavir marboxil.

    TRAW
72. Apr 15, 2026Listings

    Mustang Bio receives Nasdaq bid price deficiency notice

    Mustang Bio's common stock closed below $1.00 for 30 consecutive business days, and the company has until October 12, 2026 to regain compliance with the Nasdaq minimum bid price rule.

    MBIO
73. Apr 15, 2026Company Updates

    Cosmos Health reports 2025 revenue of $65.3 million, up 20%

    Gross profit rose 83% to $7.90 million, and cash reached $3.46 million at December 31, 2025.

    COSM
74. Apr 14, 2026Financings

    Telix Pharmaceuticals prices upsized US$600 million convertible bonds due 2031

    Telix raised its convertible notes offering from US$550 million to US$600 million and will use most of the money to buy back its 2029 convertible bonds. The reference price for the conversion terms was set at an 8.0 per cent discount to the closing share price.

    TLX
75. Apr 14, 2026Company Updates

    Pelthos CEO to attend investor meetings at Piper Sandler symposium in Boston

    Scott Plesha will hold one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company also made a presentation available on its website.

    PTHS
76. Apr 13, 2026Company Updates

    Oragenics doses first patient in Phase IIa concussion trial

    The first patient in the Phase IIa trial of ONP-002 was dosed at Mackay Hospital in Australia, the first site activated, with two more Australian sites expected to activate in the second quarter.

    OGEN
77. Apr 13, 2026Financings

    ImageneBio agrees to sell pre-funded warrants for about $30 million in private placement

    The warrants cover up to 5,770,335 shares at $5.199 per warrant share, with closing expected on or about April 14, 2026. ImageneBio plans to use the proceeds for its IMG-007 programs.

    IMA
78. Apr 13, 2026Company Updates

    Hepion signs separation agreement with former CEO Kaouthar Lbiati

    The April 13, 2026 agreement provides $225,000 and a pro-rata bonus of $30,625, plus six months of COBRA reimbursement. Dr. Lbiati also left the board that day.

    HEPA
79. Apr 13, 2026Listings

    Cue Biopharma holders approve reverse split range of 1-for-30 to 1-for-50

    Cue Biopharma holders approved a reverse split at a ratio between 1-for-30 and 1-for-50. The board will pick the ratio and the timing without another stockholder vote, and the filing does not say why the split is wanted.

    CUE
80. Apr 10, 2026Financings

    Seaport Therapeutics files for IPO, plans Nasdaq listing as SPTX

    Seaport Therapeutics filed its Form S-1 on April 10, 2026 with the share count and price range still blank. The filing shows a 2025 net loss of $74,881 thousand and a stockholders' deficit of $92,545 thousand.

    SPTX
81. Apr 10, 2026Financings

    Hemab Therapeutics Holdings files for IPO, plans Nasdaq listing as COAG

    Hemab Therapeutics Holdings, Inc. filed a Form S-1 on April 10, 2026, with the share count and price range left blank. Its lead drug has had serious thrombosis events, and the company reported a net loss of $63.9 million for 2025.

    COAG
82. Apr 10, 2026Distress

    Evofem amends Adjuvant convertible note terms and payment date

    The Fourth Amendment, dated April 10, 2026, makes the notes payable in full at the earliest of three events. It bars prepayment for six months without Adjuvant's consent.

    EVFM
83. Apr 10, 2026Financings

    AIM ImmunoTech amends at-the-market sales agreement with Maxim Group

    The amendment names Maxim Group LLC as exclusive sales agent and removes the limit on the amount of shares that can be sold under the agreement.

    AIM
84. Apr 9, 2026Company Updates

    Theriva special meeting fails quorum, new meeting to be called

    A special meeting on share issuance for warrants did not convene because too few shares were present, and the company will call another meeting.

    TOVX
85. Apr 9, 2026Listings

    Kyntra Bio gets Nasdaq deficiency notice on $50 million total assets and revenue rule

    The April 2, 2026 letter cites Listing Rule 5450(b)(3)(A) and revenue of FibroGen International held for sale. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance.

    KYNB
86. Apr 9, 2026Listings

    Gossamer Bio receives Nasdaq minimum bid price deficiency notice, has until October 5, 2026

    Gossamer Bio (Nasdaq: GOSS) says its stock did not maintain a $1.00 minimum bid price for 30 consecutive business days. It has 180 calendar days to regain compliance and may be eligible for an additional 180 days.

    GOSS
87. Apr 9, 2026Listings

    Alaunos receives Nasdaq notice on stockholders' equity requirement

    Nasdaq says Alaunos does not meet its $2,500,000 minimum for stockholders' equity, and the company plans to submit a compliance plan.

    TCRT
88. Apr 9, 2026Financings

    AN2 Therapeutics sets up $80 million at-the-market program with Jefferies

    AN2 Therapeutics set up an $80 million at-the-market sales program with Jefferies LLC on April 9, 2026 and ended an earlier agreement with TD Securities, against a 2025 net loss of $35.2 million and cash used in operations of $29.8 million.

    ANTX
89. Apr 8, 2026Financings

    Phio Pharmaceuticals sets up $6,360,000 at-the-market program

    Phio set up an at-the-market program that lets it sell up to $6,360,000 of common stock through H.C. Wainwright & Co., LLC, with a 3.0% commission. The size is capped because its public float is only $19,080,217, and its auditors have raised a going concern doubt.

    PHIO
90. Apr 8, 2026Financings

    Ensysce Biosciences closes $2 million Series B preferred stock and warrant private placement

    Ensysce Biosciences sold 2,000 shares of Series B preferred stock for $2 million on April 6, 2026, to 3i, LP. The deal comes with warrants for up to 8,727,273 common shares, all at $0.55, and the stated value of the preferred stock was raised from $1,100 to $1,200 a share.

    ENSC
91. Apr 8, 2026Financings

    Avalyn Pharma files for IPO, plans Nasdaq Global Market listing as AVLN

    Avalyn Pharma Inc. filed a Form S-1 on April 8, 2026. The cover leaves the share count and price range blank.

    AVLN
92. Apr 7, 2026Mergers

    Supernus acquires Navitor's NV-5138 assets for a study pledge and up to $350 million in milestones

    Supernus agreed on April 1, 2026 to buy the NV-5138 assets from Navitor. The price is an obligation to complete one Phase 2b study plus milestone payments of up to $350 million, and Supernus may stop pursuing the milestones if it judges the study unsuccessful.

    SUPN
93. Apr 7, 2026Company Updates

    Protagenic to end chief financial officer's employment on April 30, 2026

    The board notified Alexander Arrow, MD, on March 31, 2026, that his employment will be terminated effective April 30, 2026. The filing gives no reason for the decision.

    PTIX
94. Apr 7, 2026Mergers

    Northwest Biotherapeutics reports October 2025 closing of Advent BioServices purchase

    The company bought the UK manufacturer from a seller controlled by its chief executive. Payment is due in installments over two years.

    NWBO
95. Apr 7, 2026Financings

    Kiora Pharmaceuticals closes private placement of up to $24 million

    Kiora Pharmaceuticals, Inc. closed the deal with Perceptive Advisors and ADAR1 Capital Management on April 6, 2026, with $5.0 million in upfront funding. Up to $19 million more could come if milestone-based warrants are exercised.

    KPRX
96. Apr 7, 2026Listings

    Artelo regains Nasdaq listing compliance, under one-year panel monitor

    Nasdaq confirmed that Artelo Biosciences has regained compliance with its equity and annual meeting rules. The company is now subject to a one-year panel monitor.

    ARTL
97. Apr 7, 2026Financings

    AquaBounty exchanges $4,000,000 of senior notes for preferred stock

    A note exchange and a $500,000 preferred sale both closed April 7, 2026. Univest Securities, LLC was the placement agent for the offering.

    AQB
98. Apr 7, 2026Company Updates

    Adial grants restricted stock awards to executives and directors

    The compensation committee approved restricted stock awards on April 7, 2026 for Cary Claiborne, Vinay Shah, Tony Goodman and other directors, vesting on the first anniversary or on a change of control.

    ADIL
99. Apr 6, 2026Company Updates

    Sunshine Biopharma reports fiscal 2025 revenue of $36.3 million

    The company says 2025 revenue rose 4.1% and its net loss was $5.98 million, which it attributes partly to a $1.75 million impairment charge, and it expects cost cuts of $2 million to $3 million in 2026.

    SBFM
100. Apr 3, 2026Listings

     Matinas BioPharma receives NYSE American notice on three equity standards

     NYSE American says Matinas BioPharma is out of compliance with three stockholders' equity standards, with equity of $4.83 million at December 31, 2025, and a plan due by May 2, 2026.

     MTNB
101. Apr 3, 2026Mergers

     Lisata and Kuva Labs push back tender offer start to April 13, 2026

     Lisata and Kuva Labs agreed on April 2, 2026 to move the tender offer start from April 3 to April 13, 2026, or a later agreed date. The offer pays $5.00 in cash plus a $1.00 contingent right, and Lisata's 10-K says its $16.0 million in cash does not cover twelve months of spending.

     LSTA
102. Apr 3, 2026Financings

     Entera Bio sells 7,827,789 units to BVF-affiliated funds at $1.2775 each in private placement

     Entera Bio sold 7,827,789 units to funds affiliated with BVF Partners LP at $1.2775 a unit, with the closing on April 2, 2026. The 8-K names no placement agent or bank, and the company's 10-K says its cash covers operations only through the middle of the third quarter of 2026.

     ENTX
103. Apr 3, 2026Company Updates

     Ensysce director Curtis Rosebraugh resigns from board

     Ensysce Biosciences said director Curtis Rosebraugh resigned effective April 1, 2026, and that he had served on the Nominating and Corporate Governance Committee.

     ENSC
104. Apr 3, 2026Mergers

     Aurinia unit agrees to acquire Kezar Life Sciences in tender offer at $6.955 per share plus a CVR

     An Aurinia subsidiary will buy Kezar Life Sciences for $6.955 in cash per share plus a CVR, but the offer depends on Kezar holding at least $50.0 million of net cash at closing. The deal is expected to close in the second quarter of 2026.

     AUPH
105. Apr 3, 2026Financings

     Aardvark Therapeutics sets up $150,000,000 share sales program with Piper Sandler

     The Equity Distribution Agreement is dated March 23, 2026. Piper Sandler's commission is 3.0% of the gross sales price per share, and the prospectus says the $4.07 share price is below net tangible book value per share.

     AARD
106. Apr 3, 2026Listings

     AEON Biopharma receives additional NYSE American notice over stockholders' equity

     The notice cites a stockholders' deficit of approximately $55 million as of December 31, 2025. AEON keeps its listing and has until August 3, 2026 to regain compliance.

     AEON
107. Apr 2, 2026Company Updates

     Kiora's chief development officer Eric Daniels to depart April 17, 2026

     Kiora said Eric J. Daniels, M.D., MBA, will leave his role as Chief Development Officer on April 17, 2026, and that the company has started a search for a successor. The company's ABACUS-2 and KLARITY trials continue.

     KPRX
108. Apr 2, 2026Company Updates

     FDA grants Fast Track designation to CDI-988 for norovirus

     The oral antiviral candidate gains earlier FDA contact and a possible path to Priority Review, Cocrystal said in an April 2, 2026 release.

     COCP
109. Apr 2, 2026Debt Financing

     Caris Life Sciences takes $400,000,000 term loan from Blue Owl and Blackstone funds

     Caris Life Sciences took a $400,000,000 term loan from funds managed by Blue Owl and Blackstone to repay its 2023 credit agreement. The new deal also adds a $300,000,000 delayed draw facility for acquisitions, and the company already reported $796.3 million of cash at the end of 2025.

     CAI
110. Apr 2, 2026Financings

     Adagene prices US$70.0 million offering of 18,666,000 ADSs at US$3.75

     Adagene Inc. priced 18,666,000 American depositary shares at $3.75 for about $70.0 million gross, below the $4.61 last sale price on April 1. Leerink Partners LLC and LifeSci Capital LLC are joint book-running managers, and cash stood at $74.5 million at the end of 2025.

     ADAG
111. Apr 1, 2026Distress

     TherapeuticsMD files late notice after printer error left out auditor report

     TherapeuticsMD filed a Form 12b-25 notice on April 1, 2026 after a printer error left the predecessor auditor's report out of its 2025 annual report. The company reported a 2025 net loss of $569,000 and year-end cash of $7.5 million.

     TXMD
112. Apr 1, 2026Distress

     Scilex files NT 10-K, needs more time for financial statements including Vivasor consolidation

     Scilex Holding Company says it could not file its annual report by the March 31, 2026 due date and expects to file by April 15, 2026. It says it needs more time to finalize financial statements, including consolidating Vivasor Holding Company.

     SCLX
113. Apr 1, 2026Distress

     Quince Therapeutics (now IRulya Therapeutics) files NT 10-K after Phase 3 miss and staff cuts

     The company says it needs more time to complete its 2025 annual report because of reduced headcount and negative Phase 3 results. It expects to file within the fifteen calendar day extension under Rule 12b-25.

     IRLA
114. Apr 1, 2026Mergers

     Cyclerion (now Korsana Biosciences) agrees to all-stock merger with Korsana, $380 million financing

     Cyclerion and private Korsana Biosciences signed a merger agreement on April 1, 2026. A concurrent private financing of approximately $380 million is expected to fund Korsana's operations into 2029.

     KRSA
115. Apr 1, 2026Distress

     China Pharma Holdings files NT 10-K for late annual report, estimates $3.19 million net loss

     China Pharma says it will file its 2025 annual report within fifteen calendar days after March 31, 2026. Its estimates show revenue of $4.1 million and a net loss of about $3.19 million, and its auditors have raised going-concern doubt before.

     CPHI
116. Apr 1, 2026Financings

     Cardiol Therapeutics reports $31 million raised and cash runway into Q4 2027

     Cardiol says $31 million of gross proceeds from an October 2025 private placement and a January 2026 bought deal funds it through its Phase III pericarditis trial. The release names no underwriter or placement agent.

     CRDL
117. Apr 1, 2026Debt Financing

     Apollomics signs $2.0 million convertible note with its chairman and CEO

     Apollomics signed a $2.0 million unsecured note with its chairman and chief executive, Hung-Wen (Howard) Chen, on March 30, 2026, at 0% interest, which converts into equity at a 20% discount if the company later raises at least $10.0 million.

     APLM

March 2026

1. Mar 31, 2026Debt Financing

   Zenas BioPharma closes $200,000,000 convertible senior notes offering due 2032

   Zenas BioPharma closed a $200 million offering of 2.50% convertible senior notes due 2032, with net proceeds of about $193.7 million and Jefferies, Evercore, Citigroup and Guggenheim as representatives. Its 10-K reports substantial doubt about going concern.

   ZBIO
2. Mar 31, 2026Distress

   Traws Pharma files NT 10-K, cites financing efforts and going concern assessment

   Traws Pharma filed a Form NT 10-K on March 31, 2026, saying it has not yet signed any financing and needs time to assess how a deal would affect its going-concern evaluation. The notice also gives unaudited 2025 net income of about $9.2 million, driven by a $26.7 million warrant accounting gain.

   TRAW
3. Mar 31, 2026Distress

   TransCode Therapeutics files NT 10-K, says 2025 annual report will be late

   TransCode blames the complexity of accounting for its October 2025 deal with DEFJ, LLC, including a roughly $25 million Series B preferred placement. It expects to file within the extension period.

   RNAZ
4. Mar 31, 2026Distress

   Sunshine Biopharma files NT 10-K, says annual report will be late

   Sunshine Biopharma filed a Form 12b-25 on March 31, 2026 for its 10-K for the year ended December 31, 2025. It cites time constraints and says it will file no later than fifteen days after the original due date. Its 2024 net loss was $5,134,116.

   SBFM
5. Mar 31, 2026Mergers

   SCYNEXIS acquires Poxel's PXL-770 for $8,000,000 upfront and up to $188,000,000 in milestones

   Under an asset purchase agreement dated March 30, 2026, SCYNEXIS acquired Poxel's AMP kinase activator assets, including PXL-770, now SCY-770, and received a worldwide license.

   SCYX
6. Mar 31, 2026Mergers

   Oramed closes Oratech sale to Lifeward for shares, warrants and revenue share

   Oramed Pharmaceuticals closed the sale of its Oratech subsidiary to Lifeward Ltd. on March 25, 2026, for 1,250,363 Lifeward ordinary shares, pre-funded warrants, warrants and a 4% revenue share on ReWalk products. The same day it bought $9,000,000 of Lifeward convertible notes, and Lifeward carries a going-concern warning of its own.

   ORMP
7. Mar 31, 2026Distress

   Northwest Biotherapeutics says 10-K is late over Advent BioServices accounting

   The company cites issues tied to its Advent BioServices acquisition, including differences between UK GAAP and US GAAP. The notice gives no date for the annual report.

   NWBO
8. Mar 31, 2026Distress

   Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late

   Greenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss.

   GLSI
9. Mar 31, 2026Distress

   GeoVax Labs files NT 10-K, says 2025 annual report will be late

   GeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors.

   GOVX
10. Mar 30, 2026Listings

    ZIVO Bioscience to delist from OTC markets and file Form 15 to end SEC reporting

    The board says SEC reporting costs are no longer in the best interests of the company and its stockholders. ZIVO plans to file the form on or around March 30, 2026.

    ZIVO
11. Mar 30, 2026Company Updates

    Silo issues 2,100,000 shares for QwikAgents software and domains

    Silo filed an 8-K covering an asset purchase from Many Ads Inc. paid for with 2,100,000 shares of common stock. The filing names no underwriter or placement agent.

    SILO
12. Mar 30, 2026Financings

    OnKure Therapeutics agrees to $150.0 million private placement at $4.15 per share

    OnKure Therapeutics, Inc. is selling 26,713,636 shares and pre-funded warrants for 9,430,959 shares to institutional accredited investors. AI Biotechnology LLC is lead investor and gets a board nominee right.

    OKUR
13. Mar 30, 2026Listings

    Kazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report

    Ordinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b).

    KZIA
14. Mar 30, 2026Listings

    InMed Pharmaceuticals gets Nasdaq minimum bid price deficiency notice

    Nasdaq told InMed on March 27, 2026 that its shares closed below $1.00 for 30 consecutive trading days. The company has 180 calendar days to regain compliance and keeps trading as INM.

    INM
15. Mar 30, 2026Listings

    Dyadic International gets Nasdaq deficiency notice under Rule 5550(b) minimum listing requirements

    Dyadic received a Nasdaq notice on March 27, 2026 that it is out of compliance with Listing Rule 5550(b). It has until May 11, 2026 to submit a plan to regain compliance, and a separate bid price deadline of June 17, 2026 also stands.

    DYAI
16. Mar 27, 2026Financings

    Satellos Bioscience reports US$57.2 million February offering, runway through 2027

    Satellos Bioscience Inc closed the equity offering on February 9, 2026 and began trading on the Nasdaq Global Market under the ticker MSLE. Cash was $27.7 million at year end.

    MSCL
17. Mar 27, 2026Listings

    Quantum Biopharma reports 2025 results, believes cash lasts past January 2028

    Quantum BioPharma reports $11.3 million in cash and digital assets at the filing date and says cash lasts beyond January 2028. Its annual report shows year-end cash of $1.9 million, and the release does not split out the digital assets.

    QNTM
18. Mar 27, 2026Financings

    Palisade Bio sells $3.0 million of stock to an affiliate of Iterative Health

    The company sold 1,536,885 shares at $1.952 per share, with the sale closing on March 27, 2026. It also signed an agreement with Iterative Health to help enroll patients in its planned Phase 2 ulcerative colitis study.

    PALI
19. Mar 27, 2026Financings

    Kailera Therapeutics files for IPO, plans Nasdaq listing as KLRA

    Kailera Therapeutics, Inc. filed a Form S-1 on March 27, 2026. The cover leaves the share count and price range blank.

    KLRA
20. Mar 27, 2026Financings

    AnaptysBio board approves First Tracks spin-off, set to launch with $180 million

    AnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs.

    ANABTRAX
21. Mar 27, 2026Financings

    Alamar Biosciences files for IPO, plans Nasdaq listing as ALMR

    Alamar Biosciences filed an S-1 on March 27, 2026, reporting a 2025 net loss of $29.8 million on revenue of $74.2 million. The cover leaves the share count and price range blank.

    ALMR
22. Mar 26, 2026Financings

    Upstream Bio sets up $150,000,000 at-the-market stock program with Leerink

    Upstream Bio signed a sales agreement with Leerink Partners LLC on March 26, 2026 that lets it sell up to $150,000,000 of common stock on the Nasdaq market. Leerink may earn a commission of up to 3.0% of gross proceeds, and cash used in operations rose to $133.3 million in 2025.

    UPB
23. Mar 26, 2026Financings

    MeiraGTx extends Perceptive notes to May 2027, agrees to redeem $25,000,000

    MeiraGTx (Nasdaq: MGTX) moved the maturity of its Perceptive notes from August 2, 2026 to May 2, 2027. It will redeem $25,000,000 by June 30, 2026, and Perceptive's warrants are repriced to $8.00.

    MGTX
24. Mar 26, 2026Financings

    MapLight annual report details $200 million Series D preferred financing

    The 2025 financing closed in two parts before the IPO. Holders tied to board members were among the buyers, the proxy shows.

    MPLT
25. Mar 25, 2026Listings

    Zhengye Biotechnology shareholders approve share reclassification and consolidation

    All five resolutions passed at the March 24, 2026 annual meeting, including a share reclassification and a share consolidation.

    ZYBT
26. Mar 25, 2026Financings

    Nkarta sets up $100,000,000 at-the-market stock program with Stifel

    Nkarta set up a $100 million at-the-market program with Stifel on March 25, 2026, with commissions of up to 3%. Its 2025 net loss was $104.1 million, and its operating cash use was $88.7 million.

    NKTX
27. Mar 24, 2026Mergers

    Indaptus Therapeutics reports change in control as Lazar sells preferred stock for $11,200,000

    Five buyers including Yun Yao and Sino Lion Ventures Limited bought preferred stock that could convert into 108,936,000 shares. The board appointed Junyi Dai chairman and chief executive officer, and four directors resigned on March 18, 2026.

    INDP
28. Mar 24, 2026Mergers

    Galapagos (now Lakefront Biotherapeutics) in advanced talks with Gilead on Ouro program

    Gilead agreed to buy Ouro Medicines for $1,675 million in cash plus up to $500 million in milestones. Galapagos said it would pay 50% of the upfront cost under proposed terms, and no agreement between the two companies had been signed.

    LKFT
29. Mar 24, 2026Debt Financing

    CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%

    CytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%.

    CYDY
30. Mar 23, 2026Debt Financing

    Turn Therapeutics draws $7 million from $25 million secured loan with Avenue

    Turn Therapeutics signed a term loan of up to $25.0 million with Avenue Venture Opportunities Fund II, L.P. It bears interest of at least 12.25%, is secured on the company's assets, and only $7.0 million is committed up front.

    TTRX
31. Mar 23, 2026Financings

    RenovoRx closes private placement for about $10 million in gross proceeds

    RenovoRx (Nasdaq: RNXT) sold 8,438,790 shares, pre-funded warrants and revenue milestone warrants to 15 investors, five of them insiders. The deal closed March 20, 2026.

    RNXT
32. Mar 23, 2026Financings

    Aardvark Therapeutics sets up $150,000,000 at-the-market stock program

    Aardvark Therapeutics, Inc. signed an equity distribution agreement with Piper Sandler & Co. on March 23, 2026 and filed a Form S-3 shelf registration the same day. The company paused its main Phase 3 trial in February 2026 after cardiac observations in a healthy volunteer study.

    AARD
33. Mar 20, 2026Listings

    XTL Biopharmaceuticals to change ADS ratio to 400 ordinary shares on March 25, 2026

    The change has the same effect as a one-for-four reverse ADS split. The ordinary shares are not affected.

    XTLB
34. Mar 20, 2026Listings

    Ernexa Therapeutics gets Nasdaq minimum bid price notice, plans to request hearing

    Nasdaq staff says Ernexa's stock failed to maintain a $1.00 minimum bid price for 30 consecutive business days, and that the company is not eligible for a 180-calendar day compliance period because of a reverse stock split in the past year. The company plans to request a hearing.

    ERNA
35. Mar 19, 2026Listings

    Skye Bioscience gets Nasdaq bid price deficiency notice, has until September 14, 2026

    Nasdaq told Skye Bioscience (Nasdaq: SKYE) its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and says it will consider its options.

    SKYE
36. Mar 19, 2026Financings

    NuCana says £24.3 million in cash should fund operations into 2029

    NuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size.

    NCNA
37. Mar 19, 2026Financings

    Niagen Bioscience raises share buyback authorization to $20 million

    The board lifted the program from $10 million. The company had repurchased approximately $2.6 million of stock through March 17, 2026.

    NAGE
38. Mar 19, 2026Listings

    Chemomab reports 2025 results, cites FDA alignment and partner talks

    The March 19, 2026 release recalls an August 2025 ADS ratio change that worked as a one-for-four reverse ADS split.

    CMMB
39. Mar 18, 2026Financings

    Stoke Therapeutics files automatic shelf with $150,000,000 ATM prospectus

    Stoke's shelf includes a $150,000,000 at-the-market program with Cantor Fitzgerald, which can be paid up to 3.0% of gross proceeds in commissions. The stock's last reported sale price was $33.96 on March 16, 2026.

    STOK
40. Mar 18, 2026Listings

    Biodexa to change ADR ratio to 500,000 shares, a one-for-five reverse ADR split

    The change, aimed at Nasdaq's $1.00 minimum bid price, is expected on or about April 6, 2026. Holders must exchange five old ADRs for one new one, and the company says it cannot guarantee the change will work.

    BDRX
41. Mar 17, 2026Listings

    Purple Biotech regains Nasdaq minimum bid price compliance

    The ADSs held a closing bid of $1.00 or more for at least 10 consecutive business days, reached on March 13, 2026. The company is now compliant with applicable listing standards.

    PPBT
42. Mar 16, 2026Distress

    Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million

    The deal settles a Delaware lawsuit. Zevra says it repaid its $63 million term loan in full before signing.

    ZVRA
43. Mar 16, 2026Financings

    Talphera closes third private placement tranche for approximately $4.1 million in gross proceeds

    Talphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing.

    TLPH
44. Mar 16, 2026Financings

    InnoCan Pharma files for US IPO of 3,750,000 units, with NYSE American listing sought

    The filing assumes a $5.50 unit price, which would bring net proceeds of about $17.98 million. The financial statements carry a going-concern paragraph, and the accumulated deficit was $38,027,000 at September 30, 2025.

    INNO
45. Mar 16, 2026Legal

    Fennec Pharmaceuticals settles PEDMARK patent litigation with Cipla

    Under a license agreement, the lawsuit will be dismissed and Cipla will not sell a generic version in the U.S. until September 1, 2033, or earlier under specified circumstances. Each side bears its own costs.

    FENC
46. Mar 16, 2026Financings

    CytomX files $250,000,000 stock offering, prices it at $5.300 a share

    CytomX priced 45,990,567 shares and pre-funded warrants for 1,179,245 more at $5.300 a share, below the $5.45 last reported sale price on March 17, 2026. Its lead clinical data are interim, and the prospectus gives no patient count or response rate.

    CTMX
47. Mar 16, 2026Financings

    Amphastar adds $50 million to its share buyback program

    Amphastar's board raised its buyback by $50 million on March 12, 2026, to offset dilution from equity compensation, while 2025 net income fell to $98.1 million and cash from operations dropped.

    AMPH
48. Mar 16, 2026Financings

    Acumen Pharmaceuticals agrees to $35.75 million private placement at $3.30 per share

    Acumen Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional and accredited investors. RA Capital Management, an existing investor, led the deal, and the release names no placement agent.

    ABOS
49. Mar 13, 2026Financings

    Corvus Pharmaceuticals raises its at-the-market program to $200,000,000

    Corvus had sold no shares under its $100,000,000 Jefferies program and had suspended it in January. The amendment doubles the ceiling to $200,000,000, with Jefferies paid up to 3.0% of gross proceeds.

    CRVS
50. Mar 12, 2026Mergers

    SciSparc unit NeuroThera Labs to buy 54.01% of CliniQuantum for shares

    NeuroThera would issue 56,600,000 of its own shares, valued at approximately $9,459,954.20, plus up to $2,500,000 in earn-out payments. The release does not say what the issuance would do to SciSparc's approximately 75% stake in NeuroThera.

    SPRCNTLX
51. Mar 11, 2026Listings

    VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq bid price extension to Sept. 7, 2026

    Nasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences.

    YARW
52. Mar 10, 2026Financings

    Xenon prices $650 million stock offering at $57 after epilepsy data

    The sale came a day after phase 3 X-TOLE2 results. Xenon ended March with $1.34 billion in cash and says it funds operations into 2029.

    XENE
53. Mar 10, 2026Financings

    Septerna files automatic shelf with $150,000,000 ATM sales agreement prospectus

    Septerna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain.

    SEPN
54. Mar 10, 2026Financings

    AN2 Therapeutics agrees to about $40 million private placement at $2.85 per share

    The company is selling 8,245,611 shares and pre-funded warrants for up to 5,789,493 shares to institutional investors. Leerink Partners is the exclusive placement agent, and closing is expected March 10, 2026.

    ANTX
55. Mar 9, 2026Financings

    enGene Holdings (now enGene Therapeutics) sets up $100,000,000 stock program

    The company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold.

    ENGN
56. Mar 9, 2026Financings

    Relmada Therapeutics agrees to approximately $160.0 million private placement at $4.75 a share

    Relmada agreed to sell 29,474,569 shares and pre-funded warrants for up to 4,210,527 shares to institutional and accredited investors. It announced 12-month Phase 2 data for NDV-01 the same day, where the 12-month response rate rests on 25 patients.

    RLMD
57. Mar 9, 2026Listings

    Longeveron tells Nasdaq it lacks audit committee financial expert after director Kender resigns

    Longeveron told Nasdaq on March 4, 2026 that it was temporarily out of compliance after director Richard Kender resigned from its audit committee. The company had $19.2 million of cash at December 31, 2024, and its annual report projected that cash would last only into the fourth quarter of 2025.

    LGVN
58. Mar 9, 2026Financings

    Korro Bio agrees to $85 million private placement led by Venrock Healthcare

    Korro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028.

    KRRO
59. Mar 9, 2026Distress

    Genentech to end Xencor collaboration and license agreement September 4, 2026

    Genentech elected to terminate the agreement for convenience. Xencor says it expected the move.

    XNCR
60. Mar 9, 2026Financings

    Dianthus launches $400,000,000 stock offering, then prices it at $81.00 a share

    Dianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel.

    DNTH
61. Mar 6, 2026Financings

    Solid Biosciences agrees to $240.0 million private placement at $5.61 per share

    Solid Biosciences agreed to sell 14,973,257 shares at $5.61 and pre-funded warrants for 27,807,482 shares, for about $240.0 million gross. Its year-end 2025 cash figure is a preliminary, unaudited estimate, and the company says the deal extends runway into the first half of 2028.

    SLDB
62. Mar 6, 2026Financings

    Nurix Therapeutics lifts its at-the-market program total to $413.65 million

    Nurix raised its Piper Sandler at-the-market program to $413.65 million, of which $113.65 million has already been sold. Its fiscal 2025 net loss was $264.5 million and cash used in operations was $249.5 million.

    NRIX
63. Mar 6, 2026Distress

    InMed Pharmaceuticals to wind down BayMedica, its only revenue-generating business

    InMed's board approved exiting BayMedica's sales on March 4, 2026. The company calls BayMedica its only revenue-generating business, expects about $550,000 in severance costs and about $120,000 in other spending, and its annual report already carries a going-concern warning.

    INM
64. Mar 6, 2026Financings

    Eupraxia Pharmaceuticals reports closing of US$63.2 million public offering

    Eupraxia Pharmaceuticals Inc. sold 7,607,145 common shares at US$7.00 each, plus pre-funded warrants for 1,428,571 shares. The material change date is February 20, 2026.

    EPRX
65. Mar 5, 2026Financings

    MediWound reports $53.6 million in cash after $30.0 million registered direct offering

    MediWound ended 2025 with $53.6 million in cash, cash equivalents and deposits after a $30.0 million registered direct offering. Its net loss narrowed to $23.9 million mainly because of warrant revaluation, while revenue fell to $17.0 million.

    MDWD
66. Mar 5, 2026Financings

    Evaxion says cash funds operations into second half of 2027

    Evaxion says its cash can fund operations into the second half of 2027, after a $7.5 million option exercise fee and a debt conversion with the European Investment Bank. The release reports a cash burn of about $14 million for 2026 and names no bank or agent for its amended at-the-market facility.

    EVAX
67. Mar 5, 2026Financings

    Contineum Therapeutics amends share sales deal, registers up to $100 million

    Contineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding.

    CTNM
68. Mar 4, 2026Financings

    Regen Biopharma issues 77,849,847 shares to settle convertible debt

    Regen Biopharma issued 77,849,847 common shares between February 4 and February 27, 2026 to settle convertible debt and fees. The company had 212,318,424 shares outstanding on March 3, 2026, and its pipeline has not yet entered a clinical trial.

    RGBP
69. Mar 3, 2026Financings

    China Pharma to issue 12,600,000 shares for $6.93 million patent transfer

    China Pharma's subsidiary Helpson agreed on February 26, 2026 to buy a sublingual tablet patent for $6.93 million, paid in 12,600,000 unregistered shares at $0.55 each. The company has a going-concern warning in its latest annual report.

    CPHI
70. Mar 3, 2026Legal

    Arbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026

    Moderna agrees to pay a $950.0 million noncontingent lump sum and may owe a further $1.3 billion depending on a Federal Circuit appeal on 28 U.S.C. §1498. Arbutus is entitled to 20% of proceeds after litigation costs, or, if less, tiered low single-digit royalties.

    ABUS
71. Mar 2, 2026Financings

    Zymeworks enters $250 million royalty-backed financing with Royalty Pharma

    Zymeworks sold 30% of its future Ziihera royalties to a subsidiary that borrowed $250 million from Royalty Pharma. The loan costs about $481 million by its 2042 maturity, and it is secured by the subsidiary's assets.

    ZYME
72. Mar 2, 2026Financings

    Sionna Therapeutics files automatic shelf with $250,000,000 ATM sales agreement

    Sionna Therapeutics signed a sales agreement with Leerink Partners LLC on March 2, 2026 for up to $250,000,000 of common stock sold at the market. Leerink's commission is up to 3.0% of the gross sales price per share.

    SION
73. Mar 2, 2026Financings

    Gyre Therapeutics agrees to acquire Cullgen in all-stock deal valued at about $300 million

    Gyre Therapeutics agreed to buy privately held Cullgen in an all-stock deal valued at about $300 million, issuing common stock and Series B convertible preferred. Until stockholders approve the conversion, Gyre may not issue more than 19.99% of its stock, and Cullgen's lead drug has completed only a Phase 1 trial.

    GYRE
74. Mar 2, 2026Financings

    Geron files automatic shelf with $150,000,000 ATM prospectus via TD Cowen

    The sales agreement pays TD Securities (USA) LLC up to 3.0% of gross proceeds. Geron's stock last sold at $1.65 on February 26, 2026, and the company's 2025 net loss was $83.5 million.

    GERN
75. Mar 2, 2026Distress

    GT Biopharma issues non-reliance notice, will restate June and September 2025 quarterly financials

    On March 1, 2026 the audit committee concluded the quarterly reports contained an error: Greenshoe Rights from a May 2025 private placement required liability classification. GT Biopharma (Nasdaq: GTBP) will file Forms 10-Q/A.

    GTBP
76. Mar 2, 2026Financings

    Belite Bio says it completed a $402 million public offering of ADSs

    Belite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end.

    BLTE
77. Mar 2, 2026Listings

    Anebulo Pharmaceuticals files Form 15 to end SEC reporting duties

    Anebulo's March 2, 2026 Form 15 puts its SEC reporting duties to an end and gives 71 holders of record for its common stock, while the company's last reported cash figure was $9.0 million at December 31, 2025.

    ANEB
78. Mar 2, 2026Distress

    Acrivon ends Akoya companion diagnostic agreement and takes testing in-house

    The February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test.

    ACRV

February 2026

1. Feb 27, 2026Distress

   XORTX auditor flags going-concern doubt in 2025 financials; cash was $864,514

   The audit report says XORTX must finance its research or postpone it. The statements show an accumulated deficit of $23,824,557 at December 31, 2025.

   XRTX
2. Feb 27, 2026Listings

   Jupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value

   Nasdaq says the stock closed below $1.00 for 30 consecutive business days and that its market value of listed securities stayed below $35 million. The company has until August 25, 2026 on both, and its auditor has raised going-concern doubt.

   JUNS
3. Feb 27, 2026Mergers

   Indaptus stockholders approve preferred stock conversion and reverse split range

   Stockholders approved conversion of preferred stock that, once converted, would give David Lazar 111.0 million common shares, about 96.4% of the fully diluted common stock. They also approved up to two reverse stock splits and authorized shares rising to 1,000,000,000.

   INDP
4. Feb 27, 2026Financings

   Generate Biomedicines prices IPO of 25,000,000 shares at $16.00

   The offering totals $400,000,000 before costs, with net proceeds estimated at $368.8 million. The prospectus keeps the going-concern warning and says no pivotal trial has finished.

   GENB
5. Feb 27, 2026Mergers

   Atrium Therapeutics completes spin-off from Avidity Biosciences, starts trading on Nasdaq as RNA

   Atrium Therapeutics became independent on February 26, 2026, when Avidity Biosciences distributed all of its shares at one Atrium share for every ten Avidity shares. Atrium began trading on Nasdaq as RNA on February 27, and it signed an amended license and a transition services agreement with Avidity the same day.

   RNA
6. Feb 27, 2026Listings

   Altamira Therapeutics files Form 15 to end SEC reporting duties

   Altamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lists 48 holders of record, and the company's last business description, from April 2025, still calls its lead programs preclinical.

   CYTOF
7. Feb 26, 2026Distress

   Viatris expects $700 million to $850 million in restructuring charges, plans up to 10% staff cut

   After an enterprise-wide strategic review, Viatris committed to restructuring that it expects to cut its global workforce by up to approximately 10%. It expects potential savings of between $600 million and $700 million.

   VTRS
8. Feb 26, 2026Financings

   Lipocine raises its at-the-market program to $50,000,000

   Lipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration.

   LPCN
9. Feb 26, 2026Mergers

   Atrium Therapeutics spin-off from Avidity to give holders one share per ten

   Avidity holders of record on February 12, 2026 would receive Atrium shares, but the distribution depends on Avidity's merger with Novartis and is taxable to holders. Avidity may instead sell Atrium to a third party, in which case no distribution would occur.

   RNA
10. Feb 25, 2026Financings

    Larimar launches $75.0 million stock offering, then prices $100,000,000

    Largest stockholder Deerfield and some directors indicated interest in buying. The priced offering is 20,000,000 shares at $5.00, or $94,000,000 to the company before expenses.

    LRMR
11. Feb 24, 2026Listings

    Regentis Biomaterials discloses going concern qualification in 2025 audit opinion

    Regentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. The company reported $7.4 million in cash at December 31, 2025, and its pivotal knee cartilage trial is still enrolling.

    RGNT
12. Feb 24, 2026Financings

    Bicara Therapeutics launches $150,000,000 offering, then prices at $16.00 a share

    Bicara priced 7,175,000 shares at $16.00 and pre-funded warrants for 2,200,000 more, with underwriting discounts of $9,000,000 on a total of $149,999,780.

    BCAX
13. Feb 23, 2026Financings

    Vir Biotechnology to receive $335 million from Astellas in VIR-5500 licensing deal

    Vir Biotechnology agreed to co-develop VIR-5500 with Astellas for $335 million in upfront and near-term payments, plus up to $1.37 billion in later milestones. The drug is still in Phase 1, and the deal closes only after Hart-Scott-Rodino clearance.

    VIR
14. Feb 23, 2026Financings

    Vir Biotechnology signs $335 million Astellas deal, then prices stock offering at $8.50

    Vir Biotechnology will receive $335 million in upfront and near-term payments from Astellas for VIR-5500, a prostate cancer T-cell engager still in Phase 1. Its February 25 prospectus supplement priced a $150,000,002 stock offering at $8.50 per share.

    VIR
15. Feb 23, 2026Financings

    Oric Pharmaceuticals files new $200.0 million at-the-market prospectus with Jefferies

    Oric Pharmaceuticals, Inc. has sold 13,478,432 shares under the program for gross proceeds of approximately $139.7 million. The new supplement replaces the one from March 2024.

    ORIC
16. Feb 23, 2026Debt Financing

    MoonLake amends Hercules loan, draws $25.0 million and keeps up to $400.0 million in later tranches

    MoonLake drew $25.0 million under a Hercules loan totaling $500.0 million across six tranches. Most of the tranches still to come depend on Phase 3 results and FDA action for its lead drug, sonelokimab, and the company's 81% response figure comes from 26 patients with no comparison arm reported.

    MLTX
17. Feb 23, 2026Distress

    Galapagos (now Lakefront Biotherapeutics) lowers wind-down cost estimate, holds €3.0 billion

    The company lowered its expected cell therapy restructuring cash costs to €125 to €175 million. It expects to be a lean organization of about 35-40 employees by the end of 2026.

    LKFT
18. Feb 23, 2026Financings

    Fortress subsidiary Cyprium agrees to sell priority review voucher for $205 million

    Cyprium, a majority-owned Fortress Biotech subsidiary, agreed on February 22, 2026 to sell a priority review voucher for $205 million in cash at closing. Fortress also amended its Oaktree credit agreement, with about $29.5 million outstanding.

    FBIO
19. Feb 23, 2026Financings

    ADC Therapeutics amends HCR royalty deal, issues warrants for 9,834,776 shares

    The February 18, 2026 amendment sets the change-of-control payment to HCR at $150 million or $200 million and revises a buyout option. HCR received warrants at $3.8130 per share.

    ADCT
20. Feb 19, 2026Listings

    Psyence Biomedical shareholders approve share consolidation of up to 250:1

    Shareholders gave Psyence's board authority to consolidate the common shares at a ratio of up to 250:1, but the board has not set a ratio or timing, and the company says a consolidation may never happen.

    PBM
21. Feb 19, 2026Financings

    Opus Genetics closes private placement of Series B preferred stock for approximately $25.0 million

    Purchasers paid $3.39 per share for 7,374,632 non-voting convertible preferred shares. Conversion into common stock depends on stockholder approval at the 2026 annual meeting. Preliminary cash was $45 million at year end.

    IRD
22. Feb 18, 2026Mergers

    Sensei Biotherapeutics acquires Faeth Therapeutics, agrees to $200 million private placement

    Sensei Biotherapeutics closed its acquisition of Faeth Therapeutics on February 17, 2026, and agreed the same day to sell about $200 million of Series B preferred stock. The new investors would hold 54.3% of the company on an as-converted basis, and the lead drug's headline response rate comes from 15 patients.

    FTH
23. Feb 18, 2026Listings

    Outlook Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 17, 2026

    Nasdaq says Outlook's stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its Nasdaq Capital Market listing, and a second 180-day period may be available.

    OTLK
24. Feb 17, 2026Listings

    Mereo BioPharma gets Nasdaq minimum bid price deficiency notice on its ADSs

    Mereo BioPharma's American Depositary Shares failed to hold a $1.00 minimum bid price for 30 consecutive business days, and Nasdaq gave the company until August 17, 2026 to regain compliance. The company's 2024 annual report shows a net loss of $43.3 million and $69.8 million of cash.

    MREO
25. Feb 17, 2026Financings

    GeoVax closes registered direct offering at $2.31 per share with net proceeds of about $865,000

    GeoVax sold 402,000 shares and pre-funded warrants for up to 30,902 shares, plus Series A-1 and A-2 warrants in a concurrent private placement. H.C. Wainwright & Co., LLC was placement agent.

    GOVX
26. Feb 17, 2026Listings

    Atossa Therapeutics regains Nasdaq minimum bid price compliance

    Atossa Therapeutics received a Nasdaq letter on February 17, 2026 saying it regained the $1.00 minimum closing bid price. The stock met the test on February 13, 2026, the last trading day before the extended deadline, after a February 2025 notice and an extension granted in August 2025.

    ATOS
27. Feb 17, 2026Listings

    Anebulo Pharmaceuticals files Form 25 to withdraw its stock from Nasdaq

    Anebulo filed a Form 25 on February 17, 2026 to withdraw its common stock from Nasdaq as a voluntary withdrawal, while its lead drug candidate remains at an early stage and its cash fell in the second half of 2025.

    ANEB
28. Feb 13, 2026Distress

    Werewolf Therapeutics cuts 64% of workforce; CFO and CMO resign

    Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330.

    HOWL
29. Feb 13, 2026Mergers

    Nutriband terminates planned $5 million sale of Pocono unit

    Nutriband said its board ended the deal after the buyer missed the December 31 closing and stopped paying late fees. The annual report puts the price at $5 million, and only $30,000 in late fees was received.

    NTRB
30. Feb 13, 2026Listings

    Citius Pharmaceuticals gets Nasdaq minimum bid price notice; compliance deadline is August 10, 2026

    Nasdaq told Citius Pharmaceuticals on February 9, 2026 that its stock had closed below $1.00 for 30 consecutive business days, and the company has until August 10, 2026 to regain compliance. The same filing reports $3.9 million in first-quarter revenue from LYMPHIR, against $7.7 million in cash.

    CTXR
31. Feb 12, 2026Financings

    REGENXBIO registers up to $150,000,000 in share sales through Leerink Partners

    REGENXBIO filed a prospectus supplement for up to $150 million of at-the-market stock sales through Leerink Partners. The filing warns of substantial doubt about its ability to continue as a going concern.

    RGNX
32. Feb 12, 2026Listings

    Lunai Bioworks receives Nasdaq delisting determination over minimum bid price, requests hearing

    Nasdaq staff decided on February 6, 2026 to delist Lunai Bioworks, saying a reverse stock split in September 2025 bars the company from the usual 180-day cure period. The company has asked for a hearing, which pauses a February 18 trading suspension.

    LNAI
33. Feb 12, 2026Financings

    Evommune sells $125 million of stock privately at $27.88 a share

    Evommune's $125 million private placement was followed by a failed atopic dermatitis trial; the company says its 2026 raise brought net proceeds of $117.2 million.

    EVMN
34. Feb 9, 2026Financings

    SpyGlass closes $172.5 million IPO after underwriters take full option

    SpyGlass Pharma closed a $172.5 million IPO with Jefferies, Leerink Partners, Citigroup and Stifel running the book. The money is meant to carry a glaucoma implant through two Phase 3 trials.

    SGP
35. Feb 6, 2026Listings

    Vistagen gets Nasdaq minimum bid price deficiency notice, with until August 3, 2026 to comply

    Nasdaq told Vistagen on Feb 3, 2026, that its stock had closed below $1.00 for 30 consecutive business days. The company has until Aug 3, 2026, to regain compliance, and its last annual report carried a going-concern warning.

    VTGN
36. Feb 6, 2026Listings

    Anebulo Pharmaceuticals to delist from Nasdaq and deregister with the SEC

    Anebulo's board approved leaving Nasdaq and ending SEC reporting, with a Form 25 due about February 17, 2026 and a Form 15 about February 27, while its lead drug candidate is still in early clinical work.

    ANEB
37. Feb 6, 2026Financings

    AgomAb Therapeutics prices IPO of 12,500,000 ADSs at $16.00

    AgomAb priced 12,500,000 ADSs at $16.00 for $200,000,000 and expects about $181 million in net proceeds. Its lead drug has shown only safety results in a Phase 2a Crohn's trial, and the prospectus reports an accumulated loss of €164.3 million.

    AGMB
38. Feb 5, 2026Financings

    Veradermics completes $294.8 million IPO with full overallotment exercise

    Veradermics closed its initial public offering of 15,077,647 shares at $17.00 a share on February 5, 2026. The underwriters later exercised in full their option on 2,261,647 more shares.

    MANE
39. Feb 5, 2026Financings

    LB Pharmaceuticals agrees to $100.0 million private placement at $21.17 a share

    LB Pharmaceuticals agreed to sell 3,306,571 shares and pre-funded warrants for up to 1,417,107 shares to institutional investors. It plans to use the proceeds for a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes.

    LBRX
40. Feb 5, 2026Financings

    Eikon Therapeutics prices IPO of 21,177,600 shares at $18.00

    The offering totals $381,196,800. The stock is approved to list on Nasdaq under EIKN, and proceeds to the company are $354,513,024 before expenses.

    EIKN
41. Feb 4, 2026Distress

    Maze Therapeutics signs Hercules loan of up to $200.0 million, draws $40.0 million

    The senior secured facility matures February 1, 2031. Maze ended its Banc of California loan agreement in connection with the deal.

    MAZE
42. Feb 4, 2026Debt Financing

    Maze Therapeutics draws $40.0 million under Hercules term loan facility of up to $200.0 million

    Maze received an initial $40.0 million term loan and says net proceeds were approximately $38.4 million. Up to $160.0 million more is available if conditions are met. It also ended its Banc of California loan.

    MAZE
43. Feb 4, 2026Financings

    Generate Biomedicines files for IPO, plans Nasdaq listing as GENB

    The S-1 leaves the share count and price range blank. Management and the auditor say cash will not last twelve months, which raises going-concern doubt.

    GENB
44. Feb 3, 2026Debt Financing

    Replimune amends Hercules loan, draws $35 million and delays repayment to October 2027

    The Third Amendment raises the third tranche to $35 million, which was funded at closing, and sets the interest rate at the greater of 8.50% or Prime plus 1.75%. Replimune says its cash runway now reaches late into the first quarter of 2027.

    REPL
45. Feb 3, 2026Financings

    Perspective Therapeutics prices $175 million stock and pre-funded warrant offering

    Perspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. Piper Sandler & Co. is one of five joint book-running managers, and Hogan Lovells US LLP is counsel to the company.

    CATX
46. Feb 3, 2026Debt Financing

    Amneal cuts term loan margin by 50 basis points, estimates $11 million annual interest savings

    Amneal Pharmaceuticals LLC cut the interest margin on its term loans by 50 basis points in an amendment dated February 2, 2026, with JPMorgan Chase Bank, N.A. as administrative agent. The company estimates annual cash interest savings of about $11 million, and the loans still mature on August 1, 2032.

    AMRX
47. Feb 2, 2026Distress

    UMeWorld (formerly UMeWorld Limited) says 10-Q is late after auditor resigned

    UMeWorld filed a notice on February 2, 2026 that its quarterly report for the quarter ended December 31, 2025 will be late. Its auditor, J&S Associate PLT, resigned on December 31, 2025, and the company has not yet engaged a successor, so the review of its interim results has not started.

    UMEW
48. Feb 2, 2026Listings

    Polaryx begins Nasdaq trading through a direct listing

    Polaryx began trading on Nasdaq on February 2, 2026 without an underwriter, and the company received no money from the listing.

    PLYX

January 2026

1. Jan 30, 2026Listings

   Tenaya Therapeutics gets Nasdaq minimum bid price notice, has until July 27, 2026

   Nasdaq told Tenaya Therapeutics on January 28, 2026 that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 27, 2026 to regain compliance, and an 8-K filed January 30 also adds 2,161,000 shares to its inducement equity plan.

   TNYA
2. Jan 30, 2026Distress

   BGM Group files late notice for 20-F over XY Management acquisition accounting

   BGM Group Ltd. says it cannot file its annual report on Form 20-F for the year ended September 30, 2025 on time. It is still finishing the consolidation and acquisition accounting for its purchase of YX Management Company Limited.

   BGM
3. Jan 30, 2026Financings

   ALX Oncology raises $150 million at $1.57 a share, led by RA Capital and TCGX

   ALX Oncology priced 76,979,112 shares and pre-funded warrants for 18,574,120 more, at $1.57 a share, after a year of failed or dropped combination trials and a narrower focus on its CD47 drug evorpacept.

   ALXO
4. Jan 29, 2026Financings

   BioMarin prices $850 million of 5.5% notes to help fund its $4.8 billion Amicus purchase

   The senior notes due 2034 priced at par and will sit in escrow until the deal closes. BioMarin also completed syndication of a $2 billion term loan B.

   BMRN
5. Jan 29, 2026Financings

   Aprea Therapeutics agrees to $5.6 million private placement priced at-the-market under Nasdaq rules

   Aprea expects gross proceeds of approximately $5.6 million from selling 6,288,857 shares, or pre-funded warrants, with common warrants for the same number of shares at $0.765. Maxim Group LLC is placement agent for a 7% fee. Closing is expected January 30, 2026.

   APRE
6. Jan 28, 2026Financings

   Altimmune agrees to $75 million registered direct offering with one new investor

   Altimmune is selling 12,397,920 shares at $4.40 each, plus pre-funded warrants for 4,647,534 shares, to one investor, with Titan Partners Group LLC as sole placement agent.

   ALT
7. Jan 27, 2026Financings

   Vivani Medical prices $4.5 million stock offering; chairman's affiliate to buy $2.0 million

   Vivani will sell 1,689,200 shares in a registered direct offering and 1,351,351 shares in a private placement at $1.48 each. ThinkEquity is sole placement agent for the registered part, and the company used $20,786 thousand in operations in 2024 against $19,690 thousand of year-end cash.

   VANI
8. Jan 27, 2026Debt Financing

   Savara amends Hercules loan agreement, resets draw terms on up to $75 million of added term loans

   As amended, the loan agreement provides for up to $105 million of term loans, and the added draws depend on FDA approval of MOLBREEVI for aPAP. Two covenant compliance dates move to April 1, 2027 and September 30, 2027.

   SVRA
9. Jan 26, 2026Mergers

   Indivior PLC (now Indivior Pharmaceuticals, Inc.) completes U.S. domestication

   The company amended its November 4, 2024 note purchase agreement to reflect that Indivior U.S. now reports the financials. The board carries over, and a 2026 equity plan reserves 17,500,000 shares.

   INDV
10. Jan 26, 2026Financings

    4D Molecular swaps common stock for pre-funded warrants with RA Capital and BVF

    RA Capital exchanged 4,850,000 shares and Biotechnology Value Fund exchanged 1,750,000 shares. The company had 51,007,874 shares outstanding as of January 23, 2026.

    FDMT
11. Jan 22, 2026Financings

    Larimar swaps 2,500,000 common shares for 250,000 Series A preferred with Blue Owl fund

    Each share of Series A convertible preferred stock converts into 10 shares of common stock, subject to certain limitations. The exchange was expected to close on January 23, 2026.

    LRMR
12. Jan 22, 2026Financings

    Larimar Therapeutics to exchange 2,500,000 common shares for Series A preferred stock

    Larimar agreed with Blue Owl Healthcare Opportunities IV Public Investments LP to swap 2,500,000 common shares for 250,000 Series A convertible preferred shares. Each preferred share converts into 10 common shares, and closing is expected January 23, 2026.

    LRMR
13. Jan 21, 2026Debt Financing

    enGene Holdings (now enGene Therapeutics) expands Hercules loan to up to $125 million

    The Second Amendment draws $25 million at closing to refinance existing term loans. Further tranches depend on milestones.

    ENGN
14. Jan 21, 2026Listings

    UMeWorld begins trading on OTC Markets as UMEW after move to Delaware

    UMeWorld moved its legal home from the British Virgin Islands to Delaware, changed its name and began trading as UMEW on the OTC Markets on January 21, 2026. Its annual report for the year ended September 30, 2025 includes a going concern warning.

    UMEW
15. Jan 21, 2026Financings

    BioAge sells $115 million of stock at $19.50 after NLRP3 pill cuts CRP 86% in obese patients

    BioAge Labs priced 5.9 million shares with Goldman Sachs, Piper Sandler and Citigroup nine days after new phase 1 data on BGE-102, its brain-penetrant NLRP3 inhibitor.

    BIOA
16. Jan 21, 2026Financings

    AEON Biopharma completes Daewoong note exchange, issuing 11,918,380 shares and a $1,500,000 note

    AEON Biopharma exchanged its senior secured convertible notes held by Daewoong for new shares, pre-funded warrants and a smaller $1,500,000 note after stockholders approved the deal on January 21, 2026. The swap adds dilution, and the second closing of its private placement is still pending.

    AEON
17. Jan 16, 2026Financings

    Tiziana Life Sciences closes $8.8 million registered direct offering at $1.25 per share

    Tiziana Life Sciences Ltd sold 7,040,000 ordinary shares to senior management and existing shareholders without a placement agent. Each share came with a warrant at $1.50.

    TLSA
18. Jan 16, 2026Listings

    NRX Pharmaceuticals gets Nasdaq notice for missing annual meeting deadline

    Nasdaq said NRX Pharmaceuticals is out of compliance because it did not hold an annual meeting within twelve months of fiscal year end. The company set the 2025 Annual Meeting for March 23, 2026.

    NRXP
19. Jan 16, 2026Listings

    GRI Bio says Nasdaq found it conditionally regained stockholders' equity compliance

    Nasdaq's staff found only conditional compliance with the $2.5 million equity rule after a December 2025 deficiency notice. The company's auditors had already raised going-concern doubt in its 2024 annual report.

    GRI
20. Jan 16, 2026Financings

    AgomAb Therapeutics files for U.S. IPO of ADSs, seeks Nasdaq listing as AGMB

    AgomAb Therapeutics filed to sell American depositary shares and list them on Nasdaq as AGMB. The price range and share count are blank, and the company has a Phase 2a Crohn's trial whose published results were on safety only.

    AGMB
21. Jan 16, 2026Mergers

    Agenus completes $75.0 million manufacturing asset sale to Zydus and $16.0 million stock sale

    Agenus received $75 million, less certain expenses, for its manufacturing operations, and sold 2,133,333 shares to a Zydus affiliate at $7.50 each. Up to $50 million in further payments depends on orders for its BOT+BAL drug product.

    AGEN
22. Jan 15, 2026Debt Financing

    Cell Source closes $1.875 million convertible note placement and plans Nasdaq uplist

    Cell Source closed $1,875,000 of original issue discount convertible notes for $1,500,000 in gross proceeds. The notes convert at 90% of a recent low price, and buyers also received warrants at $.40.

    CLCS
23. Jan 15, 2026Debt Financing

    BridgeBio prices $550 million of 0.75% convertible notes to refinance 2027 debt

    The notes due 2033 carry a 45% conversion premium. Underwriters later took the full option, and BridgeBio bought back about 1.1 million shares alongside the sale.

    BBIO
24. Jan 13, 2026Financings

    BriaCell prices $30 million offering of units with warrants through ThinkEquity

    BriaCell Therapeutics sold 5.4 million units at $5.59, each with a five-year warrant struck at $6.93. The best-efforts deal closed Jan. 15.

    BCTX
25. Jan 12, 2026Listings

    Polaryx completes one-for-four reverse stock split ahead of Nasdaq listing

    Polaryx's 1-for-4 reverse split took effect on January 12, 2026, ahead of a Nasdaq direct listing that raised no money for the company.

    PLYX
26. Jan 9, 2026Financings

    iBio raises $26 million from Frazier-led investors to push obesity antibodies toward clinic

    The AI-driven antibody company sold shares and pre-funded warrants at $2.35 in a private placement. It says the cash runs into calendar 2028 and that first human trials of IBIO-610 start in early 2027.

    IBIO
27. Jan 9, 2026Financings

    Eikon Therapeutics files for IPO of common stock, seeks Nasdaq listing as EIKN

    The Delaware company applied to list on the Nasdaq Global Market. The share count and price range are blank in the preliminary prospectus.

    EIKN
28. Jan 8, 2026Financings

    Monte Rosa upsizes stock sale to $300 million after oral NEK7 degrader cuts CRP 85%

    Monte Rosa Therapeutics priced 12.5 million shares and pre-funded warrants at $24 the day after interim phase 1 data on MRT-8102, an oral molecular glue aimed at heart-disease inflammation.

    GLUE
29. Jan 8, 2026Financings

    Genelux sells $20 million of stock at $3 a share to fund ovarian cancer phase 3

    Genelux sold 6,666,667 shares at $3.00 through Lucid Capital Markets, raising about $20.0 million gross. The oncolytic virus developer is running a phase 3 trial of Olvi-Vec in platinum-resistant ovarian cancer, and its China partner Newsoara holds the rights there.

    GNLX
30. Jan 8, 2026Financings

    Aktis Oncology prices upsized IPO at $18, raising about $318 million

    The radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size.

    AKTSLLYBMYMRK
31. Jan 7, 2026Listings

    Propanc Biopharma gets Nasdaq minimum bid price deficiency notice, has until June 30, 2026

    Propanc Biopharma received a Nasdaq notice that its stock has been below the $1.00 minimum bid price, and it has until June 30, 2026 to regain compliance. Its latest annual report showed cash of $12,088 at June 30, 2025.

    PPCB
32. Jan 7, 2026Financings

    Phathom Pharmaceuticals prices stock and pre-funded warrant offering at $16.00 a share

    Phathom priced 6,875,000 shares at $16.00 plus pre-funded warrants for 1,250,078 shares, for a public offering of $129,999,998. Its cash fell from $297.3 million at the end of 2024 to a preliminary $130 million at the end of 2025, and the company expects operating profit only in the second half of 2026, excluding stock-based compensation.

    PHAT
33. Jan 7, 2026Financings

    Curis raises $20.2 million up front in a PIPE that could bring in up to $80.8 million

    The emavusertib developer sold preferred stock with three warrant series at $0.75, one of them timed to an enrollment goal in its leukemia trial.

    CRIS
34. Jan 7, 2026Debt Financing

    Arrowhead Pharmaceuticals prices $625,000,000 of 0.00% convertible notes due 2032

    Arrowhead Pharmaceuticals raised the notes from $500,000,000 to $625,000,000 while selling common stock at the same time. The notes rank behind $254.9 million of secured borrowing.

    ARWR
35. Jan 7, 2026Financings

    Alumis raises $300 million a day after psoriasis pill beats placebo and apremilast in phase 3

    Alumis sold 17.65 million shares at $17 after two phase 3 trials of its oral TYK2 inhibitor envudeucitinib met all endpoints. A prospectus had flagged going-concern doubt before the deal.

    ALMS
36. Jan 6, 2026Financings

    Praxis prices $575 million stock offering at $260 a share ahead of two NDA filings

    Praxis Precision Medicines sold 2.2 million shares to fund launch plans for two Breakthrough-designated drugs. Net proceeds later came to $621.2 million.

    PRAX
37. Jan 6, 2026Listings

    Immunic gets extra 180 days on Nasdaq bid price rule after transfer to Capital Market

    Nasdaq approved Immunic's move from the Global Select Market to the Capital Market, with trading there from January 7, 2026. The company now has until June 22, 2026 to regain compliance with the $1.00 minimum bid price and has told Nasdaq it would seek a reverse stock split if necessary.

    IMUX
38. Jan 6, 2026Financings

    IGC Pharma agrees to sell 779,997 shares at $0.30 in direct offering

    The registered direct offering is expected to bring in about $234,000 before expenses. IGC Pharma says it will use the money for working capital and general corporate purposes.

    IGC
39. Jan 6, 2026Financings

    Galecto (now Damora Therapeutics) issues warrant for up to 628,302 shares, names new COO

    The December 31, 2025 warrant went to Paramora Holding LLC at $23.01 per share under an October 7, 2025 option agreement with Paragon Therapeutics. The board named Sherwin Sattarzadeh Chief Operating Officer.

    DMRA
40. Jan 2, 2026Financings

    Zura Bio to issue 8,657,402 shares and pay $7,325,000 to Athanor Capital, ends Stone Peach deals

    Zura Bio will issue 8,657,402 Class A shares to Athanor Capital and pay it a $7,325,000 upfront fee within 30 days, ending its Stone Peach and BAFFX17 arrangements. An internal audit subcommittee review found no issue that affected previously filed financial statements, and the Athanor deal adds a $25,000,000 milestone payment.

    ZURA
41. Jan 2, 2026Listings

    Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, will appeal

    Nasdaq said on December 31, 2025 that the company missed the $1.00 minimum bid price and gets no grace period. Suspension is set for January 9, 2026 unless it appeals by January 7, 2026.

    DCOY
42. Jan 2, 2026Listings

    Northwest Biotherapeutics holders approve raising authorized shares to 2,600,000,000

    Common stock authorized rises from 1,700,000,000 to 2,600,000,000 shares. The company filed the amendment in Delaware on December 30, 2025.

    NWBO
43. Jan 2, 2026Listings

    FibroBiologics gets Nasdaq delisting notice over bid price, plans to request a hearing

    Nasdaq staff plans to delist FibroBiologics after its stock did not regain the $1.00 minimum bid price by December 29, 2025. The company will ask for a hearing and has asked stockholders to approve a reverse split of 1 for 5 to 1 for 30.

    FBLG
44. Jan 2, 2026Financings

    Eledon Pharmaceuticals swaps 4,203,764 shares for a pre-funded warrant with Coastlands

    The exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share.

    ELDN
45. Jan 2, 2026Listings

    Cybin Inc. (now Helus Pharma) files Form 25 to leave NYSE American

    The January 2, 2026 filing covers the company's common shares. It relies on the SEC rule for a voluntary withdrawal by the issuer.

    HELP
46. Jan 2, 2026Debt Financing

    Bausch + Lomb closes $2,802,125,000 term loan refinancing

    Bausch + Lomb closed a $2,802,125,000 term loan tranche maturing January 15, 2031, used to refinance its term B loans due 2028 and 2031. The margin on term SOFR loans is 3.75%, but the filing does not say how much of the tranche is new cash.

    BLCO

December 2025

1. Dec 31, 2025Legal

   Climb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment

   Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment.

   CLYM
2. Dec 30, 2025Financings

   Mesoblast registers resale of up to 500,000 ADSs issuable on warrant exercise

   Holders would receive all resale proceeds. Mesoblast would receive US$16.25 per ADS if the warrants are exercised.

   MSB
3. Dec 30, 2025Debt Financing

   Collegium closes $980 million syndicated credit facility, repays Pharmakon term loan

   The $980 million facility matures in 2030 and includes a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver. The initial term loan repaid about $581 million owed to Pharmakon, so it brought no new cash at closing.

   COLL
4. Dec 30, 2025Debt Financing

   Collegium closes $980 million syndicated credit facility with Truist Bank as agent

   The five-year facility has a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver, with Truist Bank as administrative agent. Collegium used the initial loan to repay its previous term loan in full, including its prepayment premium, which the filing does not size.

   COLL
5. Dec 30, 2025Financings

   Arcturus files $500,000,000 replacement shelf with $187,765,319 ATM prospectus

   The at-the-market sales agreement names Cantor Fitzgerald, Wells Fargo Securities and William Blair. As of December 22, 2025, the company had sold 1,179,201 shares under it for about $12 million.

   ARCT
6. Dec 29, 2025Listings

   Silo Pharma gets second 180 days from Nasdaq to meet $1.00 minimum bid price

   Silo Pharma did not regain the $1.00 minimum bid price by December 24, 2025, and Nasdaq granted it a second 180-day period to June 22, 2026. The company has told Nasdaq it may use a reverse stock split to cure the deficiency, and its annual report shows an accumulated deficit of $15,264,691.

   SILO
7. Dec 29, 2025Financings

   ImmunityBio adds up to $459,972,480 to its at-the-market stock program

   The company amended its sales agreement with Jefferies and filed a new prospectus supplement. It also confirmed a higher authorized share count.

   IBRX
8. Dec 23, 2025Legal

   Cassava Sciences (now Filana Therapeutics) agrees to $31.25 million class action settlement

   Cassava and Chief Financial Officer Eric J. Schoen accepted a mediator's recommendation to settle the consolidated securities class action for $31.25 million. Remi Barbier and Lindsay Burns did not sign the term sheet but would receive releases once the court approves.

   FLNA
9. Dec 22, 2025Listings

   Apollomics interim report shows $4,398 thousand shareholders' deficit at June 30, 2025

   Apollomics reports a $4,398 thousand shareholders' deficit at June 30, 2025, after cash fell to $2,094 thousand from $9,766 thousand at year-end and the six months produced a $12,536 thousand loss.

   APLM
10. Dec 22, 2025Listings

    Anebulo drops reverse split plan for $3.50-a-share self tender of up to 300,000 shares

    Anebulo's board dropped a planned reverse split and will instead tender for up to 300,000 shares at $3.50, to keep its holder count below 300 for a go-private plan, while its lead drug rests on a Phase 2 study in healthy volunteers.

    ANEB
11. Dec 18, 2025Mergers

    SL Science Holding files F-4 for Horizon Space Acquisition II and SL BIO merger

    SL Science Holding's F-4 says the blank-check company's trust holds $69,000,000 and that its chairman would control about 58% of the voting power of the combined company. The target's main products include cancer drugs that the filing does not show as approved.

    SLBT
12. Dec 18, 2025Financings

    Biodexa prices $10 million best-efforts offering of ADS units and warrants

    Biodexa priced 157,000 units and 2,891,781 pre-funded units at $3.28 each, with two Series L warrants per unit. The last reported sale price of the ADSs was $6.50 on December 16, 2025.

    BDRX
13. Dec 17, 2025Listings

    NYSE American accepts Azitra's stockholders' equity compliance plan, sets April 1, 2027 deadline

    NYSE American accepted Azitra's plan to restore its $4.0 million minimum stockholders' equity and set April 1, 2027 as the deadline. The stock stays listed while the plan runs, but the company's 2024 annual report carried a going-concern warning.

    AZTR
14. Dec 17, 2025Financings

    Larimar Therapeutics swaps Blue Owl fund's 2,500,000 shares for Series A convertible preferred

    Larimar Therapeutics agreed to swap 2,500,000 common shares held by a Blue Owl fund for 250,000 Series A convertible preferred shares, each convertible into 10 common shares. The filing calls the preferred "toothless," and the holder can raise its conversion blocker to 19.99%.

    LRMR
15. Dec 16, 2025Listings

    TherapeuticsMD holders approve raising authorized common stock to 640,000,000 shares

    TherapeuticsMD stockholders approved raising authorized common stock to 640,000,000 shares at the December 15, 2025 annual meeting. The company had 11,574,362 shares outstanding at the record date, and the increase drew 548,884 votes against.

    TXMD
16. Dec 16, 2025Financings

    Radiopharm Theranostics files $50,000,000 ADS shelf, sets $18,900,000 sales program

    Radiopharm Theranostics filed a $50,000,000 shelf registration on December 16, 2025 and a sales agreement with Leerink Partners the same day. A prospectus supplement filed December 23 set up to $18,900,000 of at-the-market sales.

    RAD
17. Dec 16, 2025Financings

    Lexaria closes registered direct offering and warrant placement for about $3.5 million gross

    Lexaria sold 2,661,600 shares at $1.315 in a registered direct offering and placed matching warrants at $1.19, for about $3.5 million gross. H.C. Wainwright & Co., LLC was placement agent. Its annual report says the company has substantial doubt about continuing as a going concern.

    LEXX
18. Dec 16, 2025Distress

    Geron begins restructuring, cutting about one-third of its roughly 260 employees

    Geron Corporation estimates about $18 million in restructuring charges, mostly severance and benefits, and expects the workforce reduction to be substantially complete in the first quarter of 2026.

    GERN
19. Dec 16, 2025Distress

    Geron begins restructuring that cuts about one-third of its roughly 260 employees

    The company estimates about $18 million in restructuring charges, mostly severance and benefits, hitting results in the fourth quarter of 2025 and the first quarter of 2026.

    GERN
20. Dec 16, 2025Financings

    Cadrenal Therapeutics agrees to $2.2 million registered direct offering with warrants

    Cadrenal will sell 207,374 shares at $10.85 plus unregistered warrants for up to 414,748 shares at $10.60, for expected gross proceeds of about $2.2 million. H.C. Wainwright & Co., LLC is exclusive placement agent.

    CVKD
21. Dec 15, 2025Financings

    Turn completes first GEM equity draw for $4.1 million at about $3.29 a share

    The 10-K reports GEM bought 1,235,200 shares for about $4.07 million in 2025 under an $85.0 million agreement. The company has since drawn a $7.0 million term loan and flagged going-concern doubt.

    TTRX
22. Dec 15, 2025Distress

    PharmaCyte Biotech files NT 10-Q for quarter ended October 31, 2025, citing need for more time

    PharmaCyte Biotech will miss the December 15, 2025 deadline for its quarterly report and says it will file within five calendar days. The company's latest annual report says its licensed patents have expired and that the know-how for its core technology sits with a partner, while it has cut program spending during a board review.

    PMCB
23. Dec 15, 2025Financings

    Immunome proposes $400 million stock offering, later sets $21.50 price

    Immunome said on December 15, 2025 that it planned a $400 million stock offering, and priced it the next day at $21.50 a share.

    IMNM
24. Dec 12, 2025Financings

    Tiziana Life Sciences files for best-efforts share offering via ThinkEquity

    The preliminary filing leaves the size and price blank. There is no minimum amount, so the company may sell fewer shares than offered.

    TLSA
25. Dec 11, 2025Mergers

    Tivic Health Systems (now Valion Bio) buys Scorpius CDMO assets for $16,253,147.10

    Tivic Health Systems bought the manufacturing and development assets of Scorpius Holdings at a public auction, paying $16,253,147.10 in cash funded by a senior secured convertible note sold to 3i. The note converts at a fixed price and at a discount to market, which can add shares.

    VBIO
26. Dec 11, 2025Financings

    Climb Bio agrees to swap 20,440,000 RA Capital shares for a pre-funded warrant

    Climb Bio agreed on December 11, 2025 to take back 20,440,000 shares from an entity affiliated with RA Capital in exchange for a pre-funded warrant. After the exchange, RA Capital and its affiliates will hold about 23.0% of the voting power, and the filing describes no cash payment to the company.

    CLYM
27. Dec 10, 2025Financings

    Evaxion registers up to $45,527,824 in ADS sales after public float passes $75.0 million

    Evaxion says its public float now passes $75.0 million, which lifts a sales cap and allows up to $45.52 million more in ADS sales through JonesTrading. The float figure uses an October share price, and the stock was $6.28 in early December.

    EVAX
28. Dec 10, 2025Financings

    C4 Therapeutics registers $125,000,000 in share sales through TD Cowen

    The supplement covers $125,000,000 of a sales agreement that allows up to $200,000,000 in total. TD Securities (USA) LLC can earn up to a 3.0% commission, and the filing gives a November 20, 2025 closing price of $2.38.

    CCCC
29. Dec 10, 2025Financings

    Addex amends H.C. Wainwright ATM deal for up to $3,300,000 of ADSs

    Addex Therapeutics amended its at-the-market agreement with H.C. Wainwright and filed a prospectus supplement for up to $3,300,000 of ADSs. The company reported CHF 2.2 million of cash at September 30, 2025 and says it covers expenses through mid-June 2026.

    ADXN
30. Dec 8, 2025Financings

    Wave Life Sciences proposes $250,000,000 offering, then prices upsized $350 million deal

    Wave Life Sciences filed a preliminary prospectus supplement on December 8, 2025 for a $250,000,000 offering. The pricing that followed on December 9 raised the deal to about $350 million at $19.00 per ordinary share.

    WVE
31. Dec 8, 2025Financings

    Fulcrum proposes $150.0 million stock offering, later upsized to $175.0 million

    The $150.0 million offering priced on December 10, 2025 at $13.50 a share and was upsized to $175.0 million. Its lead drug data come from 12 patients in one dose cohort, and the dose comparison rests on six.

    FULC
32. Dec 8, 2025Debt Financing

    Dyne Therapeutics borrows $50.0 million second tranche under amended Hercules term loan

    The First Amendment lets Dyne draw a $50.0 million tranche from Hercules Capital. Up to $75.0 million more depends on milestones, and the loan matures July 1, 2030 at prime plus 2.45% with a 7.50% floor.

    DYN
33. Dec 5, 2025Listings

    Polyrizon agrees to sell 552,269 shares at $9.00 in registered direct offering

    Expected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price.

    PLRZ
34. Dec 5, 2025Listings

    PharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026

    Nasdaq told PharmaCyte on December 1, 2025 that its stock had failed the $1.00 minimum bid price over 30 consecutive business days. The company has until June 1, 2026, and any reverse stock split would need shareholder approval. The filings give no share price or cash figure to show how far the company is from compliance.

    PMCB
35. Dec 5, 2025Mergers

    Natera closes Foresight Diagnostics acquisition, agrees to issue 1,127,982 shares

    Natera closed the deal on December 4, 2025. The press release describes an all-stock transaction with a $275 million upfront and $175 million in earnouts tied to milestones.

    NTRA
36. Dec 5, 2025Listings

    Intensity Therapeutics gets second 180 days to meet Nasdaq minimum bid price requirement

    Nasdaq gave Intensity until June 1, 2026 to restore a $1.00 closing bid price. The company says it may use a reverse stock split, and the notice has no immediate effect on its listing.

    INTS
37. Dec 4, 2025Financings

    Immuron to issue 45,472,000 shares at AUD 0.07910 in placement

    The 45,472,000 shares are sold to US investors through the company's at-the-market facility, according to a note in the filing. The filing names no lead manager or underwriter.

    IMC
38. Dec 4, 2025Financings

    Crescent Biopharma agrees to $185 million private placement and Kelun-Biotech license deals

    Crescent agreed to sell 13,795,685 ordinary shares at $13.41 for about $185.0 million. Two license deals with Kelun-Biotech require Crescent to pay $80.0 million within 30 days of signing, while Kelun-Biotech pays it $20.0 million in the same period.

    CBIO
39. Dec 4, 2025Financings

    Baxter closes three-series senior notes offering with about $1.99 billion in net proceeds

    Baxter closed a three-series senior notes offering on December 4, 2025 and used part of the proceeds to repay its term loan. The rest is earmarked for cash tender offers on older notes, so the company is swapping debt rather than shrinking it.

    BAX
40. Dec 2, 2025Financings

    Kazia Therapeutics prices $50.0 million private placement at $5.00 per ADS

    The deal has no common warrant coverage but includes prefunded warrants. Kazia expects net proceeds of approximately $46.5 million and says its cash runway would extend into the second half of 2028.

    KZIA
41. Dec 2, 2025Listings

    GRI Bio gets Nasdaq deficiency notice on minimum stockholders' equity requirement

    Nasdaq told GRI Bio on November 26, 2025 that it does not meet the $2,500,000 stockholders' equity requirement for the Capital Market. The company has until January 10, 2026 to submit a compliance plan, and its annual report already carried a going-concern warning.

    GRI
42. Dec 1, 2025Mergers

    Q32 Bio sells ADX-097 to Akebia Therapeutics for $7.0 million upfront

    Q32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027.

    QTTBAKBA
43. Dec 1, 2025Mergers

    Omeros closes zaltenibart sale to Novo Nordisk, receives $240.0 million and repays term loan

    Omeros got $240.0 million upfront and may earn up to $510 million in development and approval milestones and $1.3 billion in sales milestones. About $72.6 million retired its credit agreement and the board approved a buyback of up to $100.0 million.

    OMER

November 2025

1. Nov 26, 2025Financings

   PolyPid raises share sales program limit from $8,250,000 to $15,000,000

   PolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has.

   PYPD
2. Nov 26, 2025Listings

   MetaVia gets 180-day Nasdaq extension to May 26, 2026 on minimum bid price requirement

   MetaVia Inc. (Nasdaq: MTVA) was granted more time to regain compliance after its stock closed below $1.00 for 30 consecutive trading days. It says a reverse stock split is an option.

   MTVA
3. Nov 26, 2025Debt Financing

   Mesoblast holders approve convertible notes and warrants for a director and Cova Holdings

   All resolutions passed by poll at the November 25, 2025 annual meeting. Shareholders also approved option grants and prior share issues.

   MSB
4. Nov 26, 2025Listings

   GT Biopharma gets Nasdaq minimum bid price notice, has until May 19, 2026 to regain compliance

   Nasdaq told GT Biopharma on November 20, 2025 that its stock had closed below $1 for 30 consecutive business days. The company has until May 19, 2026 to regain compliance, and its last annual report carried a going-concern warning alongside a $13.2 million net loss.

   GTBP
5. Nov 26, 2025Listings

   Akari Therapeutics gets Nasdaq minimum bid price deficiency notice, has until May 25, 2026

   Nasdaq told Akari Therapeutics on November 24, 2025 that its American Depositary Shares had closed below $1.00 for 30 consecutive business days. The company has until May 25, 2026 to regain compliance, and its 2024 annual report carries a going-concern warning.

   AKTX
6. Nov 25, 2025Listings

   Artelo Biosciences gets Nasdaq delisting determination over stockholders' equity, plans appeal

   Nasdaq's staff ruled that Artelo had not completed the capital raise it promised to fix its equity shortfall. Trading continues pending a hearing panel appeal, and the company's last annual report carried going-concern doubt.

   ARTL
7. Nov 24, 2025Financings

   Verrica Pharmaceuticals agrees to about $50 million private placement to retire OrbiMed debt

   Verrica agreed to sell common stock, pre-funded warrants and Series C warrants for about $50 million, and will use $35.0 million to settle its OrbiMed credit agreement. The company says cash will last into mid-2027.

   VRCA
8. Nov 24, 2025Debt Financing

   Cumberland Pharmaceuticals extends Pinnacle Bank credit line to October 2027

   Cumberland's amended Pinnacle Bank line has up to $15 million available, a right to request $10 million more, and a maturity of October 1, 2027. The filing does not say how much is drawn.

   CPIX
9. Nov 21, 2025Listings

   Moleculin Biotech gets Nasdaq delisting determination, plans hearing panel appeal

   Nasdaq staff issued a delisting determination against Moleculin Biotech's common stock for failing the $2.5 million stockholders' equity rule. The company said it will ask a hearing panel to stay any suspension, and its last annual report showed $4.3 million of cash and a going-concern warning.

   MBRX
10. Nov 21, 2025Distress

    Cullinan unit ends MIT license for CLN-617 after dropping the program

    Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026.

    CGEM
11. Nov 21, 2025Legal

    AnaptysBio sues Tesaro and GSK in Delaware Chancery Court over Jemperli collaboration

    AnaptysBio's Verified Complaint of Nov 20, 2025 names Tesaro, Inc. and its parent GlaxoSmithKline and alleges breaches of the Jemperli collaboration. Tesaro sued AnaptysBio the same day, and the parties have agreed to ask for an expedited schedule.

    ANAB
12. Nov 20, 2025Mergers

    Abbott agrees to acquire Exact Sciences for $105 per share in cash, about $21 billion

    Abbott agreed on November 20, 2025 to buy Exact Sciences for $105 per share in cash, an equity value the companies put at about $21 billion. Abbott's commitment letter provides up to $20 billion of bridge loans, and the companies expect the deal to close in the second quarter of 2026, subject to a shareholder vote and antitrust review.

    ABT
13. Nov 18, 2025Listings

    Soligenix regains Nasdaq stockholders' equity compliance after August notice

    Nasdaq told Soligenix on November 18, 2025 that the matter is closed. The company reported stockholders' equity of $7,597,976 for the quarter ended September 30, 2025, against a $2,500,000 requirement.

    SNGX
14. Nov 18, 2025Mergers

    Harrow completes Melt Pharmaceuticals acquisition with approximately $4.3 million paid at closing

    Harrow paid about $4.3 million in cash to close its purchase of Melt Pharmaceuticals on Nov 17, 2025. The contingent milestone payments are unchanged, and the MELT-300 sedation drug still needs an NDA, which the company plans for the first half of 2027.

    HROW
15. Nov 18, 2025Debt Financing

    Cogent Biosciences completes $230,000,000 offering of 1.625% convertible notes due 2031

    Cogent Biosciences closed a $230,000,000 offering of 1.625% convertible notes due 2031 on November 18, 2025, including the full over-allotment option. The 8-K names no underwriters, and the company's 2024 annual report showed operating cash use of $207.8 million that year.

    COGT
16. Nov 18, 2025Mergers

    Bristol Myers Squibb amends cash tender offers and sets early settlement for November 20

    Bristol Myers Squibb amended its cash tender offers for its own notes after the November 17, 2025 early tender deadline. It cut the Pool 1 cap from $4,000,000,000 and raised the Pool 2 cap from $3,000,000,000, and it set early settlement for November 20. Accepted notes will be cancelled and retired.

    BMY
17. Nov 17, 2025Listings

    Shuttle Pharmaceuticals believes $2.5 million private placement restored Nasdaq equity compliance

    Shuttle reported stockholders' equity of $1,394,161 against Nasdaq's $2,500,000 minimum. Nasdaq staff will keep monitoring, and delisting is possible if compliance is not shown in the next periodic report.

    SHPH
18. Nov 17, 2025Financings

    Biodexa Pharmaceuticals plans offering of up to 3,377,110 ADS-and-warrant units

    The best efforts sale would pair each ADS with a Series L warrant whose exercise price resets after issue. The company says it will likely receive no additional cash when those warrants are exercised.

    BDRX
19. Nov 14, 2025Distress

    Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report

    Q/C Technologies told the SEC on November 14, 2025 that it needs more time to finalize its quarterly report for the nine months ended September 30, 2025. The company filed its April 2025 annual report under the name TNF Pharmaceuticals, and that report carried a going-concern warning.

    QCLS
20. Nov 14, 2025Financings

    NanoViricides closes registered direct offering with gross proceeds of about $6.0 million

    The company sold 1,970,000 shares at $1.68 per share and pre-funded warrants for up to 1,601,429 shares to one investor, and issued Series A and Series B warrants in a concurrent private placement.

    NNVC
21. Nov 14, 2025Mergers

    IGC Pharma unit sold Vancouver facility assets for supply rights, not cash

    Holi Hemp LLC completed the disposition on September 29, 2025. IGC Pharma filed pro forma financial statements showing a $1,051 thousand gain.

    IGC
22. Nov 14, 2025Mergers

    IGC Pharma subsidiary closes Vancouver facility asset sale valued at about $2.7 million

    Holi Hemp LLC sold equipment, inventory and operating assets for an agreed fair value of about $2.7 million, but the consideration was supply rights and a contingent payout, with no cash. The pro forma statements show a non-cash gain of $1,051 thousand that narrows a reported quarterly loss to $548 thousand.

    IGC
23. Nov 14, 2025Distress

    Advanced Biomed files NT 10-Q, says review of September 30, 2025 quarter is not finished

    Advanced Biomed, which carried a going-concern warning and a Nasdaq bid price notice in its last annual report, says the review of its September 30, 2025 quarter is not finished.

    ADVB
24. Nov 13, 2025Financings

    Cassava Sciences (now Filana Therapeutics) files $200,000,000 shelf, $50,000,000 ATM

    The at-the-market supplement lets Cantor Fitzgerald sell up to $50,000,000 of stock for up to 3.0% in commissions. The company's lead drug failed its Phase 3 Alzheimer's study, and its share price closed at $3.11.

    FLNA
25. Nov 13, 2025Financings

    Black Diamond Therapeutics files $500,000,000 replacement shelf with $150,000,000 ATM

    The new shelf replaces one that expires on November 22, 2025. It carries forward $400,005,680.55 of securities that remain unsold under the earlier registration.

    BDTX
26. Nov 13, 2025Financings

    Acumen Pharmaceuticals registers $50,000,000 in share sales with three agents

    Acumen has sold $12.3 million of stock under its sales agreement so far, which leaves $37.7 million available. BofA Securities, Stifel and BTIG are the sales agents.

    ABOS
27. Nov 12, 2025Financings

    Precision BioSciences prices $75,000,093 stock and warrant offering

    Guggenheim Securities, LLC is the sole underwriter. The company sells 10,815,000 shares, each with half a warrant, at a combined $6.14. Proceeds are $70,500,087 before expenses, and the as adjusted net tangible book value would be $3.74 a share.

    DTIL
28. Nov 12, 2025Distress

    Korro Bio cuts approximately 34% of workforce in restructuring, pauses Novo Nordisk deal

    Korro Bio cut about 34% of its workforce on November 12, 2025, paused its Novo Nordisk collaboration for 12 months, and said the moves extend its cash into the second half of 2027. Its chief medical officer also resigned, and its lead RNA editing candidate fell short of the protein levels the company had projected.

    KRRO
29. Nov 12, 2025Distress

    Korro Bio cuts about 34% of workforce, expects cash runway into second half of 2027

    The RNA editing company ended the third quarter of 2025 with $102.5 million in cash and securities. Its AATD drug candidate KRRO-110 did not reach projected protein levels.

    KRRO
30. Nov 12, 2025Listings

    COSCIENS Biopharma, delisted from Nasdaq in September, applies for OTCQB quotation

    COSCIENS plans to file a Form 15-F to end its U.S. reporting and has applied for OTCQB quotation. It had $8.5 million of cash on September 30, 2025, and its net loss narrowed to $1.8 million in the quarter.

    CSCI
31. Nov 12, 2025Distress

    Arcturus Therapeutics files NT 10-Q after technical error delays third-quarter report

    Arcturus blamed a technical transmission error for missing the deadline on its September 30, 2025 quarterly report. The notice gives no results, and the company's 2024 annual report shows cash use rising sharply.

    ARCT
32. Nov 12, 2025Distress

    Arcturus Therapeutics 10-Q gets November 12 filing date after transmission error

    Arcturus says a technical transmission error caused it to miss the 5:30 PM Eastern deadline on November 10, 2025 for its quarterly report. Its commercial product is KOSTAIVE, a COVID-19 vaccine sold in Japan.

    ARCT
33. Nov 12, 2025Financings

    Annexon proposes $75,000,000 stock offering, prices shares at $2.60

    Annexon priced 25,096,153 shares at $2.60 for about $75 million on November 12, 2025, with pre-funded warrants for up to 3,750,000 more shares, and its two lead programs are still in late-stage trials.

    ANNX
34. Nov 10, 2025Financings

    Lyell Immunopharma licenses LYL273 CAR T candidate for $40 million and 1.9 million shares

    Lyell Immunopharma agreed to pay $40 million in cash and issue 1.9 million shares for exclusive rights to LYL273, a CAR T candidate for colorectal cancer that has been tested in 12 patients. The deal also carries more shares, large milestone payments and tiered royalties, and the company says its cash lasts into 2027 once it closes.

    LYEL
35. Nov 10, 2025Mergers

    Galecto (now Damora Therapeutics) buys Damora, agrees to about $285 million private placement

    Galecto completed its acquisition of Damora Therapeutics on November 10, 2025. A concurrent private placement of Series C preferred stock for approximately $285 million is expected to close November 12.

    DMRA
36. Nov 7, 2025Financings

    Evommune closes NYSE IPO of 10.8 million shares at $16, nets $157.0 million

    Evommune sold 9,375,000 shares at $16.00 in its New York Stock Exchange listing, with a 30-day option on 1,406,250 more. Its most advanced drug's efficacy data come from a small Phase 2 study in a different condition than the one it is pursuing.

    EVMN
37. Nov 7, 2025Mergers

    Biofrontera sells Xepi cream assets to Pelthos Therapeutics, gets $3 million at closing

    Only $3,000,000 was paid at closing on November 6, 2025. The rest of the $10,000,000 maximum depends on a $1,000,000 payment and up to $6 million in sales milestones, and Xepi had no sales in 2024.

    BFRI
38. Nov 6, 2025Financings

    Phio Pharmaceuticals warrant inducement brings in approximately $12.6 million at initial closings

    Holders exercised existing warrants, most at a reduced $2.05 per share, in return for new Series A Warrants. Phio expects total gross proceeds of approximately $13.4 million before fees.

    PHIO
39. Nov 6, 2025Debt Financing

    Altimmune expands Hercules loan facility to $125 million and draws $20 million

    The amendment raises term loan availability from $100.0 million to $125.0 million and extends the interest-only period to 30 months. Altimmune held $210.8 million in cash, cash equivalents and short-term investments at September 30, 2025.

    ALT
40. Nov 6, 2025Financings

    4D Molecular Therapeutics prices $99,999,993 stock offering at $10.5100

    4D Molecular Therapeutics priced an offering of about $100 million in shares and pre-funded warrants at $10.51 each, with Leerink Partners LLC and Evercore Group L.L.C. as joint bookrunners. Preliminary cash of $372.2 million is unaudited, and new buyers face immediate dilution of $1.36 per share.

    FDMT
41. Nov 5, 2025Debt Financing

    Halozyme expands revolver to $750,000,000 and proposes two $650 million convertible note offerings

    Halozyme amended its credit agreement to raise the revolver to $750,000,000, with nothing drawn. It also proposed two $650 million convertible note offerings, with terms to be set at pricing.

    HALO
42. Nov 4, 2025Financings

    Taysha Gene Therapies files new shelf with up to $200,000,000 at-the-market prospectus

    Taysha filed an automatic shelf on November 4, 2025, with a sales agreement of up to $200,000,000 of common stock. As of November 3, 2025, it had sold $12,000,000 under the earlier agreement, while its third-quarter net loss was $32.7 million.

    TSHA
43. Nov 4, 2025Financings

    Prelude Therapeutics signs Incyte option deal, to get $35 million cash and $25 million stock sale

    Prelude Therapeutics gave Incyte an option on its preclinical JAK2V617F JH2 inhibitor program for a $35 million cash payment, plus a $25 million stock purchase. Exercising the option would cost Incyte $100 million, and the company is pausing a separate SMARCA2 degrader program.

    PRLD
44. Nov 4, 2025Mergers

    Absci and Totient sellers agree final milestone payout under 2021 merger agreement

    A letter agreement dated October 31, 2025 settles all potential milestone payments from Absci's 2021 Totient deal. Former Totient stockholders get about $7.6 million, and Absci gets about $8.7 million.

    ABSI
45. Nov 3, 2025Distress

    TScan Therapeutics cuts about 30% of workforce, 66 roles, to extend cash runway

    TScan expects annual cost savings of $45.0 million in 2026 and 2027 and a one-time charge of up to approximately $2.3 million. It says its cash runway now extends into the second half of 2027.

    TCRX
46. Nov 3, 2025Debt Financing

    Kyverna signs Oxford Finance loan facility of up to $150.0 million, expects to draw $25.0 million

    Kyverna signed a loan facility of up to $150.0 million with Oxford Finance and drew $25.0 million at closing, secured by substantially all of its assets. The company says its runway still runs into 2027, the same guidance it gave before the loan.

    KYTX
47. Nov 3, 2025Distress

    Gelteq files late notice for 20-F, says it needs more time on financials

    The company expects to file its annual report for the year ended June 30, 2025 within the fifteen-day grace period.

    GELS
48. Nov 3, 2025Financings

    CytoDyn secures $30 million stock purchase commitment from Yorkville Advisors Global

    CytoDyn can sell up to $30 million of common stock to Yorkville Advisors Global over 36 months, at its own discretion and with no warrants attached. The release names no placement agent or counsel, and the annual report says the company will pursue non-dilutive financing in addition to traditional fundraising.

    CYDY
49. Nov 3, 2025Financings

    Ardelyx files automatic shelf with $100,000,000 ATM sales agreement supplement

    Jefferies LLC is the sales agent for up to $100,000,000 of common stock. A second Jefferies program, dated January 18, 2023, may still sell up to approximately $80.0 million.

    ARDX

October 2025

1. Oct 31, 2025Distress

   Kazia Therapeutics says 20-F is late as audit procedures are not complete

   The company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date.

   KZIA
2. Oct 31, 2025Mergers

   Calidi Biotherapeutics sells 75% Nova Cell stake for $6,000,000, mostly deferred and contingent

   Nova Cell pays by cancelling a net $1,214,864 of debt Calidi owed it, plus $4,785,136 of deferred, contingent consideration. Nova Cell is no longer a subsidiary, and the company expects $0.5 million a year in expense cuts.

   CLDI
3. Oct 31, 2025Financings

   Alterity reports A$54.56M cash after A$20M placement in the quarter

   Operating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds.

   ATH
4. Oct 31, 2025Financings

   4D Molecular Therapeutics licenses 4D-150 to Otsuka in Asia-Pacific deal with $85 million upfront

   4D Molecular Therapeutics agreed on October 31, 2025 to license 4D-150 to Otsuka for Asia-Pacific markets in exchange for an $85 million upfront payment. The company keeps leading global Phase 3 work, and Otsuka's expected cost sharing is at least $50 million over three years.

   FDMT
5. Oct 30, 2025Listings

   Lunai Bioworks gets Nasdaq deficiency notice on $35 million market value requirement

   Lunai Bioworks received a Nasdaq notice that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days. It has until April 27, 2026 to regain compliance, and the company says the notice has no immediate effect on trading.

   LNAI
6. Oct 29, 2025Financings

   Savara prices $130.0 million stock offering at $4.20 per share

   Savara priced 23,809,524 shares at $4.20, below the $4.41 last sale price, and pre-funded warrants for 7,142,857 more. Jefferies, Piper Sandler and Guggenheim Securities are joint book-running managers, and Polsinelli PC is the company's counsel.

   SVRA
7. Oct 28, 2025Financings

   MapLight IPO closes; additional-share option brings gross proceeds to $288.4 million

   MapLight Therapeutics closed its initial public offering at $17.00 a share, and the underwriters exercised their option for more shares in full. Its lead drug has no Phase 2 results yet.

   MPLTGS
8. Oct 24, 2025Mergers

   Biofrontera Inc. closes purchase of U.S. Ameluz and RhodoLED rights, sells $2.5 million preferred

   Biofrontera Inc. closed its purchase of U.S. rights to Ameluz and RhodoLED from its former parent on October 24, 2025, paying an earnout of 12% or 15% of Ameluz revenue. The same day it closed a $2.5 million second tranche of Series C preferred, and the company says that closing and the deal together keep it above Nasdaq's equity requirement.

   BFRI
9. Oct 23, 2025Listings

   Enveric Biosciences gets Nasdaq delisting notice, sets 1-for-12 reverse split

   Nasdaq said Enveric's stock closed below $1.00 for 30 consecutive trading days and the company has no compliance period. It plans to request a hearing and will split its shares 1-for-12 on October 28, 2025.

   ENVB
10. Oct 22, 2025Financings

    Minerva Neurosciences agrees to $80 million private placement, up to $200 million with warrants

    Vivo Capital LLC led the deal, which brings $80 million upfront in Series A preferred stock. The rest comes from two warrant tranches, and the larger one is tied to a Phase 3 roluperidone trial meeting its primary endpoint.

    NERV
11. Oct 22, 2025Mergers

    Alkermes agrees to buy Avadel for $18.50 a share plus CVR, with JPMorgan bridge loan

    Alkermes offers $18.50 a share in cash, plus a CVR that pays only if two conditions are met by December 31, 2028. The deal is funded with cash and a JPMorgan bridge loan, and it has not closed.

    ALKS
12. Oct 21, 2025Listings

    Oragenics regains NYSE American equity compliance, settles Ladenburg fee claim for $700,000

    NYSE American told Oragenics on October 20, 2025 that it again meets stockholders' equity standards. The company also paid Ladenburg Thalmann $700,000 to settle a dispute over a $2,500,000 fee claim.

    OGEN
13. Oct 21, 2025Distress

    Alector cuts workforce by about 49% after latozinemab Phase 3 trial misses endpoint

    Alector expects $7.7 million in restructuring charges and reports a preliminary $291.1 million in cash and short-term investments at September 30, 2025. Its head of research and development is resigning.

    ALEC
14. Oct 20, 2025Financings

    Keros Therapeutics starts tender offer for up to 10,950,165 shares at $17.75

    Keros Therapeutics, Inc. offers to buy back its stock for cash, for up to $194.4 million in total. The Schedule TO was filed October 20, 2025.

    KROS
15. Oct 20, 2025Mergers

    BioNTech opens exchange offer for CureVac with 15,061,575 new ADSs registered

    BioNTech's offer documents register 15,061,575 new ADSs for CureVac shares, with the exchange ratio set by a $5.4641 formula and a collar. The offer opens October 21, 2025, and BioNTech's unaudited first-half figures show a net loss of €802.4 million.

    BNTX
16. Oct 17, 2025Financings

    Medicus Pharma sells 1,088,048 shares to Yorkville under standby equity purchase agreement

    Medicus Pharma (Nasdaq: MDCX) sold shares in eight transactions between September 8 and October 16, 2025 for approximate aggregate consideration of $2,526,364. It used part to prepay a Yorkville debenture.

    MDCX
17. Oct 17, 2025Financings

    Lexeo Therapeutics prices public offering at $8.00 a share, plus $10 million private placement

    Lexeo agrees to sell 15,625,000 shares for expected gross proceeds of approximately $125 million. A concurrent private placement of pre-funded warrants is expected to bring approximately $10 million.

    LXEO
18. Oct 17, 2025Listings

    Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting

    Nasdaq says Aspire's shares face delisting for missing the $50,000,000 market value rule and the $1.00 bid price rule. The company paid $20,000 to request a hearing, and its 2024 audit carried going-concern doubt.

    ASBP
19. Oct 16, 2025Listings

    Kura Oncology files amended 2023 Inducement Option Plan with 3,250,000-share reserve

    The plan was amended by the board on October 15, 2025 and is filed as an exhibit. It is built around Nasdaq's inducement-grant exemption from shareholder approval.

    KURA
20. Oct 16, 2025Listings

    HCW Biologics wins Nasdaq panel extension to meet equity rule by December 31, 2025

    A Nasdaq Hearings Panel granted HCW Biologics (Nasdaq: HCWB) continued listing on October 13, 2025. The company must show compliance with the Equity Rule by December 31, 2025 and with all other rules by February 16, 2026.

    HCWB
21. Oct 16, 2025Financings

    C4 Therapeutics prices stock and warrant offering at $2.47, expects $117.0 million net

    Each share or pre-funded warrant comes with two warrant classes, each covering 50,608,500 shares at $2.22. C4 says the net proceeds would extend its cash runway to the end of 2028, and the larger $341.7 million figure assumes every warrant is exercised for cash.

    CCCC
22. Oct 15, 2025Financings

    Quoin closes $16.6 million private placement, warrants could add up to $88.0 million

    Quoin sold ADSs and pre-funded warrants with four series of warrants whose cash exercise depends on FDA and trial events that the filings do not report as having happened. Maxim Group LLC was the exclusive placement agent, and director Dennis Langer took part.

    QNRX
23. Oct 15, 2025Mergers

    Keros agrees to buy back ADAR1 and Pontifax shares at $17.75, plans tender offer

    The repurchases are part of a $375 million capital return program. Keros also plans to share 25% of certain net cash from its Takeda license with stockholders.

    KROS
24. Oct 15, 2025Mergers

    Keros Therapeutics to repurchase 10,176,595 shares for about $181 million, plans tender offer

    Keros Therapeutics agreed on October 15, 2025 to buy 10,176,595 shares from two investors for about $181 million at $17.75 each, and plans a tender offer for up to $194 million at the same price. Two directors resigned under the Pontifax agreement, and the company's preliminary cash figure of about $693.5 million is unaudited.

    KROS
25. Oct 14, 2025Debt Financing

    Karyopharm closes recapitalization with 9.00% convertible notes and $12.5 million loan draw

    Karyopharm closed a recapitalization on October 10, 2025 that borrowed $12.5 million under its term loan, issued $15.0 million of 9.00% notes due 2028 and $103.5 million of 9.00% notes due 2029, and exchanged $100.978 million of older notes. Lenders also waived specified defaults under the loan.

    KPTI
26. Oct 14, 2025Debt Financing

    Candel signs Trinity Capital term loan of up to $130.0 million, draws $50.0 million

    Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million.

    CADL
27. Oct 14, 2025Legal

    Allogene discloses Factor Bioscience patent suit against licensor Cellectis; it is not a party

    Factor Bioscience sued Cellectis and AstraZeneca in Delaware federal court on Sept 26, 2025, over TALEN gene-editing technology. Allogene is not a party, but it licenses that technology from Cellectis and says Factor may still sue it directly.

    ALLO
28. Oct 10, 2025Financings

    Xenetic Biosciences prices $4.5 million offering of 735,000 shares at $6.12

    Canaccord Genuity is sole bookrunner. Xenetic plans to use net proceeds for working capital and general corporate purposes.

    XBIO
29. Oct 10, 2025Financings

    Cellectar Biosciences raises about $5.8 million from warrant inducement deal

    Holders exercised warrants for 1,048,094 shares at $5.25 and received new warrants at $6.00. Cellectar says cash should last into the third quarter of 2026.

    CLRB
30. Oct 10, 2025Financings

    Cellectar Biosciences gets about $5.8 million gross from warrant inducement, issues new warrants

    Holders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026.

    CLRB
31. Oct 9, 2025Financings

    MindWalk authorizes buyback of up to 2.3 million shares

    The twelve-month program starts October 15, 2025. The company says it represents approximately 5% of the 46,154,188 common shares outstanding.

    HYFT
32. Oct 9, 2025Financings

    Alzamend Neuro issues 361,743 shares on conversion of Series B preferred stock

    The shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025.

    ALZN
33. Oct 9, 2025Financings

    Agenus takes up to $10,000,000 loan from Zydus, pledges 822,910 MiNK shares

    The note bears interest at 3.81% a year and is tied to the closing of an asset and stock purchase deal the companies signed on June 3, 2025.

    AGENINKT
34. Oct 8, 2025Financings

    Zenas BioPharma licenses orelabrutinib from InnoCare, announces $120.0 million placement

    Zenas gains global rights to the BTK inhibitor outside oncology plus two early autoimmune drugs. It also registered an at-the-market program for up to $200,000,000 of stock with Jefferies.

    ZBIO
35. Oct 8, 2025Mergers

    TransCode agrees to buy Polynoma and sell CK Life Sciences $25 million of preferred stock

    After the deal, CK Life Sciences would hold about 91% of TransCode on a fully diluted basis, and existing holders about 9%. Converting the preferred stock needs stockholder approval where Nasdaq rules apply, and up to $95 million in milestones may go to CK Life Sciences.

    RNAZ
36. Oct 8, 2025Financings

    Spruce Biosciences agrees to $50.0 million private placement at $68.00 a share

    Institutional investors are buying 502,181 shares at $68.00 and pre-funded warrants for 233,144 more, for expected gross proceeds of about $50.0 million. The 8-K contains no clinical data for tralesinidase alfa, the program Spruce plans to file in the first quarter of 2026.

    SPRB
37. Oct 8, 2025Financings

    LENZ Therapeutics sells 1,748,634 shares at $45.75 in $80,000,000 block trade

    The sale to a single investor was made under the company's at-the-market agreement with TD Securities (USA) LLC. LENZ reported the 1,748,634 shares sold at $45.75 in an 8-K filed October 8, 2025.

    LENZ
38. Oct 8, 2025Financings

    Karyopharm agrees debt and equity deals it says give $100 million of flexibility

    The deals combine new loans and notes, payment deferrals, debt-for-equity exchanges and a private placement of about $8.75 million. Karyopharm expects about $36 million of gross proceeds and a cash runway into the second quarter of 2026.

    KPTI
39. Oct 7, 2025Financings

    Jade Biosciences agrees to $135 million private placement at $9.14 per share

    Jade Biosciences agreed to a PIPE financing of about $135 million at $9.14 per share, with Jefferies, TD Cowen, Stifel and Wedbush named as placement agents, and says its cash will fund operations into the first half of 2028.

    JBIO
40. Oct 7, 2025Financings

    Humacyte prices $60.0 million registered direct offering of stock and warrants

    Humacyte is selling 28,436,018 shares, with warrants for the same number of shares, at $2.11 per share and warrant. The release does not say how the proceeds will be used.

    HUMA
41. Oct 7, 2025Mergers

    Elutia closes CIED business sale to Boston Scientific, puts $8 million in escrow, repays SWK loan

    The sale closed October 1, 2025 for $88 million in cash, with $8 million held in escrow. Elutia used about $27.8 million to repay SWK Funding debt, and its 2024 annual report carried a going-concern warning after a net loss of $53.9 million.

    ELUT
42. Oct 7, 2025Mergers

    Elutia closes $88 million sale of BioEnvelope business to Boston Scientific

    Elutia sold its EluPro and CanGaroo bioenvelopes for cash. It plans to bring its NXT-41x breast reconstruction product to market in the first half of 2027.

    ELUTBSX
43. Oct 7, 2025Listings

    Adicet Bio gets until April 6, 2026 to meet Nasdaq bid price rule, moves listing

    Nasdaq granted Adicet Bio an additional 180 calendar days. The stock moves from the Nasdaq Global Market to the Nasdaq Capital Market on October 9, 2025.

    ACET
44. Oct 6, 2025Listings

    Werewolf Therapeutics breaks Nasdaq audit committee rule after director dies

    The death of director Dr. Alon Lazarus on September 30, 2025 left Werewolf's audit committee with two members, one short of Nasdaq's three-member minimum. The company plans to appoint an independent director at its earliest opportunity.

    HOWL
45. Oct 6, 2025Listings

    Salarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq minimum

    Salarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The figure is preliminary, and Nasdaq has not yet confirmed compliance.

    DCOY
46. Oct 6, 2025Listings

    Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock

    The Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security.

    ZVSA
47. Oct 6, 2025Mergers

    Entero Therapeutics (now GridAI Technologies) acquires GRID AI, whose holders get 82.5%

    GRID AI's former shareholders would own about 82.5% of Entero's fully diluted common stock, subject to shareholder approval, and could name two directors at closing.

    GRDX
48. Oct 6, 2025Financings

    Biomea Fusion prices $24,999,898 offering of stock and warrants at $2.05

    Biomea Fusion is issuing 11,195,121 shares and 1,000,000 pre-funded warrants under an October 6, 2025 prospectus supplement, for $24,999,898 before discounts. Jefferies is book-running manager and H.C. Wainwright & Co., LLC is lead manager.

    BMEA
49. Oct 3, 2025Listings

    Xilio Therapeutics moves to Nasdaq Capital Market, gets until March 30, 2026 on bid price

    Xilio moved its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market after missing the $1.00 minimum bid price. The move does not cure the bid price problem, and the company's March annual report carried a going-concern warning.

    XLO
50. Oct 3, 2025Listings

    Xilio Therapeutics moves to Nasdaq Capital Market, gets 180 more days on $1.00 bid rule

    Nasdaq approved the transfer from the Global Select Market effective October 6, 2025. Xilio now has until March 30, 2026 to regain compliance with the minimum bid price rule.

    XLO
51. Oct 3, 2025Financings

    Ovid Therapeutics agrees to PIPE financing with $80.8 million in initial gross proceeds

    Ovid Therapeutics agreed to a private placement of convertible preferred stock and warrants with initial gross proceeds of about $80.8 million and up to $175.1 million in total. The preferred cannot convert until stockholders approve more shares, and the same day the company reported Phase 1 data from 68 healthy volunteers, with the CEO among the investors.

    OVID
52. Oct 3, 2025Financings

    Onconetix sells convertible preferred and warrants for approximately $6.25 million

    Institutional investors bought 7,813 shares of Series E convertible preferred stock and warrants for 2,025,223 common shares. The preferred converts at $3.8576.

    ONCO
53. Oct 3, 2025Financings

    Microbot Medical holder exercises 600,000 options at $2.10 and gets Series J options

    Under a September 14, 2025 inducement agreement, a holder exercised 600,000 series H options and received 600,000 series J options. A separate exercise of 374,167 options produced gross proceeds of approximately $896,000.

    MBOT
54. Oct 3, 2025Mergers

    Halozyme signs merger agreement to acquire Elektrofi for $750 million in cash upfront

    Halozyme could also owe up to three $50 million milestone payments tied to product regulatory approvals. Closing requires the Hart-Scott-Rodino waiting period to expire or end, and a $36 million reverse termination fee applies in certain cases.

    HALO
55. Oct 3, 2025Listings

    Azitra gets NYSE American notice over minimum stockholders' equity requirement

    NYSE American told Azitra on October 1, 2025 that its stockholders' equity of $2.2 million is below the $4.0 million required. The company has until October 31, 2025 to submit a plan, with compliance due by April 1, 2027. Its 2024 annual report carried a going-concern warning.

    AZTR
56. Oct 3, 2025Listings

    Azitra gets NYSE American notice over $4 million stockholders' equity standard

    NYSE American says Azitra is below its $4 million stockholders' equity standard, and the company has until October 31, 2025 to file a plan to restore compliance.

    AZTR
57. Oct 3, 2025Listings

    Abpro Holdings faces Nasdaq delisting after missing $1.00 bid price deadline

    Nasdaq told Abpro on September 30, 2025 that it had not regained compliance with the $1.00 minimum bid price. The company says it will ask an appeal panel for a hearing, which would stay the suspension, but the filing gives no assurance the panel will grant it more time.

    ABPO
58. Oct 2, 2025Distress

    Theriva Biologics cuts 32% of workforce, expects cash runway into second quarter of 2026

    Theriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024.

    TOVX
59. Oct 2, 2025Distress

    Bolt Biotherapeutics cuts workforce by about 50% and extends cash runway into 2027

    Bolt will cut about 20 employees, roughly 50% of its workforce, with pre-tax charges of $1.5 million to $2.0 million. The company says the cut extends its cash runway into 2027. Initial BDC-4182 clinical data, now expected in the third quarter of 2026, will come later after a protocol change.

    BOLT
60. Oct 2, 2025Listings

    BioCardia regains compliance with Nasdaq equity rule

    Nasdaq staff told BioCardia in writing that it again meets the Equity Rule, but the 8-K gives no equity figure and does not say how the gap was closed.

    BCDA
61. Oct 1, 2025Distress

    KALA BIO receives Oxford Finance default notice, lender declares $29.1 million loan due

    Oxford Finance says an event of default under a Material Adverse Change clause is continuing and has accelerated all obligations under the 2021 loan agreement. The notice says interest began accruing at the Default Rate, and that $29.1 million is now payable.

    KALA
62. Oct 1, 2025Financings

    Jaguar Health agrees to sell shares and pre-funded warrants to Brown Stone at $1.56

    Jaguar agreed to sell 161,583 shares and 479,442 pre-funded warrants at $1.56 to Brown Stone Capital Limited. Two days later it issued 286,532 shares to cut a royalty balance by $600,000.

    JAGX

September 2025

1. Sep 30, 2025Mergers

   MIRA Pharmaceuticals closes SKNY acquisition in all-stock deal

   SKNY contributed $5 million in marketable securities to MIRA as a closing condition. MIRA says it believes it has regained compliance with Nasdaq's $2,500,000 equity rule, but the filing gives no share count for the deal.

   MIRA
2. Sep 30, 2025Financings

   Enanta launches $50,000,000 stock offering, later prices $65,000,000

   The preliminary filing left price and share count blank. The final prospectus supplement, dated September 30, 2025, priced 6,500,000 shares at $10.00, with $61,100,000 going to the company before expenses.

   ENTA
3. Sep 30, 2025Financings

   Edesa Biotech amends Canada funding deal, first repayment moves to 2032

   Edesa and the Government of Canada amended a contribution agreement worth up to CAD $23 million ($17 million USD) in partially repayable funding. Repayment would begin only if the company earns gross revenue.

   EDSA
4. Sep 30, 2025Financings

   Artelo Biosciences prices $1,999,984.67 offering at $4.40 a share

   R.F. Lafferty & Co., Inc. is the sole book-running manager. The filing also cuts the company's at-the-market program to $0 after it sold all the remaining stock under it.

   ARTL
5. Sep 30, 2025Financings

   Alpha Cognition prices $34,999,052 public offering of shares at $6.25

   Alpha Cognition priced 4,651,516 common shares and pre-funded warrants for 948,484 shares at $6.25 and $6.249, for a total of $34,999,052 before fees. Titan Partners Group is the sole bookrunner, and the company says the money will fund a sales push for ZUNVEYL.

   ACOG
6. Sep 29, 2025Distress

   Sutro Biopharma plans to cut workforce by about one-third, expects cash runway into mid-2027

   Sutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs.

   STRO
7. Sep 29, 2025Distress

   KALA BIO to cut 51% of workforce, ends KPI-012 after Phase 2b trial misses endpoint

   KALA BIO will stop developing KPI-012 and its stem cell secretome platform, cut approximately 19 employees and talk with its secured lender while it explores strategic options.

   KALA
8. Sep 29, 2025Listings

   Estrella Immunopharma regains Nasdaq compliance on bid price and market value rules

   Nasdaq sent two letters on September 23, 2025 closing both matters. The company had been notified of the deficiencies in April and August.

   ESLA
9. Sep 29, 2025Listings

   Bon Natural Life's interim results reflect 1-for-25 share consolidation and offering

   Bon Natural Life's unaudited interim statements for the six months to March 31, 2025, filed in a Form 6-K on September 29, 2025, reflect a 1-for-25 share consolidation and net proceeds of $10,543,805 from a public offering of Class A ordinary shares. Cash rose from $80,466 to $8,894,053 over the period.

   BON
10. Sep 26, 2025Listings

    Tevogen Bio Holdings Inc. (now Tevogen Inc.) gets Nasdaq minimum bid price notice

    Nasdaq told Tevogen Bio Holdings on September 23, 2025 that its shares had closed below $1.00 for 30 consecutive business days, giving it until March 23, 2026 to regain compliance. Its 2024 annual report said the company was relying on $8.0 million of grant funding it had not yet received.

    TVGN
11. Sep 26, 2025Financings

    Q/C Technologies, formerly TNF Pharmaceuticals, starts trading as QCLS

    The former TNF Pharmaceuticals began trading on Nasdaq as QCLS on September 26, 2025, under a new name tied to a licensed laser computing technology. The filing does not state how much the September private placement raised.

    QCLS
12. Sep 26, 2025Listings

    Longeveron gets Nasdaq notice for trading below the $1.00 minimum bid price

    The company has until March 23, 2026 to bring its Class A common stock back above the threshold. The notice has no immediate effect on its listing.

    LGVN
13. Sep 26, 2025Listings

    Longeveron gets Nasdaq minimum bid price notice, has until March 23, 2026 to regain compliance

    Nasdaq notified Longeveron (LGVN) on September 22, 2025 that its Class A common stock missed the $1.00 minimum bid price. The notice does not cause immediate delisting; a second 180-day period may be available.

    LGVN
14. Sep 26, 2025Debt Financing

    Journey Medical extends SWK term loan maturity to June 2028 in credit agreement amendment

    Journey Medical's $25.0 million SWK term loan now matures June 27, 2028. Principal repayments start in February 2026 unless trailing revenue tops $60.0 million at December 31, 2025.

    DERM
15. Sep 26, 2025Financings

    Fractyl Health prices $60 million stock offering at $1.00 per share

    Fractyl is selling 60,000,000 shares through BofA Securities, Evercore ISI and Ladenburg Thalmann, after a $1.05 raise in August. The prospectus supplement carries going-concern language.

    GUTS
16. Sep 26, 2025Listings

    Adaptimmune gets Nasdaq panel exception until December 1, 2025, to fix bid price

    A Nasdaq Hearings Panel gave Adaptimmune until December 1, 2025 to meet the $1.00 minimum bid price, or its American Depositary Shares will be delisted. The 8-K gives no share price and no count of days below the floor.

    ADAPY
17. Sep 26, 2025Financings

    ANI Pharmaceuticals forces conversion of last Series A preferred into 482,320 common shares

    ANI mandatorily converted the last 20,000 preferred shares into 482,320 common shares on September 26, 2025. The filing reports no cash proceeds, and no preferred shares remain outstanding.

    ANIP
18. Sep 25, 2025Listings

    Silexion Therapeutics regains Nasdaq equity and bid-price compliance

    Nasdaq's September 23, 2025 letter confirmed that Silexion meets its $2.5 million shareholders' equity rule and its $1.00 bid-price rule. The company is now under a mandatory panel monitor until September 23, 2026, and one more equity failure in that period would lead to a delisting determination.

    SLXN
19. Sep 25, 2025Financings

    Alzamend Neuro issues 300,000 shares on conversion of Series B preferred stock

    Between September 17 and September 25, 2025, 696 shares of Series B Convertible Preferred Stock converted into common stock. Alzamend had 3,439,861 common shares outstanding as of September 25, 2025.

    ALZN
20. Sep 24, 2025Debt Financing

    uniQure amends Hercules term loan and draws $50 million to refinance debt

    uniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130.

    QURE
21. Sep 24, 2025Financings

    PepGen prices $100,000,000 public offering of 31,250,000 shares at $3.200

    PepGen priced 31,250,000 shares at $3.200 for gross proceeds of $100,000,000, a price above the $2.66 close the filings report for September 24, 2025. The company says the proceeds plus its existing cash will not be enough to finish development of any product candidate.

    PEPG
22. Sep 24, 2025Financings

    Immuneering prices offering at $9.23 a share; Sanofi unit to buy $25.0 million

    Immuneering is selling 18,959,914 shares at $9.23 and expects about $164.1 million in net proceeds, plus about $23.3 million from a Sanofi unit. The company's 2024 audit report carried a going-concern paragraph.

    IMRX
23. Sep 24, 2025Financings

    Curanex repays $400,000 in loans from its CEO's wife weeks after its IPO

    Curanex paid $408,537.32 on two notes held by its secretary, Dian Ying Jing, the wife of its chief executive. The payments came on September 23 and 24, 2025, well before the notes matured in 2027.

    CURX
24. Sep 24, 2025Listings

    BioCardia believes it regained Nasdaq stockholders' equity compliance after stock sales

    BioCardia says its stockholders' equity exceeds the $2.5 million Nasdaq minimum after two private placements, an offering with net proceeds of about $5.1 million and at-the-market sales. Nasdaq will keep monitoring the company.

    BCDA
25. Sep 22, 2025Financings

    Oruka Therapeutics announces $180 million private placement led by Viking Global

    The company is selling 10,933,405 shares at $15.00 and pre-funded warrants for 1,066,666 more. Closing was expected on or about September 19, 2025.

    ORKA
26. Sep 22, 2025Financings

    MBX Biosciences files for 10,000,000-share offering, later sells 11,108,055 at $18.00

    MBX Biosciences filed an S-1 on September 22, 2025 for 10,000,000 shares. The deal priced on September 24 at $18.00 for 11,108,055 shares and closed on September 26 with net proceeds of about $187.5 million.

    MBX
27. Sep 22, 2025Debt Financing

    Cytokinetics issues $750.0 million of 1.75% convertible senior notes due 2031

    Cytokinetics issued $750.0 million of 1.75% convertible senior notes due 2031 on September 19, 2025, and expects to spend about $402.5 million of the net proceeds on the cash side of exchanges for its 2027 notes. The notes convert at about $68.42 a share. Neither the 8-K nor the release gives the company's cash balance.

    CYTK
28. Sep 22, 2025Listings

    BioAtla wins Nasdaq panel extension with deadlines to fix price and equity gaps

    A Nasdaq hearing panel let BioAtla stay listed on conditions: a transfer to the Nasdaq Capital Market by September 26, 2025, equity compliance by December 31, 2025 and bid price compliance by February 2, 2026.

    BCAB
29. Sep 22, 2025Financings

    Allarity Therapeutics agrees to $2.5 million private placement, with $7.5 million option

    The buyer gets 1,562,500 shares or pre-funded warrants at $1.60 and can add $7.5 million more within 90 days, at a price set by Nasdaq's minimum-price rule.

    ALLR
30. Sep 22, 2025Financings

    Allarity Therapeutics agrees to $2.5 million private placement of shares and pre-funded warrants

    Allarity agreed to sell 1,562,500 shares at $1.60 each, or pre-funded warrants, to one investor, closing September 23, 2025. The investor may buy $7.5 million more: within 90 days per the 8-K, 60 days per the purchase agreement.

    ALLR
31. Sep 19, 2025Listings

    Vaxart to be delisted from Nasdaq after missing hearings panel conditions

    Nasdaq told Vaxart on September 19, 2025 that its common stock will be delisted after the company withdrew a reverse stock split proposal that a hearings panel had made a condition of continued listing. Trading on Nasdaq was suspended on July 8, 2025.

    VXRT
32. Sep 19, 2025Financings

    Soligenix prices $7.5 million public offering of shares and warrants at $1.35

    The offering covers 5,555,560 shares or equivalents with matching five-year warrants. Soligenix also cut the exercise price on 1,162,064 older warrants to $1.35.

    SNGX
33. Sep 19, 2025Listings

    Prelude Therapeutics regains compliance with Nasdaq $1.00 minimum bid price rule

    Nasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice.

    PRLD
34. Sep 19, 2025Financings

    Longeveron sets up $10,700,000 at-the-market stock program with H.C. Wainwright

    The size is capped by SEC limits for companies with a public float under $75,000,000. Longeveron's stock last sold at $0.77 on September 18, 2025.

    LGVN
35. Sep 19, 2025Financings

    IGC Pharma files to sell up to $11,309,229 of stock at market

    IGC Pharma, Inc. set the amount under a $60,000,000 at-the-market sales agreement with A.G.P./Alliance Global Partners. The cap follows a rule that limits small companies to one-third of their public float.

    IGC
36. Sep 19, 2025Financings

    Equillium expands at-the-market stock program to up to $75,000,000

    Equillium's public float of about $93.7 million lifts it above Form S-3 sales limits. The company had sold $0.96 million of stock under the program so far, against the $21,950,000 covered by the earlier prospectus.

    EQ
37. Sep 18, 2025Listings

    Nasdaq to complete delisting of ZyVersa Therapeutics stock with Form 25 filing

    Nasdaq told ZyVersa it would announce the delisting on September 18, 2025. The shares have traded on the OTCQB Venture Market since July 28, 2025.

    ZVSA
38. Sep 18, 2025Debt Financing

    Medicus Pharma issues $8.0 million debenture to Yorkville fund

    The 8% debenture matures in twelve months and refinances about $1.7 million of earlier Yorkville debentures. Medicus expects net proceeds of approximately $5.7 million, and the lender can require repayment from part of any equity raise.

    MDCX
39. Sep 18, 2025Financings

    Jasper Therapeutics prices $30 million offering of stock and warrants

    Jasper priced 11,670,707 shares and 675,000 pre-funded warrants, each with a common warrant, at $2.43, for about $30 million before costs. The prospectus also discloses an unresolved trial investigation and a going concern warning.

    JSPR
40. Sep 17, 2025Distress

    X4 Pharmaceuticals cuts workforce by 50% in restructuring as four senior executives depart

    X4 is cutting about 50% of its workforce for annualized savings of about $13 million, with cash charges of about $3.3 million, after three executives were terminated and its chief medical officer resigned. Its 2024 annual report carried a going-concern warning tied to a loan covenant with Hercules.

    XFOR
41. Sep 17, 2025Distress

    Arvinas to cut about 15% of staff, seek vepdegestrant partner; approves $100 million buyback

    Arvinas said on September 17, 2025 that it will cut its workforce by a further 15%, mainly in vepdegestrant commercialization roles, and that it will seek a third party to take over the drug with Pfizer. The same day its board authorized a buyback of up to $100 million, and the filing does not give the cash balance on which that depends.

    ARVN
42. Sep 17, 2025Distress

    Arvinas cuts about 15% of staff, authorizes $100 million buyback

    The company and Pfizer have agreed to out-license vepdegestrant commercialization rights and have begun looking for a partner. Arvinas expects about $4.5 million in workforce costs.

    ARVN
43. Sep 17, 2025Listings

    AquaBounty regains compliance with Nasdaq $1.00 minimum bid price rule

    AquaBounty told the SEC on September 17, 2025 that Nasdaq closed its $1.00 bid price matter after a January 15, 2025 notice. The company no longer runs any salmon farm, and its 10-K puts 2024 impairments at $129.8 million.

    AQB
44. Sep 16, 2025Listings

    Relmada Therapeutics regains compliance with Nasdaq $1.00 bid price rule

    Relmada Therapeutics said on September 16, 2025 that Nasdaq confirmed in a September 15 notice that it has regained compliance with the $1.00 minimum bid price. The stock stays on the Nasdaq Capital Market under RLMD, but the company's lead drug failed in late 2024.

    RLMD
45. Sep 16, 2025Listings

    Ovid Therapeutics regains compliance with Nasdaq $1.00 bid price rule

    Nasdaq told Ovid on September 11, 2025 that it again meets the $1.00 minimum bid price, but the company's notice does not say how it got back above that level.

    OVID
46. Sep 16, 2025Listings

    Neuphoria Therapeutics gets Nasdaq extension to December 29, 2025 to hold annual meeting

    Nasdaq accepted Neuphoria's plan on September 10, 2025, after a July 18, 2025 notice that it had not held an annual meeting. The company has until December 29, 2025 and says it will file its Form 10-K on or before September 29, 2025.

    NEUP
47. Sep 16, 2025Financings

    Microbot Medical expects $25.2 million from first closing of option exercises

    A second closing should add about $4 million. New series J options could bring about $63 million more if fully exercised.

    MBOT
48. Sep 16, 2025Financings

    BioCardia files for best-efforts stock and warrant offering, later prices it at $1.25

    The September 16 registration covered up to 2,800,000 shares at an assumed $2.27. On September 18 the final prospectus sold 4,800,000 shares with warrants at $1.25, for $6,000,000.

    BCDA
49. Sep 16, 2025Listings

    Bio Green Med Solution preferred stock falls short of Nasdaq $1 million value rule

    Nasdaq says the 6% Convertible Exchangeable Preferred Stock has been below the $1 million minimum for publicly held shares for 30 consecutive business days. The company has until March 10, 2026 to regain compliance, and its 8-K does not say how it will get there.

    BGMS
50. Sep 15, 2025Financings

    Revelation Biosciences gets $9.6 million gross proceeds in warrant inducement deal

    Holders of 13,065,000 Class H warrants agreed to exercise at $2.20 per share and receive 13,065,000 new Class I warrants in a private placement. Roth Capital Partners advised.

    REVB
51. Sep 15, 2025Financings

    Revelation Biosciences agrees $9.6 million immediate warrant exercise

    Revelation Biosciences said on September 11, 2025 that holders will exercise warrants for up to 4,355,000 shares at $2.20 each, about $9.6 million in gross proceeds. In return they receive new Class I warrants for up to 13,065,000 shares, which cannot be exercised until stockholders approve them.

    REVB
52. Sep 12, 2025Listings

    VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq notice for sub-$1.00 stock

    VYNE Therapeutics, now Yarrow Bioscience, has until March 10, 2026 to lift its closing bid price back to at least $1.00 per share.

    YARW
53. Sep 12, 2025Listings

    VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq minimum bid price notice

    Nasdaq told the company on September 11, 2025 that its stock closed below $1.00 for 30 consecutive business days. It has until March 10, 2026 to regain compliance, and the Nasdaq Capital Market listing is unchanged for now.

    YARW
54. Sep 12, 2025Mergers

    Traws Pharma buys antiviral compound assets from related party Viriom for $2,350,000 cash

    Traws Pharma paid $2,350,000 in cash, in full, for assets tied to a pyrrolidine antiviral compound held by Viriom. The seller's executive chairman is Traws's own chief operating officer, and its 2024 annual report carries a going-concern warning.

    TRAW
55. Sep 12, 2025Mergers

    Traws Pharma buys antiviral assets from Viriom for $2,350,000 in related-party deal

    Traws Pharma paid $2,350,000 in cash for intellectual property and other assets from Viriom, a company tied to its chief operating officer. The board and audit committee approved the deal and called the price fair and reasonable.

    TRAW
56. Sep 12, 2025Financings

    Silexion Therapeutics prices $6.0 million offering at $4.00 per share and warrants

    Silexion priced a $6.0 million public offering at $4.00 per share and warrants, with H.C. Wainwright as exclusive placement agent. Its prospectus says cash was $3.5 million at June 30, 2025 and carries a going-concern warning.

    SLXN
57. Sep 12, 2025Listings

    Pluri regains Nasdaq audit committee compliance after naming independent director

    Nasdaq confirmed the matter is closed after Pluri elected Eitan Ajchenbaum as an independent director and Audit Committee chair. The gap began after the June 30, 2025 annual meeting.

    PLUR
58. Sep 12, 2025Mergers

    NRx Pharmaceuticals completes acquisition of Dura Medical clinics through HOPE unit

    NRx's subsidiary HOPE Therapeutics closed its purchase of Dura Medical, which runs two Florida clinics. The 8-K gives no purchase price, and part of the consideration is paid in later earn-outs and in interests that convert into HOPE shares.

    NRXP
59. Sep 12, 2025Financings

    LB Pharmaceuticals prices IPO of 19,000,000 shares at $15.00

    The offering totals $285,000,000, and the shares are approved for listing on Nasdaq under LBRX. Proceeds to the company are $265,050,000 before expenses, and the company's lead drug has a Phase 3 trial still ahead.

    LBRX
60. Sep 12, 2025Financings

    Curanex Pharmaceuticals raises $2,250,000 more as IPO underwriters exercise option

    Dominari Securities bought 562,500 more shares at the $4.00 IPO price. Total gross proceeds from the offering reached $17,250,000.

    CURX
61. Sep 12, 2025Financings

    Cocrystal Pharma prices $4.7 million direct offering at $1.70 per share

    The company agreed to sell 2,764,710 shares at $1.70 each, with warrants for up to 5,529,420 shares at $1.50 that could add approximately $8.3 million if fully exercised for cash. H.C. Wainwright & Co. is the placement agent.

    COCP
62. Sep 12, 2025Distress

    Benitec Biopharma says two quarterly financial reports should not be relied on, plans restatement

    Benitec's Audit Committee found share-based compensation expense was understated in the quarters ended December 31, 2024 and March 31, 2025. The company expects to file its 2025 annual report on time.

    BNTC
63. Sep 11, 2025Financings

    TuHURA Biosciences investors agree to buy $3.2 million of deferred stock now

    Four investors who could defer their purchases until December 31, 2025 agreed to buy now. In return, TuHURA extended warrants on 1.5 million shares to December 31, 2030.

    HURA
64. Sep 11, 2025Financings

    SELLAS Life Sciences expects $23.6 million gross from investor's warrant exercise

    SELLAS says an institutional investor will exercise January 2025 warrants for 19,685,040 shares, bringing about $23.6 million gross. The investor gets new unregistered warrants for the same number of shares at $1.88, so the dilution continues.

    SLS
65. Sep 11, 2025Mergers

    Bausch Health completes DURECT acquisition after tender offer draws about 62% of shares

    BHC Lyon accepted 19,984,767 DURECT shares and merged into DURECT on September 11, 2025. Holders get $1.75 per share in cash plus a contingent value right that pays only if net sales milestones are reached.

    BHC
66. Sep 10, 2025Financings

    Talphera raises about $17 million in private placement with CorMedix and investors

    Shares sold at $0.55 each. Investors other than CorMedix agreed to buy about $12 million more if the NEPHRO CRRT study meets its primary endpoint and the stock clears a price test.

    TLPH
67. Sep 10, 2025Debt Financing

    Celcuity upsizes term loan facility to $500 million with Innovatus and Oxford Finance

    Celcuity drew $30 million at closing, bringing the term loan to $130 million. The $170 million of new committed capital depends on FDA approval of gedatolisib or on commercial revenue milestones.

    CELC
68. Sep 10, 2025Financings

    CAMP4 Therapeutics signs private placement of up to $100 million, $50 million upfront

    Leerink Partners is lead placement agent for the $50 million upfront, with Piper Sandler & Co., Cantor Fitzgerald and Wedbush & Co. as co-placement agents. The second $50 million depends on milestones, including clearance to start a trial of CMP-SYNGAP-01.

    CAMP
69. Sep 10, 2025Financings

    Anixa Biosciences files $200,000,000 replacement shelf with $100,000,000 ATM

    Anixa Biosciences filed a $200,000,000 replacement shelf on September 10, 2025, with a $100,000,000 sales program through Cantor Fitzgerald & Co., because its current shelf expires on September 19, 2025 and its clinical programs are still in early trials.

    ANIX
70. Sep 9, 2025Financings

    Rein Therapeutics draws second $1.0 million advance from Yorkville

    Rein received net proceeds of $0.95 million from the $1.0 million second advance on September 8, 2025. Yorkville buys each advance at 95% of face value, charges 8% interest and can require repayment in stock.

    RNTX
71. Sep 9, 2025Listings

    OSR Holdings (now OSR Health) gets Nasdaq notice after 30 days below $1.00

    The company has until March 4, 2026 to regain compliance with the minimum bid price rule. Its shares keep trading on The Nasdaq Capital Market for now.

    OSRH
72. Sep 9, 2025Financings

    Actuate Therapeutics prices 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds

    Actuate Therapeutics priced 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds, below the $8.24 last sale price. Lucid Capital Markets is the sole underwriter, and the prospectus says the company's current liabilities exceeded its assets at June 30, 2025.

    ACTU
73. Sep 8, 2025Financings

    Rapport Therapeutics prices $250 million stock offering at $26.00 a share

    Rapport priced 9,615,385 shares at $26.00 the day after reporting Phase 2a epilepsy data for RAP-219, with net proceeds of about $234.7 million. The data came from 30 treated patients and were tested against fixed null rates, not a placebo group.

    RAPP
74. Sep 8, 2025Mergers

    Pharvaris signs registration rights agreement with General Atlantic PH B.V.

    Pharvaris agreed to file a resale shelf registration within 30 calendar days for General Atlantic PH B.V., and the investor decides when to sell, how and at what price. The company may postpone the shelf only once in any twelve months, and the filing does not say how many shares the investor holds.

    PHVS
75. Sep 8, 2025Financings

    NRx Pharmaceuticals says $8.8 million raise had no warrants or repricing terms

    The $8.8 million combines an August registered direct offering with at-the-market sales since July 1, 2025. The company says none of it carried warrants, repricing or variable-rate terms, but the filing gives no share count, price or investor names.

    NRXP
76. Sep 8, 2025Listings

    Coherus Oncology regains Nasdaq compliance with $1.00 minimum bid price rule

    Nasdaq closed the matter on September 5, 2025, ahead of the December 29, 2025 deadline the company had been given.

    CHRS
77. Sep 8, 2025Distress

    Abivax expects cash into Q4 2027 after $747.5 million gross offering

    Abivax reported a first-half net loss of EUR 100.8 million and negative shareholders' equity of EUR 48.3 million at June 30, 2025, before a July US offering and several note conversions. The company now says its cash lasts into the fourth quarter of 2027.

    ABVX
78. Sep 5, 2025Mergers

    PharmaCyte Biotech adds $3 million to its stake in TNF Pharmaceuticals

    PharmaCyte says the money is meant to support TNF's license of a light-based computing platform for cryptocurrency mining. TNF plans to change its name and ticker.

    PMCB
79. Sep 5, 2025Financings

    Optimi Health files for U.S. IPO and Nasdaq uplisting from Canadian exchange

    The British Columbia company plans a reverse share split and has applied to list on the Nasdaq Capital Market. Titan Partners Group is the sole bookrunner.

    OPTI
80. Sep 5, 2025Listings

    NuCana says Nasdaq confirmed compliance and closed its listing matter

    The company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance.

    NCNA
81. Sep 5, 2025Mergers

    FibroGen (now Kyntra Bio) completes $220 million China unit sale to AstraZeneca

    FibroGen used part of the proceeds to repay about $81 million of Morgan Stanley Tactical Value term loans. Pro forma total equity turns positive only with minority interests counted, while the stockholders' deficit attributable to FibroGen remains.

    KYNB
82. Sep 5, 2025Financings

    DBV Technologies sets up at-the-market program for up to $150 million of ADSs on Nasdaq

    DBV Technologies set up a $150 million at-the-market program for American Depositary Shares, sold through Citizens JMP Securities, LLC for a 3.0% commission. The prospectus supplement shows $3.86 per ADS of immediate dilution at a $9.18 reference price.

    DBV
83. Sep 4, 2025Listings

    Mesoblast signs option to issue up to US$50 million of convertible notes

    The notes carry a 5% coupon and convert at US$16.25 per ADR. Issuance depends on shareholder approval at the upcoming annual general meeting.

    MSB
84. Sep 4, 2025Listings

    Equillium regains compliance with Nasdaq's $1.00 minimum bid price rule

    Nasdaq notified the company on August 29, 2025. Its shares closed at $1.00 or more for at least 10 consecutive business days.

    EQ
85. Sep 4, 2025Financings

    Cyclacel (now Bio Green Med Solution) swaps Series C warrants for 559,395 shares

    Cyclacel Pharmaceuticals, now Bio Green Med Solution, agreed to exchange Series C warrants for 559,395 new common shares. The 8-K gives no exercise price and describes no cash payment.

    BGMS
86. Sep 4, 2025Listings

    CERo Therapeutics appeals Nasdaq delisting over $2,500,000 stockholders' equity rule

    Nasdaq staff set a September 8, 2025 delisting date. CERo requested a hearing on September 3, 2025, which stays the suspension, and plans to present a compliance plan.

    CERO
87. Sep 4, 2025Financings

    Bone Biologics expects cash to fund operations into second quarter of 2026

    Bone Biologics says its June offering raised $5 million gross and that it expects cash to fund operations into the second quarter of 2026, while enrollment in its pilot study is slower than planned.

    BBLG
88. Sep 4, 2025Distress

    AC Immune to cut about 30% of workforce, sees CHF 127.1 million lasting to Q3 2027

    The company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged.

    ACIU
89. Sep 3, 2025Debt Financing

    Precigen draws $100.0 million at closing of Pharmakon senior secured term loan facility

    Precigen entered a five-year senior secured loan agreement with funds managed by Pharmakon Advisors. A $25.0 million delayed draw tranche is available until June 29, 2027, and the loans mature September 3, 2030.

    PGEN
90. Sep 3, 2025Financings

    Nutriband reports $5.31 million from warrant exercises in six months to July 31

    Private investors exercised warrants for 778,041 shares and public holders for 47,076 shares. Employee options added $44,206.

    NTRB
91. Sep 3, 2025Listings

    Ironwood Pharmaceuticals regains compliance with Nasdaq $1.00 bid price rule

    Nasdaq told Ironwood on August 29, 2025 that the matter is closed. The company had received a deficiency notice on May 28, 2025.

    IRWD
92. Sep 3, 2025Listings

    Celularity regains Nasdaq compliance after filing two late quarterly reports

    Nasdaq told Celularity on September 2, 2025 that it complies with Listing Rule 5250(c)(1) again, after the company filed its Form 10-Q reports for the periods ended March 31 and June 30, 2025.

    CELU
93. Sep 3, 2025Listings

    Adial Pharmaceuticals gets 180-day Nasdaq extension on $1.00 bid price rule

    Adial Pharmaceuticals has until March 2, 2026 to hold its shares at $1.00 or more for ten consecutive business days. Its 10-K for 2024 said current cash would not cover the next twelve months, and its accumulated deficit reached $82.0 million.

    ADIL
94. Sep 2, 2025Financings

    vTv Therapeutics agrees to private placement of about $80 million

    vTv Therapeutics agreed on August 29, 2025 to sell 5,243,732 units for expected gross proceeds of about $80 million before offering expenses. Each unit carries a warrant exercisable at $22.71, and the placement was expected to close initially on September 3, 2025.

    VTVT
95. Sep 2, 2025Financings

    Zenas BioPharma signs royalty financing with Royalty Pharma for up to $300 million

    Zenas BioPharma sold Royalty Pharma a share of future obexelimab revenue for up to $300 million. It received $75 million at closing, and the other three $75 million payments depend on a Phase 3 milestone and two FDA approvals. The company says the cash lasts into the first quarter of 2027.

    ZBIORPRX
96. Sep 2, 2025Mergers

    Zenas BioPharma signs Royalty Pharma funding deal worth up to $300 million

    Royalty Pharma will pay $75 million upfront for a 5.5% royalty on worldwide net sales of obexelimab, with three more $75 million payments tied to milestones.

    ZBIORPRX
97. Sep 2, 2025Mergers

    Medicus Pharma completes Antev acquisition for about US$3.0 million cash and 1,603,164 shares

    Medicus closed its Antev deal on August 29, 2025 and could owe up to approximately $65 million more on milestones. It also sold 250,000 shares to Yorkville for approximately $490,535 and added Patrick J. Mahaffy to its board.

    MDCX
98. Sep 2, 2025Financings

    Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement

    Five accredited investors bought restricted stock under subscription agreements signed August 26, 2025 and August 29, 2025. No underwriters were used.

    MGRX
99. Sep 2, 2025Mergers

    CorMedix completes Melinta Therapeutics acquisition for $300 million in upfront consideration

    CorMedix paid $260 million in cash and $40 million in common shares to Melinta's owners. A contingent payment agreement adds up to $25 million tied to a rezafungin approval by June 30, 2029.

    CRMD
100. Sep 2, 2025Listings

     Context Therapeutics gets Nasdaq extension to February 23, 2026 on minimum bid price rule

     Nasdaq gave Context Therapeutics until February 23, 2026 to regain compliance with the $1.00 minimum bid price rule. The company says it may need a reverse stock split and cannot promise it will regain compliance.

     CNTX
101. Sep 2, 2025Listings

     Context Therapeutics gets 180 more days from Nasdaq to meet $1.00 bid price rule

     The new deadline is February 23, 2026. The company says a reverse stock split is an option if needed, and it gives no assurance it will regain compliance by then.

     CNTX

August 2025

1. Aug 29, 2025Listings

   Rallybio moves to Nasdaq Capital Market, gets 180 more days on bid price

   Rallybio moved its listing to the Nasdaq Capital Market on August 29, 2025 after missing its first bid-price deadline. It received 180 more days, to February 23, 2026, to bring its stock back to at least $1.00.

   RLYB
2. Aug 29, 2025Financings

   Purple Biotech files F-1 for ADS offering, later prices $6 million deal at $1.00

   The August filing assumed $2.22 per ADS. The September 4 pricing set a combined $1.00 with short-term warrants, for about $6 million of gross proceeds before fees.

   PPBT
3. Aug 29, 2025Financings

   Moleculin Biotech to raise up to $6.0 million through warrant inducement deal

   Holders will exercise warrants for 16,216,216 shares at $0.37. They get new Series F warrants for 64,864,864 shares at $0.55, pending shareholder approval.

   MBRX
4. Aug 29, 2025Listings

   Envoy Medical asks Nasdaq panel to review delisting determination on market value rule

   Nasdaq said Envoy did not regain compliance with its $35,000,000 market value of listed securities requirement. A hearing request filed August 29, 2025 stays any trading suspension.

   COCH
5. Aug 29, 2025Listings

   Enveric Biosciences gets Nasdaq stockholders' equity deficiency notice, plan due October 10, 2025

   Nasdaq says Enveric does not meet the $2,500,000 minimum stockholders' equity requirement. The company reported stockholders' equity of $2,184,769 in its latest 10-Q and has until October 10, 2025 to file a compliance plan.

   ENVB
6. Aug 29, 2025Listings

   Enveric Biosciences falls short of Nasdaq $2,500,000 stockholders' equity rule

   Nasdaq's deficiency letter came after the company reported stockholders' equity of $2,184,769 at June 30, 2025, below the $2,500,000 minimum for the Nasdaq Capital Market. Enveric has until October 10, 2025 to submit a plan to regain compliance.

   ENVB
7. Aug 29, 2025Listings

   Century Therapeutics gets 180 more days to meet Nasdaq bid price rule

   Nasdaq gave Century until February 23, 2026, to lift its closing bid price above $1.00, and moved its listing to the Nasdaq Capital Market. The company's own clinical data for its lead lymphoma program did not meet its bar for a transformational result.

   IPSC
8. Aug 28, 2025Listings

   Xilio Therapeutics gets Nasdaq notice over stockholders' equity below $10.0 million

   Nasdaq says Xilio reported stockholders' equity of $7,069,000 at June 30, 2025, below the $10.0 million minimum for the Global Select Market. The company has until October 6, 2025 to submit a plan, and it remains out of compliance with the $1.00 minimum bid price rule.

   XLO
9. Aug 28, 2025Financings

   Journey Medical sets up new at-the-market program for 3,750,000 shares

   Journey Medical signed an at-the-market sales agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC for up to 3,750,000 shares. It ended an older B. Riley program under which it had sold 4,121,318 shares.

   DERM
10. Aug 28, 2025Listings

    Imunon regains compliance with Nasdaq minimum bid price requirement

    Imunon (Nasdaq: IMNN) says the Nasdaq Hearings Panel notified it on August 27, 2025 that it meets the $1.00 minimum closing bid price. The stock will continue trading on the Nasdaq Capital Market.

    IMNN
11. Aug 28, 2025Listings

    Imunon regains Nasdaq minimum bid price compliance after hearings panel confirmation

    The Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent 15% stock dividend.

    IMNN
12. Aug 27, 2025Listings

    Veru regains compliance with Nasdaq minimum bid price rule

    A Nasdaq letter received August 26, 2025 says Veru has regained compliance with the $1.00 minimum bid price rule and that the matter is closed. Nasdaq first wrote to the company about the bid price on August 29, 2024.

    VERU
13. Aug 27, 2025Financings

    Grace Therapeutics NDA acceptance opens window on up to $7.6 million in warrants

    The FDA accepted the GTx-104 application on August 22, 2025, with an April 23, 2026 target date. Warrants from the September 2023 private placement, at $3.003 each, expire on the earlier of the 60th day after acceptance or September 25, 2028.

    GRCE
14. Aug 27, 2025Financings

    Curanex raises $15 million in IPO, then $2.25 million more from overallotment

    Curanex closed its initial public offering of 3,750,000 shares at $4.00 a share on August 27, 2025. Dominari Securities led the underwriters, and the proceeds are earmarked for Phyto-N, a lead drug candidate for ulcerative colitis.

    CURX
15. Aug 26, 2025Financings

    Shattuck Labs closes private placement of up to $103 million led by OrbiMed

    Shattuck says the placement could fund operations into 2029 if all warrants are exercised. Two new directors join the board, including OrbiMed's Mona Ashiya, and four directors leave.

    STTKIRON
16. Aug 26, 2025Listings

    Plus Therapeutics (now Cerenome) wins Nasdaq equity nod, more time on $1.00 bid rule

    Nasdaq confirmed compliance with both the $35 million market value standard and the $2.5 million equity standard. The bid price deadline moves to November 12, 2025.

    CNSY
17. Aug 26, 2025Distress

    Indivior PLC (now Indivior Pharmaceuticals, Inc.) expects $39 to $50 million restructuring charges

    Indivior says its Action Agenda initiative brings headcount reductions and real estate consolidations. It expects $27 million to $35 million of the charges to be cash and is exploring strategic alternatives for OPVEE and its non-U.S. business.

    INDV
18. Aug 26, 2025Mergers

    Evofem signs sixth amendment to Aditxt merger agreement

    Evofem's sixth amendment to its Aditxt merger agreement adds a new Series G-1 preferred stock to the deal and caps dissenting shares. Common holders share a total of $1,800,000, and the proxy says no fairness opinion was sought.

    EVFM
19. Aug 26, 2025Listings

    Cognition Therapeutics regains compliance with Nasdaq $1.00 bid price rule

    Nasdaq told Cognition Therapeutics on August 26, 2025 that the company again meets its listing requirements after the stock closed above $1.00 for more than ten trading days.

    CGTX
20. Aug 26, 2025Listings

    COSCIENS Biopharma files Form 25 to withdraw its shares from Nasdaq

    COSCIENS marked the voluntary withdrawal box on its Nasdaq Form 25. The form gives no reason, and the company's April 2025 annual report describes a failed Phase 3 trial and a shift to natural-based products.

    CSCI
21. Aug 26, 2025Financings

    Bright Minds Biosciences files $250,000,000 shelf with $100,000,000 ATM program

    Piper Sandler & Co. and Cantor Fitzgerald & Co. are the agents under an August 25, 2025 equity distribution agreement. The company's latest annual report shows cash used in operations of CAD 1.9 million for fiscal 2024.

    DRUG
22. Aug 26, 2025Listings

    BriaCell plans 1-for-10 share consolidation to meet Nasdaq listing rules

    BriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange.

    BCTBCTX
23. Aug 25, 2025Listings

    Liminatus Pharma gets Nasdaq deficiency notice over late Form 10-Q

    Liminatus Pharma (Nasdaq: LIMN) has until October 21, 2025 to submit a plan to regain compliance after the delayed filing of its report for the period ended June 30, 2025. The stock keeps trading for now.

    LIMN
24. Aug 25, 2025Listings

    Dermata Therapeutics regains Nasdaq compliance after hearing panel exception

    Nasdaq staff told Dermata on August 22, 2025 that the company again meets the $1.00 minimum bid price, which closes the matter. The company needed a hearing panel's exception to reach that point, and its 8-K gives no cash figure.

    DRMA
25. Aug 22, 2025Financings

    Protalix renews $20,000,000 at-the-market stock program with H.C. Wainwright

    About $15.7 million of stock remains available for sale after earlier sales of $4.3 million. The sales agent earns a 3.0% commission.

    PLX
26. Aug 22, 2025Financings

    Iovance restates Jefferies at-the-market deal, allowing sales up to $350.0 million

    Iovance may sell up to $350.0 million of stock through Jefferies, which can take up to 3.0% of gross proceeds. The company is not obliged to sell any shares, and its stock last traded at $2.60 on August 19, 2025.

    IOVA
27. Aug 22, 2025Listings

    Curis to appeal Nasdaq delisting after missing $35,000,000 market value rule

    Curis missed Nasdaq's $35 million market value rule and must ask for a hearing by August 28, 2025 to avoid delisting. It says it will ask, and its shares stay listed while a panel decides.

    CRIS
28. Aug 22, 2025Listings

    Curis gets Nasdaq delisting determination over market value rule, plans to appeal

    Nasdaq staff said Curis did not regain compliance with the $35,000,000 market value requirement by August 20, 2025. Curis must request a hearing by August 28, 2025; the request keeps its stock listed during the appeal.

    CRIS
29. Aug 21, 2025Financings

    Sarepta agrees to swap about $700.0 million of 2027 convertible notes, sell $20.0 million of stock

    Sarepta would swap about $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due 2030, about $123.3 million in cash and new shares. It also agreed to a $20.0 million private placement, with J. Wood Capital Advisors LLC as financial advisor and subscriber.

    SRPT
30. Aug 21, 2025Debt Financing

    Novavax agrees to issue $225.0 million of 4.625% convertible senior notes due 2031

    About $49.7 million of the new convertible notes would be sold for cash, and about $175.3 million would be exchanged for 2027 notes. The exchange gives Novavax no cash. The company expects to close on or about August 27, 2025.

    NVAX
31. Aug 21, 2025Listings

    Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule

    The new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed.

    ATOS
32. Aug 20, 2025Listings

    Windtree Therapeutics to be delisted by Nasdaq, shares move to OTC market

    Nasdaq will suspend trading in Windtree's common stock at the open on August 21, 2025. The company has applied for the OTCID tier.

    WINT
33. Aug 20, 2025Financings

    Invivyd prices offering of 74,811,404 shares at $0.52 each

    Invivyd sold 74,811,404 shares at $0.52 each and pre-funded warrants for up to 21,342,442 more shares, for a total public offering price of $49,997,865.68 before underwriting discounts.

    IVVD
34. Aug 20, 2025Financings

    I-Mab (now NovaBridge Biosciences) cites $61.2 million net from August offering

    Pro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients.

    NBP
35. Aug 20, 2025Listings

    Genprex gets second Nasdaq delisting basis over stockholders' equity, requests hearing

    Nasdaq says Genprex's equity of $1,391,195 is below the $2.5 million minimum, adding a second basis for delisting to an unresolved bid price failure. A hearing request has stayed any delisting for now.

    GNPX
36. Aug 20, 2025Legal

    Enanta files patent infringement suit against Pfizer over Paxlovid in EU Unified Patent Court

    Enanta Pharmaceuticals says it sued Pfizer Inc. and certain of its subsidiaries in the Unified Patent Court on Aug 20, 2025, alleging infringement of a European patent through Paxlovid sales. The claim is untested, and no hearing date is given.

    ENTA
37. Aug 19, 2025Listings

    HCW Biologics faces Nasdaq suspension over equity rule and plans to request a hearing

    Nasdaq says HCW Biologics was out of compliance with its equity rule on June 30, 2025. The shares would be suspended on August 28 unless the company asks for a hearing by August 26.

    HCWB
38. Aug 19, 2025Distress

    Evogene cuts 30% of workforce, reports $11.7 million cash and $18.71 million ICL sale

    Evogene is cutting 30% of its workforce and says an $18.71 million asset sale and a $4.4 million share program give it an 18-month runway. The $11.7 million cash figure leaves out the sale proceeds, and the company's equity attributable to shareholders is negative.

    EVGN
39. Aug 18, 2025Legal

    Unicycive discloses securities class action over oxylanthanum carbonate statements

    Unicycive said a securities class action was filed in the Northern District of California against the company and certain of its officers, who are not named. The suit concerns statements about its oxylanthanum carbonate application. The company calls the claims meritless.

    UNCY
40. Aug 18, 2025Financings

    Propanc Biopharma prices $4 million offering and moves to Nasdaq

    Propanc sold 1,000,000 shares at $4.00 each, while its prospectus carries a going-concern warning and reports $50,760 of cash on March 31, 2025. The stock left the OTC Pink market for the Nasdaq Capital Market.

    PPCB
41. Aug 18, 2025Financings

    PharmaCyte Biotech agrees $7.0 million convertible preferred private placement

    PharmaCyte agreed to sell 7,000 shares of Series C convertible preferred stock, with a $1,000 stated value each, to existing investors for $7.0 million. The preferred converts at $1.00 a share, against $4.00 for the 2023 Series B, and it carries a 7.0% quarterly dividend payable in cash.

    PMCB
42. Aug 18, 2025Listings

    Genprex gets second Nasdaq deficiency notice, with equity at $1,391,195

    Stockholders' equity of $1,391,195 at June 30, 2025 is below the $2.5 million minimum. Genprex has asked for a Nasdaq Hearings Panel hearing, which pauses any delisting while the process runs.

    GNPX
43. Aug 15, 2025Listings

    Soligenix gets Nasdaq notice for stockholders' equity below $2,500,000

    Soligenix reported stockholders' equity of $1,828,951 at June 30, 2025 and has until September 29, 2025 to submit a plan to regain compliance with the Nasdaq minimum.

    SNGX
44. Aug 15, 2025Listings

    Sol-Gel reports $24.2 million in cash, expects runway into early 2027

    Sol-Gel's second-quarter report shows $24.2 million in cash and securities at June 30, 2025, and net income of $11.6 million that came mostly from a one-time $16 million sale of U.S. product rights. The company's largest pipeline asset still has no results until the fourth quarter of 2026.

    SLGL
45. Aug 15, 2025Distress

    Sigyn Therapeutics delays quarterly report for period ended June 30, 2025

    Sigyn Therapeutics filed a Form 12b-25 notice on August 15, 2025 saying it cannot file its quarterly report for the period ended June 30, 2025 on time. It promises to file no later than five days after the original due date.

    SIGY
46. Aug 15, 2025Distress

    OS Therapies files NT 10-Q late filing notice for second quarter, cites financial close delays

    OS Therapies could not file its quarterly report for the period ended June 30, 2025 by its August 14, 2025 due date. Its last annual report carried an auditor's going concern warning and showed $5,533,527 of cash at the end of 2024.

    OSTX
47. Aug 15, 2025Distress

    OS Therapies delays quarterly report for period ended June 30, 2025

    OS Therapies says it needs more time to finish its financial statement close for the quarter ended June 30, 2025, and expects to file within the five-day extension.

    OSTX
48. Aug 15, 2025Distress

    Liminatus Pharma files late notice for quarterly report for June 30, 2025

    The company said its financial statements could not be completed in time for review and signatures. It checked the box saying it will file within the grace period.

    LIMN
49. Aug 15, 2025Mergers

    Heron Therapeutics adopts rights plan with 4.99% trigger to protect tax losses

    Heron's board adopted a Tax Benefit Preservation Plan on August 13, 2025. A holder that reaches 4.99% without board approval would trigger rights, and the company says it had about $1.37 billion of U.S. federal NOLs at December 31, 2024.

    HRTX
50. Aug 15, 2025Mergers

    Heron Therapeutics adopts rights plan to protect $1.37 billion of tax losses

    The plan, effective August 14, 2025, aims to deter any investor or group from reaching 4.99% of the common stock. The release gives no current taxable income, net loss or cash figure.

    HRTX
51. Aug 15, 2025Distress

    HCW Biologics delays quarterly report for period ended June 30, 2025

    HCW Biologics says it needs more time to finish its June quarter 10-Q and expects to file within the five-day grace period. The notice gives no revenue, loss or cash figures.

    HCWB
52. Aug 15, 2025Distress

    Cosmos Health files late notice for its June 30, 2025 quarterly report

    Cosmos Health said it could not finish its June 30, 2025 Form 10-Q on time, blaming delays in obtaining and compiling information, including its XBRL filing. It does not expect a significant change in results from a year earlier.

    COSM
53. Aug 15, 2025Distress

    Cingulate files NT 10-Q, citing management changes, for quarter ended June 30, 2025

    The company says it needs more time to review its financial statements after recent changes in management. It expects to file its Form 10-Q within the five calendar day period under Rule 12b-25.

    CING
54. Aug 15, 2025Distress

    Cingulate delays quarterly report after management changes

    Cingulate filed a late-filing notice for its report on the quarter ended June 30, 2025. It expects to file within the five-day extension period.

    CING
55. Aug 15, 2025Financings

    Calidi Biotherapeutics prices $6 million public offering of units at $2.00

    The offering combines common stock units and pre-funded warrant units, each with a Series I warrant exercisable at $2.00 for five years.

    CLDI
56. Aug 15, 2025Distress

    CERo Therapeutics delays Q2 report, estimates $18.5 million quarterly net loss

    The company needs more time to value marketable securities it received as part payment for Series D Preferred Stock. It estimates an $18.5 million net loss for the quarter and a $33.4 million loss attributable to common shareholders.

    CERO
57. Aug 15, 2025Distress

    Agentix Corp. says its June quarter report will be late

    Agentix has no meaningful revenue, and its lead drug candidate has animal efficacy data only in its annual report. It says it cannot finish its quarterly report on time and expects to file by August 19, 2025.

    AGTX
58. Aug 14, 2025Distress

    Windtree Therapeutics files late notice for quarterly report for June 30, 2025

    The company said it needs more time to finalize its financial statements and related disclosures. It expects to file within five calendar days after the due date.

    WINT
59. Aug 14, 2025Distress

    TNF Pharmaceuticals (now Q/C Technologies) delays June quarter report

    TNF Pharmaceuticals says it needs more time to finish the financial statements for the six months ended June 30, 2025, and expects to file within the extension window. The notice does not say what is holding up the numbers.

    QCLS
60. Aug 14, 2025Distress

    Protagenic Therapeutics delays 10-Q after approving move to virtual model

    Protagenic Therapeutics said on August 14, 2025 that it cannot file its June quarter report on time, because its board approved a restructuring to a virtual operating model on August 8. The company expects to file by August 19, 2025, and the notice gives no cost or cash estimate for the restructuring.

    PTIX
61. Aug 14, 2025Distress

    Ocean Biomedical delays quarterly report for period ended June 30, 2025

    The company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date.

    OCEA
62. Aug 14, 2025Distress

    NeOnc Technologies delays quarterly report to finish review of stock unit charges

    NeOnc needs more time to review non-cash expense charges tied to previously granted restricted stock units. It expects to file within five days.

    NTHI
63. Aug 14, 2025Distress

    NRx Pharmaceuticals files late notice for quarterly report for June 30, 2025

    NRx told the SEC it will miss the regular deadline for its June quarter report and needs more time to compile information. It expects to file within the form's five-day grace period, and the notice gives no figures.

    NRXP
64. Aug 14, 2025Distress

    NRx Pharmaceuticals files NT 10-Q, says second-quarter Form 10-Q will be late

    NRx Pharmaceuticals (Nasdaq: NRXP) told the SEC it needs more time to compile information for its June 30, 2025 quarterly report. It expects to file within five calendar days of the due date.

    NRXP
65. Aug 14, 2025Distress

    Jupiter Neurosciences delays quarterly report for period ended June 30, 2025

    Jupiter said it needs more time to complete the presentation and review of its financial statements. It expects to file within five calendar days of the deadline and says it anticipates no significant change in results.

    JUNS
66. Aug 14, 2025Distress

    Goldenwell Biotech files late notice for June quarter report

    Goldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has not been filed, and its latest filed balance sheet is small.

    GWLL
67. Aug 14, 2025Distress

    Eloxx Pharmaceuticals lacks funds for auditor review, expects $0.6 million cash

    The company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going concern.

    ELOX
68. Aug 14, 2025Distress

    Denali Capital Acquisition Corp. (now Semnur Pharmaceuticals) delays June 10-Q

    Denali Capital filed a Form 12b-25 notice on August 14, 2025 saying it cannot file its June 30, 2025 quarterly report on time, because it is still completing its financial statements. The notice says the report will come no later than the fifth calendar day after the due date.

    SMNR
69. Aug 14, 2025Distress

    CDT Equity, formerly Conduit Pharmaceuticals, says Q1 2025 financials should not be relied on

    The company says $0.4 million of milestone payments to Sarborg Limited were booked as research and development expense but should have been an acquired diagnostic asset. It plans to amend its first-quarter Form 10-Q.

    CDT
70. Aug 14, 2025Financings

    Aquestive Therapeutics prices $85,000,000 stock offering at $4.00 per share

    Aquestive sold 21,250,000 shares at $4.00 through Leerink Partners, Cantor and Oppenheimer, a day after agreeing to a conditional $75 million revenue-interest deal with an affiliate of RTW Investments. Anaphylm's approval is a condition of that deal.

    AQST
71. Aug 14, 2025Distress

    Apimeds Pharmaceuticals delays quarterly report for period ended June 30, 2025

    Apimeds says it cannot file its quarterly report for the period ended June 30, 2025 on time and expects to file within the five-day extension. Its lead drug, Apitox, rests on a prior Phase III trial that the company's own filing describes in conflicting terms.

    APUS
72. Aug 14, 2025Distress

    Allarity Therapeutics files NT 10-Q, says June 30, 2025 quarterly report will be late

    Allarity says its auditors have not finished reviewing the quarter. It expects to file within five calendar days of the due date and does not anticipate a significant change in results from a year earlier.

    ALLR
73. Aug 14, 2025Distress

    Allarity Therapeutics delays quarterly report while auditors finish review

    The company filed a late-filing notice on August 14, 2025 for its report on the quarter ended June 30, 2025. It expects to file within the extension period, but its auditors had not finished their review.

    ALLR
74. Aug 13, 2025Financings

    Vivani Medical agrees to sell 7,936,507 shares at $1.26 in private placement of about $10.0 million

    Vivani's Share Purchase Agreement with an entity affiliated with a director and another investor is expected to close in stages through July 15, 2026. The company says the proceeds secure its financial position into the second half of 2026.

    VANI
75. Aug 13, 2025Financings

    Vivani Medical agrees $10.0 million private placement at $1.26 per share

    Vivani sells 7,936,507 shares at $1.26 to two buyers, one of them tied to chairman Gregg Williams. Cash was $8.1 million at June 30, 2025, and the release presents the new money as securing its position into the second half of 2026.

    VANI
76. Aug 13, 2025Financings

    ProMIS Neurosciences files $50,000,000 shelf and up to $17,988,524 share sales plan

    ProMIS filed a $50,000,000 base shelf on Form S-3 and an at-the-market agreement with H.C. Wainwright & Co. for up to $17,988,524 of common shares, at a commission of up to 3.0%. The stock closed at $0.628 on August 11, 2025, and the supplement does not explain its float figures.

    PMN
77. Aug 13, 2025Mergers

    Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) completes business combination

    BridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025.

    BBOT
78. Aug 13, 2025Financings

    Enliven Therapeutics files automatic shelf with $200.0 million ATM prospectus supplement

    The Open Market Sale Agreement with Jefferies is dated June 23, 2023. Enliven's common stock is listed on the Nasdaq Global Select Market.

    ELVN
79. Aug 12, 2025Financings

    X4 Pharmaceuticals agrees to $60 million private placement and replaces CEO and CFO

    Stifel is sole placement agent for the PIPE, which Coastlands Capital led at $1.42 per share. Closing was expected on or about August 13, 2025.

    XFOR
80. Aug 12, 2025Listings

    Veru completes 1-for-10 reverse stock split on Nasdaq

    Veru's 1-for-10 reverse stock split took effect at 11:59 p.m. Central time on August 8, 2025, and the stock trades split-adjusted from August 11. The 8-K gives no reason for the split and no pre-split share count.

    VERU
81. Aug 12, 2025Listings

    Verrica Pharmaceuticals details 1-for-10 reverse split and $8.0 million Torii milestone

    Verrica's 1-for-10 reverse stock split took effect at the close of trading on July 24, 2025, cutting issued shares from 92,650,404 to 9,265,034. Second-quarter net income of $0.2 million depended on an $8.0 million Torii milestone.

    VRCA
82. Aug 12, 2025Distress

    ORIC cuts 20% of staff after $244 million gross financing, expects runway into 2028

    The company ended discovery research to focus on ORIC-944 and enozertinib. It does not expect to use its at-the-market facility for the foreseeable future.

    ORIC
83. Aug 12, 2025Distress

    ORIC Pharmaceuticals cuts 20% of workforce, closes discovery research group

    ORIC expects a one-time cost of approximately $1.9 million for the workforce reduction. The company says cash and investments should fund its revised operating plan into 2H 2028, helped by $244 million in gross proceeds.

    ORIC
84. Aug 12, 2025Distress

    Mosaic ImmunoEngineering delays its June 30, 2025 quarterly report

    Mosaic ImmunoEngineering missed the 5:30 p.m. EDT August 14, 2025 deadline for its second-quarter report, citing financial reporting and close procedures. Its annual report warned it might have to cease operations if a deal with Oncotelic and note-holder waivers were not secured by June 30, 2025.

    CPMV
85. Aug 12, 2025Listings

    Intensity Therapeutics regains Nasdaq stockholders' equity compliance

    Nasdaq said on August 8, 2025 that Intensity meets the $2,500,000 stockholders' equity requirement. That finding rests partly on share sales made in July, and the company could still face delisting if its next periodic report does not show compliance.

    INTS
86. Aug 12, 2025Distress

    Fate Therapeutics approves restructuring with 12% workforce reduction

    Fate Therapeutics (Nasdaq: FATE) expects $0.9 million to $1.2 million in severance charges in the third quarter of 2025. The company says it has $249 million in cash and investments and a runway through the end of 2027.

    FATE
87. Aug 12, 2025Financings

    DiaMedica Therapeutics sets up $100.0 million at-the-market share program with TD Cowen

    DiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance.

    DMAC
88. Aug 12, 2025Debt Financing

    CorMedix completes $150,000,000 convertible senior notes private placement due 2030

    CorMedix closed a $150,000,000 private placement of 4.00% convertible senior notes due 2030 on August 12, 2025. Each $1,000 of principal converts into 74.2515 common shares at the initial rate, and U.S. Bank Trust Company is trustee under the new indenture.

    CRMD
89. Aug 12, 2025Debt Financing

    CorMedix completes $150,000,000 convertible senior notes offering due 2030

    The 4.00% notes were sold in a private placement. The initial conversion rate is 74.2515 shares of common stock per $1,000 principal amount.

    CRMD
90. Aug 12, 2025Financings

    Compass Therapeutics prices $119,999,329 stock and warrant offering at $3.00

    Compass is selling 33,290,000 shares and pre-funded warrants for 6,710,000 shares. Proceeds before expenses are $112,800,000.

    CMPX
91. Aug 12, 2025Debt Financing

    Armata Pharmaceuticals enters $15 million secured term loan with Innoviva at 14.0% interest

    A $15 million loan from a unit of Armata's largest shareholder, Innoviva, carries a 14.0% rate, is secured by substantially all of the company's assets and matures in January 2029. Cash stood at $4.3 million on June 30, 2025.

    ARMP
92. Aug 11, 2025Financings

    Oragenics says Series H preferred raise brought $16.5 million in gross proceeds

    Net proceeds were about $15.2 million after fees and expenses. The company plans to start a Phase IIa concussion trial in Q3 2025.

    OGEN
93. Aug 11, 2025Financings

    Ocugen agrees to sell $20,000,000 of stock and warrants to Janus Henderson at $1.00

    The registered direct offering covers 20,000,000 shares and warrants for 20,000,000 more at $1.50. Full warrant exercise could bring up to $30 million more.

    OCGN
94. Aug 11, 2025Financings

    BioVie closes public offering of units and warrants with net proceeds of about $10.4 million

    ThinkEquity was sole underwriter for 5,620,000 units and 380,000 pre-funded units. Warrants carry a $2.50 exercise price and trade as BIVIW; BioVie plans to use the money for working capital.

    BIVI
95. Aug 8, 2025Listings

    Processa Pharmaceuticals gets second 180-day Nasdaq period to fix bid price

    Nasdaq has given Processa until February 2, 2026 to bring its share price back to at least $1, a second 180-day period. The company says it will consider a reverse stock split, and the filing gives no recent share price to show how far it is from the threshold.

    PCSA
96. Aug 8, 2025Legal

    ImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement

    A federal court preliminarily approved the settlement of three shareholder derivative suits naming ImmunityBio's current and former officers and directors. The company agrees to governance reforms and expects its insurer to pay the plaintiffs' attorneys' fees, which their counsel plans to ask the court to set at up to $1,400,000. The final hearing is November 4, 2025.

    IBRX
97. Aug 8, 2025Listings

    FibroBiologics gets Nasdaq notice for market value below $35.0 million

    FibroBiologics received a Nasdaq notice that its market value of listed securities is below the $35.0 million minimum. It has until February 2, 2026 to close at or above that level for ten business days, and the 8-K gives no current market value or remedy.

    FBLG
98. Aug 8, 2025Financings

    BioVie prices $12 million public offering of units at $2.00

    BioVie priced 6,000,000 units, including pre-funded units, at $2.00 each for about $12 million. ThinkEquity is sole book-running manager, and the prospectus says the financial statements raise substantial doubt about the company's ability to continue as a going concern.

    BIVI
99. Aug 7, 2025Financings

    Processa Pharmaceuticals sells 5,467,181 shares in $1.3 million private placement at $0.23

    Processa says the private placement closed August 6, 2025, with LifeSci Capital LLC as exclusive placement agent. The company also says it is evaluating corporate cryptocurrency treasury strategies.

    PCSA
100. Aug 7, 2025Mergers

     PTC Therapeutics pays about $225.0 million to cancel Censa sepiapterin sales payment rights

     Former Censa securityholders holding about 90% of its equity gave up 8% to 12% net sales payments on sepiapterin. PTC will owe milestone payments of about $90.0 million each if sales reach set thresholds.

     PTCT
101. Aug 7, 2025Mergers

     PTC Therapeutics pays about $225.0 million to cancel Censa sales payments

     PTC paid about $225.0 million in cash to former Censa holders who gave up their share of sepiapterin sales, and it is still obligated to make five milestone payments of about $90.0 million each. The filing does not say what the rights were worth.

     PTCT
102. Aug 7, 2025Listings

     Estrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement

     Nasdaq told Estrella on August 1, 2025 that its market value of listed securities fell below the $35,000,000 minimum. It has until January 28, 2026 to regain compliance, and its annual report for the year ended June 30, 2024 carried a going-concern warning.

     ESLA
103. Aug 7, 2025Mergers

     CorMedix to buy Melinta Therapeutics, closing targeted as early as September 1

     CorMedix said it will buy Melinta Therapeutics, with closing targeted as early as September 1, 2025. The company's August 7 release gives no price, no financing and no adviser for the deal.

     CRMD
104. Aug 6, 2025Financings

     Sana Biotechnology prices $75.0 million offering at $3.35 a share

     Sana sold 20,895,522 shares at $3.35 plus pre-funded warrants for 1,492,537 more, with about $70.0 million in estimated net proceeds. It reported about $90.1 million in cash at July 31, 2025 and estimates $40.0 million to $45.0 million in facility impairments.

     SANA
105. Aug 6, 2025Debt Financing

     Oncotelic Therapeutics issues $560,000 secured convertible note to Mast Hill Fund

     Oncotelic's $560,000 note converts at a fixed $0.07 per share and carries 10% interest, and a separate equity purchase agreement with the same lender could add up to $25 million of stock sales.

     OTLC
106. Aug 6, 2025Financings

     Helix Acquisition Corp. II (now BridgeBio Oncology) keeps $120 million in trust

     Helix says about $120 million remains in trust after redemptions, and that a $261 million private placement led by Cormorant Asset Management would bring the merger with BBOT to about $382 million gross.

     BBOT
107. Aug 6, 2025Financings

     Cosmos Health signs note facility of up to $300 million for Ethereum treasury

     Cosmos Health agreed to issue up to $300 million of senior secured convertible promissory notes, with at least 72.5% of each tranche's net proceeds going to an Ethereum reserve. Curvature Securities, LLC was the sole placement agent, and the release gives no note terms or investor name.

     COSM
108. Aug 6, 2025Debt Financing

     ADMA Biologics enters $300 million credit agreement led by J.P. Morgan, repays Ares facility

     The agreement provides a $75 million term loan and a $225 million revolving credit facility, both maturing August 5, 2028. ADMA used the proceeds to pay off its earlier facility with Ares Capital Corporation.

     ADMA
109. Aug 5, 2025Listings

     Ocean Biomedical's Nasdaq delisting becomes final after board declines review

     Nasdaq's board declined to review a May 15, 2025 Listing Council decision, making it Nasdaq's final action. The company's chief financial officer and a director have also resigned.

     OCEA
110. Aug 5, 2025Financings

     Nutriband distributes 3 million Series A preferred shares convertible on FDA approval

     Holders got one non-voting preferred share for every four common shares. The shares convert one-for-one only after FDA approval of an AVERSA-based product.

     NTRB
111. Aug 5, 2025Listings

     Bon Natural Life says Nasdaq closed bid price matter, with one-year panel monitor

     Bon Natural Life says Nasdaq has closed its bid price matter after the Hearings Panel decision, but the company stays under a one-year Discretionary Panel Monitor. The Nasdaq confirmation came on July 29, 2025, and the company reported it in a Form 6-K dated August 4, 2025.

     BON
112. Aug 4, 2025Financings

     Intensity Therapeutics raises $6.6 million from July 2025 at-the-market sales

     Intensity sold 19,868,658 shares at an average of $0.3323 each under its at-the-market program in July 2025. The company says its cash now reaches into the second half of 2026, but the release gives no cash balance.

     INTS
113. Aug 4, 2025Listings

     Exicure regains compliance with Nasdaq periodic filing rule

     Exicure said it met Listing Rule 5250(c)(1) as of July 1, 2025, after filing its Form 10-Q for the quarter ended March 31, 2025.

     XCUR
114. Aug 1, 2025Listings

     iBio receives Nasdaq notice for trading below $1.00 minimum bid price

     The company has until January 26, 2026 to regain compliance. Its shares keep trading on The Nasdaq Capital Market under the symbol IBIO for now.

     IBIO
115. Aug 1, 2025Legal

     Protalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees

     A Delaware stockholder class action against Protalix BioTherapeutics and its board, Thomas v. Bashan, et al., was dismissed as to the plaintiff after the board amended the bylaws. Protalix agreed to pay $160,000 in fees and expenses to the plaintiff's counsel, and it denies the allegations.

     PLX
116. Aug 1, 2025Mergers

     NeOnc Technologies signs up to $50 million investment deal with Quazar at $25 per share

     Quazar Investment would buy 1.4 million shares and fund trials and infrastructure in the UAE and MENA region. Closing still depends on a capital formation round.

     NTHI
117. Aug 1, 2025Listings

     GeoVax receives Nasdaq bid price deficiency notice, has until January 27, 2026

     GeoVax's closing bid price was below $1.00 for 30 consecutive business days, according to a July 31, 2025 deficiency letter. The first deadline is January 27, 2026, and a second 180-day period is possible.

     GOVX
118. Aug 1, 2025Debt Financing

     Celcuity completes $201,250,000 offering of 2.750% convertible senior notes due 2031

     Celcuity (Nasdaq: CELC) sold $201,250,000 of 2.750% convertible notes due 2031, including an over-allotment option the underwriters exercised on July 30, 2025. The notes convert at an initial price of about $51.30 per share, and the company sold stock and pre-funded warrants in a separate, concurrent offering.

     CELC
119. Aug 1, 2025Financings

     Alzamend Neuro issues 243,429 shares on Series B preferred conversions

     Alzamend Neuro (Nasdaq: ALZN) issued 243,429 common shares between July 23 and July 30, 2025 on conversion of Series B Convertible Preferred Stock. It had 3,139,861 common shares outstanding on July 30.

     ALZN

July 2025

1. Jul 31, 2025Mergers

   Veraxa Biotech Holding AG (now Veraxa Biotech AG) files F-4 for Voyager SPAC deal

   The Form F-4 for Veraxa Biotech Holding AG is dated July 16, 2025 and covers the business combination with Voyager Acquisition Corp. under an agreement dated April 22, 2025. The date of Voyager's shareholder meeting is still blank.

   VRXA
2. Jul 31, 2025Mergers

   Supernus completes Sage Therapeutics acquisition after tender offer, $8.50 per share plus CVR

   Supernus completed its acquisition of Sage Therapeutics on July 31, 2025 after a tender offer, paying $8.50 in cash per share plus a contingent value right worth up to $3.50. The filing puts the cash consideration at about $561 million, and says no CVR payment is assured.

   SUPN
3. Jul 31, 2025Mergers

   Adaptimmune sells cell therapy assets to US WorldMeds for $55 million upfront

   Adaptimmune sold its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to a US WorldMeds subsidiary for $55 million in cash at closing, with up to $30 million more on milestones. The $134 million gain is a pro forma estimate built on March 31, 2025 values.

   ADAPY
4. Jul 30, 2025Debt Financing

   Propanc Biopharma sells $112,350 convertible note for $107,000, with 22% annual interest

   Propanc Biopharma sold a $112,350 convertible note to 1800 Diagonal Lending LLC for $107,000. The note bears 22% interest, matures April 30, 2026 and converts at a 25% discount after 180 days, in a stock its last annual report says was quoted at $0.0003.

   PPCB
5. Jul 30, 2025Financings

   Prime Medicine prices 38,000,000 share offering at $3.30, $125,400,000 gross

   Prime sold 38,000,000 shares at $3.30, below the $3.83 closing price on July 29, 2025. The estimated net proceeds are $120.2 million, and the auditor's 2024 report carries a going-concern paragraph.

   PRME
6. Jul 30, 2025Financings

   Dyadic International prices 6,052,000-share offering at $0.95, below last trade

   Gross proceeds would be $5,749,400. The price compares with a last reported sale of $1.1750 on July 29, 2025. An executive agreed to buy 26,000 shares.

   DYAI
7. Jul 30, 2025Financings

   AIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall

   AIM ImmunoTech sold units at $4.00 with two warrants each, a month after a 1-for-100 reverse split, and its prospectus says there is likely substantial doubt about its ability to continue as a going concern. It must lift stockholders' equity to at least $6 million by June 11, 2026.

   AIM
8. Jul 29, 2025Listings

   Splash Beverage Group (now Endovia Health Sciences) faces NYSE American warrant delisting

   The exchange suspended trading in the company's $184.00 warrants because of their low trading price. The common stock is not affected.

   EDVA
9. Jul 29, 2025Distress

   PharmaCyte Biotech delays annual report for year ended April 30, 2025

   The company said it needs more time to prepare and review its financial statements. It plans to file within 15 days of the July 29, 2025 due date.

   PMCB
10. Jul 29, 2025Listings

    Passage Bio regains compliance with Nasdaq minimum bid price rule

    Nasdaq confirmed on July 28, 2025 that Passage Bio's shares had closed at $1.00 or more for at least 10 consecutive business days, closing a matter that began in August 2024.

    PASG
11. Jul 29, 2025Listings

    Ocugen regains compliance with Nasdaq $1.00 minimum bid price rule

    Ocugen's stock closed at or above $1.00 for ten business days from July 8, 2025 to July 25, 2025. Nasdaq said on July 28, 2025, that the matter is closed.

    OCGN
12. Jul 29, 2025Distress

    Merck approves 2025 restructuring program with about $3.0 billion in pretax costs

    Merck expects to eliminate certain positions in sales, administrative and research and development organizations and expects annual savings of approximately $1.7 billion, substantially realized by the end of 2027.

    MRK
13. Jul 29, 2025Listings

    ImmunoPrecise Antibodies (now MindWalk Holdings) reports fiscal 2025 results

    Revenue was $24.5 million in both fiscal 2025 and fiscal 2024, and the net loss widened to $30.2 million from $26.1 million. The release gives no date for the regained Nasdaq compliance.

    HYFT
14. Jul 29, 2025Mergers

    ImageneBio says Ikena Oncology and Imagene merger completed in July 2025

    A July 2025 corporate overview says the merger closed and that the company has raised $140 million to date. Its lead drug, IMG-007, is in a Phase 2b trial in atopic dermatitis.

    IMA
15. Jul 29, 2025Mergers

    Ikena Oncology (now ImageneBio) completes Inmagene merger, issues contingent value rights

    Ikena Oncology, now ImageneBio, closed its merger with Inmagene Biopharmaceuticals on July 25, 2025. It issued contingent value rights to both sets of shareholders, which pay only from proceeds of selected assets, and it took on a transition services deal with a company owned by Inmagene's legacy holders.

    IMA
16. Jul 25, 2025Financings

    Processa Pharmaceuticals registers up to $5,239,073 in at-the-market stock sales

    Processa filed a new prospectus supplement that lets it sell up to $5,239,073 of stock through its at-the-market program with A.G.P./Alliance Global Partners. Its shares closed at $0.2497 on July 22, 2025, down from $0.40 on June 11, 2025, the date its public float was measured.

    PCSA
17. Jul 25, 2025Financings

    Palisade Bio sets $0.9047 warrant inducement for about $3.9 million in gross proceeds

    A holder will exercise 4,318,905 Palisade warrants at a reduced price and receive new warrants for up to 8,637,810 shares. Ladenburg Thalmann is the placement agent.

    PALI
18. Jul 25, 2025Financings

    Omeros prices $22 million registered direct offering at $4.10 a share

    Polar Asset Management Partners is buying 5,365,853 shares at a premium of approximately 14% to the closing price on the agreement date. Closing was expected on or about July 28, 2025.

    OMER
19. Jul 25, 2025Financings

    Lyell Immunopharma signs private placement of up to $100 million at $13.32 per share

    Lyell's private placement starts with about $50 million at $13.32 per share. A second $50 million at $25.61 per share depends on a milestone within 12 months.

    LYEL
20. Jul 25, 2025Financings

    CytoDyn files $100,000,000 shelf registration for stock, warrants and units

    CytoDyn filed a Form S-3 shelf that would let it offer up to $100,000,000 of stock, warrants, subscription rights and units. The stock is quoted on the OTCQB, where it closed at $0.29 on July 24, 2025, and the shelf cannot be used until it takes effect.

    CYDY
21. Jul 25, 2025Financings

    Cingulate reports unregistered share issuances to a lender in exchange for debt

    Cingulate reported on July 25, 2025 that it issued common stock in three transactions with a lender, in exchange for part of the debt it owes, at $4.18 to $4.79 a share. The filing also covers a 7,538-share issuance to a service provider and a 30,000-share officer option grant. It names no bank or placement agent.

    CING
22. Jul 25, 2025Financings

    Chemomab signs at-the-market agreement with LifeSci Capital for up to $7,258,687

    The Israeli company may sell American depositary shares from time to time and is not obligated to sell any. LifeSci Capital will earn a 3.0% commission.

    CMMB
23. Jul 25, 2025Financings

    Anavex signs at-the-market sales agreement with TD Cowen for up to $150 million

    The company may sell common stock from time to time but is not obligated to sell any. TD Cowen can earn up to 3.0% in commissions.

    AVXL
24. Jul 24, 2025Financings

    Incannex Healthcare adds up to $100,000,000 to at-the-market stock program

    Incannex had already sold about $63,469,250 of stock under the program. A week later it said it has no plans to use the full capacity in the near term.

    IXHL
25. Jul 24, 2025Listings

    Advanced Biomed gets Nasdaq bid price notice, has until January 14, 2026 to comply

    The stock closed below $1.00 for 32 consecutive business days. Shares keep trading on the Nasdaq Capital Market under ADVB during the compliance period.

    ADVB
26. Jul 23, 2025Distress

    Rocket Pharmaceuticals starts restructuring with workforce reduction of about 30%

    Rocket says the plan, approved by its board on June 18, 2025, aims to extend its operational runway into the second quarter of 2027. The company expects about $3.5 million in charges in the second half of 2025, against a 2024 operating cash outflow of $209.7 million.

    RCKT
27. Jul 23, 2025Financings

    Oramed gives Scilex option to buy back warrants for $27,000,000

    Scilex will pay a $1,500,000 option fee in two installments. If the buyback is completed and paid in full, the maturity of the Tranche A Note moves to March 31, 2026.

    ORMP
28. Jul 23, 2025Distress

    Adicet Bio announces workforce reduction of about 30% and ends ADI-270 program

    Adicet's board approved a cut of about 30% of its workforce on July 22, 2025 and ended its ADI-270 cancer program. The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024.

    ACET
29. Jul 22, 2025Mergers

    Lantheus completes Life Molecular Imaging acquisition with $350 million upfront payment

    Lantheus closed the acquisition on July 21, 2025 and named Dr. Ludger Dinkelborg Head of Research and Development, effective August 1, 2025. The deal adds the Alzheimer's PET imaging agent Neuraceq.

    LNTH
30. Jul 21, 2025Financings

    SAB Biotherapeutics agrees to $175 million private placement with Sanofi

    SAB will issue convertible preferred stock convertible at $1.75 per share, plus warrants that could bring up to $284 million more if exercised in full. It expects cash to last into the middle of 2028.

    SABS
31. Jul 21, 2025Financings

    SAB Biotherapeutics agrees to $175 million private placement of Series B preferred stock

    SAB Biotherapeutics expects about $175 million in gross proceeds from Series B preferred stock, convertible into 100,000,000 common shares at $1.75. Warrants could bring in up to $284 million more, and the conversion rights wait on a stockholder vote.

    SABS
32. Jul 21, 2025Financings

    DiaMedica Therapeutics agrees to $30.1 million private placement with existing stockholders

    DiaMedica will sell 8,606,426 common shares at $3.50 each, for expected gross proceeds of $30.1 million before fees. The 8-K names no placement agent, and the company used $22,076 thousand in operations in 2024 while its equity fell to $40,718 thousand.

    DMAC
33. Jul 18, 2025Listings

    Neuphoria Therapeutics gets Nasdaq notice over annual meeting requirement

    Neuphoria Therapeutics received a Nasdaq notice that it did not hold an annual meeting within a year of its June 30, 2024 fiscal year end. It has until September 1, 2025 to submit a plan, and its annual report for that year carries a going-concern warning with cash that, combined with an ATM facility, is expected to fund work into late in the first quarter of fiscal 2026.

    NEUP
34. Jul 18, 2025Listings

    Nasdaq files Form 25 to delist Avenue Therapeutics common stock

    The Nasdaq Stock Market LLC filed a Form 25-NSE on July 18, 2025, to remove Avenue Therapeutics common stock from listing and registration.

    ATXI
35. Jul 18, 2025Debt Financing

    Abeona Therapeutics cuts term loan rate to 11.75% and issues Avenue warrants

    Abeona Therapeutics lowered the rate on its senior secured term loan from 13.5% to a fixed 11.75% and gave the Avenue lenders warrants for up to 16,474 shares at $6.07. Its 2024 net loss was $63.7 million, and its 10-K says $98.1 million in year-end cash and investments, plus later at-the-market proceeds, covers at least 12 months from issuance.

    ABEO
36. Jul 18, 2025Financings

    60 Degrees Pharmaceuticals prices $5 million offering, with warrants for $5 million more

    60 Degrees Pharmaceuticals priced 2,631,578 shares at $1.90 with warrants. About $5 million comes in up front, and the short-term warrants could bring in about $5 million more only if fully exercised for cash.

    SXTP
37. Jul 17, 2025Financings

    Windtree agrees to $60 million preferred stock sale to fund BNB treasury

    Windtree agreed on July 16, 2025 to sell about 60,000 shares of Series E preferred stock with warrants, and to use the money to buy BNB. The deal cannot close until shareholders approve it, and it lapses if approval is not obtained within 120 days.

    WINT
38. Jul 17, 2025Mergers

    I-Mab (now NovaBridge Biosciences) to buy Bridge Health Biotech for $1.8 million upfront

    The deal gives the company rights tied to the antibody in its lead drug candidate, givastomig, and removes royalties owed on it. The efficacy figure behind the program is early and comes from a dose escalation study of 17 patients.

    NBP
39. Jul 17, 2025Financings

    Gain Therapeutics prices public offering of shares and warrants for $7.0 million gross proceeds

    Gain agreed to sell 4,501,640 shares and warrants for 2,250,820 shares at $3.11 per set through Newbridge Securities. It expects net proceeds of approximately $6.3 million, with closing expected on or about July 17, 2025.

    GANX
40. Jul 17, 2025Listings

    Connect Biopharma regains compliance with Nasdaq $1.00 minimum bid price rule

    The company's American Depositary Shares closed at $1.00 or more for 10 straight business days, ending a deficiency first flagged on March 24, 2025.

    CNTB
41. Jul 16, 2025Mergers

    Onconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%

    Onconetix holders would keep 10% of the combined company. Closing was expected in the fourth quarter of 2025, subject to regulatory, stockholder and third-party approvals.

    ONCO
42. Jul 16, 2025Listings

    Indaptus Therapeutics regains Nasdaq compliance with $1.00 bid price rule

    The stock closed at $1.00 or higher for 10 consecutive business days from June 27, 2025 to July 11, 2025. Nasdaq considers the matter closed.

    INDP
43. Jul 16, 2025Listings

    Cell Source keeps filing delayed reports after its July 2025 Form 15 notice

    Cell Source's July 16, 2025 Form 15 checked the rule for suspending reporting duties. Its later filing list shows more reports, and in January 2026 the company said it was preparing a Nasdaq uplist.

    CLCS
44. Jul 14, 2025Financings

    ProKidney sets up at-the-market program for up to $200,000,000 of stock with Jefferies

    Jefferies earns up to 3.0% of gross proceeds on the new $200,000,000 program. The stock last sold at $4.54 on July 11, 2025, and the second dosing group in the Phase 2 REGEN-007 trial missed statistical significance.

    PROK
45. Jul 14, 2025Listings

    Imunon gets Nasdaq Hearing Panel exception after delisting determination

    The panel granted the exception on July 11, 2025, so Imunon can regain compliance with the $1.00 minimum bid price and the stockholders' equity requirement. Stockholders also approved 2,000,000 more plan shares, bringing the plan's limit to 3,970,000.

    IMNN
46. Jul 11, 2025Financings

    Rani Therapeutics registers resale of 13,160,172 Series D warrant shares

    Rani Therapeutics filed a resale prospectus on July 11, 2025 covering up to 13,160,172 Class A shares issuable on exercise of a Series D warrant. The company says it will receive no proceeds from the resale itself.

    RANI
47. Jul 11, 2025Listings

    Nasdaq files Form 25 to remove Bio-Path Holdings common stock from listing

    Nasdaq Stock Market LLC filed a Form 25 notification dated July 11, 2025 to strike Bio-Path Holdings' common stock from listing and registration. The notice cites Exchange Act Rule 12d2-2(b), which covers removals the exchange initiates, and it does not give the reason.

    BPTH
48. Jul 11, 2025Financings

    I-MAB (now NovaBridge Biosciences) lifts ADS sale limit to $50,000,000

    The amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under the agreement so far.

    NBP
49. Jul 11, 2025Mergers

    Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) says S-4 is effective, vote set for August 4

    The shell company says the registration statement for its merger with BBOT is effective and set a shareholder meeting for August 4, 2025, but the release gives no deal value or minimum cash figure.

    BBOTBBIO
50. Jul 11, 2025Mergers

    Denali Capital (now Semnur Pharmaceuticals) extends SPAC deadline to August 11, 2025

    Denali Capital deposited $874.78 into its trust account to extend its deadline by one month, to August 11, 2025. The blank-check company's units, shares and warrants now trade on the Pink market and the OTCQB, and it remains a shell company that depends on monthly extensions.

    SMNR
51. Jul 11, 2025Distress

    Artelo Biosciences' updated 2024 statements carry auditor going-concern doubt

    MaloneBailey said recurring losses and a net capital deficiency raise substantial doubt. Stockholders' equity fell to $2,857 thousand from $11,752 thousand.

    ARTL
52. Jul 10, 2025Listings

    Vor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs

    Vor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with.

    VOR
53. Jul 10, 2025Distress

    Pacira BioSciences cuts about 70 jobs as it decommissions 45-liter EXPAREL facility

    Pacira is closing its 45-liter EXPAREL manufacturing system and cutting about 70 Technical Operations jobs, and the employee note it filed says the larger 200-liter process in San Diego and Swindon now supplies the product.

    PCRX
54. Jul 10, 2025Distress

    Pacira BioSciences announces workforce reduction of 71 employees, about 8% of staff

    Pacira is shutting down its 45-liter EXPAREL suite in San Diego and cutting 71 employees, about 8% of its workforce. It expects $2.4 million to $2.8 million of cash charges in the third quarter and about $13 million a year in lower operating expenses.

    PCRX
55. Jul 10, 2025Listings

    Jupiter Neurosciences regains compliance with Nasdaq $1.00 minimum bid price rule

    Nasdaq confirmed on July 9, 2025 that Jupiter's stock held an average closing price of at least $1.00 over 13 days. The company's last annual report still carries a going concern warning.

    JUNS
56. Jul 9, 2025Listings

    Sensei Biotherapeutics (now Faeth Therapeutics) regains Nasdaq bid price compliance

    Nasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025.

    FTH
57. Jul 9, 2025Financings

    Nasus Pharma files for 1,000,000-share NYSE American IPO, expects $10.00 to $12.00

    Nasus Pharma seeks to list 1,000,000 shares on NYSE American at $10.00 to $12.00. Its prospectus says current cash will not fund planned operations, which raises substantial doubt about going concern, and its epinephrine Phase 2 study included 12 patients.

    NSRX
58. Jul 9, 2025Distress

    Jasper Therapeutics cuts workforce by about 50% and halts other programs to extend cash runway

    Jasper's board approved a corporate reorganization on July 8, 2025. The company will focus on briquilimab in chronic urticaria, expects $1.8 million to $2.2 million in severance cash costs, and its chief medical officer is leaving.

    JSPR
59. Jul 9, 2025Debt Financing

    Galectin Therapeutics gets new $10 million credit line from chairman Richard Uihlein

    The new $10 million line covers spending through June 2026, and $81 million of earlier borrowings from the same investor now mature September 30, 2026. The lead drug's NAVIGATE composite endpoint did not reach statistical significance.

    GALT
60. Jul 8, 2025Listings

    Unicycive regains Nasdaq minimum bid price compliance after reverse split

    Nasdaq confirmed on July 7, 2025 that Unicycive's shares had averaged at least $1.00 after a 1:10 reverse stock split took effect on June 20, 2025. The release does not say what the FDA has done on the company's lead candidate, which had a PDUFA date of June 28, 2025.

    UNCY
61. Jul 8, 2025Financings

    Recursion buys Rallybio's 50% ENPP1 venture stake, paying 1,457,952 shares plus cash

    Recursion issued 1,457,952 shares to Rallybio for its half of an ENPP1 venture, with more stock and cash due on milestones. The company's share issuance is capped at 19.9% of outstanding common stock, and the 8-K names no underwriter or placement agent.

    RXRX
62. Jul 8, 2025Mergers

    Rallybio sells ENPP1 joint venture stake to Recursion for initial $7,500,000 in stock

    Rallybio sold its 50% interest in the ENPP1 joint venture to a Recursion subsidiary on July 8, 2025. It received 1,457,952 Recursion shares for an initial $7,500,000, and it could receive $12,500,000 more in stock if milestones are met.

    RLYB
63. Jul 8, 2025Mergers

    Rallybio sells 50% stake in ENPP1 joint venture to Recursion for cash and shares

    Recursion issued 1,457,952 of its shares to Rallybio's selling subsidiary. Rallybio could receive more shares, development milestone payments and low single digit royalties later.

    RLYB
64. Jul 8, 2025Listings

    Entero Therapeutics (now GridAI Technologies) regains Nasdaq annual meeting compliance

    Nasdaq closed the matter on July 3, 2025, after the company held its annual meeting on June 30, 2025. The April annual report said the planned rescission of the ImmunogenX merger needed shareholder approval.

    GRDX
65. Jul 7, 2025Listings

    ProMIS Neurosciences gets second 180-day period to meet Nasdaq bid price rule

    ProMIS now has until December 29, 2025 to lift its share price to at least $1.00. It said it may effect a reverse stock split if necessary.

    PMN
66. Jul 7, 2025Distress

    Pacira signs $300.0 million revolving credit facility and repays term loan

    Pacira signed a $300.0 million senior secured revolving credit facility with Wells Fargo as administrative agent, and used part of it to repay its 2023 term loan A. The filing does not say how much was drawn.

    PCRX
67. Jul 7, 2025Debt Financing

    Pacira BioSciences enters $300.0 million revolving credit facility, repays term loan A

    The July 3, 2025 credit agreement is a $300.0 million senior secured revolver maturing July 3, 2030, and Pacira used part of it to repay its term loan A without prepayment penalties or fees. Wells Fargo Bank is administrative agent, and Wells Fargo Securities, Citizens Bank and Truist Securities are joint bookrunners and lead arrangers.

    PCRX
68. Jul 7, 2025Financings

    Collegium Pharmaceutical authorizes buyback of up to $150 million

    The board approved the program on July 1, 2025. It runs through December 31, 2026 and will be funded from existing cash on hand, but the 8-K gives no cash balance to measure that against.

    COLL
69. Jul 7, 2025Distress

    Century Therapeutics plans about 51% workforce cut as CFO and chief development officer leave

    Century Therapeutics (Nasdaq: IPSC) expects to cut headcount by approximately 51% and record about $3.7 million in severance charges. Its CFO and Chief Development Officer will leave in July 2025.

    IPSC
70. Jul 3, 2025Financings

    Universe Pharmaceuticals reports $3.3 million six-month loss, cash of $47,272,851

    The net loss widened to $3.3 million as third-party sales fell. Cash rose to $47,272,851, mainly because of a $15,000,000 share issue and related-party borrowings.

    UPC
71. Jul 3, 2025Financings

    Tevogen Bio Holdings sets up $50,000,000 at-the-market stock program with A.G.P.

    Tevogen can sell up to $50,000,000 of common stock through A.G.P./Alliance Global Partners, which is paid 3.0% of gross proceeds. The company's net tangible book value was negative $7.72 million at March 31, 2025, and buyers at the $1.25 reference price would face $1.07 a share of dilution.

    TVGN
72. Jul 3, 2025Listings

    Silo Pharma gets Nasdaq minimum bid price notice, has until December 24, 2025 to regain compliance

    Nasdaq notified Silo Pharma on June 27, 2025 that its common stock has not met the $1.00 minimum bid price. The company has until December 24, 2025 to regain compliance, and may consider a reverse stock split if needed.

    SILO
73. Jul 3, 2025Listings

    Silo Pharma gets Nasdaq bid price notice, has until December 24, 2025

    Nasdaq told Silo Pharma on June 27, 2025 that its common stock fell below the $1.00 minimum bid price, based on closing bids from May 14 to June 26. The company has until December 24, 2025 to regain compliance and says it may consider a reverse stock split.

    SILO
74. Jul 3, 2025Listings

    Pluri gets Nasdaq audit committee notice after director Doron Birger is not re-elected

    Pluri told Nasdaq it fell below the three-independent-director minimum for its audit committee after shareholders voted against director Doron Birger, who chaired it. The cure period ends no later than June 30, 2026, and the company says it will add an independent director.

    PLUR
75. Jul 3, 2025Listings

    Lexicon Pharmaceuticals moves to Nasdaq Capital Market to get more time on $1 bid rule

    Lexicon gets until December 30, 2025 to regain the $1 minimum bid price and moves to the Nasdaq Capital Market on July 7, 2025, with a reverse split on the table if needed.

    LXRX
76. Jul 3, 2025Financings

    Lantern Pharma sets up $15,530,000 at-the-market stock program with ThinkEquity

    ThinkEquity LLC will earn a 3.0% commission on shares sold. Lantern's public float was $46,607,112 as of July 3, 2025, which limits sales to one-third of that float in any 12-month period while the float stays below $75 million.

    LTRN
77. Jul 3, 2025Listings

    Coherus Oncology gets Nasdaq minimum bid price deficiency notice, has until December 29, 2025

    Nasdaq told Coherus on June 30, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until December 29, 2025 to regain compliance, while its cash, cash equivalents and marketable securities were $126.0 million at December 31, 2024 against $230.0 million of 2026 convertible notes.

    CHRS
78. Jul 2, 2025Financings

    Oragenics closes public offering of Series H preferred with about $16.5 million gross proceeds

    Oragenics closed a registered offering of 660,000 Series H preferred shares and warrants on July 2, 2025, for about $16.5 million gross. The preferred converts at $2.50 a share, the conversion price has no floor, and Dawson James Securities took 7.00% of gross proceeds as placement agent.

    OGEN
79. Jul 2, 2025Financings

    GeoVax Labs sells 9,235,000 units at $0.65 in public offering

    Each unit carried one share and two warrants exercisable at $0.65. Estimated net proceeds are $5,582,557.50, and the lead program is a COVID-19 vaccine whose key comparison trial is still ahead.

    GOVX
80. Jul 2, 2025Mergers

    Channel Therapeutics (now Pelthos) sets 10-for-one reverse split ahead of merger

    Channel Therapeutics will cut its share count from about 6,485,007 to about 648,501 in a 10-for-one reverse split before its merger with LNHC and a roughly $50 million raise led by Murchinson. The company says the split is meant to help it meet NYSE American initial listing requirements.

    PTHS
81. Jul 2, 2025Mergers

    Channel Therapeutics (now Pelthos Therapeutics) closes merger and $50.1 million private placement

    The July 1, 2025 closing included a one-for-ten reverse stock split, a name change and royalty sales to Nomis RoyaltyVest, Ligand and Madison Royalty LLC. The shares were to trade as PTHS.

    PTHS
82. Jul 2, 2025Listings

    Alaunos Therapeutics tells Nasdaq it falls short of audit committee rule after CEO change

    Alaunos told Nasdaq on July 2, 2025 that its audit committee falls short of Listing Rule 5605(c). The shortfall came after chief executive Dale Curtis Hogue, Jr. resigned and director Holger Weis took over as CEO and left the committee. The company plans to use a 180-day grace period.

    TCRT
83. Jul 2, 2025Financings

    Abeona closes $155 million sale of rare pediatric disease priority review voucher

    Abeona received gross proceeds of $155 million on June 27, 2025. The company says unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million as of June 30, 2025.

    ABEO
84. Jul 2, 2025Mergers

    Abeona Therapeutics closes $155 million sale of priority review voucher

    The sale closed on June 27, 2025. Abeona says cash and investments were about $225 million as of June 30, 2025, a figure it labels unaudited, and the release again does not name the buyer.

    ABEO
85. Jul 1, 2025Listings

    Ocugen gets 180 more days from Nasdaq to meet minimum bid price, until December 29, 2025

    Nasdaq granted Ocugen (Nasdaq: OCGN) an additional 180 calendar days to regain compliance with the $1.00 minimum closing bid price requirement. The first period ended June 30, 2025.

    OCGN
86. Jul 1, 2025Mergers

    Ikena Oncology (now ImageneBio) files merger partner Inmagene's Phase 2b trial start

    Inmagene dosed the first patient in its ADAPTIVE trial of IMG-007 in atopic dermatitis, with topline results expected in the fourth quarter of 2026. Ikena filed the news as merger material.

    IMA

June 2025

1. Jun 30, 2025Mergers

   TuHURA Biosciences completes acquisition of Kineta in all-stock deal

   Each Kineta share converts into 0.185298 TuHURA shares, or 2,868,169 shares in total, with 1,129,885 more due after six months. The release gives no cash balance or loss figure.

   HURA
2. Jun 30, 2025Mergers

   TuHURA Biosciences completes Kineta acquisition, paying 0.185298 TuHURA share per Kineta share

   TuHURA closed its merger with Kineta on June 30, 2025, issuing about 2,868,169 shares at closing, with about 1,129,885 more due after six months, subject to adjustment. The deal adds the antibody TBS-2025, for which the press release reports tolerability and receptor occupancy but no efficacy results.

   HURA
3. Jun 30, 2025Mergers

   Medicus Pharma agrees to buy Antev for 2,666,600 shares plus up to US$65 million

   Antev shareholders would receive about 17% of Medicus common shares, plus up to US$65 million in contingent payments tied to FDA milestones. Antev's lead drug missed a secondary endpoint in an earlier Phase 2a trial, and Medicus carries going-concern doubt.

   MDCX
4. Jun 30, 2025Financings

   InMed Pharmaceuticals agrees to sell shares at $2.561 in $5 million private placement

   A single institutional investor is buying 1,952,363 shares or pre-funded warrants plus options on the same number of shares. H.C. Wainwright is placement agent.

   INM
5. Jun 30, 2025Financings

   INmune Bio agrees to sell 3,000,000 shares at $6.30 in $19 million direct offering

   The prospectus puts the immediate dilution to new buyers at $4.97 per share. Cash was $19,377 thousand at March 31, 2025, against an accumulated deficit of $172,843 thousand.

   INMB
6. Jun 30, 2025Listings

   IN8bio regains compliance with Nasdaq $1.00 minimum bid price rule

   Nasdaq notified IN8bio on June 24, 2025 that the company again meets Listing Rule 5550(a)(2). The exchange said the matter is now closed.

   INAB
7. Jun 30, 2025Financings

   Biofrontera agrees $11.0 million preferred stock sale to fund U.S. Ameluz rights deal

   The company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake.

   BFRI
8. Jun 30, 2025Listings

   Aptevo says $15.9 million in new equity puts it back in line with Nasdaq rule

   Aptevo says about $15.9 million of gross equity raised in the June quarter puts it back above Nasdaq's $2.5 million stockholders' equity minimum. The figure is the company's own belief, and it was still awaiting formal confirmation from Nasdaq.

   APVO
9. Jun 27, 2025Financings

   Zymeworks issues 5,086,480 shares as EcoR1 funds exercise pre-funded warrants

   The warrant holders net exercised in full after Zymeworks removed a 19.99% ownership cap. Shares outstanding rose to 74,844,505.

   ZYME
10. Jun 27, 2025Listings

    Pasithea Therapeutics gets Nasdaq notice for trading below $1.00 bid price

    The company has until December 22, 2025 to regain compliance. It may qualify for a second 180-day period and is considering its options.

    KTTA
11. Jun 27, 2025Listings

    Nektar Therapeutics regains compliance with Nasdaq minimum bid price rule

    Nasdaq told Nektar on June 24, 2025 that it met the minimum bid rule after a $1.00 closing bid held for 10 consecutive business days. The 8-K gives no share price or financial figures, and the company's pipeline is still in mid-stage trials.

    NKTR
12. Jun 27, 2025Listings

    Moleculin Biotech gets Nasdaq bid price notice, has until December 24, 2025

    The stock closed below $1.00 for 30 straight business days. The company may consider a reverse stock split to regain compliance.

    MBRX
13. Jun 27, 2025Listings

    Immunic gets Nasdaq notice after stock falls below $1.00 for 30 days

    The company has until December 24, 2025 to regain compliance. The notice has no immediate effect on its listing on The Nasdaq Global Select Market.

    IMUX
14. Jun 27, 2025Debt Financing

    Bausch + Lomb closes €675 million secured notes offering, refinances 2027 term loans

    The notes mature January 15, 2031 and pay three-month EURIBOR plus 3.875%. The company also arranged a $2.325 billion term loan and an $800 million revolver, using the proceeds to repay and refinance existing debt.

    BLCO
15. Jun 26, 2025Financings

    Vor Bio licenses telitacicept from RemeGen for $45 million plus $80 million in warrants

    Vor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027.

    VOR
16. Jun 26, 2025Listings

    SCYNEXIS receives Nasdaq notice for stock below $1.00, has until December 17, 2025

    SCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.

    SCYX
17. Jun 26, 2025Listings

    SCYNEXIS gets Nasdaq minimum bid price notice, has until December 17, 2025 to comply

    SCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.

    SCYX
18. Jun 26, 2025Listings

    Rani Therapeutics gets Nasdaq notice over $1.00 minimum bid price

    Rani Therapeutics received a Nasdaq notice on June 20, 2025 that its Class A shares had a closing bid price below $1.00 for 30 consecutive business days. Its deadline to regain compliance is December 17, 2025, and the notice gives no closing price.

    RANI
19. Jun 26, 2025Legal

    Cell Source auditor Marcum resigns after CBIZ takes over its attest business

    Marcum LLP resigned as Cell Source's auditor on June 26, 2025, after CBIZ CPAs took over its attest practice. Marcum's reports on 2022 and 2023 carried a going-concern paragraph.

    CLCS
20. Jun 26, 2025Listings

    Bone Biologics regains compliance with Nasdaq $1.00 minimum bid price rule

    Nasdaq says Bone Biologics has met the $1.00 bid price rule after a 10-day run, but the release gives no share price, and its lead product still needs FDA approval before sale.

    BBLG
21. Jun 26, 2025Financings

    Actuate Therapeutics agrees to sell 666,497 shares at $7.00 in private placement

    The deal pairs each share with a $7.00 warrant and is expected to bring in approximately $4.7 million in gross proceeds. Bios 2024 Co-Invest, LP, a current stockholder, is among the purchasers, and the filing says Bios would be deemed to own about 49.9% of the company.

    ACTU
22. Jun 26, 2025Financings

    Achieve Life Sciences prices $45,000,000 offering of stock and warrants at $3.00

    Achieve priced 15,000,000 shares, each sold with a five-year warrant at $3.00, for $45,000,000 in gross proceeds, below the $3.51 last reported sale price on June 26, 2025. The company's 2024 annual report carried a going-concern warning.

    ACHV
23. Jun 25, 2025Listings

    Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price

    Sutro has until December 17, 2025 to bring its share price back above $1.00 for ten consecutive business days, or face a delisting process. The company says it plans a reverse stock split before that date if necessary, and its 10-K shows three partners that ended clinical work after Phase 1.

    STRO
24. Jun 25, 2025Listings

    Lipella Pharmaceuticals CEO says company will seek relisting after Nasdaq delisting

    Lipella's common stock was quoted on the OTC Pink Market under LIPO as of June 19, 2025. Nasdaq objected to securities paid to a placement agent and advisor.

    LIPO
25. Jun 24, 2025Financings

    Candel Therapeutics agrees to sell about $15.0 million of stock in direct offering

    Candel Therapeutics agreed on June 24, 2025 to sell 3,221,395 shares at $4.67 each in a registered direct offering. The prospectus names no placement agent or underwriter, and some buyers are directors and executive officers.

    CADL
26. Jun 24, 2025Distress

    Amarin licenses Vazkepa in Europe to Recordati for $25 million upfront, plans restructuring

    Amarin is licensing Vazkepa in Europe to Recordati for a $25 million upfront payment and starting a restructuring that targets about $70 million in cost savings over the next 12 months, while the release gives no loss or cash-flow figures.

    AMRN
27. Jun 24, 2025Distress

    Amarin licenses VAZKEPA in Europe to Recordati for $25 million upfront and starts restructuring

    Amarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually.

    AMRN
28. Jun 23, 2025Mergers

    Ocugen unit OrthoCellix to merge with Carisma alongside planned $25.0 million financing

    OrthoCellix's stockholder and the concurrent financing investors are expected to own about 90% of the combined company, with Carisma holders at about 10%. The deal is all stock and needs approval from both companies' stockholders.

    OCGNCARM
29. Jun 23, 2025Mergers

    Impact BioMedical signs reverse merger agreement with Dr Ashleys Limited

    Impact BioMedical agreed on June 21, 2025 to a reverse merger with Dr Ashleys, after which Impact holders would own 4.80% of the combined company. Closing needs shareholder approval, an effective registration statement and NYSE American listing approvals.

    IBO
30. Jun 23, 2025Mergers

    Impact BioMedical agrees to reverse merger with Hong Kong drugmaker Dr Ashleys

    The combined company would trade on the NYSE American as Dr Ashleys Limited. The deal needs Impact BioMedical shareholder approval.

    IBO
31. Jun 23, 2025Mergers

    Enzon Pharmaceuticals (now Viskase Holdings) agrees all-stock merger with Viskase

    Enzon, which calls itself a public company acquisition vehicle, agreed on June 20, 2025 to merge with Viskase in an all-stock deal. Viskase holders would own about 84.1% of the combined company, and Enzon common holders about 2.06%. The 8-K and release give no Viskase revenue, debt or earnings.

    VISK
32. Jun 23, 2025Listings

    Caribou Biosciences regains compliance with Nasdaq $1.00 bid price rule

    Caribou's Nasdaq notice covers a window of about two weeks, from June 3 to June 17, 2025, when its closing bid was $1.00 or more. The 8-K does not say what the price did before or after that window.

    CRBU
33. Jun 23, 2025Debt Financing

    Aytu BioPharma extends Eclipse term loan and revolver to 2029, adds $1.5 million advance

    Amendment No. 6 to Aytu's loan and security agreement moves both maturities to June 12, 2029 and raises the term loan principal to $13.0 million. The new advance carries SOFR plus 5.50%.

    AYTU
34. Jun 20, 2025Financings

    Theriva Biologics files to sell up to $2,534,352 of stock through at-the-market program

    Theriva Biologics filed to sell up to $2,534,352 of stock through A.G.P./Alliance Global Partners, under a cap set by its public float. Its auditor's report carries a going-concern paragraph, and the main survival result in its lead trial has a p-value of 0.0546.

    TOVX
35. Jun 20, 2025Listings

    NYSE accepts Annovis Bio plan to regain listing compliance

    The NYSE accepted Annovis Bio's plan to regain compliance with its market capitalization and stockholders' equity standards, giving the company 18 months from a March 26, 2025 notice, quarterly progress reports and a warning that trading could still be suspended.

    ANVS
36. Jun 20, 2025Financings

    AN2 Therapeutics swaps shares for pre-funded warrants in two Coastlands exchanges

    AN2 Therapeutics swapped 2,500,000 and 300,000 common shares for pre-funded warrants held by Coastlands Capital Partners LP on June 17 and June 19, 2025, and the 8-K reports no cash to the company from either exchange.

    ANTX
37. Jun 20, 2025Listings

    AIM ImmunoTech gets new NYSE American notice over stockholders' deficit

    AIM ImmunoTech had a stockholders' deficit of negative $3.9 million at March 31, 2025, and its 2024 net loss was approximately $17,320,000. Its tax-loss sales are capped, and the exchange deadline to fix the deficit is June 11, 2026.

    AIM
38. Jun 18, 2025Listings

    ReShape Lifesciences (now Vyome Holdings) says equity tops Nasdaq $2.5 million minimum

    ReShape says sales under its at-the-market program and a June 9 offering have lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The company says that does not guarantee it will stay listed.

    HIND
39. Jun 18, 2025Distress

    Prothena cuts workforce by about 63% after ending birtamimab development

    Prothena expects $16 to $20 million in severance and related charges from the workforce reduction. Its Chief Regulatory Officer and Chief People Officer will leave effective August 1, 2025.

    PRTA
40. Jun 18, 2025Distress

    Prothena cuts about 63% of workforce after ending birtamimab, expects $16 to $20 million in charges

    Prothena will cut about 63% of its workforce after ending birtamimab, and expects $16 to $20 million in charges, mostly cash. The 8-K gives no headcount, cash balance or savings figure.

    PRTA
41. Jun 18, 2025Financings

    Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq

    Jyong Biotech, a Taiwan-based drug developer, priced 2,666,667 shares at $7.50 with Joseph Stone Capital, LLC as sole underwriter. Its lead candidate failed its primary endpoint in a pivotal U.S. trial, its auditor has raised going-concern doubt, and a Chinese court judgment puts about USD 19.4 million at stake.

    MENS
42. Jun 18, 2025Mergers

    GlycoMimetics (now Crescent Biopharma) completes merger and $200 million private financing

    Crescent Biopharma completed its merger with GlycoMimetics, and the combined company began trading as CBIO on June 16, 2025. The $200 million financing includes $37.5 million of converted notes. GlycoMimetics's own 2024 10-K had raised going-concern doubt.

    CBIO
43. Jun 18, 2025Listings

    C4 Therapeutics holders approve doubling authorized shares to 300,000,000

    Stockholders voted 39,547,136 for and 20,664,896 against the increase, with 95,178 abstentions. The company filed the amendment in Delaware the same day.

    CCCC
44. Jun 17, 2025Financings

    PolyPid agrees to $26.7 million in warrant exercises at $3.50 per share

    Holders of existing PolyPid warrants will exercise them for $26.7 million at $3.50 per share and receive new warrants at $4.50. The company ties the money to a Phase 3 trial whose effect size its release does not give.

    PYPD
45. Jun 17, 2025Financings

    Plus Therapeutics (now Cerenome) cancels warrants, signs $50 million Lincoln Park deal

    Investors in a March 2025 private placement agreed to cancel all Series A warrants and cut Series B warrant shares to up to 35,536,380. Lincoln Park may buy up to $50.0 million of stock over 36 months.

    CNSY
46. Jun 17, 2025Listings

    BioNTech files purchase agreement to acquire CureVac through exchange offer

    BioNTech and CureVac signed a purchase agreement dated June 12, 2025 for a share exchange offer. The number of BioNTech shares per CureVac share moves with BioNTech's price, and the offer depends on a minimum condition.

    BNTX
47. Jun 16, 2025Financings

    NextCure licenses SIM0505 for $12 million upfront, agrees to sell $2.0 million in stock

    NextCure agreed to pay Hainan Simcere Zaiming $17 million, including a $12 million upfront payment, for rights to a Phase 1 antibody drug conjugate. A Zaiming affiliate agreed to buy 4,063,633 shares for $2.0 million, and the company now says its cash lasts into mid-2026, not the second half of 2026 that its March 6 annual report gave.

    NXTC
48. Jun 16, 2025Financings

    Aptevo files stock and warrant offering, signs $25.0 million Yorkville equity line

    Aptevo filed to sell up to 1,709,401 shares with five common warrants each and signed a $25.0 million equity line with Yorkville. Its auditor's report carries a going concern paragraph, and cash was $2,139 thousand at March 31, 2025.

    APVO
49. Jun 13, 2025Financings

    Rezolute sells 1,295,383 shares in private placement for $4,209,994.75

    An 8-K filed June 13, 2025 reports the sale. Certain insiders had agreed in April to buy up to $10,000,000 of stock at $3.25 per share in the private placement.

    RZLT
50. Jun 13, 2025Financings

    Quince Therapeutics (now IRulya) agrees to $11.5 million private placement

    Quince Therapeutics agreed to sell about $11.5 million of stock and warrants to institutional investors and three executives, and up to $10.4 million more depends on holders paying $1.20 per share.

    IRLAQNCX
51. Jun 13, 2025Listings

    Incannex Healthcare applies to move its listing to the Nasdaq Capital Market

    The transfer from the Nasdaq Global Market is part of the company's effort to meet Nasdaq continued listing requirements. Shares would keep trading as IXHL.

    IXHL
52. Jun 13, 2025Listings

    Equillium gets 180 more days from Nasdaq to meet minimum bid price requirement

    Nasdaq extended Equillium's deadline to December 8, 2025. The company says it will consider options including a reverse stock split, and its stock keeps trading on the Nasdaq Capital Market as "EQ".

    EQ
53. Jun 12, 2025Financings

    Tempest Therapeutics prices $6.25 registered direct offering, expects $4.1 million net

    Tempest sold 405,000 shares and prefunded warrants for 334,000 shares to one institutional investor at $6.25 each, for about $4.1 million net. The company's cash estimate runs only into the second quarter of 2026, and it is exploring strategic alternatives.

    TPST
54. Jun 12, 2025Listings

    Spruce Biosciences wins Nasdaq panel appeal, with bid price deadline of August 5, 2025

    A Nasdaq panel accepted Spruce Biosciences' appeal, but the stock returns to the Capital Market only if it meets the minimum bid price by August 5, 2025. Trading had been suspended on April 29, 2025, and the 10-K carries a going-concern warning.

    SPRB
55. Jun 12, 2025Listings

    Spruce Biosciences wins Nasdaq appeal, must meet bid price rule by August 5, 2025

    Spruce's shares have traded over the counter since a Nasdaq suspension on April 29, 2025. The Hearings Panel accepted the company's appeal on June 9, 2025, but the stock returns to the Nasdaq Capital Market only if it meets the bid price requirement by August 5, 2025.

    SPRB
56. Jun 12, 2025Financings

    Scinai Immunotherapeutics raises $1.38 million through Yorkville equity line drawdowns

    The sales were priced at about $3.03 per ADS, a 3% discount to market. Scinai also says a cost-cutting program will lower annual employment costs by about $815,000.

    SCNI
57. Jun 12, 2025Listings

    I-Mab (now NovaBridge Biosciences) regains Nasdaq minimum bid price compliance

    Nasdaq notified the company on June 11, 2025. Its American Depositary Shares will stay listed and traded on Nasdaq.

    NBP
58. Jun 12, 2025Listings

    AIM ImmunoTech regains NYSE American compliance as 1-for-100 reverse stock split takes effect

    AIM ImmunoTech regained NYSE American compliance on its low selling price test after a 1-for-100 reverse split effective June 12, 2025, with trading under AIM due to resume June 17. Its 2024 annual report carries a going-concern warning and a working capital deficit, and a separate stockholders' equity notice from December 2024 is not covered by this filing.

    AIM
59. Jun 12, 2025Distress

    ADC Therapeutics plans about 30% workforce cut, U.K. closure, $100 million private placement

    ADC Therapeutics approved a restructuring on June 11, 2025 that closes its U.K. research facility and cuts about 30% of its global workforce. The same day it agreed to a $100 million private placement priced at $3.53 per share.

    ADCT
60. Jun 11, 2025Financings

    Tonix sets up programs to sell up to $150.0 million and $75.0 million of stock

    Tonix set up two ways to sell new stock on June 11, 2025: up to $150.0 million through A.G.P./Alliance Global Partners and up to $75.0 million to Lincoln Park Capital Fund. Its lead drug has an FDA decision date of August 15, 2025.

    TNXP
61. Jun 11, 2025Mergers

    Salarius (now Decoy Therapeutics) cuts its valuation to $2.31 million in merger deal

    Salarius cut its relative valuation in the Decoy merger from $4.6 million to $2.31 million, so its legacy holders would keep 7.6% of the combined company instead of 14.1%. The 8-K blames "substantial deterioration" in its share price.

    DCOY
62. Jun 11, 2025Financings

    OKYO Pharma files for up to $15,500,000 at-the-market share sales

    OKYO Pharma Limited says it sold $3,999,911 under an earlier $4,000,000 supplement and will make no more sales under it. The new program is with B. Riley Securities.

    OKYO
63. Jun 11, 2025Debt Financing

    Cogent Biosciences draws $50 million from term loan facility of up to $400 million with SLR

    Cogent drew $50 million of a term loan facility of up to $400 million from SLR credit funds on June 11, 2025. Most of the rest depends on pivotal trial results and a launch the company expects in 2026, and the debt falls due in 2030.

    COGT
64. Jun 9, 2025Debt Financing

    Integra LifeSciences amends credit agreement for covenant relief on leverage ratio

    Integra LifeSciences' June 6, 2025 amendment lifts its maximum consolidated total leverage ratio to 5.00 to 1.00 through June 30, 2026, then steps it down. The company says total indebtedness does not rise, but the amendment also restricts investments, new borrowing and transfers of intellectual property until the relief period ends.

    IART
65. Jun 6, 2025Listings

    Tango Therapeutics holders approve doubling authorized shares to 400,000,000

    Common stock authorized rises from 200,000,000 shares. The vote was 85,825,060 for and 11,001,501 against, and the 8-K gives no reason for the larger share count.

    TNGX
66. Jun 6, 2025Listings

    Bolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9

    Bolt Biotherapeutics filed a one-for-twenty reverse stock split on June 6, 2025, with split-adjusted trading set for June 9. The 8-K gives no reason for the split, and the company's 2024 annual report already said there was substantial doubt about its ability to continue as a going concern.

    BOLT
67. Jun 6, 2025Listings

    Bolt Biotherapeutics effects 1:20 reverse stock split

    Bolt Biotherapeutics filed a Certificate of Amendment on June 6, 2025 to effect a one-for-twenty reverse stock split. Split-adjusted trading on the Nasdaq Capital Market under the existing ticker BOLT was scheduled to begin June 9, 2025, under a new CUSIP number.

    BOLT
68. Jun 6, 2025Mergers

    Aytu BioPharma signs EXXUA commercialization deal with Fabre-Kramer, pays $3,000,000 upfront

    Aytu paid Fabre-Kramer a $3,000,000 upfront on June 5, 2025 for U.S. rights to EXXUA and owes a second $3,000,000 tied to sales timing. Royalties start at 28% of net sales, and the annual report shows an accumulated deficit of $320.0 million.

    AYTU
69. Jun 6, 2025Mergers

    Aytu BioPharma pays $3,000,000 upfront for U.S. rights to depression drug EXXUA

    Aytu agreed to pay a $3,000,000 upfront for U.S. rights to EXXUA, with further payments and royalties of 28% to 39% of net sales that depend on sales.

    AYTU
70. Jun 5, 2025Listings

    Talphera gets second 180-day Nasdaq period, until December 1, 2025, to fix bid price

    Talphera moved its stock to the Nasdaq Capital Market on May 30, 2025 to qualify. It told Nasdaq it would do a reverse stock split if necessary.

    TLPH
71. Jun 5, 2025Listings

    Talphera gets second 180-day Nasdaq bid price period, to December 1, 2025

    Talphera (TLPH) moved its listing to The Nasdaq Capital Market on May 30, 2025 and received an additional 180 days to regain the $1.00 minimum bid price. It has told Nasdaq it will use a reverse stock split, if necessary.

    TLPH
72. Jun 5, 2025Legal

    Harmony Biosciences settles WAKIX patent suit with Lupin, generic entry set for 2030

    Lupin Limited gets a license to launch a generic WAKIX no earlier than January 2030, or July 2030 with pediatric exclusivity, and the Delaware case will be dismissed.

    HRMY
73. Jun 5, 2025Mergers

    Fortress Biotech to receive about $28.0 million as Checkpoint sale to Sun Pharma closes

    Fortress Biotech says it will receive about $28.0 million in cash from the sale of Checkpoint Therapeutics to Sun Pharma, with up to $4.8 million more if a milestone is met. The gain on deconsolidation is an accounting figure, and pro forma cash is lower than reported.

    FBIO
74. Jun 5, 2025Mergers

    Fortress Biotech to receive about $28.0 million as Checkpoint merger with Sun Pharma closes

    Checkpoint Therapeutics became a wholly owned Sun Pharma subsidiary on May 30, 2025. Fortress may also get up to $4.8 million through CVRs and a 2.5% royalty on certain net sales.

    FBIO
75. Jun 5, 2025Financings

    Cellectar Biosciences agrees to warrant inducement deal for about $2.5 million gross proceeds

    Holders of warrants for 8,301,322 shares agreed to exercise at a reduced price of $0.3041 per share. Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025.

    CLRB
76. Jun 5, 2025Financings

    Avalo Therapeutics sets up $75,000,000 at-the-market program with TD Cowen

    Avalo ended an earlier $50.0 million sales agreement with Oppenheimer. Its stock last sold at $3.72 on May 29, 2025.

    AVTX
77. Jun 4, 2025Distress

    Relay Therapeutics agrees to end Binney Street lease early and move to smaller space

    Relay paid a lease modification payment of approximately $2.5 million and a relocation payment of approximately $3.5 million. It says the changes cut rent expense by approximately $16 million.

    RLAY
78. Jun 4, 2025Listings

    Nektar sets one-for-fifteen reverse split, effective June 8, 2025

    Nektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split, and a June 6 amendment raised authorized shares to 390,000,000.

    NKTR
79. Jun 4, 2025Debt Financing

    Elicio Therapeutics takes $10 million secured loan from investor GKCC

    The note carries interest of up to 12.5% and matures on June 3, 2028. Elicio expects the cash to fund operations into the first quarter of 2026.

    ELTX
80. Jun 3, 2025Listings

    Taysha Gene Therapies holders approve raising authorized shares to 700,000,000

    Common stock authorized rises from 400,000,000 shares. The company filed the amendment in Delaware on June 2, 2025.

    TSHA
81. Jun 3, 2025Listings

    Ironwood Pharmaceuticals gets Nasdaq minimum bid price deficiency notice

    Nasdaq said Ironwood's Class A stock closed below $1.00 for 30 consecutive business days. The company has until November 24, 2025 to regain compliance, and the letter has no immediate effect on its listing.

    IRWD
82. Jun 3, 2025Financings

    Bon Natural Life announces share buyback of up to $1.0 million

    Bon Natural Life's board approved a share repurchase of up to $1.0 million of its Class A ordinary shares, to be bought in the open market by TradeUp Securities as exclusive agent. The company says it is not obliged to buy any particular number of shares and may suspend the program at any time.

    BON
83. Jun 3, 2025Mergers

    Alto Neuroscience buys depression drug candidates from Chase Therapeutics, pays $1,750,000 upfront

    Alto may owe up to $71,500,000 in milestone payments, payable in cash or restricted stock, and says its cash is still expected to fund operations into 2028.

    ANRO
84. Jun 2, 2025Listings

    Editas Medicine holders approve doubling authorized common stock to 390,000,000

    The amended charter also lifts total authorized capital stock to 395,000,000 shares. Holders also approved a revised 2015 Stock Incentive Plan that removes its evergreen provision.

    EDIT
85. Jun 2, 2025Distress

    Actuate Therapeutics presentation repeats going-concern doubt and need for capital

    Actuate Therapeutics filed a corporate overview dated May 31, 2025 that repeats its going-concern warning and says it needs capital to fund operations beyond the second quarter of fiscal 2025. The deck's survival figures are draft, unaudited data, and its progression-free survival result is not statistically significant.

    ACTU

May 2025

1. May 30, 2025Financings

   Reviva Pharmaceuticals sets up $50 million at-the-market stock program

   B. Riley Securities and Alliance Global Partners will act as sales agents for a 3% commission. The stock's last reported sale price was $1.10 on May 27, 2025.

   RVPH
2. May 30, 2025Financings

   ReShape Lifesciences (now Vyome Holdings) sets up $9,700,000 at-the-market program

   Maxim Group LLC is the exclusive sales agent for up to $9,700,000 of stock, for a 3.0% commission. Two days earlier, Nasdaq had determined to delist ReShape, whose stockholders' equity was $1.2 million at March 31, 2025.

   HIND
3. May 30, 2025Listings

   MetaVia gets Nasdaq minimum bid price notice, deadline November 25, 2025

   The company's stock closed below $1.00 for 30 consecutive business days. It may be eligible for a second period of 180 calendar days.

   MTVA
4. May 30, 2025Distress

   Adlai Nortye drops buparlisib after Phase III miss, plans workforce cut to preserve cash

   Adlai Nortye's Phase III BURAN trial of buparlisib missed its overall survival endpoint, the company is dropping the drug, and it plans to cut staff "to preserve cash," with the release giving no survival figures.

   ANL
5. May 30, 2025Financings

   Adagene files to sell up to US$100,000,000 of ADSs at market

   Adagene Inc. filed a prospectus supplement for an at-the-market program of up to US$100 million of American depositary shares, sold through Leerink Partners. The filing repeats the warning that its auditor is in mainland China, where trading in its ADSs could be barred.

   ADAG
6. May 29, 2025Legal

   Taysha Gene Therapies prices public offering of 46,868,687 shares and pre-funded warrants at $2.75

   Taysha Gene Therapies agreed to sell 46,868,687 shares and pre-funded warrants for 25,858,586 more at $2.75 a share, with net proceeds estimated at $187.4 million. The company says that money and its existing cash will last into 2028, and the filing names no lawsuit or defendant.

   TSHA
7. May 29, 2025Distress

   Keros Therapeutics plans workforce reduction of approximately 45% in restructuring

   Keros's board approved a plan on May 28, 2025 to cut its overall workforce by about 45%, with about $3.2 million in severance charges and up to about $0.4 million in retention costs. The cuts follow the January 2025 early termination of the PAH trial over pericardial effusion events, though the company held $559.9 million in cash at the end of 2024.

   KROS
8. May 29, 2025Distress

   Keros Therapeutics drops cibotercept in PAH, cuts about 45% of staff

   Headcount will fall to 85 full-time employees, with average annualized savings of about $17 million. The strategic alternatives review is still under way.

   KROS
9. May 28, 2025Financings

   ORIC Pharmaceuticals agrees to $125 million private placement led by SR One

   ORIC Pharmaceuticals agreed to sell about 19.2 million shares or pre-funded warrants at $6.50 in a private placement with roughly $125 million in gross proceeds. The company says the cash funds operations into the second half of 2027, a runway tied to a Phase 3 readout it has not yet reported.

   ORIC
10. May 28, 2025Financings

    MAIA Biotechnology agrees to $695,000 private placement with warrants

    MAIA Biotechnology (NYSE American: MAIA) expects gross proceeds of approximately $695,000 from shares sold at $1.50 with warrants at $1.71. A director is among the buyers, and closing is expected May 29, 2025.

    MAIA
11. May 28, 2025Financings

    Immunic launches pre-funded warrant offering; final terms total $64,991,334

    Immunic began an underwritten warrant offering on May 28, 2025 and set final terms on May 30: $0.7499 a unit, $64,991,334 in total. Leerink Partners is sole bookrunner.

    IMUX
12. May 28, 2025Listings

    CytomX Therapeutics regains compliance with Nasdaq minimum bid price requirement

    Nasdaq closed the matter on May 27, 2025, after the stock closed at $1.00 or above for 10 consecutive trading days. The annual report put the lead programs in Phase 1, and the 8-K gives no cash figures.

    CTMX
13. May 27, 2025Listings

    Mind Medicine (now Definium Therapeutics) grants new CFO inducement awards

    MindMed named Brandi L. Roberts chief financial officer effective June 2, 2025, with inducement awards of an option on 500,000 shares and 125,000 performance share units. The awards sit outside the company's equity plans, and the lead drug's pivotal trials have not yet reported.

    DFTX
14. May 27, 2025Financings

    Lexeo Therapeutics agrees to $80 million private placement of stock and warrants

    Lexeo Therapeutics agreed to a private placement of 20,790,120 shares and pre-funded warrants for 6,963,556 more, with common warrants attached, for gross proceeds the company expects to be about $80 million. Part of that figure depends on warrants that have not been exercised, and the runway it cites depends on a 2027 readout.

    LXEO
15. May 27, 2025Financings

    Lexeo Therapeutics agrees to $80 million private placement at $2.8825 per share

    Lexeo expects gross proceeds of approximately $80 million from 20,790,120 shares or pre-funded warrants at $2.8825, with common warrants struck at $2.82.

    LXEO
16. May 27, 2025Financings

    GT Biopharma enlarges preferred stock private placement to $5,950,000.00

    A new purchaser joined the Series L 10% Convertible Preferred deal, which now carries an aggregate purchase price of $5,950,000.00. Buyers also hold greenshoe rights for up to $21,616,514 more.

    GTBP
17. May 23, 2025Listings

    Q32 Bio gets Nasdaq notice after reporting stockholders' deficit of ($4.0 million)

    The minimum stockholders' equity requirement is $2.5 million. Q32 Bio has 45 calendar days to submit a plan to regain compliance.

    QTTB
18. May 23, 2025Listings

    Plus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form 10-Q

    Nasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan by July 21, 2025, and any exception could run until November 17, 2025.

    CNSY
19. May 23, 2025Legal

    Emergent BioSolutions derivative lawsuit settlement gets preliminary court approval

    The U.S. District Court for the District of Maryland granted preliminary approval on May 9, 2025 to a settlement of shareholder derivative suits against current and former Emergent directors and officers. The settlement provides a $15 million payment to the company from insurance and governance reforms, and final approval is set for August 6, 2025.

    EBS
20. May 23, 2025Distress

    Boundless Bio cuts about one-third of workforce, narrows pipeline, sees cash into 2028

    Boundless Bio will drop current BBI-355 trial arms and test BBI-355 with BBI-825. The cut is expected to cost about $1.2 million. Cash and short-term investments were $138.3 million on March 31, 2025, with runway expected into the first half of 2028.

    BOLD
21. May 23, 2025Listings

    Biofrontera falls below Nasdaq $2,500,000 stockholders' equity requirement

    Biofrontera reported stockholders' equity of $469,000 at March 31, 2025, far below the $2,500,000 Nasdaq requires. It has 45 calendar days to submit a plan to regain compliance.

    BFRI
22. May 23, 2025Listings

    Artelo Biosciences gets Nasdaq notice for $652,000 stockholders' equity, below $2,500,000 minimum

    The May 22, 2025 letter cites Nasdaq Listing Rule 5550(b)(1). Artelo has until July 7, 2025 to submit a plan to regain compliance, and the stock stays listed in the meantime.

    ARTL
23. May 22, 2025Listings

    Sol-Gel Technologies regains Nasdaq minimum bid price compliance after extension

    Nasdaq confirmed on May 22, 2025 that the bid price deficiency matter is closed. The stock closed at $1.00 or more for 13 consecutive business days.

    SLGL
24. May 22, 2025Listings

    Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone

    Nasdaq flagged the missing quarterly report on May 20, 2025 as another basis for delisting, ahead of a Panel hearing set for May 27, 2025. Onconetix also issued a promissory note to Keystone Capital Partners for a $250,000.00 purchase price.

    ONCO
25. May 22, 2025Listings

    Aptevo Therapeutics gets Nasdaq stockholders' equity notice, sets 1-for-20 reverse stock split

    Aptevo reported a stockholders' deficit of $1,473,000 against a $2,500,000 minimum. It also filed an at-the-market prospectus supplement for up to $3,015,515 of stock, and it set a 1-for-20 reverse stock split for May 23, 2025.

    APVO
26. May 21, 2025Financings

    Telomir Pharmaceuticals raises $3 million in private placement with largest shareholder's trust

    Telomir sold 1 million restricted shares at $3.00 each to The Bayshore Trust, an entity affiliated with its largest shareholder. The price is 18% above the $2.54 closing price on the day of signing, and an earlier insider purchase in December 2024 was made at $7.00 a share.

    TELO
27. May 21, 2025Listings

    Nasdaq panel moves to delist Petros Pharmaceuticals, trading to shift to OTC

    A Nasdaq Hearings Panel has decided to delist Petros, with trading suspended at the open on May 22, 2025, on four grounds that include equity and bid-price rules and concern over the February 2025 public offering. Petros will ask the Listing Council to review the decision.

    PTPI
28. May 21, 2025Mergers

    Alumis completes merger with ACELYRIN at 0.4814 shares per ACELYRIN share

    The closing release uses 0.4814 shares per ACELYRIN share, while the merger agreement and Alumis's annual report set 0.4274, and the release does not explain the gap.

    ALMS
29. May 21, 2025Mergers

    Alumis completes ACELYRIN merger at 0.4814 Alumis shares per ACELYRIN share

    Alumis Inc. says the merger closed May 21, 2025, making ACELYRIN a wholly owned subsidiary. Alumis says its cash runway now extends into 2027, and Lynn Tetrault joined its board.

    ALMS
30. May 20, 2025Financings

    Rani Therapeutics cuts warrant exercise price to $0.65 for about $4.3 million in gross proceeds

    Rani Therapeutics cut the exercise price of two outstanding warrants from $3.08 and $3.00 to $0.65 so an existing institutional investor would exercise them, for gross proceeds of about $4.3 million before advisory fees. The investor also receives a new Series D warrant for up to 13,160,172 shares.

    RANI
31. May 20, 2025Listings

    Intensity Therapeutics gets Nasdaq stockholders' equity deficiency notice

    Nasdaq says the company, whose cash was $2,590 thousand at year-end 2024, fell short of the $2,500,000 stockholders' equity minimum and has until July 3, 2025 to submit a compliance plan.

    INTS
32. May 20, 2025Legal

    Acadia Pharmaceuticals wins Delaware ruling on NUPLAZID formulation patent

    A federal court in Delaware ruled for Acadia on infringement and validity of the '721 patent against Aurobindo and MSN entities. The company also signed a lease of 12 years and two months for new Princeton offices.

    ACAD
33. May 19, 2025Mergers

    Royalty Pharma completes acquisition of RP LLC for $200,000,000 cash and 24,530,266 Class E shares

    Royalty Pharma Holdings Ltd also assumed a $380 million term loan facility. The 8-K reports a loan amendment with Bank of America, N.A., an exchange agreement and amended articles of association.

    RPRX
34. May 19, 2025Debt Financing

    REGENXBIO receives $150 million at closing of royalty bond loan with HealthCare Royalty

    A REGENXBIO subsidiary signed a limited recourse royalty bond with an affiliate of HealthCare Royalty Management, repaid only from royalties. The company says the $150 million received at closing extends its cash runway into early 2027.

    RGNX
35. May 19, 2025Mergers

    Protagenic Therapeutics combines with Phytanix Bio in all-stock deal

    Phytanix Bio holders would own about 65% of the combined company before financing, on a fully diluted basis, and their preferred stock and warrants need Nasdaq stockholder approval before they can convert or be exercised. The release's count of six drug candidates includes five preclinical assets.

    PTIX
36. May 19, 2025Financings

    China SXT sells 10,000,000 shares with warrants for $5,100,000 gross

    China SXT sold 10,000,000 shares with two warrants each for a combined $0.51 a share. The warrant exercise price resets to $0.24 on the seventh day, and the warrants could cover up to 100,000,000 shares. No placement agent or underwriter was used.

    SXTC
37. May 16, 2025Listings

    Neumora gets Nasdaq minimum bid price notice, has until November 10, 2025 to comply

    Nasdaq told Neumora Therapeutics on May 14, 2025 that it is below the $1.00 minimum bid price requirement. The company is weighing a reverse stock split, with a stockholder vote set for May 28, 2025.

    NMRA
38. May 16, 2025Listings

    Neumora Therapeutics gets Nasdaq notice for stock below $1.00 bid price

    The company has until November 10, 2025 to regain compliance. Stockholders vote on a possible reverse stock split on May 28, 2025.

    NMRA
39. May 16, 2025Listings

    Dermata regains Nasdaq stockholders' equity compliance but gets bid price delisting notice

    Dermata said on May 16, 2025 that Nasdaq's staff has confirmed it regained compliance with the stockholders' equity requirement, but a bid price notice says its securities will be suspended on May 23, 2025 unless it requests a hearing by May 21. The company plans to request one.

    DRMA
40. May 15, 2025Listings

    Tivic Health (now Valion Bio) ends quarter with $669,000 cash, lines up financing

    Tivic reported $669,000 of cash at March 31, 2025 and a $1.5 million net loss for the quarter. It then lined up a $25 million equity line and a purchase agreement for up to $8.4 million of securities.

    VBIO
41. May 15, 2025Distress

    ReShape Lifesciences (now Vyome Holdings) files NT 10-Q, delaying its first-quarter 10-Q

    The company says it needs more time to compile its financial statements for the quarter ended March 31, 2025, including to reflect the May 9, 2025 reverse stock split.

    HIND
42. May 15, 2025Distress

    ReShape Lifesciences (now Vyome Holdings) delays first-quarter 10-Q

    ReShape says a reverse stock split on May 9, 2025 is one reason its March quarter 10-Q needs more time. It expects to file within the five-day extension and says it does not expect a significant change in results.

    HIND
43. May 15, 2025Mergers

    Pulmatrix says Cullgen merger registration is effective, plans to divest assets

    Pulmatrix said the SEC declared effective the registration statement for its proposed merger with Cullgen, which it expects to close in June 2025. It plans to divest PUR3100 and its other assets as part of the deal. Its cash was $7.7 million on March 31, 2025.

    PULM
44. May 15, 2025Mergers

    Pulmatrix says Cullgen merger filing is effective, expects June 2025 close

    Pulmatrix says the SEC has declared effective its Form S-4 for the Cullgen merger, and expects a June 2025 close while it seeks buyers for its own assets. It had $7.7 million of cash at March 31, 2025, which it says lasts through the anticipated closing.

    PULM
45. May 15, 2025Distress

    Plus Therapeutics (now Cerenome) says first-quarter 10-Q will be late over warrant accounting

    The company filed an NT 10-Q on May 15, 2025. It needs more time to account for warrants from a March 2025 private placement and expects lower stockholders' equity at March 31, 2025.

    CNSY
46. May 15, 2025Distress

    Plus Therapeutics (now Cerenome) delays Q1 report over warrant accounting from March PIPE

    The company needs more time to finalize accounting for common stock purchase warrants issued in its March 2025 private placement. It expects a warrant liability that will lower stockholders' equity.

    CNSY
47. May 15, 2025Debt Financing

    Omeros exchanges $70.8 million of 2026 convertible notes for 9.50% notes due 2029

    The one-for-one exchange also means Omeros no longer has to make a $20.0 million term loan prepayment. Separately, it agreed to convert $10 million of the old notes into common stock.

    OMER
48. May 15, 2025Distress

    OSR Holdings (now OSR Health) delays quarterly report, expects $11.4 million loss

    The company blamed a delay in finalizing its statements with its auditors after its February 14, 2025 business combination.

    OSRH
49. May 15, 2025Distress

    NovelStem International delays first-quarter 2025 report as auditors finish review

    NovelStem says its auditors need more time to finish their review of the March quarter, and it expects to file within five calendar days after the due date. NewStem, in which it holds about 31%, ceased operations and began liquidation in October 2024.

    NSTM
50. May 15, 2025Distress

    Neuphoria Therapeutics delays quarterly report for period ended March 31, 2025

    Neuphoria said it needs more time to compile supporting documents and let its auditor finish its review. It expects to file within the five-day extension period.

    NEUP
51. May 15, 2025Distress

    Hepion Pharmaceuticals delays quarterly report for three months ended March 31, 2025

    Hepion says it is still compiling information for its March quarter 10-Q and expects to file within five calendar days. The notice previews research and development spending of $22,235, down from $2.5 million.

    HEPA
52. May 15, 2025Financings

    HCW Biologics closes $5.0 million offering of 671,140 units at $7.45

    Each unit carries two warrants exercisable at $7.45, and Maxim Group was sole placement agent. The prospectus carries going-concern doubt and a Nasdaq compliance warning.

    HCWB
53. May 15, 2025Distress

    Greenwich LifeSciences delays first-quarter report, expects to file by May 20, 2025

    The company filed a late-filing notice for its quarterly report for the three months ended March 31, 2025. Its lead candidate, GLSI-100, is in a Phase III trial that is still expanding.

    GLSI
54. May 15, 2025Distress

    Exicure files NT 10-Q late-filing notice, needs more time on March 31, 2025 quarterly report

    Exicure told the SEC on May 15, 2025 that it cannot file its quarterly report for the period ended March 31, 2025 on time, because it has not finished the accounting for its acquisition of GPCR Therapeutics USA, Inc. The company expects to file within the five-day extension that Rule 12b-25 allows, and it says the acquisition will make the quarter's results hard to compare with last year.

    XCUR
55. May 15, 2025Distress

    Exicure delays first quarter report over GPCR acquisition accounting

    The company said it needs more time on the purchase price allocation for GPCR Therapeutics USA, Inc. It expects results to change significantly from the March 31, 2024 quarter.

    XCUR
56. May 15, 2025Distress

    Eloxx Pharmaceuticals files NT 10-Q, cites lack of funds for accountant review

    Eloxx says it cannot afford to engage its auditor to review first quarter 2025 financials, and it expects to disclose substantial doubt about its ability to continue as a going concern. It expects cash of $0.4 million at March 31, 2025.

    ELOX
57. May 15, 2025Financings

    Atara Biotherapeutics prices about $16.0 million registered direct offering at $6.61

    The deal includes 834,237 shares and pre-funded warrants for 1,587,108 more. Atara plans to use the money toward approval of tab-cel.

    ATRA
58. May 15, 2025Distress

    Aspira Women's Health delays first-quarter report to finish debt and equity accounting

    Aspira says it needs more time to finish accounting for debt and equity deals from the first quarter, and it expects a smaller net loss helped by a milestone payment.

    AWHL
59. May 14, 2025Financings

    Oncolytics Biotech flags going concern doubt in first-quarter statements

    Oncolytics had cash of 15,303 thousand Canadian dollars at March 31, 2025, and said it can fund operations through the third quarter of 2025.

    ONCY
60. May 14, 2025Financings

    MetaVia closes private placement with about $10.0 million in gross proceeds

    MetaVia sold 9,479,345 shares at $0.71 each and pre-funded warrants for 4,605,162 shares. Ladenburg Thalmann was the exclusive placement agent, for a cash fee of 9.0% of gross proceeds.

    MTVA
61. May 14, 2025Financings

    MetaVia announces $10.0 million private placement priced at the market

    Investors are buying 9,479,345 shares at $0.71 and 4,605,162 pre-funded warrants. Proceeds go mainly to development of obesity candidate DA-1726.

    MTVA
62. May 14, 2025Mergers

    Jade Biosciences files Q1 financials after Aerovate merger and $334.2 million financing

    Jade Biosciences (Nasdaq: JBIO) reported a net loss of $38,169 thousand and cash of $49,929 thousand for the quarter ended March 31, 2025, a period that ended before the merger and pre-closing financing closed April 28.

    JBIO
63. May 14, 2025Mergers

    Jade Biosciences (formerly Aerovate) details $334.2 million pre-merger financing

    Aerovate Therapeutics took the Jade Biosciences name when the deal closed on April 28, 2025. Pre-merger Jade's management team runs the combined company.

    JBIO
64. May 14, 2025Distress

    Citius Pharmaceuticals 10-Q cites going-concern doubt and Nasdaq compliance

    The company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31.

    CTXRCTOR
65. May 14, 2025Distress

    Citius Oncology 10-Q cites auditor's going-concern doubt

    Citius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price.

    CTORCTXR
66. May 13, 2025Listings

    Sangamo Therapeutics prices $23.0 million offering of stock and warrants at $0.50

    Sangamo's underwritten offering is expected to bring in about $23.0 million. The 46,633,393 purchase warrants in the deal outnumber the 12,235,000 common shares, and Cantor Fitzgerald & Co. represents the underwriters.

    SGMOQ
67. May 13, 2025Debt Financing

    Altimmune draws $15.0 million under Hercules loan agreement for up to $100.0 million

    The term loan has four tranches and matures June 1, 2029. The company reported $150 million in cash, cash equivalents and short-term investments as of March 31, 2025.

    ALT
68. May 12, 2025Financings

    Zeo ScientifiX issues 100,000 shares and warrants for 500,000 shares to a consultant

    The company also granted fully vested options at $2.86 per share to its interim chief executive and directors.

    ZEOX
69. May 12, 2025Legal

    United Therapeutics files patent infringement suit against Liquidia over YUTREPIA

    The complaint alleges Liquidia infringes U.S. Patent No. 11,357,782 and seeks to bar Liquidia from commercializing YUTREPIA if approved. Liquidia says the claims mirror a patent that the Patent Trial and Appeal Board held invalid.

    LQDA
70. May 12, 2025Financings

    Tango Therapeutics files $400,000,000 replacement shelf with $100,000,000 ATM supplement

    The new shelf replaces one that expires on September 12, 2025. Jefferies LLC would earn up to 3.0% on ATM sales, and Tango's stock closed at $1.10 per share on May 8, 2025.

    TNGX
71. May 12, 2025Listings

    Nasdaq panel delists Hepion Pharmaceuticals; company expects OTC quotation

    Nasdaq's hearings panel decided to delist Hepion after it failed the $1.00 minimum bid price and Nasdaq said it believes the company is a public shell. Trading was set to stop on May 13, 2025, and Hepion expects its shares to quote on the OTC Markets.

    HEPA
72. May 12, 2025Listings

    Immunome reports $317.3 million in cash and expects runway into 2027

    Immunome's cash total includes $161.7 million from a January 2025 financing, and the quarter ended with a $41.6 million net loss. Its lead drug's Phase 3 data are not due until the second half of 2025.

    IMNM
73. May 12, 2025Financings

    CervoMed sets up at-the-market program for up to $50,000,000 with Leerink Partners

    Leerink Partners earns 3.0% of any gross proceeds, and CervoMed is not obliged to sell any shares. The prospectus supplement notes an auditor going-concern paragraph.

    CRVO
74. May 12, 2025Distress

    Atara Biotherapeutics cuts workforce by about 30%, expects $1.4 million in severance

    The company will keep about 23 employees after the cut and expects about $1.4 million in severance. Its latest annual report said cash of $42.5 million would not last twelve months and that about $15 million more was needed to pursue US approval of its lead drug.

    ATRA
75. May 12, 2025Financings

    Abeona Therapeutics agrees to sell priority review voucher for $155 million

    Abeona received the voucher when the FDA approved ZEVASKYN on April 28, 2025. The company says the proceeds give it cash for more than two years of operating expenses, but the release does not name the buyer.

    ABEO
76. May 9, 2025Financings

    Nuvectis Pharma sets up $60 million at-the-market stock program with Leerink

    Nuvectis can sell up to $60 million of stock through Leerink. It ended an earlier $40 million program with H.C. Wainwright after selling about $18.6 million under it.

    NVCT
77. May 9, 2025Financings

    Apimeds Pharmaceuticals US prices $13.5 million IPO at $4.00 a share

    Apimeds is selling 3,375,000 shares at $4.00 for $13.5 million gross and listing on the NYSE American as APUS. Its controlling holder stays above 54%, and the company carries a going-concern paragraph from its auditor.

    APUS
78. May 8, 2025Distress

    Vor Biopharma winds down clinical operations, cuts 147 jobs and explores strategic alternatives

    Vor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause.

    VOR
79. May 8, 2025Distress

    Liquidia files 2024 financials with going-concern doubt, revised debt accounting

    The auditor's report cites recurring losses. Management also changed how it accounts for two amendments to a $100.0 million royalty-backed financing.

    LQDA
80. May 8, 2025Financings

    Elutia issues 1,105,528 shares to Ligand to settle $2.2 million in royalties

    Elutia receives no cash from the issuance. In its first-quarter results it said the change reduces cash outflows by $2.2 million in H1 2025.

    ELUT
81. May 7, 2025Listings

    TransCode Therapeutics faces Nasdaq delisting with no grace period, plans hearing

    TransCode received a Nasdaq notice on May 6, 2025 that its stock would be delisted from the Nasdaq Capital Market unless it appeals. Earlier reverse splits left it with no compliance period, so it must request a hearing by May 13, 2025.

    RNAZ
82. May 7, 2025Financings

    NuCana plc prices best-efforts offering of 2,452,935 ADSs with warrants

    The combined price of $0.6454 per ADS is set below the $1.10 last sale price on May 5, 2025. Warrant terms and a zero exercise price option on the Series B warrants could issue far more ADSs than the 2,452,935 sold.

    NCNA
83. May 7, 2025Distress

    Korro Bio announces 20% workforce reduction, expects cash runway into 2027

    Korro Bio began a restructuring on May 7, 2025, cutting about 20% of its workforce and taking one-time charges of about $1.2 million. The company cut costs before its first interim data readout, and its net loss widened in the first quarter.

    KRRO
84. May 7, 2025Financings

    Design Therapeutics files $300,000,000 shelf with $100,000,000 ATM sales agreement

    Jefferies LLC is the sales agent under an Open Market Sale Agreement for the $100,000,000 at-the-market portion. The May 7, 2025 filing gives a last reported sale price of $4.36 on May 5, 2025 and does not state a cash balance.

    DSGN
85. May 7, 2025Financings

    Cyclerion Therapeutics (now Korsana Biosciences) sets up ATM program with Guggenheim

    The agreement covers up to $20,000,000 of stock, but small-float limits cap current sales at $2,994,080.

    KRSA
86. May 7, 2025Listings

    Cosmos Health gets second 180-day Nasdaq period to lift stock above $1.00

    Nasdaq gave the company until November 3, 2025 to lift its bid above $1.00 for 10 straight business days. The first 180-day period expired on May 5, 2025, and the release gives no plan beyond the CEO's stated confidence.

    COSM
87. May 6, 2025Financings

    Exicure buys about $3.125 million of convertible bonds from South Korean subsidiary

    The bonds of KC Creation Co., Ltd. mature on April 30, 2028 and yield 2.9% a year. KC Creation expects to use the money to buy stocks of other corporations.

    XCUR
88. May 6, 2025Financings

    Cogent Biosciences files for $50,000,000 at-the-market stock sales

    The amount is what remains under a $75,000,000 sales agreement with Guggenheim Securities after $25,000,000 was sold earlier. Dilution to new buyers at the May 2 price is $4.05 per share, and the company has recorded net losses in every year since it was founded.

    COGT
89. May 5, 2025Debt Financing

    Evolus signs amended loan agreement with $150,000,000 first tranche to refinance debt

    Evolus signed term loans of up to $250,000,000 in three tranches, with $150,000,000 advanced at the effective date. The loans carry 3-month SOFR plus 5.0%, with a 3.50% floor, and mature five years after the first tranche. Early repayment carries an exit payment of 2% of principal prepaid.

    EOLS
90. May 2, 2025Listings

    Palisade Bio gets Nasdaq notice for trading below $1.00 minimum bid price

    Palisade Bio has 180 calendar days from an April 30, 2025 Nasdaq notice to get its shares back above $1.00, and its lead candidate is still in a Phase 1 study.

    PALI
91. May 2, 2025Listings

    Palisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance

    Palisade Bio received a Nasdaq minimum bid price notice on April 30, 2025, after its stock closed below $1.00 for 30 consecutive trading days. It has 180 calendar days to regain compliance, and its 2024 annual report carries a going-concern warning alongside $9.8 million of cash.

    PALI
92. May 2, 2025Debt Financing

    PDS Biotechnology sells convertible debentures for $20,000,000 to retire Horizon loan

    PDS Biotechnology sold $22,222,222 of senior secured convertible debentures for $20,000,000 on April 30, 2025, and used about $19 million to repay its Horizon Technology loan. The filing names no placement agent, underwriter, financial adviser or counsel.

    PDSB
93. May 1, 2025Distress

    XORTX Therapeutics files late-filing notice for 2024 annual report

    The company says it needs more time for financial reporting, closing procedures and other disclosure items.

    XRTX
94. May 1, 2025Distress

    Pliant Therapeutics to cut workforce by about 45%, expects $3.6 million in severance costs

    Pliant expects to substantially complete the reduction by the end of the second quarter of 2025, with about $3.6 million in severance and related benefits. The cut follows the discontinuation of its BEACON-IPF Phase 2b trial of bexotegrast.

    PLRX
95. May 1, 2025Financings

    Pasithea Therapeutics files for share and warrant offering, later prices at $1.40

    The May 1, 2025 registration statement covered up to 3,246,753 shares at an assumed $1.54. The deal priced on May 6, 2025 at $1.40 for 3,571,428 shares or pre-funded warrants.

    KTTA
96. May 1, 2025Distress

    Nymox says 20-F is late, citing unfinished work and slow vendor replies to auditors

    The company says it is still compiling required information for its annual report for the year ended December 31, 2024.

    NYMXF
97. May 1, 2025Distress

    Arvinas cuts workforce by about 33% and drops two Phase 3 vepdegestrant trials with Pfizer

    Arvinas expects about $10 million in severance and termination costs, mostly in the second quarter of 2025. It and Pfizer removed two planned Phase 3 combination trials from the joint development plan.

    ARVN
98. May 1, 2025Listings

    Armata Pharmaceuticals flags going concern paragraph, gets $4.65 million from DoD

    The audit opinion in Armata's 2024 annual report contains a going concern explanatory paragraph. The company also received $4.65 million of additional Department of Defense award funding.

    ARMP
99. May 1, 2025Mergers

    Aerovate Therapeutics (now Jade Biosciences) completes merger and private placement

    Aerovate Therapeutics, whose only drug candidate missed its Phase 2b primary endpoint, closed its merger with Jade Biosciences on April 28, 2025. Aerovate holders kept about 1.4% of the combined company, and the financing includes $95 million of converted notes.

    JBIO
100. May 1, 2025Distress

     AN2 Therapeutics reports EBO-301 miss, projects $78.5 million in cash lasts into 2028

     AN2 Therapeutics says the Phase 3 portion of its EBO-301 study missed its primary endpoint, and it projects $78.5 million in cash lasting into 2028 while it shifts to Chagas, melioidosis and oncology programs that have no human efficacy data yet.

     ANTX

April 2025

1. Apr 30, 2025Distress

   XTL Biopharmaceuticals 20-F lists going-concern and delisting risks

   The annual report for 2024 also lists dilution risk and the availability of capital for working capital needs.

   XTLB
2. Apr 30, 2025Mergers

   TriSalus agrees to sell 5,500,000 shares at $4.00 in $22.0 million private placement

   TriSalus agreed to sell 5,500,000 shares at $4.00 in a private placement of about $22.0 million. The same deal ties it to an exchange offer for its Series A preferred stock, and the filing says the preferred terms would change.

   TLSI
3. Apr 30, 2025Listings

   Scilex Holding regains compliance with Nasdaq minimum bid price rule

   Scilex met the $1.00 minimum closing bid price requirement on April 30, 2025. Its common stock and public warrants stay on the Nasdaq Capital Market.

   SCLX
4. Apr 30, 2025Listings

   Quoin Pharmaceuticals regains compliance with Nasdaq $1.00 minimum bid price rule

   Nasdaq said on April 29, 2025 that Quoin's ADSs closed at $1.00 or more from April 9 to April 28, closing the minimum bid price matter. The company says it has no commercialized product and has generated no revenue to date.

   QNRX
5. Apr 30, 2025Mergers

   Avenue Therapeutics ends AJ201 license and transfers program back to AnnJi

   AnnJi will pay Avenue $2.0 million over 90 days, plus possible milestones and a 1.75% royalty.

   ATXI
6. Apr 30, 2025Listings

   ABVC BioPharma gets Nasdaq equity notice and sells 724,372 shares offshore

   ABVC reported stockholders' equity of $723,959, below the $2,500,000 Nasdaq minimum. It also sold shares to 15 non-U.S. buyers for a little more than $436,000.

   ABVC
7. Apr 29, 2025Distress

   Zhengye Biotechnology files late-filing notice, auditor needs more time on 20-F

   The company says it is still compiling information for its annual report for the year ended December 31, 2024.

   ZYBT
8. Apr 29, 2025Distress

   Scinai files late 20-F notice over accounting for $29 million loan conversion

   The company cites the conversion of its European Investment Bank debt to preferred equity and personnel losses after year-end, and expects to file by May 15, 2025.

   SCNI
9. Apr 29, 2025Distress

   Pfizer expands cost realignment program, adds $1.2 billion in expected savings

   Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program.

   PFE
10. Apr 29, 2025Distress

    Entrada Therapeutics to cut about 20% of workforce in strategic plan

    Entrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another.

    TRDA
11. Apr 29, 2025Distress

    Entrada Therapeutics plans workforce reduction of about 20% to focus on Duchenne programs

    The board approved a strategic plan on April 29, 2025 that expects about $2 million in charges, mostly severance. The company says its cash runway still reaches into the second quarter of 2027.

    TRDA
12. Apr 29, 2025Listings

    Amarin regains compliance with Nasdaq minimum bid price requirement

    Nasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq.

    AMRN
13. Apr 28, 2025Listings

    Tempest Therapeutics regains compliance with Nasdaq $1.00 bid price rule

    Nasdaq sent the company a formal notice of compliance on April 24, 2025. The 8-K does not say how the price was restored, and the lead drug's Phase 3 timeline is subject to funding.

    TPST
14. Apr 28, 2025Financings

    Serina Therapeutics sets up $13,270,500 at-the-market share sales program

    Serina can sell up to $13,270,500 of stock through JonesTrading, which earns up to a 3.0% commission. Its auditor has raised going concern doubt, its lead drug is still preclinical, and the program's size is capped by an SEC float rule.

    SER
15. Apr 28, 2025Financings

    IN8bio expects about $1.9 million from reduced-price warrant exercises and exchanges

    Holders agreed to exercise Series A and Series B warrants for cash at $0.1784 to $0.1844 per share by May 2, 2025. Two holders will swap warrants for pre-funded warrants, and IN8bio will cut the price of certain other Series B warrants to $0.45.

    INAB
16. Apr 25, 2025Financings

    Verastem agrees to $75 million private placement of stock and pre-funded warrants

    Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.

    VSTM
17. Apr 25, 2025Financings

    Verastem Oncology announces $75 million private placement led by RTW

    Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.

    VSTM
18. Apr 25, 2025Listings

    Spruce Biosciences gets Nasdaq delisting notice, suspension set for April 29, cuts staff 55%

    Nasdaq will suspend trading on April 29, 2025, and the company's appeal will not stop it. The company is cutting 55% of staff to focus on a rare-disease therapy it has not yet filed for approval, with going-concern doubt on record.

    SPRB
19. Apr 25, 2025Listings

    Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, plans appeal

    Nasdaq says the stock's bid price was below $1.00 for 30 consecutive business days and, after a recent reverse stock split, no compliance period applies. The company plans to appeal by April 30, 2025.

    DCOY
20. Apr 25, 2025Financings

    Pluri swaps 976,139 shares held by director's company for pre-funded warrants

    The investor is a company wholly beneficially owned by director Alejandro Weinstein. The new warrants can be exercised only after shareholder approvals required by Nasdaq rules.

    PLUR
21. Apr 25, 2025Listings

    NYSE American accepts AEON Biopharma plan, sets August 3, 2026 deadline

    NYSE American accepted AEON Biopharma's plan to regain compliance with three continued listing standards and gave the company until August 3, 2026. The 8-K does not say which financial measures the company missed, and the company's migraine trials failed their primary endpoints.

    AEON
22. Apr 25, 2025Listings

    Incannex Healthcare Inc. gets Nasdaq minimum bid price notice, has until October 20, 2025

    Nasdaq told Incannex on April 23, 2025 that its shares had closed below $1.00 for 30 consecutive trading days, giving it until October 20, 2025 to regain compliance. Its annual report for the year ended June 30, 2024 carries an auditor's going concern paragraph.

    IXHL
23. Apr 24, 2025Financings

    NuCana files for offering of up to 16,049,383 ADSs with Series A and B warrants

    The offering is a best-efforts deal placed by Laidlaw & Company (UK) Ltd. Warrant terms with a zero exercise price option and reset provisions could push the number of ADSs issued far above the 16,049,383 offered.

    NCNA
24. Apr 24, 2025Distress

    Caribou Biosciences cuts 47 jobs, drops programs, sees cash runway into second half of 2027

    Caribou will reduce its workforce by 47 employees, discontinue its lupus trial, a CB-012 trial and preclinical research, and focus on CB-010 and CB-011. It reported a preliminary $212.5 million in cash and securities at March 31, 2025.

    CRBU
25. Apr 23, 2025Financings

    Rezolute prices registered direct offering of about $90 million at $3.25 per share

    Rezolute will sell 20,786,923 shares at $3.25 and pre-funded warrants for up to 6,905,385 shares, through Guggenheim Securities as representative of the underwriters. Estimated net proceeds are $84.2 million, and insiders separately agreed to buy up to $10,000,000 of stock at the same price.

    RZLT
26. Apr 22, 2025Financings

    Pacira BioSciences approves new buyback of up to $300.0 million

    Pacira BioSciences says its board approved a $300.0 million repurchase program on April 17, 2025, replacing the program announced in May 2024, while EXPAREL still accounts for most of its revenue.

    PCRX
27. Apr 22, 2025Financings

    CERo Therapeutics signs up to $8 million Series D convertible preferred financing

    About $5 million is expected at the first closing. The company said the money will also help address Nasdaq shareholders' equity deficiencies.

    CERO
28. Apr 21, 2025Mergers

    Scilex unit Semnur amends Denali merger deal, moves outside date to September 30, 2025

    Semnur signed Amendment No. 1 on April 16, 2025, covering Denali's move from Nasdaq to OTC quotation and extending its deadlines.

    SCLX
29. Apr 21, 2025Debt Financing

    Mind Medicine (now Definium Therapeutics) amends K2 loan to up to $120.0 million

    The amendment allows up to $120.0 million of term loans, with a $42.0 million first tranche that refinanced existing loans. Interest carries a floor of 10.25%, lenders can convert up to $7.0 million into shares, and the 8-K gives no cash balance or net loss.

    DFTX
30. Apr 21, 2025Debt Financing

    Mind Medicine (MindMed) Inc. (now Definium Therapeutics, Inc.) refinances with $42.0 million loan

    The company refinanced its K2 HealthVentures term loans with a $42.0 million first tranche, cut the interest rate and gave lenders the right to convert up to $7.0 million into shares. Up to $120.0 million is available in total, but the filing reports only the first tranche as funded.

    DFTX
31. Apr 21, 2025Mergers

    Jazz Pharmaceuticals completes acquisition of Chimerix for about $935 million in cash

    Jazz paid $8.55 per share in cash after its tender offer for Chimerix expired on April 17, 2025. Chimerix is now a wholly owned subsidiary of Jazz.

    JAZZ
32. Apr 21, 2025Debt Financing

    Invivyd signs term loan facility of up to $30 million with Silicon Valley Bank

    Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, can lend Invivyd up to $30 million in three tranches. Only the first $10 million is open without revenue milestones, and the loans are due March 1, 2029.

    IVVD
33. Apr 18, 2025Listings

    Tenaya Therapeutics gets Nasdaq notice for trading below $1.00

    Tenaya has until October 13, 2025 to regain compliance, and may get another 180 days if it moves to the Nasdaq Capital Market.

    TNYA
34. Apr 18, 2025Distress

    Tempest Therapeutics cuts 21 of 26 employees as it explores strategic alternatives

    Tempest Therapeutics will cut 21 of its 26 full-time employees as it explores strategic alternatives, with cuts effective April 30, 2025. It expects about $1.5 million in cash costs, mostly severance, and its 2024 10-K said cash of $30.3 million would last at least 12 months.

    TPST
35. Apr 18, 2025Financings

    Citius Pharmaceuticals sells CEO one Series A preferred share for $100 ahead of share vote

    Citius Pharmaceuticals sold one share of a newly designated Series A preferred stock for $100 to Chairman and CEO Leonard Mazur on April 17, 2025. The share carries 1,000,000,000 votes on a proposal to raise authorized common shares from 16,000,000 to 250,000,000, and the board also cut the quorum for stockholder meetings to one-third.

    CTXR
36. Apr 18, 2025Listings

    Aspire Biopharma (now Aspire-Lakewood Holdings) gets two Nasdaq deficiency letters

    One letter cites the $50,000,000 market value of listed securities rule, with a deadline of October 13, 2025. The other cites the $1.00 minimum bid price rule.

    ASBP
37. Apr 17, 2025Financings

    Zura Bio swaps shares for pre-funded warrants with Venrock affiliates and AI Biotechnology

    Shareholders will surrender 3.5 million and 3.0 million Class A ordinary shares for no consideration and receive pre-funded warrants with a $0.001 exercise price.

    ZURA
38. Apr 17, 2025Listings

    PainReform (now PRF Technologies) says Nasdaq found it compliant with Rule 5550(b)(1)

    Nasdaq found PainReform complies with Rule 5550(b)(1), but warned that delisting could follow if the next periodic report does not show compliance.

    PRFX
39. Apr 17, 2025Distress

    Cuprina Holdings files late notice for 2024 annual report on Form 20-F

    The Singapore-based company says it needs more time to finalize the report and plans to file within the fifteen-day grace period.

    CUPR
40. Apr 17, 2025Financings

    Cadrenal Therapeutics files to sell up to $2,169,272 more stock through ATM program

    Cadrenal can sell up to $2,169,272 of common stock through H.C. Wainwright & Co., LLC, after it has already sold $7,655,240 under the same agreement. The sales are capped by an SEC rule that applies because its public float is under $75 million.

    CVKD
41. Apr 17, 2025Distress

    Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group

    The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going.

    AVIRCOYA
42. Apr 16, 2025Listings

    Nasdaq panel delists Aspira Women's Health over $2.5 million equity rule

    Nasdaq's hearings panel has decided to delist Aspira Women's Health, which says its shares will trade on OTC markets under the symbol AWH.

    AWHL
43. Apr 16, 2025Listings

    Athira Pharma (now LeonaBio) wins Nasdaq Capital Market move and 180 more days

    The transfer takes effect April 17, 2025. Athira, now LeonaBio, has until October 13, 2025 to lift its stock to $1.00 and is seeking approval for a reverse split.

    LONA
44. Apr 15, 2025Mergers

    OS Therapies completes purchase of Advaxis immunotherapy assets from Ayala

    OS Therapies says the purchase adds three clinical-stage and eight preclinical listeria-based cancer immunotherapy candidates, but the release gives neither the price nor the terms.

    OSTX
45. Apr 15, 2025Mergers

    Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split

    Cara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported.

    TVRD
46. Apr 15, 2025Distress

    Abpro Holdings restates prior statements over understated license liabilities

    The company found it had understated liabilities under one of its license agreements and expects a $3.3 million increase in each affected period. Statements for three earlier periods should no longer be relied upon.

    ABPO
47. Apr 14, 2025Mergers

    Coherus BioSciences (now Coherus Oncology) completes UDENYCA sale, gets $483.4 million upfront

    Coherus received $483.4 million in cash at the April 11, 2025 closing and says it has a $250 million post-close cash balance. It is eligible for milestone payments of up to $75 million.

    CHRS
48. Apr 14, 2025Mergers

    Coherus (now Coherus Oncology) completes UDENYCA sale to Intas for $483.4 million upfront

    Coherus can earn up to $75 million more in sales milestones and says it has $250 million in cash after closing, enough to fund work into 2027.

    CHRS
49. Apr 11, 2025Listings

    Nasdaq closes Creative Medical Technology clawback policy compliance matter

    Nasdaq said the company had not adopted or disclosed a required clawback policy on time, but is now in compliance and the matter is closed.

    CELZ
50. Apr 11, 2025Listings

    MIRA Pharmaceuticals gets Nasdaq notice over $2.5 million equity rule

    MIRA reported stockholders' equity of $2,199,750 as of December 31, 2024, below the $2.5 million Nasdaq minimum. It has until May 23, 2025 to submit a plan to regain compliance, and its main fix is an acquisition the release says it expects to complete.

    MIRA
51. Apr 11, 2025Listings

    MIRA Pharmaceuticals gets Nasdaq notice on $2.5 million stockholders' equity requirement

    Nasdaq says MIRA's stockholders' equity of $2,199,750 at December 31, 2024 is below the $2.5 million minimum. The company has until May 23, 2025 to submit a plan, and says a pending acquisition would bring a $5 million capital infusion.

    MIRA
52. Apr 10, 2025Mergers

    Pulmatrix and Cullgen amend merger agreement, switching to a one-step merger

    Amendment No. 1, dated April 7, 2025, drops the second merger so Cullgen survives the merger as a wholly owned Pulmatrix subsidiary. It also clarifies the fractional shares provision.

    PULM
53. Apr 10, 2025Mergers

    Pulmatrix amends Cullgen merger agreement to a one-step merger

    Pulmatrix and Cullgen signed Amendment No. 1 to their merger agreement on April 7, 2025, dropping the planned second merger. The 8-K gives no exchange ratio, share count or valuation, and does not say why the structure changed.

    PULM
54. Apr 10, 2025Listings

    Palatin Technologies gets NYSE American delisting notice, plans to appeal

    NYSE Regulation said it will start proceedings to delist Palatin Technologies (NYSE American: PTN) after the company did not regain compliance within an 18-month plan period. Palatin intends to appeal.

    PTN
55. Apr 9, 2025Listings

    Nasdaq moves to delist Denali Capital (now Semnur Pharmaceuticals), the Semnur SPAC

    Nasdaq staff said Denali Capital Acquisition Corp. had not regained compliance with its $50.0 million market value and total assets rules and also failed the public float rule. The blank-check company's securities will be delisted unless it appeals by April 9, 2025.

    SMNR
56. Apr 9, 2025Financings

    Immunic, Inc. prices $5.1 million registered direct offering at $0.90 per share

    Immunic agreed on April 9, 2025 to sell 5,666,667 shares at $0.90 each for about $5.1 million, with Titan Partners Group LLC as sole placement agent. The company's 2024 annual report carried a going concern doubt and reported $35.7 million in cash at year end.

    IMUX
57. Apr 9, 2025Listings

    Amarin sets 1-for-20 ADS ratio change for April 11 to keep Nasdaq listing

    Each American Depositary Share will represent twenty ordinary shares instead of one. The company says the aim is to meet Nasdaq's $1.00 minimum bid price.

    AMRN
58. Apr 7, 2025Mergers

    Zevra Therapeutics closes $150 million sale of rare pediatric disease priority review voucher

    Zevra received gross proceeds of $150.0 million at the April 1, 2025 closing. The press release puts net cash proceeds at $148.3 million and cash, cash equivalents and investments at approximately $68.7 million on March 31, 2025.

    ZVRA
59. Apr 7, 2025Listings

    XBiotech tells Nasdaq of audit committee vacancy after director retires

    W. Thorpe McKenzie retired from the board effective March 27, 2025. XBiotech will run one-member audit and compensation committees for now.

    XBIT
60. Apr 7, 2025Financings

    Traws Pharma sets at-the-market sales limit at $7,427,749 under baby shelf cap

    Traws Pharma raised its at-the-market limit to $7,427,749 under the baby shelf cap, after selling 42,100 shares for about $122,210. The float that sets the cap uses an $8.29 high close, while the stock closed at $1.96 on April 4, 2025.

    TRAW
61. Apr 7, 2025Debt Financing

    Neogen refinances term loan and revolver with $450 million term loan, $250 million credit facility

    Neogen refinanced its term loan and revolving credit facility on April 4, 2025, with a new $450.0 million term loan and a $250.0 million revolver that matures April 4, 2030. The revolver had $100.0 million drawn at closing, and the company says the deal is leverage-neutral and cuts its rate, a claim the 8-K and the release do not test against the old terms.

    NEOG
62. Apr 7, 2025Listings

    AIM ImmunoTech gets NYSE American delisting notice over low stock price

    NYSE American suspended trading in AIM ImmunoTech (NYSE American: AIM) and began delisting proceedings, citing the low selling price of the stock. The company plans to appeal and expects Pink Open Market trading on April 7, 2025.

    AIM
63. Apr 4, 2025Distress

    MeiraGTx signs new New York lab lease and ends sublease early

    MeiraGTx will pay base rent of $111.00 per square foot a year on a new 14,235 square foot lab at 450 East 29th Street, and it moved to end its current sublease at the same address earlier than scheduled. The 8-K does not say what the total commitment will cost.

    MGTX
64. Apr 3, 2025Debt Financing

    MoonLake draws $75.0 million of Hercules Capital loan facility of up to $500.0 million

    MoonLake's subsidiary, MoonLake Immunotherapeutics AG, borrowed the first tranche on March 31, 2025. Most further tranches depend on trial and FDA milestones, and the facility matures April 1, 2030.

    MLTX
65. Apr 3, 2025Listings

    Dogwood Therapeutics says it has regained Nasdaq stockholders' equity compliance

    Dogwood says a $19.9 million debt exchange with Conjoint and a sale of about $4.8 million in common stock lifted its stockholders' equity above the $2.5 million minimum. Nasdaq had set a May 14, 2025 deadline, and the release does not include a Nasdaq decision.

    DWTX
66. Apr 3, 2025Legal

    Arbutus says court moved Moderna patent trial to September 29, 2025

    Arbutus Biopharma and Genevant Sciences sued Moderna, Inc. and a Moderna affiliate, which the filing does not name, over patents tied to the MRNA-1273 COVID-19 vaccine. On March 31, 2025 the court moved the patent trial from September 24 to September 29, 2025.

    ABUS
67. Apr 1, 2025Distress

    Vaccinex delays annual report for fiscal year ended December 31, 2024

    The company cited delays in completing its financial statements. It expects to file within the extension period of up to fifteen calendar days under Rule 12b-25.

    VCNX
68. Apr 1, 2025Distress

    Tevogen Bio Holdings (now Tevogen) delays 10-K, sees 2024 loss of about $13.7 million

    Tevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal controls.

    TVGN
69. Apr 1, 2025Distress

    ReShape Lifesciences (now Vyome Holdings) files NT 10-K late notice for 2024 annual report

    ReShape Lifesciences filed a Form NT 10-K on April 1, 2025, saying it needs more time to compile information for its 2024 annual report. The notice does not explain the delay, and the company's 2023 annual report set a cost reduction target of about 55.4% for 2024.

    HIND
70. Apr 1, 2025Distress

    Onconetix files NT 10-K late filing notice, says cash fell to $0.6 million at year end

    Onconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities.

    ONCO
71. Apr 1, 2025Distress

    Onconetix delays 10-K as cash falls to $0.6 million at year end

    The company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023.

    ONCO
72. Apr 1, 2025Distress

    Lyell Immunopharma to close West Hills plant and cut about 73 jobs, reiterates 2025 cash guidance

    Lyell expects $3.0 million to $4.0 million in closure and severance costs and net cash use of $175 million - $185 million in 2025. Its Chief Business Officer is also resigning.

    LYEL
73. Apr 1, 2025Mergers

    Lantheus completes Evergreen Theragnostics acquisition, paying about $275 million in cash

    Lantheus said on April 1, 2025 that it completed its acquisition of Evergreen Theragnostics, paying about $275 million in cash at closing. That is a $250 million upfront payment plus a $25 million milestone, and up to $727.5 million in further milestone payments remain possible.

    LNTH
74. Apr 1, 2025Distress

    Genprex delays 2024 annual report to finish financial statements and audit

    The company says it needs more time on its 2024 financial statements and audit procedures. Its lead drug, REQORSA, has a Phase 2a trial whose enrollment rules changed twice in 2024 and 2025.

    GNPX
75. Apr 1, 2025Distress

    Entero Therapeutics (now GridAI Technologies) delays 10-K over accounting review

    Entero says it is reviewing the accounting treatment of a significant transaction and needs more time for its 2024 annual report. The business section describes an ImmunogenX rescission that the company expects to close by June 30, 2025.

    GRDX
76. Apr 1, 2025Distress

    Emmaus Life Sciences delays 2024 annual report, sees revenue down more than $12 million

    The company needs more time for the first audit by an accounting firm it retained in September 2024. It estimates a loss from operations of about $1.9 million for 2024.

    EMMA
77. Apr 1, 2025Distress

    Eloxx Pharmaceuticals files NT 10-K, cannot fund audit and expects going concern doubt

    The late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic reports it has not filed.

    ELOX
78. Apr 1, 2025Listings

    Conduit Pharmaceuticals (now CDT Equity) says it meets Nasdaq equity standard

    The company reported pro forma stockholders' equity of $2.8 million as of March 31, 2025, against a $2.5 million minimum. It also said it meets the market value of publicly held securities rule.

    CDT
79. Apr 1, 2025Financings

    Coherus (now Coherus Oncology) to repurchase about $170 million of convertible notes

    The buyback depends on closing the sale of the UDENYCA franchise. Coherus plans to buy back the remaining $60 million after that deal closes.

    CHRS
80. Apr 1, 2025Mergers

    Cara Therapeutics (now Tvardi Therapeutics) stockholders approve Tvardi merger share issuance

    Cara stockholders approved the share issuance for the merger with Tvardi, a reverse split range of 1-for-2 to 1-for-4, and an increase in authorized shares to 150,000,000.

    TVRD
81. Apr 1, 2025Financings

    Boundless Bio files $400.0 million shelf and $14.5 million Jefferies stock program

    Boundless Bio filed a Form S-3 on April 1, 2025 covering up to $400.0 million of securities. The same day it signed an at-the-market sales agreement with Jefferies LLC for up to $14.5 million of common stock, which can start only after the SEC declares the registration effective.

    BOLD
82. Apr 1, 2025Distress

    Abpro Holdings delays annual report for fiscal year ended December 31, 2024

    The company says it needs more time to prepare its financial statements and expects to file within the fifteen-day extension period.

    ABPO

March 2025

1. Mar 31, 2025Distress

   TransCode Therapeutics delays 2024 annual report to account for direct offering

   TransCode said it needs time to account for a registered direct offering that closed on March 25, 2025. It expects to file within the Rule 12b-25 extension period.

   RNAZ
2. Mar 31, 2025Distress

   Sunshine Biopharma files late notice for annual report for December 31, 2024

   The Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results.

   SBFM
3. Mar 31, 2025Distress

   Sunshine Biopharma files NT 10-K late-filing notice for 2024 annual report

   The company says it needs additional time to complete its financial statements for the period ended December 31, 2024. It checked the box for filing within the fifteenth calendar day after the due date.

   SBFM
4. Mar 31, 2025Distress

   Spruce Biosciences delays annual report and flags going-concern doubt

   Spruce expects cash to be insufficient to fund research and development for at least 12 months without new financing. It expects collaboration revenue to fall about 50%.

   SPRB
5. Mar 31, 2025Distress

   Skinvisible delays annual report for year ended December 31, 2024

   The company said it could not compile all the information for its financial statements in time. It expects to file within the fifteen-day grace period.

   SKVI
6. Mar 31, 2025Distress

   Savara ends $100.0 million at-the-market stock program with Evercore

   Savara told Evercore it is ending a $100.0 million at-the-market sales agreement, effective April 2, 2025. The company says it owes no termination penalty and has sold no shares under the agreement since December 31, 2024.

   SVRA
7. Mar 31, 2025Distress

   Reviva Pharmaceuticals delays 2024 annual report and expects to report material weaknesses

   The company said it needs more time to finalize its financial statements and audit. It plans to file within the fifteen-day extension.

   RVPH
8. Mar 31, 2025Distress

   RenovoRx files late notice for 2024 annual report, cites auditor accounting work

   RenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period.

   RNXT
9. Mar 31, 2025Distress

   RenovoRx files NT 10-K, says annual report will be late

   RenovoRx (Nasdaq: RNXT) filed a late-filing notice for its 2024 annual report, citing technical accounting work with its current and former auditors. It expects to file within the 15-day grace period.

   RNXT
10. Mar 31, 2025Distress

    Rein Therapeutics, formerly Aileron, files NT 10-K and expects $37.0 million impairment

    Rein Therapeutics, formerly Aileron, filed a late-filing notice for its 2024 annual report and expects an impairment loss of about $37.0 million tied to a delay in developing LTI-01. The charge is non-cash, but the company's 2023 annual report already carried a going-concern warning.

    RNTX
11. Mar 31, 2025Distress

    Rein Therapeutics delays 10-K, expects $37.0 million impairment on LTI-01

    The impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impairment assessment.

    RNTX
12. Mar 31, 2025Mergers

    ProKidney files to move incorporation from the Cayman Islands to Delaware

    ProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent.

    PROK
13. Mar 31, 2025Distress

    Oncotelic Therapeutics delays 2024 annual report, expects to file within extension

    The company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year.

    OTLC
14. Mar 31, 2025Distress

    Matinas BioPharma files NT 10-K, says it needs more time to complete 2024 annual report

    Matinas said it needs more time to review its financial statements for the year ended December 31, 2024 and plans to file its Form 10-K within the fifteen calendar day extension. It does not anticipate a significant change in results of operations.

    MTNB
15. Mar 31, 2025Distress

    Matinas BioPharma delays annual report for year ended December 31, 2024

    The company needs more time to complete the review of its financial statements and plans to file within the fifteen calendar day extension.

    MTNB
16. Mar 31, 2025Financings

    Instil Bio sets up $100 million at-the-market stock sale program with Jefferies

    Instil Bio signed a $100 million at-the-market sales agreement with Jefferies, which earns 3.0 percent of gross sales. The last reported sale price before the filing was $19.36, and the lead drug's clinical data come from a partner's small Chinese trial.

    TIL
17. Mar 31, 2025Distress

    Greenwich LifeSciences files NT 10-K, expects late annual report by April 15, 2025

    The company says it cannot file its 2024 annual report on time and expects to use the 15-day extension. Research and development expenses rose to $12,952,029, and the Phase IIb data behind its lead trial carry unresolved record gaps.

    GLSI
18. Mar 31, 2025Financings

    Emergent BioSolutions authorizes repurchase of up to $50 million of stock

    The board approved the Share Repurchase Program on March 31, 2025. The 8-K says the full terms are in a press release attached as Exhibit 99.1, and the 8-K body gives none of them.

    EBS
19. Mar 31, 2025Distress

    DBV Technologies delays annual report while it works on private placement

    DBV said talks on financing for its Viaskin Peanut program diverted management time. It plans to file the 10-K within the 15-day extension period.

    DBV
20. Mar 31, 2025Distress

    Cyclacel (now Bio Green Med Solution) delays 2024 annual report

    Cyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days.

    BGMS
21. Mar 31, 2025Distress

    Celularity delays 2024 annual report, citing liquidity and staffing constraints

    Celularity expects 2024 revenue of $54.2 million and a loss from operations of $37.3 million, figures it says are still under review.

    CELU
22. Mar 31, 2025Listings

    CNS Pharmaceuticals regains Nasdaq bid price compliance, faces one-year monitor

    Nasdaq told CNS Pharmaceuticals on March 31, 2025 that it meets the $1.00 bid price rule. For one year, a new lapse leads to a delisting determination, with no compliance plan or extra time.

    CNSP
23. Mar 31, 2025Distress

    Bioxytran delays annual report as auditor needs more time on 2024 audit

    The company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period.

    BIXT
24. Mar 31, 2025Distress

    Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) files NT 10-K, delays 2024 annual report

    Aspire Biopharma told the SEC on March 31, 2025 that it needs more time to finish its 2024 financial statements. The notice gives no reason beyond that, and its narrative refers to a 10-Q deadline that does not match the annual report it is about.

    ASBP
25. Mar 31, 2025Distress

    Aspire Biopharma (now Aspire-Lakewood Holdings) delays 2024 annual report

    The company said it could not file by April 15, 2025, the original due date, because it needs more time for its financial statements.

    ASBP
26. Mar 31, 2025Distress

    Akari Therapeutics delays 2024 annual report over merger accounting

    The company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension.

    AKTX
27. Mar 31, 2025Distress

    ABVC BioPharma files NT 10-K late filing notice for 2024 annual report

    The company says it is still completing its audit for the year ended December 31, 2024 and expects to file the 10-K within 15 calendar days of the due date. It does not expect a significant change in results.

    ABVC
28. Mar 31, 2025Distress

    ABVC BioPharma delays annual report for fiscal year ended December 31, 2024

    ABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period.

    ABVC
29. Mar 28, 2025Distress

    TriSalus Life Sciences files NT 10-K, citing errors and material weaknesses

    TriSalus says it cannot file its 2024 annual report on time after finding errors in stock-based compensation and clinical trial expenses. It expects to file by the fifteenth calendar day after the due date. Preliminary 2024 revenue was $29.4 million.

    TLSI
30. Mar 28, 2025Distress

    TriSalus Life Sciences delays 10-K after finding errors and material weaknesses

    The company found errors in the timing of stock-based compensation and clinical trial expenses. It expects to file its annual report within fifteen calendar days of the due date.

    TLSI
31. Mar 28, 2025Financings

    Surrozen closes first tranche of private placement for about $76.4 million in gross proceeds

    Surrozen sold 6,586,415 units in a first closing on March 26, 2025, for about $76.4 million gross before fees. Placement agent Guggenheim Securities, LLC was named in the purchase agreement. A second closing of about $98.6 million depends on FDA clearance of the SZN-8141 IND by October 31, 2026.

    SRZN
32. Mar 28, 2025Financings

    Lipella Pharmaceuticals files to register 5,617,259 shares for resale, then sets up ATM

    The shares come from Series B and Series C preferred stock and placement agent warrants tied to its private offerings. On April 4, 2025 Lipella added an at-the-market program of up to $2,641,881.

    LIPO
33. Mar 28, 2025Distress

    Kairos Pharma delays annual report for 2024

    The company expects to file within the 15-day extension period after its accounting staff finalizes the statements.

    KAPA
34. Mar 28, 2025Mergers

    FibroGen (now Kyntra Bio) extends Fortis merger option deadline to December 31, 2027

    FibroGen, now Kyntra Bio, and Fortis Therapeutics amended their evaluation agreement and option and merger agreement, moving the option exercise deadline.

    KYNB
35. Mar 28, 2025Financings

    Dermata Therapeutics expects $6.2 million as holders exercise warrants at $1.284

    Dermata agreed with holders of warrants for 4,834,470 shares to exercise at a reduced $1.284 a share, for about $6.2 million before fees. In return they receive new Series A and Series B warrants for up to 4,980,806 and 4,688,134 shares.

    DRMA
36. Mar 28, 2025Distress

    Cell Source delays annual report for year ended December 31, 2024

    The company says it is still compiling information for the report. It expects to file no later than the fifteenth calendar day after the due date.

    CLCS
37. Mar 28, 2025Listings

    Acurx Pharmaceuticals gets Nasdaq stockholders' equity deficiency notice

    Acurx Pharmaceuticals received a Nasdaq letter saying it no longer meets the $2,500,000 stockholders' equity minimum for the Capital Market. The company must submit a plan to regain compliance by May 9, 2025, and the notice rests on its 2024 annual report.

    ACXP
38. Mar 27, 2025Listings

    Ironwood Pharmaceuticals gets Nasdaq deficiency notice over late 2024 Form 10-K

    Ironwood (Nasdaq: IRWD) has until May 20, 2025, to submit a plan to regain compliance with Nasdaq's timely filing rule and says it plans to file the 2024 Form 10-K as soon as practicable.

    IRWD
39. Mar 27, 2025Listings

    Annovis Bio gets NYSE continued listing notice, will submit compliance plan within 45 days

    The NYSE says Annovis's 30-day average market capitalization was approximately $37.9 million and its stockholders' equity was $9.3 million, both under the $50 million floor. The company's 10-K already carries a going-concern warning and says its cash lasts into the fourth quarter of 2025.

    ANVS
40. Mar 26, 2025Mergers

    Whitehawk Therapeutics completes sale of Aadi Subsidiary to Kaken for $102.4 million

    The buyer paid the cash on closing after purchase price adjustments. The deal was signed on December 19, 2024 under the company's former name, Aadi Bioscience.

    WHWK
41. Mar 26, 2025Mergers

    Whitehawk Therapeutics (formerly Aadi Bioscience) completes $102.4 million sale of Aadi Subsidiary

    KAKEN INVESTMENTS INC. paid $102.4 million in cash at closing on March 25, 2025, after purchase price adjustments, for 100% of the stock of Aadi Subsidiary, Inc.

    WHWK
42. Mar 26, 2025Debt Financing

    Savara draws $30 million under Hercules Capital loan agreement, repays Silicon Valley Bank debt

    Savara drew the first $30 million of a loan of up to $200 million from a group led by Hercules Capital, and used it to repay its Silicon Valley Bank term loan. Later draws depend on FDA approval of MOLBREEVI, a revenue milestone or lender approval.

    SVRA
43. Mar 26, 2025Financings

    Relmada licenses NDV-01 from Trigone, agrees to pay $3,500,000 and issue 3,017,420 shares

    Relmada Therapeutics agreed on March 24, 2025 to license NDV-01 from Trigone Pharma for a $3,500,000 upfront fee and 3,017,420 restricted shares, which the press release says is 10% of its outstanding stock. Milestones can reach $200 million, and from 2026 Relmada must spend at least $5,000,000 a year on the drug.

    RLMD
44. Mar 26, 2025Financings

    Precision BioSciences updates its stock sales limit to $14,868,926

    Precision BioSciences, Inc. became subject to a one-third-of-float cap on shelf offerings on March 26, 2025, when it filed its 2024 annual report. It filed a supplement to its Jefferies at-the-market program to reflect that.

    DTIL
45. Mar 26, 2025Distress

    Nkarta to cut 34% of workforce in restructuring, expects cash runway into 2029

    Nkarta is cutting 53 positions, about 34% of its staff, at an expected cost of $5.5 million to $6.5 million. It says its $380.5 million of cash and investments can fund operations into 2029, while the first clinical data from its lead program are not due until the second half of 2025.

    NKTX
46. Mar 26, 2025Distress

    Nkarta cuts 34% of workforce (53 positions), sees $380.5 million in cash lasting into 2029

    Nkarta is cutting 34% of its workforce and freezing some hires, and it says $380.5 million in cash will fund operations into 2029. Its release reports no efficacy data for NKX019, and the trials enroll small groups.

    NKTX
47. Mar 26, 2025Financings

    MAIA Biotechnology cuts at-the-market program to $11,200,000 from $30,000,000

    The smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far.

    MAIA
48. Mar 26, 2025Financings

    Benitec Biopharma prices $30 million stock sale at $13.00 per share

    Benitec Biopharma is issuing 2,043,000 shares and 300,000 pre-funded warrants at $13.00 a share. The prospectus says 900,000 of the shares go directly to Averill funds that are affiliates of Suvretta Capital, while the pricing release names Suvretta Capital itself.

    BNTC
49. Mar 25, 2025Financings

    TransCode Therapeutics agrees to sell 10,250,000 shares and warrants at $0.98

    TransCode is selling 10,250,000 shares and warrants at $0.98 per share and warrant, through ThinkEquity LLC as exclusive placement agent, for a total offering price of $10,045,000 before fees. The prospectus shows an immediate dilution of $0.72 per share to new investors, and the auditor's report carries a going concern paragraph.

    RNAZ
50. Mar 25, 2025Financings

    NeOnc Technologies sets Nasdaq direct listing, registers 2,101,313 shares for resale

    NeOnc's prospectus registers 2,101,313 shares for resale in a Nasdaq direct listing, and the company gets none of the proceeds. Its financial advisor RBW Capital Partners is also the placement agent for a $10 million private placement, and the auditor's report carries a going concern paragraph.

    NTHI
51. Mar 25, 2025Listings

    Jupiter Neurosciences gets Nasdaq minimum bid price deficiency notice

    Jupiter Neurosciences received a Nasdaq letter on March 21, 2025 saying its stock fails the $1.00 minimum bid price rule. The company has until September 17, 2025 to regain compliance.

    JUNS
52. Mar 25, 2025Financings

    Genelux prices $10.5 million underwritten offering of 3,000,000 shares at $3.50

    Net proceeds are about $9.1 million. The auditor has raised going-concern doubt, and preliminary year-end cash was $30.9 million.

    GNLX
53. Mar 25, 2025Financings

    GRI Bio prices $5.0 million public offering at $3.60 with three warrant series

    The prospectus puts gross proceeds at $4,999,878 and says auditors have raised going-concern doubt. Cash covers operations into the third quarter of 2025 with the money.

    GRI
54. Mar 25, 2025Mergers

    Entero (now GridAI Technologies) signs deal to unwind ImmunogenX merger

    Entero Therapeutics, now GridAI Technologies, signed a rescission agreement with all former ImmunogenX shareholders. It still needs shareholder approval on or before June 30, 2025.

    GRDX
55. Mar 25, 2025Listings

    Dermata Therapeutics gets Nasdaq stockholders' equity deficiency notice, has until May 9, 2025

    Dermata reported stockholders' equity of about $1.6 million against the $2.5 million Nasdaq minimum. It must regain compliance or submit a plan by May 9, 2025.

    DRMA
56. Mar 25, 2025Financings

    Climb Bio sets up $22,350,000 at-the-market stock program with Oppenheimer

    The sales agent earns up to 3.0% of gross sales. Climb Bio reported $212.5 million of cash and securities at year end and expects to fund operations through 2027.

    CLYM
57. Mar 24, 2025Financings

    Senti Biosciences files $300,000,000 shelf and sets up $17,500,000 at-the-market program

    Leerink Partners will act as sales agent for a 3.0% commission. The company's public float was approximately $57.81 million.

    SNTI
58. Mar 24, 2025Financings

    Opus Genetics closes public offering with $20.0 million gross proceeds, plus insider placement

    The Nasdaq-listed company sold shares, warrants and pre-funded warrants through Craig-Hallum for gross proceeds of approximately $20.0 million. Its CEO and board chairman bought in a separate private placement.

    IRD
59. Mar 21, 2025Financings

    Vaxart sets up $50,000,000 at-the-market stock program

    Vaxart agreed on March 21, 2025 to sell up to $50 million of common stock through Citizens JMP Securities and B. Riley Securities, which may each receive a commission of up to 3% of gross sales. The stock closed at $0.5754 on March 17, 2025.

    VXRT
60. Mar 21, 2025Listings

    TNF Pharmaceuticals (now Q/C Technologies) gets Nasdaq minimum bid price notice

    Nasdaq told TNF Pharmaceuticals on March 17, 2025 that its closing bid price was below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and remains listed on the Nasdaq Capital Market.

    QCLS
61. Mar 21, 2025Listings

    TNF Pharmaceuticals (now Q/C Technologies) gets Nasdaq minimum bid notice

    TNF Pharmaceuticals, now Q/C Technologies, has until September 15, 2025 to bring its closing bid price back to $1.00 for ten business days.

    QCLS
62. Mar 20, 2025Financings

    Foghorn Therapeutics cuts at-the-market program to $100 million from $200 million

    An amendment with TD Cowen cuts the program to $100 million, and the 8-K gives no reason for the cut. The new supplement shows immediate dilution of $3.78 per share at the $4.44 reference price.

    FHTX
63. Mar 20, 2025Financings

    CNS Pharmaceuticals increases its at-the-market stock program to $43.5 million

    The company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025.

    CNSP
64. Mar 19, 2025Listings

    Minerva Neurosciences keeps Nasdaq listing after meeting $500,000 net income rule

    Minerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital.

    NERV
65. Mar 19, 2025Mergers

    Bausch Health launches $4.0 billion senior secured notes offering to refinance debt

    Bausch Health's subsidiary launched a $4.0 billion offering of senior secured notes due 2032, and the parent began syndicating new secured credit facilities. The proceeds would retire 2025 and 2027 debt, but the filing gives no interest rate on the new notes or the term loan.

    BHC
66. Mar 19, 2025Financings

    Akebia launches stock offering, then prices 25,000,000 shares at $2.00 for $50.0 million

    Akebia priced 25,000,000 shares at $2.00 for gross proceeds of $50.0 million, below the $2.84 last sale price the final prospectus cites for March 19, 2025. The company estimates net proceeds of about $46.5 million and reports an accumulated deficit of $1,678,360 thousand.

    AKBA
67. Mar 18, 2025Financings

    Milestone Pharmaceuticals lifts Jefferies at-the-market program to up to $77,800,000

    Milestone amended its Jefferies sales agreement to allow up to $75,000,000 of new common shares, within a $77,800,000 total that includes about $2.8 million already sold. Jefferies can earn up to 3.0% commission, and the shares closed at $2.41 on March 17, 2025.

    MIST
68. Mar 18, 2025Mergers

    Kalaris Therapeutics closes merger with AlloVir; stock trades as KLRS from March 19, 2025

    Pre-merger Kalaris holders own about 74.47% of the combined company. Cash of about $100 million is expected to last into the fourth quarter of 2026.

    KLRS
69. Mar 18, 2025Mergers

    AlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19

    The combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Former Kalaris holders own about 74.47% on a fully diluted basis.

    KLRS
70. Mar 17, 2025Listings

    Vaccinex files Form 25 to voluntarily withdraw its stock from Nasdaq

    The Rochester, New York company filed the notice on March 17, 2025. It covers its common stock, par value $0.0001 per share.

    VCNX
71. Mar 17, 2025Financings

    OPKO Health buys 3,685,226 Entera Bio shares at $2.17 in obesity collaboration

    The two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Phase 1.

    ENTXOPK
72. Mar 17, 2025Listings

    Nasdaq panel delists Avenue Therapeutics; stock moves to OTC on March 19, 2025

    The company failed to meet Nasdaq's $2,500,000 stockholders' equity rule by the panel's deadline. Trading moves to the OTC Markets under the ATXI symbol.

    ATXI
73. Mar 17, 2025Financings

    Metagenomi files $250,000,000 shelf and $75,000,000 at-the-market program

    Metagenomi filed a $250,000,000 shelf and signed a $75,000,000 at-the-market sales agreement with Jefferies LLC, which can earn up to 3.0% commission. The filing does not state the company's cash balance, and sales can start only after the registration statement is declared effective.

    MGX
74. Mar 17, 2025Distress

    Harrow files NT 10-K late filing notice for 2024 annual report, citing controls review

    Harrow says it needs more time for accounting analyses and its internal controls evaluation. It expects no changes to preliminary 2024 results, including revenues of between $198 million and $200 million.

    HROW
75. Mar 17, 2025Listings

    FibroGen (now Kyntra Bio) appeals Nasdaq delisting notice after missing minimum bid price deadline

    FibroGen did not regain compliance by March 11, 2025 and appealed a Nasdaq delisting decision on March 14, 2025. The delisting is stayed pending a Hearings Panel ruling.

    KYNB
76. Mar 17, 2025Financings

    Entera Bio signs OPKO oral GLP-1/glucagon deal and sells OPKO shares for $8.0 million

    OPKO bought 3,685,226 Entera ordinary shares at about $2.17. Entera will hold the money in escrow to fund its 40% share of development costs. Entera can opt out after Phase 1.

    ENTX
77. Mar 14, 2025Listings

    Tiziana Life Sciences regains compliance with Nasdaq minimum bid price rule

    The requirement was met on March 12, 2025 after a notice dated January 29, 2025. Nasdaq considers the matter closed.

    TLSA
78. Mar 14, 2025Listings

    Gelteq signs deal to sell up to $12,000,000 of shares to Lincoln Park

    Gelteq cannot sell to Lincoln Park until a resale registration statement is declared effective. The agreement caps issuance at 1,881,328 shares unless shareholders approve more or the average price reaches $1.29.

    GELS
79. Mar 13, 2025Distress

    Sutro Biopharma to cut about 50% of workforce in restructuring, names new CEO

    Sutro will deprioritize luvelta, exit its manufacturing facility and cut about 50% of staff, with costs of $40 million to $45 million. Jane Chung succeeds William J. Newell as CEO. Cash was $316.9 million at year-end.

    STRO
80. Mar 13, 2025Listings

    Shuttle Pharma prices $5.75 million underwritten offering at $0.30 per share

    Shuttle Pharmaceuticals priced 19,166,667 shares, or pre-funded warrants, at $0.30 per share for gross proceeds expected to be about $5.75 million. WestPark Capital, Inc. is the sole book-runner on a firm commitment basis.

    SHPH
81. Mar 13, 2025Financings

    Rallybio cuts at-the-market stock program to $9,550,000 from $100,000,000

    Rallybio cut its at-the-market stock program from $100,000,000 to $9,550,000 on March 13, 2025. The company says it has sold no shares under the agreement, and the cut follows an SEC rule that limits sales for companies with a public float below $75.0 million.

    RLYB
82. Mar 13, 2025Mergers

    Pliant Therapeutics, Inc. adopts stockholder rights plan with $12.64 exercise price

    Pliant's board adopted a limited-duration rights plan on March 12, 2025, citing recent accumulations of its common stock. The rights trigger at 10% ownership, or 20% for certain passive investors, and expire on March 11, 2026.

    PLRX
83. Mar 13, 2025Mergers

    Pliant Therapeutics adopts one-year shareholder rights plan after stock buildup

    Pliant's board adopted a one-year stockholder rights plan, and the company's trigger is a 10% stake bought without board approval. The release cites unspecified "recent accumulations" of stock and does not name who was buying, less than two weeks after its annual report disclosed the discontinuation of its lead Phase 2b trial.

    PLRX
84. Mar 12, 2025Financings

    Eterna Therapeutics (now Ernexa Therapeutics) issues $1,500,000 note to Charles Cherington

    Eterna Therapeutics (now Ernexa Therapeutics, Nasdaq: ERNA) received $1,500,000 on March 11, 2025, under a promissory note with 5.0% interest that matures no later than June 15, 2025.

    ERNA
85. Mar 12, 2025Financings

    Dogwood Therapeutics exchanges $19.5 million Conjoint loan for preferred stock

    Dogwood will cancel its loans from Conjoint Inc., a subsidiary of its largest shareholder, for 284.2638 shares of Series A-1 preferred stock convertible into 10,000 common shares each.

    DWTX
86. Mar 12, 2025Debt Financing

    Armata Pharmaceuticals signs $10 million loan from largest holder Innoviva at 14.0%

    The secured term loan matures on March 12, 2026. Armata also pushed back the maturity of three earlier Innoviva credit agreements to the same date.

    ARMPINVA
87. Mar 12, 2025Mergers

    AlloVir (now Kalaris Therapeutics) stockholders approve merger with Kalaris

    AlloVir holders backed all proposals at a special meeting on March 12, 2025. The combined company is expected to be renamed Kalaris Therapeutics and trade on Nasdaq as KLRS.

    KLRS
88. Mar 12, 2025Mergers

    AlloVir (now Kalaris Therapeutics) stockholders approve Kalaris merger and change of control

    At a March 12, 2025 special meeting, AlloVir holders approved the share issuance and change of control under Nasdaq rules, and a stock plan increase. The merger is expected to close as soon as practicable.

    KLRS
89. Mar 11, 2025Financings

    Xilio Therapeutics sets up $50,000,000 at-the-market stock program with Leerink

    Leerink Partners will earn 3.0% of gross proceeds on any sales. The stock last sold at $0.8449 on March 10, 2025.

    XLO
90. Mar 11, 2025Financings

    Viking Therapeutics agrees to $150 million in prepayments to CordenPharma for VK2735 supply

    Viking Therapeutics' Irish subsidiary agreed on March 10, 2025 to make prepayments to CordenPharma for supply of its obesity candidate VK2735. The 8-K puts the prepayments at $90.0 million through 2028, and the press release gives a $150 million total. This is money Viking pays out, not money it raises, and neither document gives a cash balance against which to test it.

    VKTX
91. Mar 11, 2025Distress

    Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) files annual report

    The blank-check company's annual report says it must liquidate if it does not close its deal with BridgeBio Oncology by February 14, 2026, and that doubt over its ability to continue is substantial.

    BBOT
92. Mar 11, 2025Mergers

    Anika Therapeutics sells Parcus Medical to Medacta for $4,500,000 in cash

    Anika completed the sale of its former subsidiary Parcus Medical to Medacta Americas Manufacturing on March 7, 2025 for $4,500,000 in cash at closing, still subject to post-closing adjustments. The 2023 annual report shows a $62.2 million impairment on the Parcus and Arthrosurface intangibles.

    ANIK
93. Mar 11, 2025Mergers

    Anika Therapeutics completes sale of Parcus Medical to Medacta Group

    The deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative solutions.

    ANIK
94. Mar 10, 2025Mergers

    Fortress Biotech's Checkpoint unit agrees to Sun Pharma deal at $4.10 a share plus CVR

    Checkpoint Therapeutics, the majority-controlled unit of Fortress Biotech, agreed to be bought by Sun Pharma for $4.10 in cash per share plus a contingent value right of up to $0.70. Fortress has agreed to vote in favor and will receive a 2.5% royalty.

    FBIO
95. Mar 10, 2025Distress

    Alector to cut workforce by approximately 13%, expects $2.4 million in restructuring charges

    The company says the cut affects about 25 employees and will cost about $2.4 million. It still says cash lasts through 2026, while its lead frontotemporal dementia trial has yet to report and its term loan is secured on substantially all assets.

    ALEC
96. Mar 10, 2025Financings

    Acurx Pharmaceuticals agrees to $1.1 million registered direct offering at $0.40 a share

    Acurx Pharmaceuticals sold 2,150,000 shares and pre-funded warrants for 595,000 more at about $0.40 each, and added private warrants for up to 8,235,000 shares. The price is far below the $1.015 the company got in a January offering, and a Nasdaq bid-price notice arrived on February 24, 2025.

    ACXP
97. Mar 7, 2025Financings

    Replimune adds Baker Bros. employee to board, grants BBA Funds resale registration rights

    Replimune's board grew from nine to ten members on March 5, 2025 to seat Michael Goller, an employee of Baker Bros. Advisors. The same day the company agreed to resale registration rights for the BBA Funds, which bought stock in two financings in 2024.

    REPL
98. Mar 7, 2025Financings

    Creative Medical Technology Holdings signs warrant inducement for about $3.7 million gross proceeds

    Holders of warrants for 837,104 shares agreed to exercise at $4.42 per share and receive new warrants at $3.75. Roth Capital Partners acted as financial advisor.

    CELZ
99. Mar 7, 2025Financings

    Arrowhead registers resale of 11,926,301 shares by a selling stockholder

    The company will not receive any proceeds from sales by the stockholder. The shares were acquired under a stock purchase agreement dated November 25, 2024.

    ARWR
100. Mar 7, 2025Listings

     Adial Pharmaceuticals gets Nasdaq minimum bid price deficiency notice, has until September 1, 2025

     Nasdaq told Adial Pharmaceuticals on March 5, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until September 1, 2025 to regain compliance, and its annual report carries a going-concern warning.

     ADIL
101. Mar 6, 2025Financings

     Tenax Therapeutics agrees to $25 million private placement with RTW Investments

     RTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials.

     TENX
102. Mar 6, 2025Financings

     Nuvation Bio files automatic shelf with $200,000,000 ATM sales agreement supplement

     Nuvation Bio's automatic shelf lets it sell up to $200,000,000 of common stock through Jefferies LLC as sales agent, at up to 3.0% of gross proceeds. The stock last sold at $1.82 on March 4, 2025, and the company's lead drug is still waiting on an FDA decision.

     NUVB
103. Mar 5, 2025Mergers

     Jazz Pharmaceuticals agrees to acquire Chimerix for $8.55 per share in cash

     Jazz Pharmaceuticals agreed to buy Chimerix for $8.55 a share in cash, about $935 million in total, through a tender offer. The main asset, dordaviprone, is still awaiting an FDA decision, and Chimerix owes Jazz a $35 million fee in some cases if it accepts a rival offer.

     JAZZ
104. Mar 5, 2025Debt Financing

     CalciMedica signs loan agreement for up to $32.5 million, funds $10 million at close

     The Avenue Venture Opportunities Fund II loan matures September 1, 2028 and carries a warrant for 641,163 shares at $2.32. CalciMedica says the first tranche extends its cash runway to the middle of 2026.

     CALC
105. Mar 5, 2025Distress

     ALX Oncology approves 30% workforce reduction, will eliminate president and CSO role

     ALX Oncology's board approved a cut of about 30% of staff on Feb 28, 2025, and eliminates its president and chief scientific officer role. The company estimates about $2.2 million in severance and benefits for a lead drug that has not completed a pivotal trial.

     ALXO
106. Mar 4, 2025Financings

     Aadi Bioscience (now Whitehawk Therapeutics) closes $100 million private placement

     Aadi Bioscience closed a private placement of about $100 million on March 4, 2025, selling 21,592,000 shares at $2.40 and pre-funded warrants for 20,076,500 more shares. The company says the money, with the FYARRO sale, should fund operations into 2028.

     WHWK
107. Mar 3, 2025Listings

     iBio files Form 25 to withdraw its common stock from NYSE American

     The company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so.

     IBIO
108. Mar 3, 2025Financings

     Tenaya Therapeutics prices $52.5 million offering of 75,000,000 units at $0.70

     Tenaya priced 75,000,000 units at $0.70 for about $52.5 million, with two warrant series attached to each unit. Its lead gene therapies are in early trials with only a few patients dosed, and the stock's last reported sale price on the pricing day was $0.9469.

     TNYA
109. Mar 3, 2025Distress

     Ironwood Pharmaceuticals delays 10-K and expects a material weakness finding

     Ironwood said it expects its internal control over financial reporting to be ineffective as of December 31, 2024. It plans to file within the 15-day grace period.

     IRWD
110. Mar 3, 2025Listings

     Envoy Medical receives Nasdaq deficiency notice on $35,000,000 market value requirement

     Nasdaq says the market value of Envoy Medical's listed securities did not meet the minimum for 31 consecutive business days. The company has until August 25, 2025 to regain compliance.

     COCH
111. Mar 3, 2025Mergers

     Aerovate Therapeutics (now Jade Biosciences) files merger material from Jade

     Aerovate filed a Jade communication on March 3, 2025, under their October 30, 2024 merger agreement. The combined company is expected to trade on Nasdaq as JBIO.

     JBIO
112. Mar 3, 2025Distress

     ADMA Biologics files NT 10-K, says 2024 annual report will be late

     ADMA Biologics said on March 3, 2025 that KPMG LLP has not finished its audit of 2024 and expects to file the annual report by March 18, 2025. The notice attaches unaudited 2024 net income of 197,673 thousand dollars, against a 2023 net loss of 28,239 thousand dollars.

     ADMA

February 2025

1. Feb 28, 2025Legal

   Court denies Liquidia's challenge to FDA exclusivity for Tyvaso DPI

   A federal judge in Washington denied Liquidia's summary judgment motion on February 27, 2025, upholding the FDA's three-year exclusivity for United Therapeutics' Tyvaso DPI. The exclusivity still ends May 23, 2025, and a related cross claim remains pending.

   LQDA
2. Feb 27, 2025Financings

   Zevra Therapeutics agrees to sell priority review voucher for $150 million

   The company expects the sale to close within 30 to 45 days, subject to customary conditions including a Hart-Scott-Rodino waiting period.

   ZVRA
3. Feb 27, 2025Financings

   Shuttle Pharmaceuticals pays Alto $75,000 to waive rights to $10 million of notes

   Shuttle paid Alto Opportunity Master Fund $75,000 under an amendment signed February 26, 2025. The holder gave up its right to buy up to $10 million of additional notes and warrants, and waived its right to join a contemplated registered offering.

   SHPH
4. Feb 27, 2025Mergers

   Mustang Bio sells fixed assets to AbbVie for $1.0 million and exits Worcester facility

   The company expects about $2.0 million in lease savings over 24 months. It has moved its headquarters to Waltham, Massachusetts.

   MBIO
5. Feb 27, 2025Mergers

   Mustang Bio sells Worcester equipment to AbbVie for $1.0 million and exits facility lease

   Mustang Bio received the $1.0 million purchase price from escrow on February 25, 2025. It expects about $2.0 million in cash savings on the lease over the next 24 months and has moved its headquarters to Waltham.

   MBIO
6. Feb 27, 2025Listings

   Curis gets Nasdaq deficiency notice on market value of listed securities

   Nasdaq told Curis that its listed securities were worth less than $35,000,000 for 30 consecutive business days. The company has until August 20, 2025 to regain compliance.

   CRIS
7. Feb 27, 2025Mergers

   Crescent still expects GlycoMimetics reverse merger to close in second quarter of 2025

   Crescent Biopharma said on February 24, 2025 that it still expects its reverse merger with GlycoMimetics to close in the second quarter of 2025. The merger filing says the deal depends on a financing transaction and on GlycoMimetics stockholder approval.

   CBIO
8. Feb 27, 2025Financings

   Altimmune files $400,000,000 shelf with $150,000,000 equity distribution program

   Altimmune's $400 million shelf would also carry a $150 million share sales program, with Leerink Partners, Piper Sandler and Stifel as sales agents. The filing itself sells no shares.

   ALT
9. Feb 27, 2025Financings

   AbCellera Biologics files automatic shelf registration for shares, debt and warrants

   AbCellera's common shares last sold at $2.92 per share on February 26, 2025. The prospectus sets no dollar amount for the offerings and names no bank or agent.

   ABCL
10. Feb 26, 2025Financings

    SINTX Technologies closes $5.0 million private placement with warrants

    SINTX (Nasdaq: SINT) sold shares, pre-funded warrants and warrants for gross proceeds of $5.0 million before fees. H.C. Wainwright & Co. was placement agent, and the company will use net proceeds for working capital.

    SINT
11. Feb 26, 2025Listings

    CytomX Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 25, 2025

    Nasdaq said CytomX stock did not hold a $1.00 minimum bid for 30 consecutive business days. The company has 180 calendar days to regain compliance, and the notice has no immediate effect on its listing.

    CTMX
12. Feb 26, 2025Financings

    Agenus extends $10.5 million of 2015 notes to July 2026 and reprices warrants at $3.25

    The interest rate on the notes rises from 8% to 9%, and Agenus will grant a subordinate mortgage on properties owned by Agenus West, LLC. New warrants cover 67,500 shares.

    AGEN
13. Feb 25, 2025Listings

    Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F

    The company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on the report.

    UPC
14. Feb 25, 2025Listings

    Rallybio gets Nasdaq minimum bid price notice, has until August 25, 2025

    Rallybio's closing bid price was below $1.00 for 30 consecutive business days. It may be eligible for another 180-day period if it applies to move its listing to the Nasdaq Capital Market.

    RLYB
15. Feb 25, 2025Financings

    MAIA Biotechnology prices $1.43 million private placement of shares and warrants

    MAIA Biotechnology agreed on February 24, 2025 to sell 894,300 shares at $1.50 each, with warrants at $1.85, to accredited investors and certain directors. Combined gross proceeds are expected to be about $1.43 million, and the company's 2023 annual report carried a going-concern warning.

    MAIA
16. Feb 25, 2025Distress

    Kiniksa ends abiprubart Phase 2b trial and terminates mavrilimumab license with MedImmune

    Kiniksa has incurred about $19 million in expenses from ending the Sjögren's trial and expects $14 million to $17 million more. It reported $243.6 million in cash, cash equivalents and short-term investments and no debt, and its 2024 net loss was $43.2 million.

    KNSA
17. Feb 24, 2025Financings

    Inhibikase acquires CorHepta in merger, paying $15.0 million in 4,979,101 shares of stock

    Inhibikase paid $15.0 million for CorHepta in 4,979,101 newly issued shares, with part held in escrow or tied to a milestone. The 8-K names no bank, placement agent or financial adviser for the stock issuance.

    IKT
18. Feb 24, 2025Financings

    FibroGen (now Kyntra Bio) sets up $30.0 million at-the-market stock program

    BofA Securities will sell shares as agent for a commission of up to 3.0%. The stock last sold at $0.7724 before the filing.

    KYNB
19. Feb 24, 2025Listings

    Atossa Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 20, 2025

    Nasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until August 20, 2025 to cure, and a second 180-day period is possible.

    ATOS
20. Feb 20, 2025Financings

    UroGen buys IconOVir assets for 374,843 shares and a possible $15.0 million payment

    The deal covers the product candidate ICVB-1042. A director's affiliates hold IconOVir notes that may entitle them to about 28.3% of the purchase price.

    URGN
21. Feb 20, 2025Financings

    UroGen Pharma issues 374,843 shares to IconOVir in ICVB-1042 asset purchase

    UroGen paid for IconOVir Bio's ICVB-1042 candidate with shares tied to a $4.0 million price, a possible $15.0 million sales milestone and a low single-digit royalty. Entities tied to UroGen's board chair hold IconOVir notes.

    URGN
22. Feb 20, 2025Listings

    Pharming lifts its stake in Abliva to 92.70 percent and extends cash offer to March 6

    Pharming's subsidiary now controls 92.70 percent of Abliva through its SEK 0.45 cash offer, and it has extended the acceptance period to March 6, 2025 for holders who have not yet tendered. Pharming plans a compulsory acquisition of the rest and a delisting from Nasdaq Stockholm.

    PHARMPHAR
23. Feb 20, 2025Debt Financing

    Heron Therapeutics extends Hercules loan maturity to as late as September 1, 2027

    The later date applies only if none of the company's 1.5% convertible notes due May 24, 2026 remain outstanding. Otherwise the loan comes due earlier.

    HRTX
24. Feb 19, 2025Financings

    TriSalus Life Sciences receives $10 million second loan tranche, issues warrants for 91,263 shares

    The Second Tranche loan matures on April 30, 2029. Warrants issued to the initial lender and its affiliate carry an exercise price of $5.4787 and a term of 7 years.

    TLSI
25. Feb 19, 2025Financings

    Petros Pharmaceuticals prices $9.6 million offering of stock and warrants at $0.24

    Petros is selling about 40,000,000 shares, or pre-funded warrants in their place, at $0.24 for about $9.6 million gross. Dawson James Securities, Inc. is the placement agent, paid 8% of the gross proceeds, and the warrants cannot be exercised until stockholders approve them.

    PTPI
26. Feb 19, 2025Listings

    Conduit Pharmaceuticals (now CDT Equity) repays Nirland note as Nasdaq cites more delisting grounds

    Nasdaq's staff found on February 12, 2025 that Conduit Pharmaceuticals had not met two market value requirements within the 180-day grace period. The next day the company repaid the last $926,149 of a senior secured note to Nirland Limited, which it says was meant to help with the Nasdaq deficiencies.

    CDT
27. Feb 19, 2025Financings

    AbbVie prices four series of senior notes, expects about $3.98 billion in net proceeds

    The notes mature in 2028, 2030, 2035 and 2055. AbbVie plans to use the money and cash on hand to repay 2025 senior notes, and the sale is expected to close February 26, 2025.

    ABBV
28. Feb 18, 2025Mergers

    PainReform (now PRF Technologies) agrees to buy DeepSolar business for shares and warrants

    The drug-delivery company is acquiring an AI solar analytics platform from BladeRanger Ltd. BladeRanger would receive 178,769 ordinary shares plus four sets of warrants, and the release gives no price or valuation for the business.

    PRFX
29. Feb 14, 2025Listings

    Nasdaq withdraws Evaxion Biotech (now Evaxion A/S) delisting determination

    Evaxion says it restored stockholders' equity above the $2.5 million minimum and has cash runway into mid-2026. Nasdaq imposed a one-year monitor.

    EVAX
30. Feb 14, 2025Financings

    Cumberland Pharmaceuticals registers up to $10,000,000 in share sales

    The sales agreement with H.C. Wainwright still limits what it can sell now to $5,800,000, because of a cap tied to its public float.

    CPIX
31. Feb 14, 2025Listings

    Citius Pharmaceuticals reports $1.1 million cash and expects to raise capital

    Citius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes.

    CTXRCTOR
32. Feb 13, 2025Distress

    Xencor says 2023 and 2024 interim financials can't be relied on, will restate royalty as debt

    Xencor's audit committee concluded that a 2023 royalty deal with OMERS Life Sciences should be debt, not deferred income, and the company says its 2023 operating cash flow was overstated by $163.0 million. It also found tax misstatements. The company says cash and marketable debt securities are not affected.

    XNCR
33. Feb 13, 2025Listings

    Ovid Therapeutics gets Nasdaq minimum bid price notice, has until August 11, 2025

    Nasdaq says Ovid's average closing bid price was below $1.00 for 31 consecutive trading days. The company has 180 calendar days to regain compliance and says its Nasdaq listing is unaffected for now.

    OVID
34. Feb 13, 2025Financings

    Edesa Biotech closes $15.0 million private placement led by Velan Capital

    Edesa sold 834 Series B-1 preferred shares at $10,000 each and 3,468,746 common shares at $1.92. A Velan Capital analyst joined its board.

    EDSA
35. Feb 13, 2025Listings

    BriaCell Therapeutics regains compliance with Nasdaq minimum bid price requirement

    Nasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00.

    BCTBCTX
36. Feb 13, 2025Distress

    Bio-Rad restructuring to cut about 5% of workforce, with $45 million to $50 million in costs

    Bio-Rad began the plan on February 7, 2025 and expects it to be substantially completed by the end of fiscal 2025. The company also made a binding offer to buy Stilla Technologies.

    BIO
37. Feb 12, 2025Listings

    Genprex gets Nasdaq minimum bid price deficiency notice, has until August 6, 2025

    Nasdaq says Genprex does not meet the $1.00 minimum bid price, based on the last 30 consecutive business days. Separately, Nasdaq extended the company's deadline on the stockholders' equity requirement.

    GNPX
38. Feb 12, 2025Financings

    Aligos Therapeutics announces $105 million private placement

    Aligos is selling shares, pre-funded warrants and warrants at $26.0825 per share and warrant to fund a Phase 2 study of ALG-000184 and extend cash into the second half of 2026.

    ALGS
39. Feb 11, 2025Financings

    Microbot Medical agrees to $13.0 million registered direct offering at $2.13 per share

    Microbot Medical agreed to sell 6,103,289 shares at $2.13 in a registered direct offering, with unregistered warrants for up to 12,206,578 more shares. H.C. Wainwright & Co., LLC is the exclusive placement agent, and the company pays it a 7.0% cash fee.

    MBOT
40. Feb 10, 2025Distress

    Q32 Bio announces restructuring and workforce reduction to focus on bempikibart

    Q32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance.

    QTTB
41. Feb 10, 2025Financings

    Grace Therapeutics agrees to private placement, expects about $13.8 million net proceeds

    Grace Therapeutics expects about $13.8 million in net proceeds from a private placement at $3.395 a share, with TD Securities (USA) LLC as placement agent. The same day, its Phase 3 safety trial of GTx-104 was reported, and the company's own release says the trial was not powered to show efficacy.

    GRCE
42. Feb 7, 2025Financings

    Sionna Therapeutics prices IPO of 10,588,233 shares at $18.00

    The offering totals $190,588,194, and the stock is approved to list on Nasdaq under SION. Proceeds to the company are $177,247,020 before expenses.

    SION
43. Feb 7, 2025Financings

    Mustang Bio prices $8 million offering at $3.01 with two series of warrants

    The warrants can be exercised only after stockholders approve. The offering follows a 1-for-50 reverse stock split on January 15, 2025.

    MBIOFBIO
44. Feb 7, 2025Financings

    Belite Bio sells 258,309 ADSs with warrants for $15,000,004

    Belite Bio is selling 258,309 ADSs and warrants for the same number of ADSs at $58.07 each through Titan Partners Group LLC. The prospectus says the company has recorded net cash outflows from operations since inception.

    BLTE
45. Feb 7, 2025Debt Financing

    Akebia extends Kreos loan tranche, draws $10.0 million and issues 1,153,846-share warrant

    Akebia received net proceeds of $9.3 million on February 3, 2025. The warrant has an exercise price of $1.30 per share and runs eight years.

    AKBA
46. Feb 7, 2025Debt Financing

    Akebia Therapeutics draws $10.0 million Tranche C loan from Kreos, receives $9.3 million net

    Akebia drew the extended $10.0 million Tranche C loan on February 3, 2025, the last day of its extension. It received $9.3 million net and issued a warrant to a Kreos affiliate for 1,153,846 shares at $1.30 a share.

    AKBA
47. Feb 6, 2025Distress

    X4 Pharmaceuticals announces restructuring and workforce reduction of 43 employees, about 30%

    X4 will close its Vienna facility and pause preclinical programs to focus on mavorixafor in chronic neutropenia. It expects annual spending to fall by $30-35 million and believes its funds will last into the first half of 2026.

    XFOR
48. Feb 6, 2025Financings

    RenovoRx prices 11,523,810-share offering at $1.05 for $12,100,001 in gross proceeds

    RenovoRx sold 11,523,810 shares at $1.05, below the $1.46 last sale on February 6, 2025, with Titan Partners Group as sole bookrunner. The company held about $9.6 million in cash and short-term securities at September 30, 2024, and its prospectus carries a going concern paragraph.

    RNXT
49. Feb 6, 2025Mergers

    Alumis and ACELYRIN agree to all-stock merger with $737 million pro forma cash

    ACELYRIN holders would receive 0.4274 Alumis shares for each share they own, and the $737 million pro forma cash figure rests on preliminary year-end balances.

    ALMS
50. Feb 6, 2025Mergers

    Alumis agrees to all-stock merger with ACELYRIN, with pro forma cash of about $737 million

    ACELYRIN holders would receive 0.4274 Alumis shares for each share and own about 45% of the combined company. The cash figures behind the deal are preliminary and unaudited, and ACELYRIN's lead program is being re-evaluated.

    ALMS
51. Feb 6, 2025Financings

    60 Degrees Pharmaceuticals sells 1,503,500 shares in $1.075 million registered direct offering

    60 Degrees Pharmaceuticals sold 1,503,500 shares at $0.715 each in a registered direct offering that closed Feb 6, 2025. H.C. Wainwright was the placement agent, and the company reports about $908,627 of net proceeds, with matching warrants at $0.59.

    SXTP
52. Feb 5, 2025Financings

    BriaCell closes $3.05 million best-efforts public offering of 762,500 shares at $4.00

    BriaCell sold 762,500 common shares at $4.00 each through placement agent ThinkEquity. The $3.05 million in gross proceeds is before fees and expenses, and the agent also received warrants on 38,125 shares.

    BCTX
53. Feb 3, 2025Financings

    Enveric Biosciences prices $5 million public offering at $3.00 per share

    H.C. Wainwright & Co. is the exclusive placement agent for a $3.00 offering of shares and warrants. The auditor's report on the 2023 financial statements already raised substantial doubt about the company's ability to continue as a going concern.

    ENVB
54. Feb 3, 2025Mergers

    Baxter completes Kidney Care business sale and receives about $3.71 billion in net cash proceeds

    Baxter completed the sale of its Kidney Care business on January 31, 2025 and received about $3.71 billion in net, pre-tax cash at closing, against a $3.80 billion price set at signing. The price is still subject to post-closing adjustments, and executive Chris Toth stepped down on the closing date.

    BAX
55. Feb 3, 2025Financings

    ArriVent BioPharma files automatic shelf with $250,000,000 ATM sales agreement

    Jefferies is the sales agent. ArriVent's stock last sold at $29.09 per share on January 30, 2025.

    AVBP
56. Feb 3, 2025Financings

    Annovis Bio prices $21,000,000 public offering of units at $4.00

    Annovis Bio priced 5,250,000 units at $4.00 for $21,000,000 on February 3, 2025, through ThinkEquity as underwriter, with a $1,260,000 discount and warrants exercisable at $5.00, which is 125% of the offering price.

    ANVS
57. Feb 3, 2025Financings

    Alto Neuroscience files $300,000,000 shelf with $75,000,000 at-the-market program

    Alto Neuroscience filed a $300,000,000 shelf on February 3, 2025 and signed a $75,000,000 at-the-market sales agreement with Leerink Partners LLC, but no sale can start until the SEC declares the shelf effective, and its year-end cash figure is still preliminary.

    ANRO

January 2025

1. Jan 31, 2025Financings

   Maze Therapeutics prices IPO of 8,750,000 shares at $16.00

   Maze priced at $16.00 and expects net proceeds of approximately $127.7 million. The company reported a net loss of $100.4 million for 2023 and has no product approved for sale.

   MAZE
2. Jan 31, 2025Financings

   Beta Bionics closes IPO and $17.00 private placement for $229.1 million in gross proceeds

   Beta Bionics told the SEC that its initial public offering and a concurrent private placement brought in gross proceeds of $229.1 million before underwriting discounts and expenses. The company's own release puts its share of the IPO at about $212.1 million, well below the $234.6 million headline figure.

   BBNX
3. Jan 30, 2025Financings

   Tectonic cites $159 million cash runway, then agrees to $185.0 million private placement

   Tectonic's January 30, 2025 presentation put cash at $159 million as of September 30, 2024. On February 3 it agreed to a $185.0 million PIPE, with 3,689,465 shares sold at $50.00 each to funds and $54.14 each to officers and directors.

   TECX
4. Jan 28, 2025Distress

   Zentalis Pharmaceuticals announces restructuring with workforce reduction of approximately 40%

   The board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027.

   ZNTL
5. Jan 27, 2025Distress

   Universe Pharmaceuticals says its 20-F will be late, expects $20.33 million net loss

   The company expects a net loss of about $20.33 million for the year ended September 30, 2024, up from $6.16 million a year earlier.

   UPC
6. Jan 27, 2025Financings

   Lineage Cell Therapeutics closes second tranche, offering proceeds reach $30 million

   Lineage received $6 million more after shareholders approved a sale to a director's affiliate. Milestone-linked warrants could add up to $36 million.

   LCTX
7. Jan 27, 2025Listings

   China SXT Pharmaceuticals files securities purchase agreement priced at $0.20 per share

   The January 21, 2025 agreement sells up to $2,840,000 of shares at $0.20 each, with warrants for 200 percent of each buyer's shares at $1.00. It also sets a penalty of 2.0 percent of the subscription amount for public information failures.

   SXTC
8. Jan 24, 2025Financings

   Ascentage Pharma prices U.S. IPO of 7,325,000 ADSs at US$17.25

   The ADSs are approved to list on Nasdaq under AAPG, with J.P. Morgan and Citigroup as the underwriters named on the cover. The company's ordinary shares have traded in Hong Kong under code 6855 since October 28, 2019.

   6855
9. Jan 23, 2025Financings

   Aardvark Therapeutics files for IPO of common stock, seeks Nasdaq listing as AARD

   The company applied to list on the Nasdaq Global Market. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are the underwriters named on the cover.

   AARD
10. Jan 22, 2025Debt Financing

    Provectus Biopharmaceuticals approves plan to seek up to $10,000,000 in convertible notes

    The unsecured notes carry 8% interest and convert into Series D-1 preferred stock at $2.8620 per share. The board also approved the closing of a 2024 financing under which the company had received $1,000,000 in notes.

    PVCT
11. Jan 22, 2025Distress

    Arvinas subsidiary ends New Haven lab lease, effective December 31, 2024

    Under the January 15, 2025 agreement, Arvinas Operations owes no rent after the termination date if it clears the space by January 21, 2025.

    ARVN
12. Jan 21, 2025Listings

    Pluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance

    Nasdaq accepted Pluri's compliance plan after a November 25, 2024 deficiency letter. The company must show $2,500,000 in stockholders' equity by the deadline or may face delisting, and its shares keep trading as PLUR.

    PLUR
13. Jan 21, 2025Mergers

    Aadi Bioscience (now Whitehawk Therapeutics) seeks vote on $100 million FYARRO sale

    Aadi Bioscience's preliminary proxy, filed January 21, 2025, asks holders to approve a $100 million cash sale of its FYARRO business to Kaken and a private placement of 21,592,000 shares at $2.40 each. The meeting date is still blank in that filing.

    WHWK
14. Jan 17, 2025Financings

    Sionna Therapeutics files for IPO of common stock, seeks Nasdaq listing as SION

    Sionna Therapeutics filed a preliminary S-1 on January 17, 2025 for an IPO of common stock on the Nasdaq Global Market under SION. The filing leaves the share count, price range and net proceeds blank, and lists Goldman Sachs & Co. LLC, TD Cowen, Stifel and Guggenheim Securities as underwriters without marking a lead.

    SION
15. Jan 17, 2025Listings

    PolyPid says $14.5 million private placement restored Nasdaq equity compliance

    The company says stockholders' equity is now about $7.5 million, up from $2.2 million at September 30, 2024. Nasdaq staff will keep monitoring, and the company could face delisting if it cannot show compliance in its next periodic report.

    PYPD
16. Jan 17, 2025Financings

    Phio Pharmaceuticals closes registered direct offering with warrants, nets about $1.6 million

    Phio sold 610,000 shares at $3.00 per share and issued short-term warrants for up to 1,220,000 shares in a concurrent private placement. Net proceeds are approximately $1.6 million, after a placement agent fee of 7.5% plus a 1.0% management fee.

    PHIO
17. Jan 17, 2025Financings

    Kairos Pharma closes $3,497,500 private placement of pre-funded units and warrants

    Kairos Pharma (NYSE American: KAPA) sold 2,500,000 pre-funded units, each with a common warrant at $1.40 per share. Boustead Securities and D. Boral Capital were co-placement agents.

    KAPA
18. Jan 16, 2025Debt Financing

    Alto Neuroscience amends K2 HealthVentures loan, $20.0 million funded and maturity now 2029

    Alto Neuroscience's January 13, 2025 amendment lifts the maximum term loans from $35.0 million to $75.0 million and moves maturity to January 1, 2029. Only $20.0 million was funded at signing, and about $10 million of that went to refinance the old loan and pay fees.

    ANRO
19. Jan 15, 2025Listings

    Gain Therapeutics regains compliance with Nasdaq $50 million market value requirement

    Gain Therapeutics received a Nasdaq deficiency notice on January 8, 2025 over its Market Value of Listed Securities. Nasdaq staff confirmed in writing on January 15 that the company is back in compliance.

    GANX
20. Jan 14, 2025Listings

    Evaxion Biotech (now Evaxion A/S) completes ADS ratio change, like a 1-for-5 split

    Each ADS now represents fifty ordinary shares instead of ten. The company says the change is meant to support liquidity in its ADSs on Nasdaq.

    EVAX
21. Jan 14, 2025Mergers

    Coherus BioSciences (now Coherus Oncology) seeks vote on $483.4 million UDENYCA sale

    Coherus could also earn two $37.5 million payments if UDENYCA sales hit set targets. The board unanimously recommends a vote for the sale.

    CHRS
22. Jan 13, 2025Financings

    iBio sells 240,807 shares to officers and directors in $655,000 private placement

    iBio sold 240,807 common shares at $2.72 each to its directors and officers, for about $655,000 in gross proceeds, and the placement closed on January 10, 2025. The company says the price was at-the-market.

    IBIO
23. Jan 13, 2025Debt Financing

    Verastem sells $75.0 million of notes to Oberland Capital and repays Oxford loan

    The note purchase agreement allows up to $150.0 million of notes with interest capped at 9.75%. Verastem also sold 1,416,939 shares to Oberland funds at $5.2931 per share and received about $32.3 million in net proceeds from the notes after the Oxford payoff. Its year-end cash figure is unaudited and preliminary.

    VSTM
24. Jan 13, 2025Financings

    Protara Therapeutics puts cash runway into 2027, counting $102.7 million offering

    Protara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Its balance sheet figure is $81.5 million at September 30, 2024, and its bladder cancer efficacy data come from a small single-arm trial.

    TARA
25. Jan 13, 2025Financings

    Opus Genetics sets up $40,000,000 at-the-market program with Leerink Partners

    Opus Genetics can sell up to $40,000,000 of stock through Leerink Partners, which takes 3.0% of gross proceeds. The company's last reported sale price was $1.42 on January 10, 2025, and the earlier JonesTrading program had sold about $26.4 million of stock.

    IRD
26. Jan 13, 2025Debt Financing

    Inhibrx Biosciences gets $100.0 million at close of Oxford Finance term loan facility

    The loan agreement allows up to $150.0 million, with the remaining $50.0 million at the lenders' sole discretion. The loan matures January 1, 2030 and comes with warrants for 140,741 shares at $14.21. Oxford Finance LLC is collateral agent.

    INBX
27. Jan 13, 2025Debt Financing

    Inhibrx Biosciences closes Oxford Finance loan of up to $150 million, funds $100 million

    The five-year facility pays interest only until March 2028. Oxford also received warrants for 140,741 shares at $14.21 per share.

    INBX
28. Jan 10, 2025Distress

    Neogen files NT 10-Q late-filing notice, expects $461.4 million goodwill impairment

    Neogen filed a late-filing notice on January 10, 2025 for its quarterly report for the quarter ended November 30, 2024. The company expects a $461.4 million goodwill impairment on its Food Safety unit and a net loss of $456.3 million, against a loss of $3.5 million a year earlier.

    NEOG
29. Jan 10, 2025Listings

    Matinas BioPharma gets NYSE American deficiency notice for missing 2024 annual meeting

    The January 6, 2025 letter cites Section 704 of the NYSE American Company Guide. The shares stay listed with a ".BC" indicator, and Matinas says it will hold its annual meeting no later than December 31, 2025.

    MTNB
30. Jan 10, 2025Distress

    Intellia plans about 27% net workforce cut, drops NTLA-3001, ends 2024 with $862 million

    Intellia says it is cutting its workforce by about 27% net in 2025 and dropping NTLA-3001 to focus on NTLA-2002 and nex-z. It ended 2024 with approximately $862 million and expects about $8 million in charges, but the release gives no headcount or savings figure.

    NTLA
31. Jan 10, 2025Listings

    Incannex gets Nasdaq deficiency notice on $50.0 million market value requirement

    Incannex Healthcare received a Nasdaq notice on January 3, 2025 that its market value of listed securities fell below the $50.0 million minimum for the Global Market. It has until July 2, 2025 to regain compliance, and its 2024 annual report carries a going-concern warning with $5.6 million of cash at June 30, 2024.

    IXHL
32. Jan 10, 2025Financings

    Entera Bio adds up to 30,000,000 shares to its at-the-market program

    Entera Bio Ltd. nearly used up the 5,000,000 shares first registered with Leerink Partners. The new supplement covers an additional block under the same sales agreement.

    ENTX
33. Jan 10, 2025Financings

    Compass Pathways prices about $150 million offering of ADSs and warrants

    Each ADS sells for $4.275 with a warrant to buy another at $5.796. Full cash exercise of the warrants could lift gross proceeds to about $353 million.

    CMPS
34. Jan 10, 2025Financings

    Citrine Global (now Skytech Orion Global) converts partnership loans into shares at $0.01

    The company also agreed to sell units to Deer Light Ltd. for $137,000 and has received about $120,000 so far.

    SKTG
35. Jan 7, 2025Listings

    Sensei Biotherapeutics, Inc. (now Faeth Therapeutics, Inc.) gets 180 more days to meet Nasdaq bid price rule

    Sensei Biotherapeutics told investors on January 7, 2025 that Nasdaq had moved its stock to the Capital Market and given it until July 7, 2025 to lift its share price above $1.00. Its 2023 annual report showed a $34,101 thousand net loss and cash that fell to $13,011 thousand at year end.

    FTH
36. Jan 7, 2025Mergers

    Renovaro (now Lunai Bioworks) signs binding letter to buy Predictive Oncology

    Renovaro plans to pay for Predictive Oncology with preferred stock in an all-stock deal. The letter of intent sets out the main terms, and the release gives no exchange ratio or value for the shares.

    LNAI
37. Jan 7, 2025Listings

    Nasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split

    The Nasdaq Hearings Panel kept the stock listed on two conditions: a reverse stock split by January 31, 2025 and a $1.00 close for ten straight trading days by February 14, 2025. The panel confirmed the equity deficiency is cured.

    REVB
38. Jan 7, 2025Financings

    Maze Therapeutics files for IPO of common stock, seeks Nasdaq listing as MAZE

    Maze's IPO filing names four underwriters and leaves the share count and price range blank. The nine months to September 30, 2024 include $167,500 thousand of license revenue.

    MAZE
39. Jan 7, 2025Financings

    Lifecore Biomedical sells unused filling equipment for $17 million, $7 million paid so far

    The contract manufacturer received $7 million at closing and expects the rest in three tranches over 18 months. It says current capacity supports up to $300 million in annual revenue.

    LFCR
40. Jan 7, 2025Distress

    Cassava Sciences (now Filana Therapeutics) cuts workforce by about 33%, reports $128.6 million cash

    The Alzheimer's drug developer expects about $0.4 million in one-time costs. The release gives no efficacy numbers for the two Phase 3 studies, and it still plans to report topline results from the one it is discontinuing.

    FLNA
41. Jan 7, 2025Distress

    Cassava Sciences (now Filana Therapeutics) cuts 33% of workforce, reports $128.6 million cash

    After its Phase 3 ReThink-ALZ study of simufilam missed its co-primary endpoints, Cassava is cutting 10 employees, or 33% of its staff, at a one-time cost of about $0.4 million. It reported unaudited cash of about $128.6 million at December 31, 2024.

    FLNA
42. Jan 7, 2025Financings

    Acurx Pharmaceuticals prices $2.5 million registered direct offering at $1.015 per share

    Acurx will sell 2,463,058 shares at $1.015 to institutional investors and six insiders, with Series E warrants for the same number of shares at $0.90. H.C. Wainwright & Co. is the exclusive placement agent, and it receives a 7.0% cash fee plus a 1.0% management fee.

    ACXP
43. Jan 6, 2025Distress

    CytomX Therapeutics to cut about 40% of headcount, expects $5 million to $6 million in charges

    The restructuring focuses the company on CX-2051 and its research collaborations. CytomX expects the changes to extend its cash runway into the second quarter of 2026.

    CTMX
44. Jan 6, 2025Mergers

    Cyclacel (now Bio Green Med Solution) agrees to sell $3.1 million of preferred stock

    Investor David Lazar agreed to subscribe for $3.1 million of convertible preferred stock and become interim chief executive. A separate warrant exchange would issue 24,844,725 common shares and pay $1,100,000 in cash. The Series D closing and the warrant exchange need stockholder approval, and the Nasdaq deadline is February 6, 2025.

    BGMS
45. Jan 6, 2025Distress

    Citius Oncology hires Jefferies to explore strategic alternatives

    Citius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed.

    CTORCTXR
46. Jan 6, 2025Financings

    AEON Biopharma prices $20.0 million offering of units at $0.50 each

    AEON Biopharma priced 40,000,000 units at $0.50 each for about $20.0 million gross, with Aegis Capital Corp. as sole book-running manager. Each unit carries two warrants that cannot be exercised until stockholders approve them, and their exercise price can reset lower.

    AEON
47. Jan 6, 2025Financings

    ABVC BioPharma cuts warrant price to $0.40 as Lind agrees to exercise 1,029,167

    It is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing.

    ABVC
48. Jan 3, 2025Distress

    Veru sells FC2 female condom business to Clear Future for $18.0 million in cash

    The sale closed December 30, 2024. Veru expects about $12.5 million in net proceeds after a $4.2 million change of control payment to SWK Funding LLC, which ended a residual royalty agreement.

    VERU
49. Jan 3, 2025Distress

    Veru closes $18.0 million sale of FC2 female condom business

    Veru closed the sale of its FC2 female condom business on December 30, 2024 for $18.0 million in cash. After a $4.2 million change of control payment to SWK Funding and other fees, it estimates about $12.5 million in proceeds.

    VERU
50. Jan 3, 2025Listings

    Ocugen gets Nasdaq minimum bid price deficiency notice, has until June 30, 2025

    Ocugen received a Nasdaq deficiency notice because its stock closed below $1.00 for 30 consecutive business days. It has until June 30, 2025 to regain compliance and may qualify for a second 180-day period.

    OCGN
51. Jan 3, 2025Mergers

    Eton Pharmaceuticals completes acquisition of Galzin from Teva for $7.0 million at closing

    Eton bought the Wilson Disease treatment on December 31, 2024 for $7.0 million at closing plus $0.2 million for inventory. It will also pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of its first U.S. sale.

    ETON
52. Jan 2, 2025Financings

    iBio in-licenses anti-myostatin antibody from AstralBio, paying $750,000 upfront in stock

    iBio agreed to license an anti-myostatin antibody from AstralBio and paid the $750,000 upfront fee in common stock. AstralBio can earn up to $28 million in milestones, and the antibody's data so far are preclinical.

    IBIO

December 2024

1. Dec 31, 2024Listings

   Psyence Biomedical agrees to $2.0 million private placement with warrants

   The deal covers 1,000,000 common shares at $2.00 each, plus two series of warrants. H.C. Wainwright & Co. is placement agent.

   PBM
2. Dec 30, 2024Financings

   Precigen agrees to $79.0 million private placement of convertible preferred stock

   Precigen agreed to sell 8.00% Series A convertible perpetual preferred stock for anticipated gross proceeds of $79.0 million, with warrants for 52,666,669 shares at $0.75 attached. The company says the money extends its cash runway into 2026, provided the PRGN-2012 launch comes after approval.

   PGEN
3. Dec 30, 2024Financings

   KALA BIO agrees to $10,750,000 private placement of common and preferred stock

   The company is selling 1,340,603 shares at $6.44 and 3,286 Series I preferred shares at $644.00. It expects the money to fund operations into the first quarter of 2026.

   KALA
4. Dec 27, 2024Financings

   Ascentage Pharma files for U.S. IPO of ADSs, plans Nasdaq listing as AAPG

   The Cayman Islands company's shares have traded in Hong Kong under stock code 6855 since October 28, 2019. The ADS count and price are blank, and J.P. Morgan and Citigroup are named on the cover.

   6855
5. Dec 26, 2024Financings

   TScan Therapeutics agrees to sell $30.0 million of pre-funded warrants to Lynx1

   TScan sold pre-funded warrants for 7,500,000 voting shares at $4.00 each in a registered direct offering to Lynx1 entities, for about $30.0 million gross. It says cash will fund operations into the first quarter of 2027, on assumptions that may prove wrong.

   TCRX
6. Dec 26, 2024Mergers

   Serina Therapeutics sells UniverXome to Juvenescence, which takes on $11.2 million of debt

   The unit held the legacy AgeX assets. Juvenescence, Serina's largest holder, paid a nominal cash amount on top of assuming the secured debt.

   SER
7. Dec 26, 2024Listings

   Regen Biopharma files Form 15 for common and Series A preferred stock

   The notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii).

   RGBP
8. Dec 26, 2024Mergers

   PowerUp Acquisition (now Aspire-Lakewood) gets loan of up to $500,000 before merger

   The lender is an entity controlled by Aspire Biopharma's director of investor relations. $184,543.80 had been loaned as of the filing.

   ASBP
9. Dec 23, 2024Financings

   Quoin Pharmaceuticals prices $6.8 million offering of ADSs and warrants at $0.45

   Quoin Pharmaceuticals priced a $6.8 million offering at $0.45 per ADS, below the $0.647 close on December 19. Older warrants were repriced to the same level, and the prospectus sets no minimum amount for the deal to close.

   QNRX
10. Dec 23, 2024Financings

    Monopar Therapeutics agrees to sell 798,655 shares at $23.79 plus pre-funded warrants

    The underwritten offering and a concurrent private placement are expected to bring net proceeds of about $37.6 million.

    MNPR
11. Dec 23, 2024Financings

    Context Therapeutics sells 14,705,882 shares for about $15 million to MPM BioImpact

    The shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024.

    CNTX
12. Dec 23, 2024Debt Financing

    Cingulate raises $5 million net through $5,480,000 unsecured promissory note

    The note carries 9% annual interest and matures in 18 months. Cingulate says the money extends its cash runway into the fourth quarter of 2025.

    CING
13. Dec 20, 2024Financings

    Fennec Pharmaceuticals repays $13 million of convertible debt early

    The payment to Petrichor comes from available cash. It cuts about $1.5 million in annual interest and removes about 1.6 million potential shares.

    FENC
14. Dec 20, 2024Financings

    BioAtla agrees to about $9.2 million registered direct offering at $0.9520

    BioAtla is selling 9,679,158 shares with warrants at a combined $0.9520 each, through sole placement agent Tungsten Advisors, for about $9.2 million gross and about $8.5 million net.

    BCAB
15. Dec 20, 2024Listings

    Altamira Therapeutics moves from Nasdaq to OTCQB after panel decision

    The Nasdaq Hearings Panel denied the company's request to stay listed over the $1.00 minimum bid price rule. Shares are to trade as CYTOF, and the company says it plans no reverse stock split.

    CYTOF
16. Dec 19, 2024Financings

    Marker Therapeutics signs $16.1 million private placement

    Investors agreed to buy 1,783,805 shares plus warrants. The warrants need stockholder approval before they can be exercised.

    MRKR
17. Dec 18, 2024Mergers

    Cara Therapeutics (now Tvardi Therapeutics) agrees all-stock merger with private Tvardi

    Cara Therapeutics agreed on December 18, 2024 to combine with private Tvardi Therapeutics in an all-stock deal. Pre-merger Cara holders would own about 17.0% of the combined company, and the closing depends on Cara holding at least $18.0 million of net cash.

    TVRD
18. Dec 16, 2024Mergers

    Bionomics (now Neuphoria Therapeutics) wins court approval for its US move

    The Supreme Court of New South Wales approved the scheme of arrangement. Neuphoria shares are expected to start trading on Nasdaq as NEUP on December 24, 2024.

    NEUP
19. Dec 13, 2024Financings

    Taysha Gene Therapies files $300,000,000 shelf with $100,000,000 ATM prospectus

    Taysha Gene Therapies filed a $300,000,000 shelf registration on December 13, 2024, with a $100,000,000 at-the-market sales agreement inside it. The company had sold $12,000,000 under its earlier agreement, and the stock's last reported price was $2.25.

    TSHA
20. Dec 13, 2024Financings

    Salarius Pharmaceuticals (now Decoy Therapeutics) signs equity line for up to $10 million

    Salarius Pharmaceuticals agreed on December 12, 2024 to let C/M Capital Master Fund, LP purchase up to $10 million of its common stock over 36 months, once a resale registration is effective. The 8-K names no placement agent or counsel, and it gives the company's Nasdaq symbol as SLRX.

    DCOY
21. Dec 12, 2024Listings

    Neutra Corp. files Form 15 to end SEC reporting duties

    The notice, dated December 11, 2024, lists 16 holders of record of its common stock.

    NTRR
22. Dec 12, 2024Financings

    Inovio Pharmaceuticals prices $30 million offering of stock and warrants at $3.00

    Inovio is selling 10,000,000 shares at $3.00 with warrants for 10,000,000 more shares at $3.76. The filing gives net proceeds of about $27.6 million and immediate dilution of $0.19 per share.

    INO
23. Dec 12, 2024Financings

    Eton sells 583,334 shares at $12.00 in $7.0 million registered direct offering

    The shares went to one institutional investor, and the prospectus says no placement agent or underwriter was involved. The prospectus puts the immediate dilution to the buyer at $11.35 per share.

    ETON
24. Dec 12, 2024Distress

    Editas Medicine ends reni-cel program, cuts about 180 positions (65% of workforce)

    The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027.

    EDIT
25. Dec 10, 2024Financings

    Rocket Pharmaceuticals launches $150,000,000 stock offering, prices at $12.50

    Rocket Pharmaceuticals priced 13,200,000 shares at $12.50 on December 10, 2024, below the $13.84 last sale price on December 9. Net proceeds are about $154.8 million before the underwriters' option, and the company's own prospectus says the money will last into the second quarter of 2026.

    RCKT
26. Dec 10, 2024Financings

    Cardiff Oncology prices $40 million share offering at $2.60, above last sale

    The company is selling 15,384,619 shares. The stock last traded at $2.44 on December 9, 2024. Cardiff plans to use proceeds for onvansertib trials in colorectal cancer.

    CRDF
27. Dec 6, 2024Financings

    Celcuity files for up to $125,000,000 of at-the-market stock sales

    The supplement covers up to $125,000,000 of common stock sold through Jefferies LLC under a February 4, 2022 sales agreement. Shares with an aggregate offering price of up to $22,182,550 remained unsold under the 2022 supplement, and the filing gives a $12.71 last sale price on December 4, 2024.

    CELC
28. Dec 2, 2024Financings

    Olema Oncology announces $250.0 million private placement and Novartis supply deal

    Olema is selling 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares. Novartis will supply ribociclib for the planned Phase 3 OPERA-02 trial.

    OLMA
29. Dec 2, 2024Mergers

    Nektar completes sale of Huntsville, Alabama plant to Ampersand affiliate

    Nektar sold the Huntsville plant, certain other related manufacturing assets and certain related liabilities to the buyer under an agreement dated November 1, 2024.

    NKTR
30. Dec 2, 2024Financings

    Korro Bio files $400,000,000 shelf with a $100,000,000 stock sales program

    Korro Bio's S-3 shelf registers up to $400,000,000 of securities. Its sales agreement with TD Securities (USA) LLC covers up to $100,000,000 of common stock, and the filing gives no cash balance.

    KRRO
31. Dec 2, 2024Financings

    Jupiter Neurosciences prices $11 million IPO of 2,750,000 shares at $4.00

    Jupiter Neurosciences priced a firm commitment IPO of 2,750,000 shares at $4.00, or $11,000,000 gross. Its prospectus carries a going concern warning and an accumulated deficit of $23,903,481 at June 30, 2024.

    JUNS

November 2024

1. Nov 27, 2024Financings

   Gyre Therapeutics sets up $50,000,000 at-the-market stock program with Jefferies

   Jefferies LLC is the sales agent for up to $50,000,000 of common stock. Its commission is up to 3.0% of gross proceeds, and a significant part of the business runs through a Chinese subsidiary.

   GYRE
2. Nov 25, 2024Mergers

   TuHURA Biosciences signs letter of intent to acquire Kineta's KVA12123

   The letter is non-binding and the release states no price. TuHURA targets a definitive agreement in Q4 2024 and completion of the acquisition in H1 2025.

   HURA
3. Nov 22, 2024Financings

   Scilex noteholders waive defaults tied to late third quarter report

   Oramed and the Tranche B holders waived the missed quarterly filing on November 21, 2024. Scilex must deliver its September 2024 financial statements by January 20, 2025, through a new independent auditor.

   SCLX
4. Nov 21, 2024Distress

   Iovance moves San Carlos headquarters to smaller space, cutting monthly rent

   A 24-month sublease with Vaxcyte at $99,549.53 per month replaces a lease with original monthly rent of $279,540.80.

   IOVA
5. Nov 21, 2024Financings

   ChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program

   B. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents.

   NAGE
6. Nov 20, 2024Financings

   Verrica Pharmaceuticals prices $42,007,776 stock and warrant offering at $0.89

   Verrica priced 44,964,045 shares at $0.89 with Series A and B warrants, for a total public offering price of $42,007,776. Entities tied to director Paul B. Manning agreed to buy 22.9 million shares, and the filing carries a going-concern warning.

   VRCA
7. Nov 20, 2024Financings

   PMV Pharmaceuticals files $200,000,000 shelf with $113,792,846.40 ATM supplement

   PMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program.

   PMVP
8. Nov 19, 2024Financings

   Atossa Therapeutics sets up $100,000,000 at-the-market stock program with Jefferies

   Jefferies will earn a commission of up to 3.0% on any shares sold. The stock last sold at $1.28 on November 15, 2024.

   ATOS
9. Nov 18, 2024Financings

   Aclaris Therapeutics licenses two Biosion antibodies, ends strategic review

   Aclaris also pointed to a private placement financing announced the same morning and said it maintains its cash runway into 2028. The release gives no license payment terms.

   ACRS
10. Nov 15, 2024Distress

    Aditxt delays quarterly report for period ended September 30, 2024

    The company filed a late-filing notice on November 15, 2024. It plans to file the report no later than 5 days after the original due date.

    ADTX
11. Nov 14, 2024Distress

    Scilex Holding delays third-quarter 10-Q, notice cites an ongoing review

    The company missed the November 14, 2024 due date for its report on the quarter ended September 30, 2024. The notice warns that an ongoing review may identify errors or control deficiencies in its accounting practices.

    SCLX
12. Nov 14, 2024Distress

    Neurogene delays quarterly report for period ended September 30, 2024

    The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days.

    NGNE
13. Nov 13, 2024Financings

    Rockwell Medical files to sell up to $25,000,000 of stock at market

    Rockwell Medical may sell up to $25,000,000 of stock through Cantor Fitzgerald, which takes a commission of up to 3.0%. At the assumed $4.43 price, the filing says new buyers would face an immediate dilution of $3.33 a share.

    RMTI
14. Nov 13, 2024Distress

    Oruka reports $410,875 thousand in cash at September 30, 2024

    A separate exhibit carries an audited balance sheet dated February 6, 2024, the company's inception. The auditor's report on it raises going-concern doubt.

    ORKA
15. Nov 13, 2024Distress

    Cellectar Biosciences delays quarterly report after restating past results

    The company found that certain warrants and preferred stock issued before 2023 had not been accounted for properly. It estimated cash of $34.3 million at September 30, 2024.

    CLRB
16. Nov 12, 2024Financings

    Mereo BioPharma reports $80.5 million cash, says it funds operations into 2027

    The balance includes net proceeds of a $50 million registered direct offering priced June 14, 2024. Third-quarter net loss was $15.0 million.

    MREO
17. Nov 8, 2024Mergers

    Akari Therapeutics shareholders approve share issuance for Peak Bio merger

    About 99% of shares present voted in support. Akari targets a close on November 13, 2024 and expects the deal to fix its Nasdaq equity deficiency.

    AKTX
18. Nov 7, 2024Mergers

    Pieris (now Palvella Therapeutics) files merger partner's Phase 3 dosing news

    Palvella said the first patient was dosed in its SELVA Phase 3 trial. Later, Pieris added merger disclosures after nine stockholder demands and two lawsuits alleging disclosure gaps, which the defendants deny.

    PVLA
19. Nov 7, 2024Mergers

    Geron completes $250 million Royalty Pharma and Pharmakon financings

    Geron drew $125 million under a Pharmakon term loan and took $125 million from Royalty Pharma, in a quarter with a $26.4 million net loss. The release gives no royalty rates or loan interest rate.

    GERN
20. Nov 7, 2024Financings

    Assembly Biosciences sets up $75,000,000 at-the-market program with Jefferies

    Jefferies will earn up to 3.0% of gross proceeds. The stock last sold at $16.65 before the agreement.

    ASMB
21. Nov 6, 2024Financings

    SCYNEXIS sets up at-the-market program for up to $50,000,000 of stock with Cantor

    SCYNEXIS can sell up to $50,000,000 of stock through Cantor Fitzgerald, which earns a 3.0% commission, with the stock at $1.33 on November 5, 2024. Its approved drug is off the market under a recall, and the supplement gives no cash balance.

    SCYX
22. Nov 5, 2024Mergers

    Relief Therapeutics (now MindMaze) signs non-binding LOI for Renexxion reverse merger

    Renexxion holders would own about 72.2% of the combined company under the initial ratio. The companies aim to sign a definitive agreement by December 31, 2024.

    MMTX
23. Nov 5, 2024Financings

    AnaptysBio files $500,000,000 shelf with a $100,000,000 stock sales program

    AnaptysBio's new shelf replaces one that expires January 11, 2025, and its $100,000,000 sales program with TD Securities (USA) LLC could sell up to 4,819,277 shares at $20.75 each, with immediate dilution of $15.59 per share for new buyers.

    ANAB
24. Nov 4, 2024Financings

    Neurogene agrees to $200.0 million private placement at $50.00 per share

    Neurogene is selling 1,835,000 shares and pre-funded warrants for up to 2,165,042 shares to a group of healthcare investors.

    NGNE

October 2024

1. Oct 31, 2024Mergers

   Lyell Immunopharma completes acquisition of ImmPACT Bio

   Lyell adds IMPT-314, a CAR T-cell candidate, through the ImmPACT Bio deal. The release gives no purchase price and no cash balance, and says cash will fund operations into 2027.

   LYEL
2. Oct 29, 2024Mergers

   Immunome buys licensed Zentalis ROR1 assets for 1,805,502 shares

   Immunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement.

   IMNM
3. Oct 29, 2024Financings

   Eterna (now Ernexa) closes $1.1 million placement at $0.75 after stockholder vote

   Stockholders approved the share issuances at the annual meeting on October 29, 2024, the same day the placement closed. The company also agreed to register the new shares for resale, and its equity had been below Nasdaq's $2.5 million minimum.

   ERNA
4. Oct 28, 2024Listings

   NYSE American files to remove Calidi Biotherapeutics warrants from listing

   The notice, dated October 28, 2024, covers the company's redeemable warrants with a $115.00 exercise price, not its common stock.

   CLDI
5. Oct 28, 2024Financings

   Molecular Partners prices $20 million offering of 3,642,988 ADSs at $5.49

   The Swiss company plans to use the money for its radiopharmaceutical pipeline and working capital. Leerink Partners and TD Cowen are joint bookrunners.

   MOLN
6. Oct 28, 2024Mergers

   Bellevue Life Sciences Acquisition (now OSR Health) lends $300,000 to OSR Holdings

   Bellevue's note to its merger partner bears interest at 3.96% a year and is due on October 25, 2025. Bellevue's chief executive is also chairman of OSR Holdings.

   OSRH